{"data":[{"id":638,"name":"Joe Kiani","title":"Founder and Chief Executive Officer","photo":{"id":1337,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1337\/joe-kiani-willow.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1337\/conversions\/joe-kiani-willow-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1337\/conversions\/joe-kiani-willow-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1337\/conversions\/joe-kiani-willow-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"Willow Laboratories","linkedin_profile":"https:\/\/www.linkedin.com\/in\/joe-kiani\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2025-02-02T22:30:25.000000Z"},{"id":25,"name":"Lisa Earnhardt","title":"Executive Vice President and Group President, Medical Devices","photo":{"id":1300,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1300\/Lisa-Earnhart-800x800.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1300\/conversions\/Lisa-Earnhart-800x800-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1300\/conversions\/Lisa-Earnhart-800x800-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1300\/conversions\/Lisa-Earnhart-800x800-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Abbott","linkedin_profile":"https:\/\/www.linkedin.com\/in\/lisaearnhardt\/","biography":"

I lead Medical Devices at Abbott, a $17 billion business with over 40,000 employees, and am proud to work with exceptionally talented teams around the globe that push the boundaries of medical technology to help people live better. I have spent the last 25+ years in healthcare, almost entirely in medtech, and feel fortunate to work in an industry that combines two of my greatest passions: healthcare and technology. An engineer by training, I am inspired by innovation that solves problems. I’ve led medtech businesses – large and small– focused on creating products that have meaningful impact for patients and for healthcare broadly. I am an advocate for diversity and believe that when we bring together great ideas, great technology and great people – great things happen.<\/p>","companies":[],"created_at":"2024-04-26T20:01:17.000000Z"},{"id":416,"name":"Gary Guthart","title":"CEO","photo":{"id":881,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/881\/gary-guthart-intuitive.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/881\/conversions\/gary-guthart-intuitive-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/881\/conversions\/gary-guthart-intuitive-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/881\/conversions\/gary-guthart-intuitive-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Intuitive","linkedin_profile":"https:\/\/www.linkedin.com\/in\/garyguthart\/","biography":"

Gary Guthart, PhD., is chief executive officer and member of the Board of Directors at Intuitive.

Drawing on more than 25 years of medical, engineering and management experience, Dr. Guthart has served as CEO and member of the Board since 2010. As CEO, Dr. Guthart leads Intuitive’s work in advancing what’s possible in the surgical robotics field.

Dr. Guthart joined the first engineering team at Intuitive in 1996 as a Control Systems Analyst and was promoted to vice president of engineering in 1999. He began serving as a senior vice president of product operations in 2002, and was appointed President and Chief Operating Officer 2006.

Before joining Intuitive, Dr. Guthart was part of the core team developing foundational technology for computer-enhanced surgery at SRI International, a renowned nonprofit scientific research institution. He also supported a team at NASA studying human performance assessment of pilots.

Dr. Guthart is on the Board of Directors for Illumina, and serves as a Board member for the Silicon Valley Leadership Group. He received a B.S. in engineering from the University of California, Berkeley, and an MS and PhD in engineering science from the California Institute of Technology.<\/p>","companies":[],"created_at":"2024-11-15T20:03:16.000000Z"},{"id":447,"name":"Duke Rohlen","title":"CEO","photo":{"id":941,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/941\/11111111111.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/941\/conversions\/11111111111-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/941\/conversions\/11111111111-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/941\/conversions\/11111111111-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Ajax Health","linkedin_profile":"https:\/\/www.linkedin.com\/in\/duke-rohlen-7610a2a\/","biography":"

Coming soon.<\/p>","companies":[],"created_at":"2024-11-27T17:04:45.000000Z"},{"id":4,"name":"Jay Watkins","title":"Co-Chair and Partner","photo":{"id":329,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/329\/JayWatkins.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/329\/conversions\/JayWatkins-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/329\/conversions\/JayWatkins-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/329\/conversions\/JayWatkins-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Sonder Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jaywatkinsvc\/","biography":"

Jay Watkins has over 30 years experience founding and funding healthcare companies. Jay’s career in healthcare began when he co-founded Origin Medsystems, a venture funded medical technology start-up that was acquired by Eli Lilly & Company and later spun out as part of Guidant Corporation (NYSE: GDT).<\/div>\r\n
He served as president of several Guidant divisions, led its global business development activities, and later served as a managing director at DeNovo Ventures. Jay lectures at the Stanford Graduate School of Business and at the Stanford Byers Center for Biodesign.<\/div>\r\n

He is widely sought after for his strategic insight and knowledge of structuring M&A transactions and currently serves on the boards of several healthcare companies, including Shockwave Medical (NASDAQ: SWAV), Avail Medsystems, RefleXion Medical, Tissium and Neptune Medical.<\/p>","companies":[],"created_at":"2024-04-26T18:15:50.000000Z"},{"id":430,"name":"Josh Makower","title":"Director & Co-Founder, Stanford Byers Center for Biodesign","photo":{"id":905,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/905\/josh-makower-stanford.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/905\/conversions\/josh-makower-stanford-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/905\/conversions\/josh-makower-stanford-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/905\/conversions\/josh-makower-stanford-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Venture Partner, Sofinnova Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/josh-makower\/","biography":"

Medical & Health Technology Innovator, Entrepreneur, Inventor, Venture Capitalist<\/p>","companies":[],"created_at":"2024-11-19T17:21:27.000000Z"},{"id":541,"name":"Catherine Mohr","title":"President","photo":{"id":1304,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1304\/catherine-mohr-intuitive-crop.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1304\/conversions\/catherine-mohr-intuitive-crop-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1304\/conversions\/catherine-mohr-intuitive-crop-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1304\/conversions\/catherine-mohr-intuitive-crop-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Intuitive Foundation","linkedin_profile":"https:\/\/www.linkedin.com\/in\/catherine-mohr-627a203\/","biography":"

A HealthTech executive with over 25 years of experience in the areas of strategy, research, and product development. Catherine has a diverse background which covers surgery, medical technology, engineering, product design, healthcare, alternative energy, automotive, aerospace, global entrepreneurship, IP litigation, FDA compliance, education, and product development. From this she brings extensive industry experience and deep insights into emerging opportunities, trends, issues and challenges.

She has a proven history of visionary thought-leadership and has served as an independent board member on the boards of a variety of public and private companies in healthcare, technology and microfinance. She serves as a scientific advisor in the healthcare space to a wide variety of entities from startup companies to government technology development programs, venture capital funds, and entrepreneurship programs worldwide. She regularly speaks internationally on the subject of the future of surgery, technology, surgical education, entrepreneurship, and robotics.<\/p>","companies":[],"created_at":"2025-01-09T19:17:07.000000Z"},{"id":774,"name":"Raymond Cohen","title":"Chairman of the Board","photo":{"id":1633,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1633\/ray-cohen-sonivie.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1633\/conversions\/ray-cohen-sonivie-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1633\/conversions\/ray-cohen-sonivie-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1633\/conversions\/ray-cohen-sonivie-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"SoniVie","linkedin_profile":"https:\/\/www.linkedin.com\/in\/cohenraymondw\/","biography":"

Accredited Public Company Director. Proven leader, entrepreneur, team builder and creator of shareholder value with over 40 years of private and public company experience. Expert at leveraging medical technology, identifying market opportunities, clinical and regulatory strategy, pre-clinical and clinical study development, developing viable commercial products and driving revenue through establishment of direct sales and distribution networks and strategic OEM partnerships. Highly skilled at raising equity and debt capital, licensing, strategic partnerships, mergers and acquisitions, investor relations and strategic planning. <\/p>","companies":[],"created_at":"2025-03-05T05:56:29.000000Z"},{"id":111,"name":"Celine Martin","title":"Company Group Chairman, Electrophysiology, Neurovascular, and Aesthetics & Reconstruction","photo":{"id":326,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/326\/CelineMartin.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/326\/conversions\/CelineMartin-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/326\/conversions\/CelineMartin-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/326\/conversions\/CelineMartin-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Johnson & Johnson MedTech","linkedin_profile":"https:\/\/www.linkedin.com\/in\/celine-martin-\/","biography":"

Across Johnson & Johnson MedTech, for more than century, we have harnessed the power of science, innovation, and technology to enable people to live their best lives possible. We strive to go beyond what's next to positively impact the future for humanity.

I'm proud to have spent 25+ years leaning into that purpose -- developing new categories and elevating standards of care in minimally invasive surgery, AFib and stroke. Our stand-out innovation, technology and service, has resulted in global market leadership for Biosense Webster and Mentor, and emerging leadership for Cerenovus and Acclarent. I’m also proud to serve as a board member of Octane OC and as an executive committee member of the CEO Leadership Alliance Orange County, two organizations working to accelerate our SoCal economy and attract the world’s top talent.

None of this would be possible without our purpose-drive, high-performing, diverse & inclusive teams. Across our Cardiovascular & Specialty Solutions Group businesses, we take a \"One Team, One Win\" approach guided by Our Credo.<\/p>","companies":[],"created_at":"2024-06-18T16:19:07.000000Z"},{"id":5,"name":"Paul LaViolette","title":"Managing Partner & Chief Operating Officer","photo":{"id":331,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/331\/LaViolette,_Paul_2018_CROPPE.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/331\/conversions\/LaViolette,_Paul_2018_CROPPE-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/331\/conversions\/LaViolette,_Paul_2018_CROPPE-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/331\/conversions\/LaViolette,_Paul_2018_CROPPE-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"SV Health Investors","linkedin_profile":"https:\/\/www.linkedin.com\/in\/paul-laviolette-a0356411\/","biography":"

Paul brings over 35 years of global medical technology management experience to SV.<\/p>\r\n

He joined SV in 2009 as a Venture Partner and in 2011 was made a Partner. Paul was promoted to Managing Partner & COO in 2014 and heads our medical device investments.<\/p>\r\n

Prior to SV, Paul built and ran medical device businesses for 29 years before joining SV Health Investors. Most recently he was Chief Operating Officer at Boston Scientific (BSC), an $8 billion medical device leader. During his 15 years at BSC, Paul served as Chief Operating Officer; Group President, Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International. During his tenure, the company grew revenue over 20 times. Paul integrated two dozen acquisitions and led extensive product development, manufacturing and worldwide commercial organizations. Previously, Paul held marketing and general management positions at CR Bard and various marketing roles at Kendall (Medtronic).<\/p>\r\n

Outside of SV, Paul serves on the board of Edwards Lifesciences Corporation and the Medical Device Manufacturers Association, and is Chairman of the Innovation Growth Board at the Mass General Brigham health system. In addition, Paul serves on the board of Vibrato Medical, Inc. as a Director. He also served on the board of Advamed for 10 years and is a routine speaker at industry meetings.<\/p>","companies":[],"created_at":"2024-04-26T18:23:06.000000Z"},{"id":215,"name":"Murielle Thinard McLane","title":"Director","photo":{"id":469,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/469\/1710355150764.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/469\/conversions\/1710355150764-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/469\/conversions\/1710355150764-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/469\/conversions\/1710355150764-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Intuitive Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/murielle-thinard-mclane\/","biography":"

\uf0a7 Seasoned healthcare executive with successful track record at establishing strategy, securing resources and executing both in the corporate and venture backed world
\uf0a7 Expert in analytics applied to commercial and clinical operations in biopharma and health systems
\uf0a7 Unique breadth of experience across the healthcare eco-system: payor, provider, supply chain, biopharma and health IT companies. Deep understanding of stakeholder dynamics and value creation opportunities<\/span><\/p>","companies":[],"created_at":"2024-08-26T20:58:56.000000Z"},{"id":9,"name":"John Ryan","title":"Managing Director","photo":{"id":332,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/332\/JohnRyan.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/332\/conversions\/JohnRyan-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/332\/conversions\/JohnRyan-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/332\/conversions\/JohnRyan-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Wells Fargo Strategic Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/john-ryan-86490630\/","biography":"

John leads the healthcare division of WFSC which is focused on direct equity and debt investments in companies across all subsectors of the healthcare industry. John has been a venture capital and private equity investor for more than 24 years and has participated in the founding, building, and financing of companies, ranging from startups to established industry leaders in a wide array of healthcare sectors. John started his career as an investment banker covering the healthcare industry.  John earned a BS with high honors from the University of Colorado at Colorado Springs and an MBA from Harvard Business School.  John is based in San Francisco, California.<\/p>","companies":[],"created_at":"2024-04-26T18:49:54.000000Z"},{"id":613,"name":"Justin Klein","title":"Managing Partner","photo":{"id":1298,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1298\/Screenshot-2025-01-26-185735.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1298\/conversions\/Screenshot-2025-01-26-185735-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1298\/conversions\/Screenshot-2025-01-26-185735-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1298\/conversions\/Screenshot-2025-01-26-185735-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Vensana Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/justinklein\/","biography":"

Justin Klein is a co-founder and Managing Partner at Vensana Capital. Justin was previously a partner at NEA, where he was a leader of the firm's medical technology investing practice.<\/p>\r\n

Justin Klein, MD, JD, is a co-founder and Managing Partner at Vensana Capital, a leading venture capital and growth equity firm dedicated to medtech innovation. Justin currently or previously served on the board of directors of Apella, Cartiva (acquired), ChromaCode, Cleerly, Curate BioSciences, CV Ingenuity (acquired), Epix Therapeutics (acquired), Evident Vascular, Intact Vascular (acquired), Personal Genome Diagnostics (acquired), PhaseBio Pharmaceuticals (IPO), Relievant Medsystems (acquired), Senseonics (IPO), Topera (acquired), Ulthera (acquired), Vertiflex (acquired), Vesper Medical (acquired), and VytronUS (acquired). Justin currently serves as a member of the board of directors of the Medical Device Manufacturers Association and that of AdvaMed Accel, where he is the Vice Chair of the Investor Advisory Committee of AdvaMed's board. He is also a member of the board of directors of CareFirst BlueCross BlueShield, one of the country's largest not-for-profit healthcare organizations that serves over 3.5 million patients in the greater Washington, DC, region. Prior to Vensana, Justin was a partner and leader of the medical technology investing practice at NEA, one of the largest and most active venture capital firms in the world. Justin also worked at the Duke University Health System where his experience included roles in strategy, finance, and operations as Duke built one of the nation's first integrated healthcare delivery systems. Justin graduated with an AB in Economics, a BS in Biological Anthropology & Anatomy, and a Minor in Chemistry from Duke University. He also concurrently earned an MD from the Duke University School of Medicine and a JD from Harvard Law School.<\/p>","companies":[],"created_at":"2025-01-27T03:03:37.000000Z"},{"id":6,"name":"Greg Madden","title":"Managing Partner","photo":{"id":10,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/10\/greg-madden-svhealth.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/10\/conversions\/greg-madden-svhealth-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/10\/conversions\/greg-madden-svhealth-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/10\/conversions\/greg-madden-svhealth-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"SV Health Investors","linkedin_profile":"https:\/\/www.linkedin.com\/in\/maddeng\/","biography":"

Greg is a senior private equity investment professional. Expert in investment due diligence, equity and debt financing structures, private capital formation and has extensive M&A and IPO exit experience. Greg is a proven portfolio strategy executive and director on the company boards he serves.<\/p>","companies":[],"created_at":"2024-04-26T18:27:27.000000Z"},{"id":214,"name":"Chris Eso","title":"Vice President, Global Head of Corporate and Business Development, M&A and Ventures","photo":{"id":468,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/468\/1713054945623.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/468\/conversions\/1713054945623-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/468\/conversions\/1713054945623-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/468\/conversions\/1713054945623-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Medtronic","linkedin_profile":"https:\/\/www.linkedin.com\/in\/chriseso\/","biography":"

\r\n
\r\n
\r\n
Specialties: Mergers and acquisitions<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T20:55:42.000000Z"},{"id":15,"name":"Nick Pachuda","title":"Innovation & New Ventures","photo":{"id":19,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/19\/nick-pachuda-precisionlife.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/19\/conversions\/nick-pachuda-precisionlife-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/19\/conversions\/nick-pachuda-precisionlife-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/19\/conversions\/nick-pachuda-precisionlife-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Precision Life Science Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/nickpachuda\/details\/experience\/","biography":"

Dr. Nicholas Pachuda serves as the Chief Operating Officer of Portfolio & Development at Peptilogics and has approximately 28 years of clinical and industry experience in life sciences including orthopedics\/medtech and biotech. These included senior R&D, Clinical, Innovation, BD and Commercial P&L leadership roles. He was involved with several successful startups, midcaps and multinationals, including 10 years at Johnson & Johnson. He has led multiple global organic and inorganic development programs with diverse technologies and teams. Dr. Pachuda was trained as a foot and ankle surgeon and completed an international orthopedic trauma fellowship.<\/p>","companies":[],"created_at":"2024-04-26T19:35:16.000000Z"},{"id":216,"name":"Colin Morrison","title":"Senior Director of Venture Capital","photo":{"id":470,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/470\/1563506733640.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/470\/conversions\/1563506733640-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/470\/conversions\/1563506733640-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/470\/conversions\/1563506733640-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Boston Scientific","linkedin_profile":"https:\/\/www.linkedin.com\/in\/colin-morrison-45b55012\/","biography":"

\r\n
\r\n
\r\n
Business Development, Venture Capital Investment, Mergers & Acquisitions, Sales Management, and Marketing in Medical Device

Specialties: Venture Capital Investment, Mergers and Acquisitions, Market analysis and business plan development for emerging technologies; upstream market strategy, sales management and team leadership; sales team training and development.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T21:01:22.000000Z"},{"id":11,"name":"Kristien Esser","title":"CEO","photo":{"id":333,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/333\/kristien.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/333\/conversions\/kristien-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/333\/conversions\/kristien-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/333\/conversions\/kristien-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"GS Capital Connect","linkedin_profile":"https:\/\/www.linkedin.com\/in\/kristienesser2008\/","biography":"

For over 27 years, I have been connecting Talent & Capital with Early-Stage MedTech companies.

I have spent my professional career as an Executive Search Consultant and Headhunter within the Medical Device & Medtech sector. I recruit Board Level Executives and MedTech professionals around the world.

Typically my customers are Early-Stage, or Growth focussed companies that want to benefit from Guided Solutions' vast Global Network and my skill in attracting talent to companies that develop disruptive technology.

I maintain a network of VCs and Angel Investors that have a particular interest in High-technology Medical Device companies. Through \"GS Capital Connect\", we attract investors who fuel this incredible sector's growth.<\/p>","companies":[],"created_at":"2024-04-26T19:08:35.000000Z"},{"id":2,"name":"Gerry Brunk","title":"Managing Director","photo":{"id":338,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/338\/AAT5OKPxbC085nz4ZOqAp6Z5rIAh2KClwsqtjAVs.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/338\/conversions\/AAT5OKPxbC085nz4ZOqAp6Z5rIAh2KClwsqtjAVs-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/338\/conversions\/AAT5OKPxbC085nz4ZOqAp6Z5rIAh2KClwsqtjAVs-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/338\/conversions\/AAT5OKPxbC085nz4ZOqAp6Z5rIAh2KClwsqtjAVs-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Lumira Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/gerrybrunk\/","biography":"

For many years I’ve enjoyed talking to students just embarking on the beginning of their careers. I tell them about a lesson an early influence of mine shared: that every step along the way is an apprenticeship journey that never ends (perhaps that’s why the mid-stage progression is referred to as Journeyman…).<\/p>\r\n

In any apprenticeship, success is a function of hours devoted to the craft and the skill and temperament of the master guiding you. My early apprenticeship under my parents had passed 157,600 hours by the time I went off to college to study biology and business. From humble roots in small towns of Maryland’s Chesapeake Bay and with one high school diploma between them, their success and values still inspire me (Dad, a three-decade career as a Coast Guard captain, after an early stint as a commercial fisherman; Mom, a self-taught accountant for non-profits). With their guidance, I was no longer a greenhorn when it came to devotion to duty, curiosity, compassion, and leadership. These lessons continue.<\/p>\r\n

Summers tending the register, stocking the shelves, and delivering orders at my grandfather’s modest grocery store in my hometown of two thousand (1,650 hours). Humility, patience, how to make change in my head. Arguably still my favorite apprenticeship; there was free ice cream and penny candy. A heart attack and then Parkinson’s disease took my grandfather from us far too early. It was not a battle, which implies a fair fight, because he didn’t have a chance. A profession helping give other people one seemed a worthwhile pursuit. After college and graduate school, the apprenticeship clock re-set, with stints in investment banking (8,230 hours) and healthcare management consulting (15,620 hours). Here, the mentors were peers, bosses and clients, some masters and some still novices themselves. Their lessons were equally valuable regardless of tenure – teamwork, analytical rigor, have fun, love what you do.<\/p>\r\n

“Not all those who wander are lost.” -J.R.R. Tolkien
Two start-ups later as a co-founder and operator (12,780 hours), I thought I’d made it to Journeyman. But in 2002 I was about to start what is a true apprenticeship business. Now approaching 53,900 hours as an investor and venture capitalist, my team and portfolio company management teams have been my latest mentors. More lessons: challenge assumptions, do the work, and keep patients first. I’m still hopeful to become a Master soon. A few more hours perhaps.<\/p>\r\n

And what exciting hours these promise to be. I’m still driven by the opportunity we have to make a difference for folks brought low by sickness. I feel privileged to work at our four-way intersection of science, medicine, business, and impact. I’m also grateful to share with our entrepreneurs what the hours honing this craft and the ones that came before it have taught me. And fortunately, I meet new mentors and masters every day, as the apprenticeship never stops.<\/p>","companies":[],"created_at":"2024-04-26T18:11:13.000000Z"},{"id":3,"name":"Charles Hamilton","title":"Managing Director, Healthcare Investment Banking","photo":{"id":337,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/337\/bio_hamilton_charles_23.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/337\/conversions\/bio_hamilton_charles_23-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/337\/conversions\/bio_hamilton_charles_23-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/337\/conversions\/bio_hamilton_charles_23-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Piper Sandler","linkedin_profile":"https:\/\/www.linkedin.com\/in\/chhamilton\/","biography":"

Charles Hamilton is a managing director within the Piper Sandler healthcare group and a senior partner of the medical technology team. Charles advises clients across a full range of investment banking services, including sell-side, buy-side and cross-border M&A, corporate carve-outs, public and private equity and debt financings, capital allocation and defensive advisory. Charles has 20 years of healthcare investment banking and capital markets experience, and has completed over 80 M&A and capital markets transactions on behalf of his medical technology clients at Piper Sandler.<\/p>","companies":[],"created_at":"2024-04-26T18:14:03.000000Z"},{"id":24,"name":"Amanda DePalma","title":"SVP, Head of Corporate and Regional Marketing, Ultrasound","photo":{"id":28,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/28\/amanda-depalma-siemens.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/28\/conversions\/amanda-depalma-siemens-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/28\/conversions\/amanda-depalma-siemens-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/28\/conversions\/amanda-depalma-siemens-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Siemens Healthineers","linkedin_profile":"https:\/\/www.linkedin.com\/in\/amandaldepalma\/","biography":"

With over 25 years of experience in the Medtech sector, I am a results-oriented executive who leads with vision, passion, and purpose. I have a proven track record of building and motivating diverse, high-performing teams to drive worldwide growth and market share gain through customer-driven strategies and focused execution.

As the Vice President of Marketing at FUJIFILM Sonosite, I am responsible for delivering the global marketing strategy, product management, education and downstream marketing for the market-leading $360M point-of-care ultrasound business. I leverage my core competencies in strategic planning, merger and acquisition, diversity, equity and inclusion, branding and communications, new product development and launch, market development, product and portfolio management, team development and leadership, and digital marketing and demand generation to create value for our customers, partners, and stakeholders. I am committed to advancing the field of point-of-care ultrasound and improving the quality of care for patients around the world.<\/p>","companies":[],"created_at":"2024-04-26T19:59:03.000000Z"},{"id":8,"name":"Khurram Mir","title":"Managing Director UCI Health Ventures","photo":{"id":1216,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1216\/Profile-Photo-2.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1216\/conversions\/Profile-Photo-2-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1216\/conversions\/Profile-Photo-2-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1216\/conversions\/Profile-Photo-2-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"UCI Health","linkedin_profile":"https:\/\/www.linkedin.com\/in\/khurramir\/","biography":"

Khurram Mir serves as the Managing Director of UCI Health Ventures and leads Corporate Innovation at the University of California, Irvine Health System. His leadership has driven significant growth in a $50M investment fund, over the last three years. Khurram's strategic investments span healthcare technologies including AI diagnostics, digital health, biotechnology, and medical devices. In addition to his role in portfolio management, Khurram is dedicated to mentoring and leadership, initiating UCI Health Ventures' first multi-campus initiative and a venture capital immersion program for physicians.  Khurram holds a Master of Science in Biomedical Informatics from the University of Texas and maintains credentials as a Certified Healthcare Chief Information Officer and Certified Digital Healthcare Executive through CHIME. He actively participates in various professional organizations, including the College of Healthcare Information Management Executives and the American College of Healthcare Executives.<\/p>","companies":[],"created_at":"2024-04-26T18:48:04.000000Z"},{"id":34,"name":"Jeffrey O'Donnell, Jr.","title":"CEO","photo":{"id":339,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/339\/8b0da5d2ee7789b42f8ca77731a731f0.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/339\/conversions\/8b0da5d2ee7789b42f8ca77731a731f0-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/339\/conversions\/8b0da5d2ee7789b42f8ca77731a731f0-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/339\/conversions\/8b0da5d2ee7789b42f8ca77731a731f0-large.webp"},"category":"innovators","roles":["C"],"company_name":"Runway Healthcare","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jeffodonnelljr\/","biography":"

Jeffrey O'Donnell Jr. is a healthcare entrepreneur who has been creating and growing innovative MedTech companies for over ten years. He has a diverse and extensive background in sales, marketing, product development, and executive leadership.

Currently, he serves as the CEO of the Runway Healthcare portfolio companies, which include Waypoint Orthopedics, Toetal Solutions, and Pace Surgical. He is the co-founder of Toetal Solutions and Pace Surgical. In addition to his role as CEO, he is a General Partner of Runway Healthcare, LP, a MedTech Venture Studio that merges capital and management to bring commercially ready opportunities to existing strategic organizations.

Jeffrey is also a General Partner at MAST Labs, LLC, the premier surgical training company in the mid-Atlantic region, with locations in Philadelphia, PA, Bethesda, MD, and Richmond, VA.

In these roles, he leverages his expertise and passion to address unmet needs in the medical field and to support the growth and innovation of the MedTech ecosystem. He is a proud graduate of the Haub School of Business at Saint Joseph's University in Philadelphia.<\/p>","companies":[{"id":11,"name":"Runway Healthcare","logo":{"id":47,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/47\/runway.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/47\/conversions\/runway-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/47\/conversions\/runway-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/47\/conversions\/runway-large.webp"},"type":"presenter","description":"

Runway Healthcare is a medical device venture studio helping bring innovative, early-stage technologies to market in partnership with entrepreneurial doctors, professionals, and businesses. The company's portfolio currently consists of multiple orthopedic-focused businesses dedicated to enabling physicians and improving patient care.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-04-26T21:23:19.000000Z"}],"created_at":"2024-04-26T21:24:20.000000Z"},{"id":13,"name":"Yuriy Onyskiv","title":"Principal","photo":{"id":17,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/17\/yuriy-onyskiv-olando_health_ventures.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/17\/conversions\/yuriy-onyskiv-olando_health_ventures-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/17\/conversions\/yuriy-onyskiv-olando_health_ventures-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/17\/conversions\/yuriy-onyskiv-olando_health_ventures-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Orlando Health Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/yuriyonyskiv\/","biography":"

My mission is to change US healthcare for the better. One of the strengths of a combined privatized\/public healthcare system is access to innovative technology, at scale, across various specialties and networks. I want to invest in that technology, help scale\/commercialize it, and make it readily accessible to healthcare systems across the country.<\/p>","companies":[],"created_at":"2024-04-26T19:13:31.000000Z"},{"id":12,"name":"Chris Neil","title":"Partner \/ Co-Founder","photo":{"id":16,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/16\/chris-neil-medtech_advantage.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/16\/conversions\/chris-neil-medtech_advantage-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/16\/conversions\/chris-neil-medtech_advantage-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/16\/conversions\/chris-neil-medtech_advantage-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"MedTech Advantage Fund","linkedin_profile":"https:\/\/www.linkedin.com\/in\/chris-neil-sfo\/","biography":"

Chris Neil is an experienced venture & angel investor, senior executive, and start-up advisor. He is Partner and Co-Founder of MedTech Advantage Fund, investing in a broad portfolio of medtech, biotools, and digital health start-ups that have graduated from the MedTech Innovator accelerator program.

In addition, he is an active participant in Life Science Angels as Board Member and Chair of their Device Screening Committee.

Previously he was Senior VP at Maxim Integrated (running their $1B revenue Industrial & Medical Solutions Group) and then as co-creator and Head of Maxim Ventures - investing in medical devices & life sciences.

He served as observer \/ advisor on several other start-up boards, including Unaliwear, Ontera, toSense (now part of Baxter), and Profusa. He was Board Member at Spire Health - which makes a respiratory monitoring system focused on COPD - through their Series-C funding.

He graduated MIT with BSEE and MSEE in 1990.<\/p>","companies":[],"created_at":"2024-04-26T19:10:35.000000Z"},{"id":14,"name":"Janine Schoeller","title":"Director Asia","photo":{"id":365,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/365\/Janine-Schoeller.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/365\/conversions\/Janine-Schoeller-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/365\/conversions\/Janine-Schoeller-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/365\/conversions\/Janine-Schoeller-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"pfm medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/janine-schoeller-490aaab4\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-04-26T19:31:53.000000Z"},{"id":16,"name":"Derrick Woodard","title":"Investment Banker","photo":{"id":20,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/20\/derrick-woodard-rbc.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/20\/conversions\/derrick-woodard-rbc-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/20\/conversions\/derrick-woodard-rbc-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/20\/conversions\/derrick-woodard-rbc-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"RBC Capital Markets","linkedin_profile":"https:\/\/www.linkedin.com\/in\/derrick-woodard-7966965\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-04-26T19:37:45.000000Z"},{"id":17,"name":"Nirav Dalal","title":"Divisional Vice President, Global Data Science & Analytics","photo":{"id":341,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/341\/1516269073928.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/341\/conversions\/1516269073928-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/341\/conversions\/1516269073928-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/341\/conversions\/1516269073928-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Abbott","linkedin_profile":"https:\/\/www.linkedin.com\/in\/nirav-dalal-904a78\/","biography":"

Nirav Dalal leads the Global Data Science and Analytics function at Abbott medical devices. Nirav is interested in methods and tools to improve healthcare and create value using “Big Data” and machine learning. He has published more than fifty peer-reviewed journal articles, conference abstracts and US patents.

He is a frequent speaker on medical devices, real-world evidence, digital health, health economics and data science. His selected past speaking engagements include talks at FDA, NMPA, AdvaMed, Big Data in Healthcare, American Chamber of Commerce, Medical Design & Manufacturing, and Global Cardiovascular Clinical Trialists Forum.<\/p>","companies":[],"created_at":"2024-04-26T19:40:09.000000Z"},{"id":18,"name":"Kevin Rocco","title":"VP Bioinductive Technologies","photo":{"id":343,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/343\/Kevin-Rocco_CEO-DistrictHeadShots13460.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/343\/conversions\/Kevin-Rocco_CEO-DistrictHeadShots13460-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/343\/conversions\/Kevin-Rocco_CEO-DistrictHeadShots13460-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/343\/conversions\/Kevin-Rocco_CEO-DistrictHeadShots13460-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"CONMED","linkedin_profile":"https:\/\/www.linkedin.com\/in\/kevinrocco\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-04-26T19:42:23.000000Z"},{"id":19,"name":"Jason Halac","title":"Senior Director, Dexcom Ventures CVC","photo":{"id":23,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/23\/jason-halac-dexcom.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/23\/conversions\/jason-halac-dexcom-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/23\/conversions\/jason-halac-dexcom-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/23\/conversions\/jason-halac-dexcom-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Dexcom","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jason-halac\/","biography":"

Jason is the co-founder of Dexcom Ventures where he leads technology scouting and strategic pipeline development.  He is a seasoned innovator in the medical device field and a key contributor in Dexcom product development over the past decade.<\/p>\r\n

Committed to Dexcom’s mission of ”Empowering people to take control of diabetes” he has advanced the simplicity, reliability, and comfort of Dexcom’s continuous glucose monitoring systems.  Jason has been a prolific inventor and is named on well over 100 worldwide patents and patent applications.<\/p>\r\n

With Dexcom Ventures, Jason is chartered with building a portfolio as value-added strategic investors by leveraging access to Dexcom’s unique industry expertise and technology leadership.<\/p>\r\n

Prior to Dexcom, Jason held a variety of engineering and leadership roles as a consultant and with Black and Decker.  He holds a B.S. in mechanical engineering from San Diego State University.<\/p>","companies":[],"created_at":"2024-04-26T19:44:35.000000Z"},{"id":20,"name":"Peter Reimer","title":"Group Executive Healthcare Platform","photo":{"id":24,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/24\/peter-reimer-heraues.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/24\/conversions\/peter-reimer-heraues-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/24\/conversions\/peter-reimer-heraues-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/24\/conversions\/peter-reimer-heraues-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Heraeus","linkedin_profile":"https:\/\/www.linkedin.com\/in\/peter-reimer-a4a87217\/","biography":"

Executive with 20+ years experience in leadership, general management & business management, sales & marketing, strategy & portfolio management, innovation, change management, operational excellence, contract manufacturing, Danaher Business System (DBS), intercultural management, talent and team development.<\/p>","companies":[],"created_at":"2024-04-26T19:48:36.000000Z"},{"id":21,"name":"Robert Abrams","title":"General Manager- Global Business Development","photo":{"id":25,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/25\/robert-abrams-kaneka.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/25\/conversions\/robert-abrams-kaneka-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/25\/conversions\/robert-abrams-kaneka-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/25\/conversions\/robert-abrams-kaneka-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Kaneka North America","linkedin_profile":"https:\/\/www.linkedin.com\/in\/rob-abrams-09556b\/","biography":"

Currently:
- Advisor to J&J Neurovascular (former CEO of Pulsar Vascular) , a neurovascular device company w special vascular implants to treat bifurcation cerebral aneurysms.
Acquired by Codman Neurovascular J & J Dec 2016
- Executive Chairman for Dynatherm Inc, a normathermia device to assure patient temp management during surgery - \"plus\"
- Former CEO for Theregen Corp, a cell delivery patch device to treat angina patients, w potential for CHF patients. ( In Clinical trials )

Medical Device product design and development for Guidant, Boston Scientific, and small start-ups...mostly minimally invasive disposable technologies.
- 75 patents in medical devices
- Invented, developed and launched numerous products .
e,g Guidant BMW guidewire, MultiLink Stent, Target Therapeutic coils and stents, vascular recontruction devices

Highly proficient in materials technology - especially Nitinol material development and stent design and process technology.

Very active in new business developement and company assessment and unmet clinical needs strategic planning.
- Performed deal structuring for numerous transactions for BSC ( apprx $2B of ionvestments, including Smart Therapeutics, Advanced Bionics Corp, Precision Vascular Systems, plus

Specialties: Contract negotiations, IP review and licensing, Deal structuring and execution, technology assessment for medical devices, including, pre-clinical and clinical data interpretation \/ assessment. Hands- on device testing and analysis. Highly inventive and familiar w IP analysis and submissions,<\/p>","companies":[],"created_at":"2024-04-26T19:52:32.000000Z"},{"id":22,"name":"David Hochman","title":"Chairman, CEO & Founder","photo":{"id":26,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/26\/david-hochman-orchestra_biomed.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/26\/conversions\/david-hochman-orchestra_biomed-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/26\/conversions\/david-hochman-orchestra_biomed-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/26\/conversions\/david-hochman-orchestra_biomed-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Orchestra BioMed","linkedin_profile":"https:\/\/www.linkedin.com\/in\/david-hochman-829b9832\/","biography":"

David Hochman has served as Chairman and Chief Executive Officer of Orchestra BioMed since May 2018. From 2006 to 2019, he was Managing Partner of Orchestra Medical Ventures, a medical technology venture capital firm. He also served as President of Accelerated Technologies, Inc., a medical device accelerator company managed by Orchestra. David has over 23 years of healthcare entrepreneurial, venture capital and investment banking experience. He is also Chairman of the Board of Motus GI (NASDAQ: MOTS). He was a co-founder and served as a board member of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage biopharmaceutical company, from 2013 to 2020. Prior to joining Orchestra Medical Ventures, Mr. Hochman was Chief Executive Officer of Spencer Trask Edison Partners, LLC, an investment partnership focused on early stage healthcare companies. He was also Managing Director of Spencer Trask Ventures, Inc. during which time he led financing transactions for over twenty early-stage companies raising over $420 million. From 1999 to 2006, Mr. Hochman was a board advisor of Health Dialog Services Corporation, a leader in collaborative healthcare management that was acquired in 2008 by the British United Provident Association for $750 million. From 2005 to 2007, he was a co-founder and board member of PROLOR Biotech, Inc., a biopharmaceutical company developing longer lasting versions of approved therapeutic proteins, which was purchased by Opko Health (NYSE: OPK) in 2013 for over $600 million. He currently serves as President of the Board of the Mollie Parnis Livingston Foundation. He has a B.A. degree with honors from the University of Michigan.<\/p>","companies":[],"created_at":"2024-04-26T19:55:35.000000Z"},{"id":23,"name":"David Rezac","title":"VP, AGILE Product Development (US)","photo":{"id":27,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/27\/david-rezac-resonetics.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/27\/conversions\/david-rezac-resonetics-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/27\/conversions\/david-rezac-resonetics-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/27\/conversions\/david-rezac-resonetics-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Resonetics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/david-rezac-43079a46\/","biography":"

Driven technical leader with experience incubating medical device concepts from napkin sketch through to market introduction, launch and acquisition. Passionate about improving patient outcomes through clinically-minded concept generation and disciplined technical execution. Well versed in ISO 13485 Design Control practices and Risk Mitigation via ISO 14971.<\/p>","companies":[],"created_at":"2024-04-26T19:57:31.000000Z"},{"id":26,"name":"Patrick Anquetil","title":"CEO","photo":{"id":30,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/30\/patrick-anquetil-portal_instruments.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/30\/conversions\/patrick-anquetil-portal_instruments-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/30\/conversions\/patrick-anquetil-portal_instruments-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/30\/conversions\/patrick-anquetil-portal_instruments-large.webp"},"category":"innovators","roles":["C"],"company_name":"Portal Instruments","linkedin_profile":"https:\/\/www.linkedin.com\/in\/patrick-anquetil-780787\/","biography":"

As the Founder and CEO of Portal Instruments, Patrick Anquetil, Ph.D., MBA, leads a team of engineers, scientists, and business professionals who are developing a connected needle-free drug delivery device that improves the patient experience and adherence of injectable therapies. With over 15 years of experience in the medtech and biotech industries, Patrick has a passion for creating innovative solutions that address unmet medical needs and enhance patient outcomes.

Patrick has successfully established strategic partnerships with leading pharmaceutical companies, such as Takeda, LEO Pharma, and Sanofi, to launch combination products with Portal's needle-free technology. He has also raised over $60 million in venture capital and non-dilutive funding to support Portal's growth and development. Prior to founding Portal, Patrick co-founded SynapDx, an autism diagnostic company, and Aretais, a blood glucose monitoring venture. He also worked as a science and nanotechnology equity research analyst at Susquehanna International Group. Patrick holds a doctorate in bio-instrumentation from MIT, an MBA from Harvard Business School, and a master's degree from ETH Zurich and the University of Tokyo. He has published his scientific work in peer-reviewed journals and mainstream media, and has been featured in MIT Technology Review, Wired Magazine, PBS, and CNBC.<\/p>","companies":[{"id":2,"name":"Portal Instruments","logo":{"id":31,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/31\/portal_instruments_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/31\/conversions\/portal_instruments_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/31\/conversions\/portal_instruments_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/31\/conversions\/portal_instruments_logo-large.webp"},"type":"presenter","description":"

Portal Instruments is developing a needle-free technology for the delivery of biologics. The handheld device is capable of delivering small and large molecules through subcutaneous, intradermal and intramuscular tissue layers. Portal's technology will improve the patient experience, providing greater comfort during drug administration.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-04-26T20:22:24.000000Z"}],"created_at":"2024-04-26T20:19:57.000000Z"},{"id":27,"name":"Alan Lucas","title":"CEO","photo":{"id":342,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/342\/7caffe67-c953-43e0-ac22-f9a3c9c68302.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/342\/conversions\/7caffe67-c953-43e0-ac22-f9a3c9c68302-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/342\/conversions\/7caffe67-c953-43e0-ac22-f9a3c9c68302-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/342\/conversions\/7caffe67-c953-43e0-ac22-f9a3c9c68302-large.webp"},"category":"innovators","roles":["C"],"company_name":"Navigation Sciences","linkedin_profile":"https:\/\/www.linkedin.com\/in\/alandlucas\/","biography":"

Alan has served in senior business development and marketing positions at development stage and emerging medical technology companies for more than 25 years. He has global senior management experience enhancing investor value, including execution of successful fund raising through IPOs, private placements, and cross border M&A transactions. His experience includes work at Alira Health, EnlightenVue, Simplicity Orthopedics, ABIOMED, Implant Sciences, Kirschner Orthopedics and ACUFEX MicroSurgical.<\/p>","companies":[{"id":4,"name":"Navigation Sciences","logo":{"id":33,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/33\/navigation_sciences_inc_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/33\/conversions\/navigation_sciences_inc_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/33\/conversions\/navigation_sciences_inc_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/33\/conversions\/navigation_sciences_inc_logo-large.webp"},"type":"presenter","description":"

Navigation Sciences™ is a clinical-stage company developing the NaviSci™ System for the tissue conserving removal of lung cancer and other soft tissue tumors. The system integrates Augmented Reality (AR) and advanced software with surgical hardware to guide precise surgical resection by enabling for the first time, real-time in-vivo margin measurement.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-04-26T20:32:33.000000Z"}],"created_at":"2024-04-26T20:38:05.000000Z"},{"id":29,"name":"Berk Tas","title":"CEO","photo":{"id":38,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/38\/berk-tas-sentiAR.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/38\/conversions\/berk-tas-sentiAR-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/38\/conversions\/berk-tas-sentiAR-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/38\/conversions\/berk-tas-sentiAR-large.webp"},"category":"innovators","roles":["C"],"company_name":"SentiAR","linkedin_profile":"https:\/\/www.linkedin.com\/in\/berk-tas-ab537722\/","biography":"

Mr. Tas will share the story of SentiAR at the Emerging Medtech Summit and will provide updates on strategic partnering and investment opportunities.<\/p>\r\n

Berk serves as the Chief Executive Officer and President of SentiAR. Berk has led development of emerging technologies and companies in Fortune 500, private equity, venture capital funded and privately held organizations. Prior to joining SentiAR he led the development of a novel Trans-aortic Valve Replacement technology into CE Mark studies at HLT Medical. In 2016, he played an integral role in the acquisition of Sensium, Oxford UK, a novel wireless monitoring technology. Prior to that he served in various leadership roles at Sunshine Heart developing a first of its kind, heart failure therapy and at Boston Scientific developing several novel therapies and technologies focused in Cardiac Rhythm Management. He holds an MBA from the Carlson School of Business at the University of Minnesota and a BS in Electrical Engineering and Physics from the School of Engineering at St Thomas University.<\/p>","companies":[{"id":6,"name":"SentiAR","logo":{"id":37,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/37\/sentiAR.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/37\/conversions\/sentiAR-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/37\/conversions\/sentiAR-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/37\/conversions\/sentiAR-large.webp"},"type":"presenter","description":"

Transforming the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-04-26T20:45:59.000000Z"}],"created_at":"2024-04-26T20:46:59.000000Z"},{"id":30,"name":"Yossi Bar","title":"CEO","photo":{"id":39,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/39\/yossi-bar-lemsurgical.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/39\/conversions\/yossi-bar-lemsurgical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/39\/conversions\/yossi-bar-lemsurgical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/39\/conversions\/yossi-bar-lemsurgical-large.webp"},"category":"innovators","roles":["C"],"company_name":"LEM Surgical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/yossi-bar-b701b524\/","biography":"

Innovative leader with diverse experience in design and commercialization of robotic medical device products.
Experienced with multilayered product’s market definitions and up-stream product's strategy establishment.
Hands-on experience with recruiting and managing diverse and multidisciplinary teams.<\/p>","companies":[{"id":7,"name":"LEM Surgical","logo":{"id":40,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/40\/lem_surgical_ag_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/40\/conversions\/lem_surgical_ag_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/40\/conversions\/lem_surgical_ag_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/40\/conversions\/lem_surgical_ag_logo-large.webp"},"type":"presenter","description":"

LEM Surgical is focused on creating and providing the next generation of robotic surgical systems. The company's flagship product, the Dynamis System, is a multi-arm robotic surgical system that incorporates novel navigation capabilities and has an open architecture for handling concentric tools. Dynamis is intended to be a platform technology for orthopedic and neurosurgical applications.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-04-26T20:55:38.000000Z"}],"created_at":"2024-04-26T20:51:22.000000Z"},{"id":31,"name":"Patryk Kania","title":"CEO and President","photo":{"id":42,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/42\/patryk-kania-field_orthopaedics.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/42\/conversions\/patryk-kania-field_orthopaedics-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/42\/conversions\/patryk-kania-field_orthopaedics-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/42\/conversions\/patryk-kania-field_orthopaedics-large.webp"},"category":"innovators","roles":["C"],"company_name":"Field Orthopaedics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/patryk-j-kania-7bb5727\/","biography":"

Patryk Kania is a seasoned leader with over 20 years of experience in the healthcare industry across Europe, APAC, and the US. As CEO and President USA of Field Orthopaedics Pty Ltd., he drives the company's strategy to reinvent orthopaedic hand surgery. Under his leadership, Patryk has led Field Orthopaedics to become a revenue-stage company, poised for global growth. His focus on innovation, talent, and growth underscores his commitment to improving patient care.<\/p>","companies":[{"id":8,"name":"Field Orthopaedics","logo":{"id":41,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/41\/field_orthopaedics.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/41\/conversions\/field_orthopaedics-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/41\/conversions\/field_orthopaedics-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/41\/conversions\/field_orthopaedics-large.webp"},"type":"presenter","description":"

Field Orthopaedics is dedicated to developing innovative products to meet the needs of complex fracture management, arthritis and microsurgery. The company's portfolio of cannulated screws and intramedullary nailing system address the challenges critical to advancing hand surgery.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-04-26T21:02:22.000000Z"}],"created_at":"2024-04-26T21:03:55.000000Z"},{"id":32,"name":"David Constantine","title":"CEO","photo":{"id":44,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/44\/david-constantine-juniper.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/44\/conversions\/david-constantine-juniper-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/44\/conversions\/david-constantine-juniper-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/44\/conversions\/david-constantine-juniper-large.webp"},"category":"innovators","roles":["C"],"company_name":"Juniper Biomedical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/davidnconstantine\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":9,"name":"Juniper Biomedical","logo":{"id":43,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/43\/juniper_biomedical.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/43\/conversions\/juniper_biomedical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/43\/conversions\/juniper_biomedical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/43\/conversions\/juniper_biomedical-large.webp"},"type":"presenter","description":"

Juniper Biomedical is developing a precision neuromodulation micro-implant to treat pelvic health conditions.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-04-26T21:09:18.000000Z"}],"created_at":"2024-04-26T21:11:33.000000Z"},{"id":33,"name":"Monica Wellejus","title":"CCO","photo":{"id":1727,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1727\/monica-wellejus-ossiform.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1727\/conversions\/monica-wellejus-ossiform-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1727\/conversions\/monica-wellejus-ossiform-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1727\/conversions\/monica-wellejus-ossiform-large.webp"},"category":"innovators","roles":["C"],"company_name":"Ossiform","linkedin_profile":"https:\/\/www.linkedin.com\/in\/monicawellejus\/","biography":"

I'm a forward-looking commercial leader with international industry experience in medical devices and biotech – well versed in musculoskeletal product innovation, upstream marketing, and medtech market dynamics and strategies.

As the CCO at Ossiform®, I oversee all commercial and go-to-market activities relating to our R&D products and medical devices, respectively, and I lead a small team of talented sales and marketing professionals. Additionally, I am fortunate to work with a fantastic group of seasoned industry advisors and clinical partners.

My professional expertise lies in the disciplines of business strategy and commercialization which I practice through:
- a deep understanding of customers' and end-users' needs as well as market trends and dynamics
- evidence-based marketing and product management
- strong ties with clinical KOLs
- value creation & demonstration strategies
- strategic leadership: bringing innovative solutions to life
- a persistently high level of tenacity, vision, and agility

Driven to help shape a better world for people and animals through science, innovation, and compassion <\/p>","companies":[{"id":10,"name":"Ossiform","logo":{"id":46,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/46\/ossiform.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/46\/conversions\/ossiform-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/46\/conversions\/ossiform-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/46\/conversions\/ossiform-large.webp"},"type":"presenter","description":"

Ossiform<\/span> is the developer of fully resorbable patient-matched implants, tailored to improve bone healing outcomes in orthopedics and spine. According to Ossiform<\/span>: We Print Bone™.<\/span><\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-04-26T21:17:34.000000Z"}],"created_at":"2024-04-26T21:16:20.000000Z"},{"id":35,"name":"Gopal K. Chopra","title":"Co-CEO","photo":{"id":50,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/50\/gopal-chopra-cdx.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/50\/conversions\/gopal-chopra-cdx-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/50\/conversions\/gopal-chopra-cdx-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/50\/conversions\/gopal-chopra-cdx-large.webp"},"category":"innovators","roles":["C"],"company_name":"CDX Medical Technologies","linkedin_profile":"https:\/\/www.linkedin.com\/in\/gopalkchopra\/","biography":"

Dr. Chopra MD, MBA, FRACS, is an experienced neurosurgeon and entrepreneur with more than 20 years of strategic advisory, investment, clinical research and operational experience in the healthcare sector across the medical device, diagnostic, services, information technology and pharma verticals. Dr. Chopra has worked with early stage as well as large cap private and public companies in developed and emerging markets and is is the co-founder, managing partner of TCG, an executive accelerator focused on cutting edge smart and personalized medical and wellness technologies.<\/p>","companies":[{"id":12,"name":"CDX Medical Technologies","logo":{"id":49,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/49\/CDX-MedicalTechnologies.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/49\/conversions\/CDX-MedicalTechnologies-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/49\/conversions\/CDX-MedicalTechnologies-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/49\/conversions\/CDX-MedicalTechnologies-large.webp"},"type":"presenter","description":"

CDX is a compact portable extracorporeal bypass pump for partial cardio-pulmonary support, adaptable to multiple circuit configurations including oxygenators. CDX's technology is an innovative, light-weight support system with multiple power options. The CDX pump platform is a disposable cartridge combined with a re-useable controller and stator. The entire system is less than 6 pounds in weight and can be primed and ready to support in less than 2 minutes.<\/p>\r\n

visit website<\/em><\/a><\/p>","created_at":"2024-04-26T21:27:54.000000Z"}],"created_at":"2024-04-26T21:29:15.000000Z"},{"id":36,"name":"Henry (Chip) Appelbaum","title":"President & CEO","photo":{"id":52,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/52\/Henry-(Chip)-Appelbaum---Novian-Health.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/52\/conversions\/Henry-(Chip)-Appelbaum---Novian-Health-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/52\/conversions\/Henry-(Chip)-Appelbaum---Novian-Health-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/52\/conversions\/Henry-(Chip)-Appelbaum---Novian-Health-large.webp"},"category":"innovators","roles":["C"],"company_name":"Novian Health","linkedin_profile":"https:\/\/www.linkedin.com\/in\/chip-appelbaum-73ab74\/","biography":"

Mr. Appelbaum has more than 25 years of life sciences & biotech experience, including business development, marketing, sales, and management. He was appointed President & CEO of Novian Health in 2005 and has led the development of an image-guided, laser ablation therapy for treating tumors. He has successfully raised over $20 million and led the development of Novian’s manufacturing operations.<\/p>\r\n

Previously, Chip spent five years as Vice President of Corporate Development at Source Precision Medicine, a molecular diagnostics startup he helped found and nine years at Amgen where he managed the business development department and then led the Infergen® launch team. Prior to Amgen, he served in a technology transfer role at Argonne National Laboratory and conducted contract research at Battelle. He holds an MBA from the University of Chicago and an S.M. in Chemical Engineering from MIT.<\/p>","companies":[{"id":13,"name":"Novian Health","logo":{"id":51,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/51\/Novian-Health-Logo.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/51\/conversions\/Novian-Health-Logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/51\/conversions\/Novian-Health-Logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/51\/conversions\/Novian-Health-Logo-large.webp"},"type":"presenter","description":"

Novian Health has developed a laser-based system for the treatment of tumors. The technology is intended to be a minimally invasive alternative to surgery in select cancerous and non-cancerous tumors. Novian has received the CE Mark for the treatment of malignant and benign breast tumors. The company's Novilase technology is currently cleared in the US for the treatment of benign breast tumors and soft tissue ablation.<\/p>\r\n

Visit website<\/a>.<\/em><\/p>","created_at":"2024-04-26T21:31:30.000000Z"}],"created_at":"2024-04-26T21:32:38.000000Z"},{"id":37,"name":"Olivier Delporte","title":"CEO","photo":{"id":348,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/348\/oliver-delporte-2023.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/348\/conversions\/oliver-delporte-2023-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/348\/conversions\/oliver-delporte-2023-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/348\/conversions\/oliver-delporte-2023-large.webp"},"category":"innovators","roles":["C"],"company_name":"SamanTree Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/olivier-delporte-3229a3\/","biography":"

Olivier Delporte is an international executive with over 20 years of sales, marketing and general management experience, mostly in the medical device industry. He was Senior Vice President, Sales & Marketing, U.S. at PneumRx (acquired by BTG in 2015) and Vice President Commercial Operations, Sales and Marketing of Tryton Medical in Europe, Middle East and Africa. Previously, Olivier held leadership positions at Guidant Corporation and Abbott Vascular. Olivier has studied and worked in the U.S., France, Spain, and Belgium. He is currently a Director of Endotoxins Therapeutics. Olivier earned a Master’s Degree in Business from the Université Catholique de Louvain, Belgium, and a Master’s in Business Administration from The University of Chicago Booth School of Business.<\/p>","companies":[{"id":14,"name":"SamanTree Medical","logo":{"id":53,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/53\/samantree.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/53\/conversions\/samantree-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/53\/conversions\/samantree-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/53\/conversions\/samantree-large.webp"},"type":"presenter","description":"

SamanTree Medical's Histolog Scanner is a digital microscopy scanner for high-resolution imaging of the surface of fresh tissue. The device utilizes novel, ultra-fast confocal microscopy technology to enable rapid histological assessment in the operating room or pathology laboratory. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-04-26T21:35:28.000000Z"}],"created_at":"2024-04-26T21:36:34.000000Z"},{"id":38,"name":"Ken Corrado","title":"Chief Commercial Officer","photo":{"id":985,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/985\/Screenshot-2024-12-17-104941.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/985\/conversions\/Screenshot-2024-12-17-104941-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/985\/conversions\/Screenshot-2024-12-17-104941-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/985\/conversions\/Screenshot-2024-12-17-104941-large.webp"},"category":"innovators","roles":["C"],"company_name":"AGADA Medical","linkedin_profile":null,"biography":"

Over 25 years experience in the Spinal Implant Sales Arena. Ken has held key roles with Medtronic, Zimmer Spine, and has participated in introducing new novel Spinal Implant Technologies. Serial entrepreneur, investor, and owner in multiple innovative medical device companies.<\/p>","companies":[{"id":15,"name":"Agada Medical","logo":{"id":55,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/55\/agada_medical_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/55\/conversions\/agada_medical_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/55\/conversions\/agada_medical_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/55\/conversions\/agada_medical_logo-large.webp"},"type":"presenter","description":"

Agada Medical is innovating in the field of spine surgery through their development of an Enterprise AI system named THE SPINE ORACLE™. This system aims to revolutionize spine surgery planning by using anthropometric, demographic, diagnostic data, and biomechanical models to predict surgical outcomes and costs. It leverages AI to analyze spine motion, surgical simulations and force distributions, offering prescriptive and predictive analytics to reduce unnecessary surgeries by comparing various surgical options.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-04-26T21:39:07.000000Z"}],"created_at":"2024-04-26T21:42:23.000000Z"},{"id":39,"name":"Carlos Bremer","title":"President North American Division","photo":{"id":58,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/58\/carlos-bremer-brain4care.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/58\/conversions\/carlos-bremer-brain4care-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/58\/conversions\/carlos-bremer-brain4care-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/58\/conversions\/carlos-bremer-brain4care-large.webp"},"category":"innovators","roles":["C"],"company_name":"Brain4Care","linkedin_profile":"https:\/\/www.linkedin.com\/in\/carlos-bremer-7b6131\/","biography":"

Carlos is an entrepreneur and thought leader in Business\/ Innovation Strategy, Value Chain\/ Knowledge Management, and a researcher in Conscious Business\/ ESG. 
From 2003 to 2012, he was a senior partner and co-founder of Axia Value Chain consulting, and in 2017 he joined brain4care as an angel investor, knowledge management, and innovation leader. In 2022 he assumed the position of President of the North America Division in charge of developing and entering the US market.
In his career as an advisor, he would help organizations by first defining and clarifying their value proposition and, second, designing and implementing the value chain that would enable the value delivery.
Carlos has a Ph.D. University of São Paulo, Brazil, and a Post Doc in Virtual Enterprises from the Technology University of Aachen, Germany. His research focused on a Systems Thinking perspective to guide Enterprise Transformation. 
In 1999 Carlos won the “SAP Award for Best Research in America” granted by SAP Americas.<\/p>","companies":[{"id":16,"name":"Brain4Care","logo":{"id":57,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/57\/brain4care_us_logo.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/57\/conversions\/brain4care_us_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/57\/conversions\/brain4care_us_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/57\/conversions\/brain4care_us_logo-large.webp"},"type":"presenter","description":"

Brain4care offers an FDA-cleared and non-invasive Intracranial Pressure (ICP) dynamics monitoring technology, eliminating the invasiveness of the current gold standard and unlocking its applicability for patients with brain damage, beyond the ICU. By breaking down the barriers to accessibility and expanding its utility by using an AI platform, the company aims to make ICP monitoring a routine and essential part of patient care anytime and anywhere.<\/p>\r\n

Visit website<\/a>.<\/p>","created_at":"2024-04-26T22:07:21.000000Z"}],"created_at":"2024-04-26T22:09:24.000000Z"},{"id":40,"name":"Dimitri Sokolov","title":"CEO","photo":{"id":60,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/60\/dimitri-sokolov-spiro.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/60\/conversions\/dimitri-sokolov-spiro-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/60\/conversions\/dimitri-sokolov-spiro-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/60\/conversions\/dimitri-sokolov-spiro-large.webp"},"category":"innovators","roles":["C"],"company_name":"Spiro Robotics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/dimitri-sokolov-a405a611\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":17,"name":"Spiro Robotics","logo":{"id":59,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/59\/spiro-robotics.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/59\/conversions\/spiro-robotics-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/59\/conversions\/spiro-robotics-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/59\/conversions\/spiro-robotics-large.webp"},"type":"presenter","description":"

Spiro Robotics is developing an innovative handheld robot intended to automate airway management in patients requiring tracheal intubation. <\/p>\r\n

Visit website<\/a>.<\/p>","created_at":"2024-04-26T22:11:20.000000Z"}],"created_at":"2024-04-26T22:12:40.000000Z"},{"id":41,"name":"Vijit Sabnis","title":"Co-Founder","photo":{"id":62,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/62\/vijit-sabnis-adaptyx.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/62\/conversions\/vijit-sabnis-adaptyx-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/62\/conversions\/vijit-sabnis-adaptyx-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/62\/conversions\/vijit-sabnis-adaptyx-large.webp"},"category":"innovators","roles":["C"],"company_name":"Adaptyx Biosciences","linkedin_profile":"https:\/\/www.linkedin.com\/in\/vijitsabnis\/","biography":"

He has spent 20 years at the intersection of cutting-edge technology development as an inventor, entrepreneur, and investor. Vijit previously worked with Andrew and Euan while a Partner at Khosla Ventures.<\/p>\r\n

Vijit was previously a Co-founder-In-Residence at Deep Valley Labs, a hypothesis validation incubator founded by Jagdeep Singh (CEO of Quantumscape) that generates ideas and spins out companies.<\/p>\r\n

Prior to DVL, Vijit was a partner at Khosla Ventures for almost five years, where he invested in and helped build deep tech startups in biotechnology, healthcare, additive manufacturing, food technology, computation, and photonics. Vijit’s involvement included Overture Life, Genalyte, Inflammatix, Ontera, and Apton Biosystems in healthcare; Arevo, Casca, DDM Systems, and Digital Alloys in advanced manufacturing; Mojo Vision and Light Field Lab in photonics; and Commonwealth Fusion Systems and Joywell Foods in sustainability.<\/p>\r\n

Prior to Khosla Ventures, Vijit was co-founder and CEO of Solar Junction, which commercialized the world’s highest efficiency solar cells at that time. Vijit was also an early employee at Translucent, which developed new materials solutions for silicon photonics and electronics applications. Vijit received M.S. and Ph.D. degrees in Electrical Engineering from Stanford University and a B.S. in Electrical Engineering and Computer Sciences from UC Berkeley. He holds over 15 publications and 4 patents.<\/p>","companies":[{"id":18,"name":"Adaptyx Biosciences","logo":{"id":61,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/61\/Adaptyx-Logo.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/61\/conversions\/Adaptyx-Logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/61\/conversions\/Adaptyx-Logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/61\/conversions\/Adaptyx-Logo-large.webp"},"type":"presenter","description":"

Adaptyx Biosciences, a Stanford University spin-off, is building a biomonitoring platform that leverages 15 years of research in molecular switches and microarray patches, enabling minimally-invasive real-time, continuous sensing of small molecules and proteins. Adaptyx's library of multi-analyte sensors will enable deeply personalized medicine across drug dosing, hormone regulation, kidney health, cardiovascular disease, and oncology.<\/p>","created_at":"2024-04-26T22:16:13.000000Z"}],"created_at":"2024-04-26T22:17:21.000000Z"},{"id":42,"name":"Mark Salley","title":"CEO","photo":{"id":65,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/65\/Screenshot-2024-04-26-152321.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/65\/conversions\/Screenshot-2024-04-26-152321-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/65\/conversions\/Screenshot-2024-04-26-152321-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/65\/conversions\/Screenshot-2024-04-26-152321-large.webp"},"category":"innovators","roles":["C"],"company_name":"Alara Med","linkedin_profile":"https:\/\/www.linkedin.com\/in\/mark-salley-2b5773239\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":19,"name":"Alara Med","logo":{"id":66,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/66\/alaramed.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/66\/conversions\/alaramed-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/66\/conversions\/alaramed-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/66\/conversions\/alaramed-large.webp"},"type":"presenter","description":"

The cumulative exposure to ionizing radiation during medical procedures poses serious health risks to patients, surgical staff, and surgeons. AlaraMed is rethinking radiation safety with a portfolio of products designed to reduce unnecessary radiation exposure. The company’s lead product is a device for endoscopic kidney surgery and other fluoroscopy procedures that reduces fluoroscopy time by ~80%. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-17T22:26:36.000000Z"}],"created_at":"2024-04-26T22:21:40.000000Z"},{"id":47,"name":"Augustine Lien","title":"CEO","photo":{"id":74,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/74\/augistine-lien-aulisa.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/74\/conversions\/augistine-lien-aulisa-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/74\/conversions\/augistine-lien-aulisa-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/74\/conversions\/augistine-lien-aulisa-large.webp"},"category":"innovators","roles":["C"],"company_name":"Aulisa Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/augustine-augie-lien-3aa9541a\/","biography":"

Augie Lien is a successful serial entrepreneur in the medical devices field. He is most recently founder, Chairman, and CEO of Taiwan Aulisa Medical Device Technologies, Inc, which develops wireless, wearable FDA cleared vitals monitoring systems for at home use as well as systems integration at the healthcare institution level. By combining medical device sciences and information communication technologies, Aulisa’s proprietary innovations address unmet needs in the medical field and technological and operational trends within the healthcare industry.<\/p>\r\n

Augie’s prior start-ups include Nellcor (IPO and subsequently acquired by Medtronic), which provides patient monitoring; Menlo Care (merged with Johnson and Johnson Medical), focusing on Hospital supplies; Gynecare (IPO and then acquire by Johnson and Johnson\/Ethicon), addressing Gynecology Surgery needs; and EPI (acquired by Boston Scientific), which focuses on interventional Cardiology. These start-ups have all been acquired by multi-national companies or had an IPO in the US stock market. His fifth company, Cardiva Medical, is a successful interventional cardiology company which has been acquired by Haemonetics recently in February 2021.<\/p>\r\n

Augie holds an MBA from the University of Santa Clara and an MS from Stanford University. He also graduated with an MA from National Chen Chi University and a BS from National Cheng Kung University, both in Taiwan.<\/p>","companies":[{"id":22,"name":"Aulisa Medical","logo":{"id":69,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/69\/Aulisa.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/69\/conversions\/Aulisa-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/69\/conversions\/Aulisa-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/69\/conversions\/Aulisa-large.webp"},"type":"presenter","description":"

Aulisa specializes in the development and commercialization of wearable solutions for continuous remote monitoring of patient vitals. The company's proprietary technology continuously monitors vital signs to identify health incidents prior to them occurring. Rapid spot-checking of patient vitals allows the device to alert providers and parents to health incidents, expanding the window in which appropriate treatment and care can be delivered. The company's flagship product, the Guardian Angel RX system, has been adapted for use in infants, children, and adults.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-04-26T22:33:12.000000Z"}],"created_at":"2024-04-26T22:37:51.000000Z"},{"id":48,"name":"Jim O'Connor","title":"General Counsel & Chief Financial Officer","photo":{"id":1325,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1325\/jim-oconnor-axena.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1325\/conversions\/jim-oconnor-axena-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1325\/conversions\/jim-oconnor-axena-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1325\/conversions\/jim-oconnor-axena-large.webp"},"category":"innovators","roles":["C"],"company_name":"Axena Health","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jim-oconnor\/","biography":"

With over 20 years of business and legal experience in various sectors, I am a versatile and strategic leader who can drive growth, innovation, and compliance in complex and dynamic environments. As the General Counsel and Chief Financial Officer at Axena Health, a commercial-stage medical device company focused on pelvic floor disorders, I lead multiple functions, including legal, compliance, intellectual property, finance, corporate governance, investor relations, corporate business development, human resources, privacy, and information technology. I am passionate about leveraging my multidisciplinary skills and knowledge to create value, solve problems, and advance the mission and vision of Axena Health.

Prior to joining Axena Health, I held several roles of increasing responsibility at United Technologies Corp. (UTC), a Fortune 50 company, where I gained exposure to diverse industries, such as technology, renewable energy, and building systems. I served as the Chief of Staff for UTC's $29B commercial business unit and Deputy General Counsel for Carrier Corporation. My UTC responsibilities included legal, compliance, antitrust, mergers and acquisitions, joint ventures, technology licensing, litigation management, and corporate governance.<\/p>","companies":[{"id":23,"name":"Axena Health","logo":{"id":76,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/76\/axena_health_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/76\/conversions\/axena_health_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/76\/conversions\/axena_health_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/76\/conversions\/axena_health_logo-large.webp"},"type":"presenter","description":"

Axena Health is dedicated to improving the lives of women with pelvic floor disorders. The company's Leva Pelvic Health system helps women train and strengthen their pelvic floor muscles from their homes to improve the management of stress, mixed, and mild-to-moderate urinary incontinence and chronic fecal incontinence. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-04-26T22:46:31.000000Z"}],"created_at":"2024-04-26T22:44:30.000000Z"},{"id":50,"name":"Bradford Conlan","title":"CEO","photo":{"id":80,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/80\/BRADFORD_CONLAN-bimini.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/80\/conversions\/BRADFORD_CONLAN-bimini-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/80\/conversions\/BRADFORD_CONLAN-bimini-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/80\/conversions\/BRADFORD_CONLAN-bimini-large.webp"},"category":"innovators","roles":["C"],"company_name":"Bimini Health Tech","linkedin_profile":"https:\/\/www.linkedin.com\/in\/bradford-a-conlan-6804086\/","biography":"

Mr. Conlan is the co-founder of Bimini Health Tech and has served as CEO and board member since 2013.<\/p>\r\n

Mr. Conlan has over 15 years of experience in the medical device and regenerative medicine fields. He received a B.S. in Biomedical and Industrial Engineering from the University of Iowa and an M.S. in Biomedical Engineering from the University of Southern California.<\/p>","companies":[{"id":25,"name":"Bimini Health Tech","logo":{"id":79,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/79\/bimini-health.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/79\/conversions\/bimini-health-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/79\/conversions\/bimini-health-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/79\/conversions\/bimini-health-large.webp"},"type":"presenter","description":"

Bimini Healthtech is developing a diverse portfolio of regenerative technologies and therapeutics that enable people to live better lives. The company is commercializing and investigating autologous and allogenic products and therapies intended for use at the point-of-care to eliminate the need for matching patients with donors. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-04-26T23:14:13.000000Z"}],"created_at":"2024-04-26T23:16:24.000000Z"},{"id":51,"name":"David Danielsen","title":"CEO","photo":{"id":82,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/82\/David-Danielsen-CairnSurgical.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/82\/conversions\/David-Danielsen-CairnSurgical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/82\/conversions\/David-Danielsen-CairnSurgical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/82\/conversions\/David-Danielsen-CairnSurgical-large.webp"},"category":"innovators","roles":["C"],"company_name":"CairnSurgical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/dave-danielsen-1b53858\/","biography":"

General management and commercial leader in medical devices, diagnostics, imaging capital equipment, and health care IT; US Surgical, Boston Scientific, Genzyme Genetics, Hologic, Oxford Immunotec, CRA Health.<\/p>","companies":[{"id":26,"name":"CairnSurgical","logo":{"id":81,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/81\/CairnSurgical.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/81\/conversions\/CairnSurgical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/81\/conversions\/CairnSurgical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/81\/conversions\/CairnSurgical-large.webp"},"type":"presenter","description":"

CairnSurgical is developing an innovative tool to guide surgical interventions in patients with cancer. The company's Breast Cancer Locator (BCL) is a proprietary, patient-specific, 3D printed surgical guide intended to reduce positive margins during breast cancer tumor removal. The solution uses MRI data to create a personalized model that assist surgeons in localization and excision of tumors to reduce positive margins.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-04-26T23:19:51.000000Z"}],"created_at":"2024-04-26T23:22:09.000000Z"},{"id":52,"name":"Manfred Franke","title":"CEO","photo":{"id":84,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/84\/manfred-franke-neuronoff.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/84\/conversions\/manfred-franke-neuronoff-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/84\/conversions\/manfred-franke-neuronoff-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/84\/conversions\/manfred-franke-neuronoff-large.webp"},"category":"innovators","roles":["C"],"company_name":"Neuronoff","linkedin_profile":"https:\/\/www.linkedin.com\/in\/dr-franke\/","biography":"

Entrepreneur with Research Background, developing class II and III medical devices to restore and improve (augment) organ function using minimally-invasive Neuromodulation.

EXPERIENCE:
• Leadership by Value, Principles, and Data. No dogma.
• Startup (Neuronoff, Oculeve) and Big Corp (Allergan, Boston Scientific).
• Conceived and developed implantable & topical neuromodulation devices.
• Extensive Clinical (incl. FDA pivotal) and Pre-Clinical experience, designing IRB \/ IACUC cleared protocols & executing studies. Designed or actively cut in 50+ acute and chronic surgeries.
• 59 GRANTED Patents.
• Lead inventor on ~136 out of ~194 patent applications. To date only 4 dropped ones.

RESPONSIBILITIES
• Ran MoA studies for Oculeve\/Allergan TrueTear. Conveyed Value to Clin & Marketing.
• Designed and\/or executed 10 Clinical Studies in 5 countries world-wide. Multilingual.
• Defined new Clinical Label by optimizing Neuromod Therapy, doubling Market Value.
• Co-Development of regulatory pathway, reimbursement strategy, and Marketing \/ PR pitches.
• Headed the Pre-Clinical for Oculeve. Designed & executed studies to support IRB clearance.
• Co-Designed a new QA\/QMS prior to US clinical studies - ISO 13485, CE, FDA 510(k) De-Novo.
• Trained clinicians and their staff on novel neuromodulation devices and clinical data acquisition.<\/p>","companies":[{"id":27,"name":"Neuronoff","logo":{"id":83,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/83\/neuronoff.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/83\/conversions\/neuronoff-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/83\/conversions\/neuronoff-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/83\/conversions\/neuronoff-large.webp"},"type":"presenter","description":"

Neuronoff is developing an injectable electrode platform that is an adaptive, minimally invasive technology that transforms complex neuromodulation procedures into simple outpatient procedures. The Injectrode technology enables the electrical stimulation of hard to reach nerves and tissues using an 18 ga needle and self-anchor to prevent lead migration.<\/p>\r\n

Visit website<\/a><\/em>.<\/p>","created_at":"2024-04-26T23:24:55.000000Z"}],"created_at":"2024-04-26T23:26:42.000000Z"},{"id":53,"name":"Nora Herzog","title":"CMO","photo":{"id":1709,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1709\/nora-herzog-conncons.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1709\/conversions\/nora-herzog-conncons-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1709\/conversions\/nora-herzog-conncons-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1709\/conversions\/nora-herzog-conncons-large.webp"},"category":"innovators","roles":["C"],"company_name":"ConnCons","linkedin_profile":"https:\/\/www.linkedin.com\/in\/nora-herzog-563ab6239\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":28,"name":"ConnCons","logo":{"id":88,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/88\/ConnCons-Logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/88\/conversions\/ConnCons-Logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/88\/conversions\/ConnCons-Logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/88\/conversions\/ConnCons-Logo-large.webp"},"type":"presenter","description":"

ConnCons integrates connectivity into infusion consumables to create a cloud to vessel end-to-end digital solution. The system enables safer, faster and automated therapies with a superior patient experience. First clinical applications are targeted at both center-based and home oncological therapy.<\/p>\r\n

Visit website<\/a>.<\/em><\/p>","created_at":"2024-04-29T23:24:14.000000Z"}],"created_at":"2024-04-29T23:23:20.000000Z"},{"id":57,"name":"Richard Hughen","title":"CEO","photo":{"id":95,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/95\/Richard-Hughen-Linshom.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/95\/conversions\/Richard-Hughen-Linshom-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/95\/conversions\/Richard-Hughen-Linshom-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/95\/conversions\/Richard-Hughen-Linshom-large.webp"},"category":"innovators","roles":["C"],"company_name":"Linshom Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/richardhughen\/","biography":"

Mr. Richard Hughen is a high impact executive leader, business builder with start-up, small-cap, and fortune 100 experience, innovative thinker and creative problem solver with expertise in building shareholder value, milestone achievement with unrelenting focus, leading complex, cross-functional teams, marketing strategy and business development, product development and commercialization, trial, regulatory and reimbursement strategy, international market development and launch, sales - management and operations, intellectual property and licensing, fund raising - equity and debt, licensing and intellectual property.<\/p>","companies":[{"id":31,"name":"Linshom Medical","logo":{"id":94,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/94\/LINSHOM.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/94\/conversions\/LINSHOM-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/94\/conversions\/LINSHOM-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/94\/conversions\/LINSHOM-large.webp"},"type":"presenter","description":"

Linshom (“to breathe”) is first to deliver an Operating Room quality respiratory profile to the patient bedside and home for continuous, predictive respiratory monitoring (CPRM). Our FDA cleared device provides a full respiratory profile delivered continuously and in real time to predict and intercept respiratory decline before an emergency develops.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-04-30T00:15:00.000000Z"}],"created_at":"2024-04-30T00:16:32.000000Z"},{"id":58,"name":"Michael Goeree","title":"Founder & Chairman","photo":{"id":96,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/96\/michael-goeree-medfiniti.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/96\/conversions\/michael-goeree-medfiniti-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/96\/conversions\/michael-goeree-medfiniti-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/96\/conversions\/michael-goeree-medfiniti-large.webp"},"category":"innovators","roles":["C"],"company_name":"Medfiniti","linkedin_profile":"https:\/\/www.linkedin.com\/in\/michael-j-goeree-0516109\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":32,"name":"Medfiniti","logo":{"id":97,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/97\/medfiniti.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/97\/conversions\/medfiniti-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/97\/conversions\/medfiniti-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/97\/conversions\/medfiniti-large.webp"},"type":"presenter","description":"

Medfiniti is focused on specialized medtech solutions to market through expertise in business strategy and M&A. It's lead portfolio company, HemWell MD, is pioneering an electrosurgical procedure for the treatment of symptomatic hemorrhoids. Performed in an outpatient setting, the device ligates hemorrhoids to provide rapid relief to patients in less. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-04-30T00:22:50.000000Z"}],"created_at":"2024-04-30T00:21:02.000000Z"},{"id":59,"name":"Ana Maiques","title":"CEO","photo":{"id":351,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/351\/Maiques.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/351\/conversions\/Maiques-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/351\/conversions\/Maiques-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/351\/conversions\/Maiques-large.webp"},"category":"innovators","roles":["C"],"company_name":"Neuroelectrics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ana-maiques-b0a0682\/","biography":"

Ms. Maiques will share the story of Neuroelectrics at the Emerging Medtech Summit and discuss strategic partnering and investment opportunities.<\/p>\r\n

Ana is the CEO of Neuroelectrics, a company aiming to change the way we interact with the brain; developing innovative technologies to monitor and stimulate the brain. She was nominated by IESE as one of the most influential entrepreneurs under 40 in Spain in 2010, she was the only woman on that list. She received the EU Prize for Women Innovators from the European Commission EC in 2014. Also in 2014, she was an award recipient of the International Women’s Entrepreneurial Challenge. In 2015 & 2016, she was named one of most inspiring women on the Inspiring Fifty list in Europe of women technological leaders and innovators. As a company, Neuroelectrics received the Best Start-up in Health Award in 2015 by Wired UK magazine and in 2016 was recognized as one of the “Best Entrepreneurial Companies in America” by Entrepreneur Magazine’s Entrepreneur 360™ List, the most comprehensive analysis of private companies in America. Ana continues to break the barriers for women and entrepreneurs bringing together science and technology in an impactful way.<\/p>","companies":[{"id":33,"name":"Neuroelectrics","logo":{"id":98,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/98\/neuroelectrics.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/98\/conversions\/neuroelectrics-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/98\/conversions\/neuroelectrics-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/98\/conversions\/neuroelectrics-large.webp"},"type":"presenter","description":"

Diagnostic and treatment telemedicine wireless platforms based on Starstim and Enobio, combining multichannel transcranial current stimulation such as tDCS with EEG.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-01T19:56:04.000000Z"}],"created_at":"2024-05-01T19:57:14.000000Z"},{"id":61,"name":"Brian Kannard","title":"Founder","photo":{"id":103,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/103\/BRIAN-KANNARD_PercuSense.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/103\/conversions\/BRIAN-KANNARD_PercuSense-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/103\/conversions\/BRIAN-KANNARD_PercuSense-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/103\/conversions\/BRIAN-KANNARD_PercuSense-large.webp"},"category":"innovators","roles":["C"],"company_name":"PercuSense","linkedin_profile":"https:\/\/www.linkedin.com\/in\/briantkannard\/","biography":"

More than a decade of experience leading cross-functional glucose sensor development teams, previously led product development of sensors and connected devices.<\/p>","companies":[{"id":35,"name":"PercuSense","logo":{"id":102,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/102\/percusense.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/102\/conversions\/percusense-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/102\/conversions\/percusense-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/102\/conversions\/percusense-large.webp"},"type":"presenter","description":"

PercuSense’s continuous multi-analyte sensor system combines monitoring of multiple biosensors with knowledge of how diseases and illness progress to intelligently and proactively recommend treatment.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-01T20:05:05.000000Z"}],"created_at":"2024-05-01T20:06:22.000000Z"},{"id":62,"name":"Richard Hanbury","title":"CEO","photo":{"id":105,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/105\/richard-hanbury-sanahealth.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/105\/conversions\/richard-hanbury-sanahealth-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/105\/conversions\/richard-hanbury-sanahealth-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/105\/conversions\/richard-hanbury-sanahealth-large.webp"},"category":"innovators","roles":["C"],"company_name":"Sana Health","linkedin_profile":"https:\/\/www.linkedin.com\/in\/richard-hanbury\/","biography":"

Richard will share the story of SANA Health at the Emerging Medtech Summit and discuss partnering and investment objectives.<\/p>\r\n

With an MBA in Healthcare and Entrepreneurial Studies from Wharton Business School, Hanbury went on to become the founder of Sana, a device that allows anyone to have deep relaxation and pain relief anywhere in an average of 8-10 mintues. Sana has decades of research and anecdotal data and has just complete their first internal controlled trial. <\/p>","companies":[{"id":36,"name":"Sana Health","logo":{"id":104,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/104\/sana-health.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/104\/conversions\/sana-health-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/104\/conversions\/sana-health-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/104\/conversions\/sana-health-large.webp"},"type":"presenter","description":"

Non-invasive bio-therapeutic device for pain management.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-01T20:08:42.000000Z"}],"created_at":"2024-05-01T20:12:25.000000Z"},{"id":63,"name":"Roberta Lee","title":"CEO","photo":{"id":1022,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1022\/roberta-lee-sonofii-cropped.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1022\/conversions\/roberta-lee-sonofii-cropped-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1022\/conversions\/roberta-lee-sonofii-cropped-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1022\/conversions\/roberta-lee-sonofii-cropped-large.webp"},"category":"innovators","roles":["C"],"company_name":"Sonofii","linkedin_profile":"https:\/\/www.linkedin.com\/in\/roberta-lee-86a41211\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":37,"name":"Sonofii","logo":{"id":106,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/106\/sonofii.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/106\/conversions\/sonofii-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/106\/conversions\/sonofii-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/106\/conversions\/sonofii-large.webp"},"type":"presenter","description":"

Sonofii has developed a Dynamic Dual Therapy to treat intractable soft tissue infections. The company's first clinical trial had an 80% success in curing infections that failed conventional therapy. In this multi billion dollar market, Sonofii is poised to advance treatment, improve patients’ lives and significantly reduce costs to the health care system.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-01T20:16:08.000000Z"}],"created_at":"2024-05-01T20:17:37.000000Z"},{"id":64,"name":"Upma Sharma","title":"President & CEO","photo":{"id":110,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/110\/upma-sharma_arsenal_medical.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/110\/conversions\/upma-sharma_arsenal_medical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/110\/conversions\/upma-sharma_arsenal_medical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/110\/conversions\/upma-sharma_arsenal_medical-large.webp"},"category":"innovators","roles":["C"],"company_name":"Arsenal Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/upmasharmaphd\/","biography":"

I have dedicated my career to study of the intersection of materials science and medicine with the goal of creating products to improve patients’ lives. At Arsenal Medical, I have led the development of our in situ forming foam platform. This exciting technology platform has commercial application in treating severely injured patients with abdominal hemorrhage through our ResQFoam product. I have managed ResQFoam from concept through development, securing $25M from the DOD (through DARPA and ARO). I was also the PI and inventor of an Arsenal technology that has enabled the scale up of electrospinning fibers, supported by $2.3M from NIST.

At 480 Biomedical, I was on the team that developed a novel bioresorbable scaffold technology to treat peripheral arterial disease. Through this novel composite design, we were able to achieve properties similar to metal stents, with a stent that is fully absorbable. I drove initial materials selection and oversaw preliminary drug delivery formulations. I also spearheaded the submission of a Fast-Track SBIR, resulting in a $1.7M award and initiating the development of our stent for pediatric pulmonary artery stenosis. Additionally, I oversaw our application for funding from Broadview Ventures, resulting in an additional $1.2M for the pediatric stent program.

My key areas of expertise:

--Grant Writing: Directed ideation and led the submission of government proposals resulting in over $27M of funding from DARPA and NIH

--Product Development: Led development and execution of our ResQFoam product including regulatory strategy and submissions, design control process and contract manufacturing, project timeline and budget, and establishment of a world-class advisory board

--Technical Management: Managed R&D group of up to 10 engineers & technicians

--Intellectual Property: Inventor on more than 25 pending or issued patents

--Publications: Authored 18 peer-reviewed scientific publications and 30+ presentations<\/p>","companies":[{"id":39,"name":"Arsenal Medical","logo":{"id":109,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/109\/arsenalmedical_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/109\/conversions\/arsenalmedical_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/109\/conversions\/arsenalmedical_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/109\/conversions\/arsenalmedical_logo-large.webp"},"type":"presenter","description":"

Arsenal Medical develops purpose-built biomaterials to solve challenging and underserved medical problems. Our lead products target neurovascular and trauma conditions providing control of blood flow to tumors and hemorrhage. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-01T20:21:28.000000Z"}],"created_at":"2024-05-01T20:22:44.000000Z"},{"id":66,"name":"Rob Krummen","title":"CEO","photo":{"id":113,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/113\/rob-krummen-vektor.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/113\/conversions\/rob-krummen-vektor-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/113\/conversions\/rob-krummen-vektor-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/113\/conversions\/rob-krummen-vektor-large.webp"},"category":"innovators","roles":["C"],"company_name":"Vektor Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/robertkrummen\/","biography":"

For nearly two decades, Rob has served in a variety of roles, leading and advising corporations, nonprofits, institutions of higher education, and state entities. Before being appointed CEO he served as president and chief operating officer at Vektor, where he led clinical, regulatory, engineering, and operations. Rob is a former partner at Vorys, Sater, Seymour and Pease LLP and a former Deputy Solicitor General for the State of Ohio. He had the privilege of clerking for the Honorable R. Guy Cole of the United States Court of Appeals for the Sixth Circuit. Rob earned his JD from Harvard Law School.<\/p>","companies":[{"id":40,"name":"Vektor Medical","logo":{"id":111,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/111\/Vektor-Medical.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/111\/conversions\/Vektor-Medical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/111\/conversions\/Vektor-Medical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/111\/conversions\/Vektor-Medical-large.webp"},"type":"presenter","description":"

Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-based, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency.<\/p>\r\n

Visite website<\/em><\/a>.<\/p>","created_at":"2024-05-01T20:25:12.000000Z"}],"created_at":"2024-05-01T20:27:32.000000Z"},{"id":67,"name":"Rick O'Connor","title":"CEO","photo":{"id":115,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/115\/rick-oconnor-invicta.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/115\/conversions\/rick-oconnor-invicta-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/115\/conversions\/rick-oconnor-invicta-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/115\/conversions\/rick-oconnor-invicta-large.webp"},"category":"innovators","roles":["C"],"company_name":"Restera","linkedin_profile":"https:\/\/www.linkedin.com\/in\/rickoconnor1\/","biography":"

Rick is a proven executive in the medical device industry, having successfully developed and commercialized innovative products at both industry-leading public corporations and privately funded start-up entities. Most recently as SVP, Technology and Development at Triple Ring Technologies, Rick led all business units and R&D and brought multiple incubated medical technologies to production. In the pain management field, Rick led the development and commercialization of the first wearable and implantable dorsal root ganglion neural stimulator (VP, Engineering and Operations at Spinal Modulation, acquired by Abbott). In the cardiac space, he developed and brought several generations of implantable cardiac defibrillators and surgical devices to market (Director of R&D at Ventritex, acquired by Abbott and Guidant Corp, acquired by Boston Scientific).<\/span><\/p>\r\n

During his 25 years in medical devices, Rick has raised multiple rounds of capital at Lectus Medical, Spinal Modulation and Triple Ring Technologies. He has led organizations through multiple acquisitions and integrations (Hill-Rom, Abbott, Boston Scientific), while successfully leading R&D, operations, quality, marketing and sales teams. Rick began his career in the United States Air Force, where he served as Captain and led F-22 and A-10 developmental flight test engineering. He has 32 issued patents, a B.S. in Aerospace Engineering from Clarkson University and an M.B.A. from the University of San Francisco.<\/span><\/p>","companies":[{"id":41,"name":"Restera","logo":{"id":680,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/680\/restera.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/680\/conversions\/restera-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/680\/conversions\/restera-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/680\/conversions\/restera-large.webp"},"type":"presenter","description":"

Restera is developing an outpatient injectable stimulation solution for all obstructive sleep apnea (OSA) indications. The company's<\/span> disruptive, injectable, dual-target stimulation solution offers immediate and unrivaled therapy. Their landmark published therapy won the 2024 best abstract award. Founded by serial entrepreneurs with multiple exits.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-02T19:49:59.000000Z"}],"created_at":"2024-05-02T19:52:19.000000Z"},{"id":68,"name":"Stuart Simpson","title":"CEO","photo":{"id":352,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/352\/THINK_Surgical_Inc_Stuart_Simpson.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/352\/conversions\/THINK_Surgical_Inc_Stuart_Simpson-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/352\/conversions\/THINK_Surgical_Inc_Stuart_Simpson-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/352\/conversions\/THINK_Surgical_Inc_Stuart_Simpson-large.webp"},"category":"innovators","roles":["C"],"company_name":"THINK Surgical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/stuart-f-simpson\/","biography":"

Chief Executive Officer of THINK Surgical, an orthopedic robotics and digital surgery company, committed to a new business model offering more choice to physicians and their patients.

Executive chairman and board member responsible for company strategy, financing and corporate governance.

Globally experienced medical device and healthcare executive with a reputation for achieving tangible operating results.

Transformative growth leader adept at creating vision, providing strategic direction and executing ambitious plans.

Core competencies:

Global Strategy Development & Execution • Shareholder Value Creation • Top Line Growth • Efficiencies • P&L • Business Development • Sales & Marketing Leadership • Strategic Investments • Market Innovation • Research & Development • Acquisitions & Integrations • Change Management • Turnaround Management • Team Leadership • Vision & Goal Setting • Strategic Planning • Talent Development • Mentorship • Board and Board Committee Leadership<\/p>","companies":[{"id":42,"name":"THINK Surgical","logo":{"id":116,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/116\/THINK-Surgical.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/116\/conversions\/THINK-Surgical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/116\/conversions\/THINK-Surgical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/116\/conversions\/THINK-Surgical-large.webp"},"type":"presenter","description":"

THINK Surgical develops and commercializes robotic surgery systems for the orthopedics market. The company's TSolution One is indicated for total knee arthroplasty. The system is capable of fully automated bone preparation that is personalized and prepared utilizing proprietary planning tools to achieve optimal fit of the selected knee implant.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-02T19:55:49.000000Z"}],"created_at":"2024-05-02T19:57:27.000000Z"},{"id":69,"name":"Peter Vranes","title":"CEO","photo":{"id":353,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/353\/peter-vranes-co-founder-co-ceo-of-nutromics.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/353\/conversions\/peter-vranes-co-founder-co-ceo-of-nutromics-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/353\/conversions\/peter-vranes-co-founder-co-ceo-of-nutromics-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/353\/conversions\/peter-vranes-co-founder-co-ceo-of-nutromics-large.webp"},"category":"innovators","roles":["C"],"company_name":"Nutromics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/peter-vranes-085bb810\/","biography":"

Peter Vranes is a Chemical Engineer and serial entrepreneur. Peter is the co-founder of Nutromics, an Australian MedTech company revolutionising healthcare through continuous real time molecular monitoring. The company’s innovative Smart Patch biosensor platform will solve some of the biggest healthcare challenges we face today in the fields of chronic disease prevention, chronic disease management, acute diseases and Therapeutic Drug Monitoring. 

Prior to Nutromics, Peter founded Biocore Technologies and lead the team with the development and commercialisation of several natural cosmeceutical skincare brands that were distributed in 1,500 retailers throughout Australia. The company was successfully sold in 2013.<\/p>","companies":[{"id":43,"name":"Nutromics","logo":{"id":118,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/118\/nutromics.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/118\/conversions\/nutromics-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/118\/conversions\/nutromics-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/118\/conversions\/nutromics-large.webp"},"type":"presenter","description":"

Nutromics is pioneering Continuous Molecular Monitoring (CMM), a real-time biomarker monitoring platform that offers molecular patient data. The technology integrates into a wearable smart patch that continuously captures and transmits data to mobile and web-based applications for easy integration with hospital and consumer health software. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-02T19:59:56.000000Z"}],"created_at":"2024-05-02T20:00:49.000000Z"},{"id":70,"name":"Dimitrios Angelis","title":"Co-Founder","photo":{"id":243,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/243\/dimitrios-angelis-sparta.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/243\/conversions\/dimitrios-angelis-sparta-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/243\/conversions\/dimitrios-angelis-sparta-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/243\/conversions\/dimitrios-angelis-sparta-large.webp"},"category":"innovators","roles":["C"],"company_name":"Sparta Biomedical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/dimitrios-angelis-jd-8851a03\/","biography":"

Dimitrios<\/strong> has held multiple C-suite roles within large and small life science and technology organizations. In addition to being the CEO and Chairman of a publicly traded NASDAQtechnology company possessing a significant IP estate, he has served as General Counsel to several companies. He has held several leadership roles in HR, IR, Compliance, and Industrial relations. He has been instrumental in assisting several companies and entrepreneurs see their visions through to successful international companies. He currently serves as a board member of several public and private companies.<\/p>","companies":[{"id":44,"name":"Sparta Biomedical","logo":{"id":120,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/120\/sparta-biomedical.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/120\/conversions\/sparta-biomedical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/120\/conversions\/sparta-biomedical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/120\/conversions\/sparta-biomedical-large.webp"},"type":"presenter","description":"

The first osseointegrative biomimetic knee cartilage implant.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-02T20:02:52.000000Z"}],"created_at":"2024-05-02T20:05:03.000000Z"},{"id":72,"name":"Jennifer Fried","title":"CEO","photo":{"id":124,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/124\/Jennifer-Fried-Flow-Medical.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/124\/conversions\/Jennifer-Fried-Flow-Medical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/124\/conversions\/Jennifer-Fried-Flow-Medical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/124\/conversions\/Jennifer-Fried-Flow-Medical-large.webp"},"category":"innovators","roles":["C"],"company_name":"Flow Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/friedjennifer\/","biography":"

I recently joined Flow Medical as CEO and Co-Founder, where we are developing a next-generation thrombolysis catheter to treat pulmonary embolism. Learn more at www.flowmedical.co!

Previously, I was the co-founder and CEO of Explorer Surgical, a digital playbook for the operating room and procedure suites. Explorer Surgical was founded at the University of Chicago in 2015 out of a research laboratory in the Department of Surgery. After raising $10M in funding and commercializing our software to a global base of medtech and hospital customers, our company was acquired by GHX in 2021.

My passion is building innovative businesses in the healthcare industry, especially those that use technology to solve inefficiencies and improve patient care. I invest personal capital as well as institutional as a Partner in Portfolia's FemTech Fund and as a GP at The Fund Midwest.

I have been fortunate to benefit from several key mentors in my career and to be a part of communities that bolster the entrepreneurial ecosystem and take pride in supporting other entrepreneurs and investors. Please include a note and reach out to connect!<\/p>","companies":[{"id":45,"name":"Flow Medical","logo":{"id":122,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/122\/flow-medical.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/122\/conversions\/flow-medical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/122\/conversions\/flow-medical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/122\/conversions\/flow-medical-large.webp"},"type":"presenter","description":"

Flow Medical is developing a novel thrombolytic catheter for the treatment of pulmonary embolism. The device will combine imaging, infusion, and monitoring into a single solution to streamline procedures, improve therapeutic efficacy, and reduce inventory needs.<\/p>\r\n

Visit website<\/a>.<\/p>","created_at":"2024-05-02T20:08:24.000000Z"}],"created_at":"2024-05-02T20:11:49.000000Z"},{"id":73,"name":"Ryan Shelton","title":"Interim CEO","photo":{"id":983,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/983\/ryan-shelton-photonicare.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/983\/conversions\/ryan-shelton-photonicare-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/983\/conversions\/ryan-shelton-photonicare-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/983\/conversions\/ryan-shelton-photonicare-large.webp"},"category":"innovators","roles":["C"],"company_name":"PhotoniCare","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ryan-shelton-92289231\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":46,"name":"PhotoniCare","logo":{"id":125,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/125\/photonicare.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/125\/conversions\/photonicare-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/125\/conversions\/photonicare-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/125\/conversions\/photonicare-large.webp"},"type":"presenter","description":"

The OtoSight Middle Ear Scope enables clinicians to quickly and easily see directly through the eardrum to directly visualize the middle ear, drastically improving care for middle ear infections, the leading cause of hearing loss, antibiotic use, and surgeries in children. The novel device has new reimbursement codes that are seeing robust payment rates.<\/p>\r\n

Visit website<\/a>.<\/em><\/p>","created_at":"2024-05-02T20:14:05.000000Z"}],"created_at":"2024-05-02T20:16:03.000000Z"},{"id":75,"name":"Ariana McGee","title":"Founder & Chief Executive Officer","photo":{"id":718,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/718\/ariana-mcgee-navigate.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/718\/conversions\/ariana-mcgee-navigate-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/718\/conversions\/ariana-mcgee-navigate-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/718\/conversions\/ariana-mcgee-navigate-large.webp"},"category":"innovators","roles":["C"],"company_name":"Navigate Maternity","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ariana-mcgee-a220642b\/","biography":"

Ariana McGee is the Founder and CEO of Navigate Maternity (NM). NM has created a remote patient monitoring system for prenatal and postpartum patients. Mothers are dying and specifically, Black women are dying 3-4x the national average during childbirth and postpartum due to reactive care, data gaps, and bias. Ariana experienced the inequity in perinatal care after almost dying during childbirth with her fourth child. As a healthcare leader in the medical device and biopharmaceutical industries (BD, Biogen, Genzyme, etc.) for the last 13 years, Ariana brings a wealth of knowledge and is uniquely positioned as a mother and healthcare leader.  In her free time, she enjoys spending time with her husband, AJ, and their four little ones – Jade, Trey, Naomi, and Aliya. “We’re here to save the mamas and the babies.”<\/p>","companies":[{"id":48,"name":"Navigate Maternity","logo":{"id":719,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/719\/NM-Logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/719\/conversions\/NM-Logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/719\/conversions\/NM-Logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/719\/conversions\/NM-Logo-large.webp"},"type":"presenter","description":"

Navigate Maternity is a tech-enabled medical device company dedicated to improving maternal health. Their system enhances care coordination through remote monitoring, capturing key biometric data from the first prenatal appointment to twelve months postpartum via a mobile app and Bluetooth devices. The app also provides validated questionnaires for better clinical decision-making.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-02T20:55:52.000000Z"}],"created_at":"2024-05-02T20:54:52.000000Z"},{"id":77,"name":"Marcin Golebicki","title":"CEO","photo":{"id":134,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/134\/Marcin-Golebicki-EP-Solutions.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/134\/conversions\/Marcin-Golebicki-EP-Solutions-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/134\/conversions\/Marcin-Golebicki-EP-Solutions-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/134\/conversions\/Marcin-Golebicki-EP-Solutions-large.webp"},"category":"innovators","roles":["C"],"company_name":"EP Solutions","linkedin_profile":"https:\/\/www.linkedin.com\/in\/marcin-go%C5%82%C4%99bicki-5428a8155\/","biography":"

Marcin joined the company in June 2022 as CEO to take it into a new phase. He brings a vast industrial and business experience in electrophysiology. He is also a Director on the board of several companies in this space.<\/p>","companies":[{"id":50,"name":"EP Solutions","logo":{"id":132,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/132\/EPSolutions-(1).png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/132\/conversions\/EPSolutions-(1)-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/132\/conversions\/EPSolutions-(1)-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/132\/conversions\/EPSolutions-(1)-large.webp"},"type":"presenter","description":"

EP Solutions is improving clinical outcomes in cardiac resynchronization therapy cases through the use of noninvasive cardiac mapping technology. The company's Amycard 01C is an electrophysiology workstation that records body surface electrograms to create optimized 3D heart models that merge ECG data with anatomical data obtained from medical imaging. EP Solutions' technology helps physicians accurately place CRT leads during implantation and optimize devices during follow-up visits.<\/p>\r\n

Visit website<\/a>.<\/p>","created_at":"2024-05-02T20:59:23.000000Z"}],"created_at":"2024-05-02T21:01:30.000000Z"},{"id":78,"name":"Donald Buck","title":"CEO","photo":{"id":1031,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1031\/donald-buck-bucksurgical-cropped.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1031\/conversions\/donald-buck-bucksurgical-cropped-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1031\/conversions\/donald-buck-bucksurgical-cropped-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1031\/conversions\/donald-buck-bucksurgical-cropped-large.webp"},"category":"innovators","roles":["C"],"company_name":"Buck Surgical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/donaldbuckmd\/","biography":"

A graduate of the Johns Hopkins University School of Medicine, Donald W. Buck II, MD, FACS has spent nearly 20 years pioneering innovative plastic and reconstructive surgery techniques. Throughout his career, he has had the opportunity to attend – and work for – some of the finest academic institutions in the world, including Johns Hopkins, Northwestern University, the University of Toronto and the Washington University School of Medicine.<\/p>\r\n

Dr. Buck’s frustrations with outdated anastomotic modalities led him to explore the potential for new technologies to revolutionize surgical outcomes. He founded Buck Surgical in 2021 to develop a platform for innovative technologies that will change the way surgery is performed, optimize outcomes for challenging procedures and expand access to life- and limb-saving surgery.<\/p>","companies":[{"id":51,"name":"Buck Surgical","logo":{"id":136,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/136\/buck_surgical_llc_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/136\/conversions\/buck_surgical_llc_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/136\/conversions\/buck_surgical_llc_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/136\/conversions\/buck_surgical_llc_logo-large.webp"},"type":"presenter","description":"

Buck Surgical is dedicated to addressing the challenges of gastrointestinal, microvascular, and vascular surgery with its patented coupling technology. The company has developed a novel and efficient solution that rapidly creates a connection (anastomoses) to provide unobstructed flow.<\/p>\r\n

Visit websit<\/em><\/a>e.<\/p>","created_at":"2024-05-02T21:06:47.000000Z"}],"created_at":"2024-05-02T21:05:28.000000Z"},{"id":79,"name":"Sanjeev Bhatia","title":"CEO","photo":{"id":138,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/138\/SANJEEV-BHATIA-jointpreservation.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/138\/conversions\/SANJEEV-BHATIA-jointpreservation-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/138\/conversions\/SANJEEV-BHATIA-jointpreservation-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/138\/conversions\/SANJEEV-BHATIA-jointpreservation-large.webp"},"category":"innovators","roles":["C"],"company_name":"Joint Preservation Innovations","linkedin_profile":"https:\/\/www.linkedin.com\/in\/sanjeevbhatiamd\/","biography":"

Dr. Sanjeev Bhatia is a Board Certified orthopaedic surgeon specializing in sports medicine and arthroscopic treatment of hip, knee and shoulder injuries. He is presently the Director of the Hip & Knee Joint Preservation Center of the Northwestern Medicine West Region as well as a co-founder of Joint Preservation Innovations. <\/p>\r\n

Dr. Bhatia brings with him unique experience in repairing and reconstructing hip labral tears, which involves the ring of cartilage that goes around the hip socket. He has personally cared for and treated thousands of individuals including professional athletes and US Olympians in addition to high school, college and recreational athletes.<\/p>\r\n

Originally from Chicago, Dr. Bhatia attended the University of Wisconsin-Madison and Northwestern University Medical School. From there, he completed his orthopaedic residency at Rush University Medical Center. After residency, Dr. Bhatia went on to complete a sports medicine and hip arthroscopy fellowship at the renowned Steadman-Philippon Research Institute in Vail, Colorado. As a fellow, Dr. Bhatia gained expertise in the most innovative techniques in hip arthroscopy from one of the pioneers of the procedure, Dr. Marc Philippon. He also trained extensively in complex multiligament knee ligament surgery, shoulder instability and rotator cuff repair while participating in the care of athletes from the NHL, NFL, PGA, USTA, and international Olympic teams, among others. <\/p>\r\n

Dr. Bhatia's clinical and research interests involve injuries of the hip, knee and shoulder. He has authored over 65 peer-reviewed articles and book chapters on topics such as shoulder instability, rotator cuff repair, complex meniscus repair and ACL reconstruction. More recently, he helped pioneer and publish the \"Kite Technique,\" a novel method for arthroscopic hip labral reconstruction that is now being taught to many surgeons around the country.<\/p>\r\n

An innovator by heart, Dr. Bhatia is also the co-founder and CEO of Joint Preservation Innovations, an emerging medical device company aimed at reducing the surgical footprint for many orthopaedic, spinal and robotic procedures.<\/p>","companies":[{"id":52,"name":"Joint Preservation Innovations","logo":{"id":137,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/137\/Joint-Preservation-Innovations.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/137\/conversions\/Joint-Preservation-Innovations-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/137\/conversions\/Joint-Preservation-Innovations-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/137\/conversions\/Joint-Preservation-Innovations-large.webp"},"type":"presenter","description":"

Joint Preservation Innovations (JPI) is proud to present the Articulator Bone Resector, a novel arthroscopic articulating bone resection tool. Developed over 7 years with input from leading surgeons along with automotive, aerospace and medical device engineers, Articulator gives minimally invasive surgeons the freedom to finally articulate rotary cutting tools for bone resection in a manner never before possible. Awarded an FDA Breakthrough Device Designation in 2023, Articulator aims to reduce the surgical footprint of various musculoskeletal procedures, including large market applications in arthroscopic, endoscopic spinal and robotic surgery.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-02T21:08:44.000000Z"}],"created_at":"2024-05-02T21:10:11.000000Z"},{"id":81,"name":"Ilan Uchitel","title":"CEO & Co-Founder","photo":{"id":142,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/142\/Ilan-Uchitel_CAPS-Medical.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/142\/conversions\/Ilan-Uchitel_CAPS-Medical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/142\/conversions\/Ilan-Uchitel_CAPS-Medical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/142\/conversions\/Ilan-Uchitel_CAPS-Medical-large.webp"},"category":"innovators","roles":["C"],"company_name":"CAPS Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ilan-uchitel-9a15b9b\/","biography":"

Ilan, CEO and Co-founder of CAPS Medical, has over 20 years of experience in the medical device and defense industries, having held executive management positions in multiple biomedical device companies in the fields of electrophysiology, invasive cardiology, and minimally invasive implantable maxillofacial solutions. He has served in executive leadership positions at OSSIO, and Rainbow Medical portfolio companies, contributing to these companies’ continuous growth through a deep understanding of the medical device market, strategic product development, regulatory road-map building and execution, including CE and FDA compliance and successful product commercialization and revenue growth in US and European markets. Earlier, Ilan held R&D and project management positions in Unit 81, Israeli military intelligence’s elite technology unit, where during his tenure, his teams delivered numerous technologically and operationally complex projects, playing an important role in winning the top Israeli defense prizes. Ilan holds a BSc degree in mechanical engineering, an MSc in biomedical engineering, and an MBA – all received from Tel Aviv University.<\/p>","companies":[{"id":54,"name":"CAPS Medical","logo":{"id":141,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/141\/CAPS-Medical.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/141\/conversions\/CAPS-Medical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/141\/conversions\/CAPS-Medical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/141\/conversions\/CAPS-Medical-large.webp"},"type":"presenter","description":"

CAPS Medical is developing a solution to treat a wide range of solid tumors using Non-thermal Atmospheric Plasma (NTAP). This minimally invasive procedure selectively destroys cancer cells without damaging the surrounding healthy tissue. Clinically tested ,working towards commercialization.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-02T21:22:14.000000Z"}],"created_at":"2024-05-02T21:24:34.000000Z"},{"id":82,"name":"Lali Sekhon","title":"Chief Medical Office and Founder","photo":{"id":144,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/144\/lali-sekhon-spinepoint.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/144\/conversions\/lali-sekhon-spinepoint-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/144\/conversions\/lali-sekhon-spinepoint-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/144\/conversions\/lali-sekhon-spinepoint-large.webp"},"category":"innovators","roles":["C"],"company_name":"SpinePoint","linkedin_profile":"https:\/\/www.linkedin.com\/in\/lalisekhon\/","biography":"

Dr. Sekhon has been involved in the comprehensive delivery of spinal surgery, spinal implant research and development and spinal education for over 25 years. <\/p>\r\n

World renowned for his work in cervical surgery and is a pioneer in cervical arthroplasty. Known as a thought leader for spine surgery. <\/p>\r\n

Dr. Sekhon holds multiple spinal implant patents and is the recipient of numerous awards related to his academic and surgical success, including “Becker’s 60 Spine Inventors to Know”. <\/p>\r\n

Dr. Sekhon has worked in both academic and private practice in Australia, Canada, and the U.S.  <\/p>\r\n

One of the few neurosurgeons who are practising with a PhD and an MBA.  <\/p>","companies":[{"id":55,"name":"SpinePoint","logo":{"id":143,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/143\/spinepoint.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/143\/conversions\/spinepoint-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/143\/conversions\/spinepoint-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/143\/conversions\/spinepoint-large.webp"},"type":"presenter","description":"

SpinePoint is developing next generation spine surgery implants. Differentiated ideas today for better outcomes tomorrow. Made by surgeons for surgeons.<\/span><\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-02T21:29:35.000000Z"}],"created_at":"2024-05-02T21:32:04.000000Z"},{"id":83,"name":"Per Langoe","title":"CEO","photo":{"id":223,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/223\/Per-Langoe_CEO_GT-Medical-Technologies-color.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/223\/conversions\/Per-Langoe_CEO_GT-Medical-Technologies-color-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/223\/conversions\/Per-Langoe_CEO_GT-Medical-Technologies-color-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/223\/conversions\/Per-Langoe_CEO_GT-Medical-Technologies-color-large.webp"},"category":"innovators","roles":["C"],"company_name":"GT Medical Technologies","linkedin_profile":"https:\/\/www.linkedin.com\/in\/per-langoe-62a2244\/","biography":"

With a unique blend of visionary leadership and artistic insight, Per Langoe defines success beyond cutting-edge products. It’s about fostering a culture of innovation, nurturing our people, and refining our process to break down barriers. He believes that by comprehensively assessing the landscape of life sciences, identifying the issues and roadblocks impeding patient success, and innovating solutions to surmount those barriers, we can truly make a difference.   <\/p>\r\n

Mr. Langoe brings more than 20 years of experience successfully managing commercial, clinical, M&A, and other functions at MedTech companies such as Parmacia Corporation, Q-Med, Galderma and Nestlé Skin Health. <\/p>\r\n

Most recently, Mr. Langoe was the co-founder, President and CEO of Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes.  Under Per’s leadership, the Palette team successfully designed and navigated a complex randomized controlled trial and subsequent regulatory approval process. Following product approval, the company commercialized the product to a multi-disciplinary set of clinicians, with particular emphasis on radiation oncologists, and the product’s rapid adoption led to the company’s acquisition by Teleflex in 2023 <\/p>\r\n

As an avid art collector, Per has seen many beautiful things, but one image stays with him. In his early days, working with an intraocular eye lens company he interviewed a patient in her mid 80s who cried tears of joy because she could now actually see her grandchildren again. Profound patient experiences like this is what propels Per’s commitment to advance the mission of improving the lives of patients with brain tumor at GT Medical Technologies.<\/p>\r\n

Per received an MSc in Business Studies and Economics with a major in Business Studies, and a BSc in Business Administration and Economics with a major in International Business Studies, from Uppsala University in Sweden. <\/p>","companies":[{"id":56,"name":"GT Medical Technologies","logo":{"id":224,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/224\/GammaTile-Logo-R_RGB.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/224\/conversions\/GammaTile-Logo-R_RGB-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/224\/conversions\/GammaTile-Logo-R_RGB-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/224\/conversions\/GammaTile-Logo-R_RGB-large.webp"},"type":"presenter","description":"

GT Medical's GammaTile Therapy is a targeted approach for delivering radiation to brain tumor cells. The company's technology minimizes complication while optimizes therapeutic efficacy. Placed by a neurosurgeon during resection, GammeTile's provide uniform radiation-source spacing to ensure even dose distribution. <\/p>\r\n

Visit website<\/a>.<\/em><\/p>","created_at":"2024-05-03T22:23:27.000000Z"}],"created_at":"2024-05-03T22:24:35.000000Z"},{"id":84,"name":"Adam Rosenwach","title":"Chief Business Officer","photo":{"id":147,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/147\/adam-rosenwach-deerfieldcatalyst.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/147\/conversions\/adam-rosenwach-deerfieldcatalyst-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/147\/conversions\/adam-rosenwach-deerfieldcatalyst-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/147\/conversions\/adam-rosenwach-deerfieldcatalyst-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Deerfield Catalyst","linkedin_profile":"https:\/\/www.linkedin.com\/in\/adamrosenwach\/","biography":"

Adam Rosenwach holds the dual roles of Chief Business Officer at Deerfield Catalyst and Chief Business Officer\/Chief Financial Officer at Coridea. Since 2016, he has spearheaded the successful fundraising of over $150 million in seed and early-stage Medtech venture capital, facilitating the launch of seven innovative companies.<\/p>","companies":[],"created_at":"2024-05-06T23:04:48.000000Z"},{"id":85,"name":"Brian Martin","title":"VP of Corporate Development","photo":{"id":148,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/148\/brian-martin-gtmedical.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/148\/conversions\/brian-martin-gtmedical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/148\/conversions\/brian-martin-gtmedical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/148\/conversions\/brian-martin-gtmedical-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"GT Medical Technologies","linkedin_profile":"https:\/\/www.linkedin.com\/in\/brian-martin-aaab618\/","biography":"

Prior to joining GT Medical Technologies, Mr Martin held positions in business development at several startups, investment roles at a venture capital firm and life sciences incubator, and roles in marketing at a Fortune 500 medical device company. This diverse experience informs Mr Martin’s decision-making across the organization and his leadership in strategic partnering, finance, and investor relations. His focus is on bringing analytical frameworks to strategic decision-making in medtech and capital allocation.  <\/p>","companies":[],"created_at":"2024-05-06T23:07:53.000000Z"},{"id":86,"name":"Jeremy Stueven","title":"CEO","photo":{"id":354,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/354\/f8cbf18e-3a21-4b72-8cd3-77ef21fbe894_thumb.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/354\/conversions\/f8cbf18e-3a21-4b72-8cd3-77ef21fbe894_thumb-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/354\/conversions\/f8cbf18e-3a21-4b72-8cd3-77ef21fbe894_thumb-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/354\/conversions\/f8cbf18e-3a21-4b72-8cd3-77ef21fbe894_thumb-large.webp"},"category":"innovators","roles":["C"],"company_name":"Vitazi.AI","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jeremystueven\/","biography":"

I'm a board-certified emergency physician and digital health innovator with experience in providing smart, cost-effective, and timely health care. I leverage AI-powered tools to improve access and enhance outcomes for patients and providers, especially in the face of limited resources and the growing care shortage crisis.

As the founder and CEO of Vitazi.ai, Inc., I lead a team of talented engineers, researchers, and clinicians who develop and implement cutting-edge AI solutions that empower physicians, like me. We've successfully built AI-powered and digital health products that have improved patient satisfaction and health outcomes, and have received positive feedback from providers, insurers, and health systems. I'm also a collaborative member of TOUCH-TSC, a global telehealth organization that integrates information and communication technologies to improve health. I've provided telehealth services to patients across 30 states through a leading telehealth platform. I have extensive skills and expertise in digital health, including AI, software design and development, product development, electronic health records, and telehealth. I'm also experienced as a Sponsor of clinical trials for software as a medical device.<\/p>","companies":[{"id":57,"name":"Vitazi.AI","logo":{"id":225,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/225\/vitazi.ai.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/225\/conversions\/vitazi.ai-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/225\/conversions\/vitazi.ai-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/225\/conversions\/vitazi.ai-large.webp"},"type":"presenter","description":"

It is estimated that over 100 million people worldwide are affected by diabetic retinopathy (DR). Vitazi-DR is an AI solution that can be deployed on industry-leading retinal scanners to detect DR and reduce the workflows of ophthalmologists by 75%. Eliminating the need for specialized training and analysis, Vitazi-DR can be deployed in nearly any clinical environment to make routine DR screening accessible. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-16T19:41:57.000000Z"}],"created_at":"2024-05-16T19:43:25.000000Z"},{"id":87,"name":"Gulam Khan","title":"CEO","photo":{"id":227,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/227\/Gulam_Khan_Headshot.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/227\/conversions\/Gulam_Khan_Headshot-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/227\/conversions\/Gulam_Khan_Headshot-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/227\/conversions\/Gulam_Khan_Headshot-large.webp"},"category":"innovators","roles":["C"],"company_name":"Centerline Biomedical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/gulam-khan-75312612\/","biography":"

Mr. Khan has more than 20 years of medical device leadership experience. Having led organizations that focused on new product development, Mr. Khan is passionate about building great teams that collaborate with physicians, nurses and technicians to improve patient care through product innovation.<\/p>","companies":[{"id":58,"name":"Centerline Biomedical","logo":{"id":228,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/228\/Centerline_Logo.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/228\/conversions\/Centerline_Logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/228\/conversions\/Centerline_Logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/228\/conversions\/Centerline_Logo-large.webp"},"type":"presenter","description":"

Centerline is a Cleveland Clinic spinoff company commercializing the Intra-Operative Positioning System (IOPS®) technology — an innovative, non-x-ray based 3D GPS-like surgical navigation technology that improves endovascular procedure outcomes and reduces radiation exposure.<\/span><\/p>","created_at":"2024-05-16T19:52:11.000000Z"}],"created_at":"2024-05-16T19:48:52.000000Z"},{"id":88,"name":"Leo Smit","title":"CEO","photo":{"id":231,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/231\/Leo-Smit-Hy2Care.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/231\/conversions\/Leo-Smit-Hy2Care-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/231\/conversions\/Leo-Smit-Hy2Care-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/231\/conversions\/Leo-Smit-Hy2Care-large.webp"},"category":"innovators","roles":["C"],"company_name":"Hy2Care","linkedin_profile":"https:\/\/www.linkedin.com\/in\/leosmitinnovator\/","biography":"

Ir. Leo Smit graduated as a chemical engineer at the Delft University of Technology in 1986. He joined DSM in 1988. Following a 11 year career in R&D, he joined DSM’s Dyneema® Business Unit, where he became responsible for New Business Development.<\/p>\r\n

Here he developed and launched DSM’s first implantable polymer material Dyneema Purity®, currently used worldwide and the golden standard for use in orthopedic reinforcement textiles. He served 4 years as Management Team member in the then newly installed Business Unit Biomedical Materials, responsible for passive biomaterials in orthopedic applications. Subsequently he acted 4 years as Director of Communications at the DSM Innovation Center, responsible for DSM’s (corporate) communications on science and innovation.<\/p>\r\n

In 2016 Leo left DSM to found his own businesses. He started insightfully Innovate, advising and supporting companies both large and small in the field of medical devices. In 2019 Leo joined Hy2Care as CEO, responsible for the company & team development, strategy and financing of the company.<\/p>\r\n

Personal quote:
“Hy2Care is a wonderful company to lead. We have a solid team of strong experts and above all great drive and commitment. Together we can bring forward the injectable hydrogel platform, delivering on the promise of better cartilage healing and much improved outcomes for patients all around the world!”<\/p>","companies":[{"id":60,"name":"Hy2Care","logo":{"id":230,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/230\/hy2care.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/230\/conversions\/hy2care-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/230\/conversions\/hy2care-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/230\/conversions\/hy2care-large.webp"},"type":"presenter","description":"

Hy2Care's vision is to support patients in the fight against osteoarthritis. The company's lead product, CartRevive, is a hydrogel implant composed of dextran and hyaluronic acid conjugates that form a resorbable scaffold when injected. The hydrogel enables natural restoration of tissue defects by creating an environment conducive to cell regrowth that proceeds towards the restoration of smooth hyaline cartilage. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-16T20:02:22.000000Z"}],"created_at":"2024-05-16T20:03:22.000000Z"},{"id":89,"name":"Chris Barron","title":"CEO","photo":{"id":234,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/234\/Chris-Barron-embiosys.JPG","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/234\/conversions\/Chris-Barron-embiosys-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/234\/conversions\/Chris-Barron-embiosys-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/234\/conversions\/Chris-Barron-embiosys-large.webp"},"category":"innovators","roles":["C"],"company_name":"EMBioSys","linkedin_profile":"https:\/\/www.linkedin.com\/in\/chris-barron\/","biography":"

Results driven executive with 30+ years of product development and commercialization experience in the medical device industry. Proven leadership skills with a solid track record in both early start-up and established company environments. Experienced in a broad range of medical device technologies including induced electric field therapy (iEFs) for treatment of solid metastatic cancers, cardiac assist devices\/systems, miniaturization of electronics for implantable devices, ultrasonic generator\/control systems, aesthetic laser systems, hard and soft tissue dental lasers, intravenous infusion systems, radio-frequency generators for cardiac, neuro and liver ablation, ECG and EMG data acquisition systems, programmable heart stimulators, and impedance based respiratory monitoring.<\/p>","companies":[{"id":61,"name":"EMBioSys","logo":{"id":1391,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1391\/EMBioSys_large-logo_blue.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1391\/conversions\/EMBioSys_large-logo_blue-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1391\/conversions\/EMBioSys_large-logo_blue-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1391\/conversions\/EMBioSys_large-logo_blue-large.webp"},"type":"presenter","description":"

EMBioSys is developing a platform technology of therapeutic non-pharmacological, electrode-free wearables that deliver iEF Therapy (induced electric fields) to improve patient outcomes for treatment of triple-negative breast cancer (TNBC).  TNBC accounts for 40% of all breast cancer mortality.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-22T22:33:29.000000Z"}],"created_at":"2024-05-22T22:36:19.000000Z"},{"id":90,"name":"Justin Anderson","title":"CEO","photo":{"id":356,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/356\/Justin-Anderson1.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/356\/conversions\/Justin-Anderson1-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/356\/conversions\/Justin-Anderson1-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/356\/conversions\/Justin-Anderson1-large.webp"},"category":"innovators","roles":["C"],"company_name":"Tensor Surgical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/justinanderson01\/","biography":"

ustin Anderson has 25 years’ experience in the medical device industry as a founder, board member and\/or executive of public and private companies and is recognized as a key contributor in 2 IPO’s and 6 exits valued at over $4 Billion, including Tornier (acquired by Wright Medical, now part of Stryker Corporation), Axya Medical (acquired by Tornier), Opus Medical (acquired by ArthroCare, now part of Smith+Nephew), and Oratec Interventions (acquired by Smith+Nephew).

Mr. Anderson is the CEO and President of Tensor Surgical, Inc., and serves on the Board of Directors of 4 entities.

Mr. Anderson is the Co-Founder and Chairman of G9MD, Inc., and Co-Founder of Passer Stitch, LLC.<\/p>","companies":[{"id":62,"name":"Tensor Surgical","logo":{"id":235,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/235\/tensorsurgical_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/235\/conversions\/tensorsurgical_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/235\/conversions\/tensorsurgical_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/235\/conversions\/tensorsurgical_logo-large.webp"},"type":"presenter","description":"

Tensor Surgical develops technologies for orthopedic soft tissue repair sports medicine. The company’s portfolio of products consists of solutions to simplify and reduce the cost rotator cuff repair and bicep tenodesis procedures. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-22T22:40:28.000000Z"}],"created_at":"2024-05-22T22:42:36.000000Z"},{"id":91,"name":"Eman Namati","title":"CEO","photo":{"id":317,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/317\/eman-namati-spectrawave.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/317\/conversions\/eman-namati-spectrawave-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/317\/conversions\/eman-namati-spectrawave-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/317\/conversions\/eman-namati-spectrawave-large.webp"},"category":"innovators","roles":["C"],"company_name":"SpectraWave","linkedin_profile":"https:\/\/www.linkedin.com\/in\/eman-namati\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":63,"name":"SpectraWave","logo":{"id":237,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/237\/spectrwave.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/237\/conversions\/spectrwave-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/237\/conversions\/spectrwave-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/237\/conversions\/spectrwave-large.webp"},"type":"presenter","description":"

SpectraWAVE combines optical coherence tomography (OCT) and near-infrared spectroscopy (NIRS) to provide greater clarity during complex coronary interventions. The company's HyperVue Imaging System brings next-generation intravascular imaging to the cath lab to provide interventional cardiologists with powerful images and simplified workflows. HyperVue consists of a mobile control station where images are displayed and the Starlight Imaging Catheter. Starlight is a low-profile, no-flush-prep catheter that enables rapid pullback that facilitates efficient imaging of complex lesions.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-22T22:45:57.000000Z"}],"created_at":"2024-05-22T22:48:39.000000Z"},{"id":92,"name":"James Dacombe","title":"CEO","photo":{"id":355,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/355\/fdHoi66h_400x400.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/355\/conversions\/fdHoi66h_400x400-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/355\/conversions\/fdHoi66h_400x400-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/355\/conversions\/fdHoi66h_400x400-large.webp"},"category":"innovators","roles":["C"],"company_name":"CoMind","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jamesdacombe\/","biography":"

James founded CoMind at the age of seventeen, having already developed a strong understanding of software engineering. James was named on the 2022 Forbes 30 under 30 Technology list and awarded a Thiel Fellowship. The Fellowship empowers individuals under 23 years old who have distinguished themselves in business, science or social causes.<\/p>","companies":[{"id":64,"name":"CoMind","logo":{"id":239,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/239\/comind.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/239\/conversions\/comind-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/239\/conversions\/comind-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/239\/conversions\/comind-large.webp"},"type":"presenter","description":"

CoMind is developing a noninvasive solution to transform the way the brain is monitored. The company provides a multidimensional view of brain activity using light. CoMind's mission is to change the way neuroscience and neurosurgery is conducted by expanding the amount of information available to clinicians to enhance the clinical management of neurological disorders.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-22T22:55:22.000000Z"}],"created_at":"2024-05-22T22:57:26.000000Z"},{"id":93,"name":"James Heinz","title":"CEO","photo":{"id":577,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/577\/1722375542236.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/577\/conversions\/1722375542236-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/577\/conversions\/1722375542236-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/577\/conversions\/1722375542236-large.webp"},"category":"innovators","roles":["C"],"company_name":"Amsel Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/james-a-heinz-msl-4523559\/","biography":"

39 years in healthcare. James founded the Center for Venous Disease and held key roles at Zimmer, Synthes, and Smith\/Nephew in orthopedics and trauma. He also made significant contributions to the vascular space with VNUS Medical Technologies\/ Medtronic and as a VENCLOSE C Suite Consultant\/ Becton Dickinson. His expertise contributed to the successful exits in the chronic venous disease market at high valuation with VNUS and VENCLOSE. James holds a bachelor's degree in marketing and a master's degree in organizational leadership. Outside of healthcare, for over 15 years, James has been a United States Coast Guard Auxiliary Member supporting the operations of the United States Coast Guard under the supervision of the Department of Homeland Security.<\/p>","companies":[{"id":65,"name":"Amsel Medical","logo":{"id":241,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/241\/amsel_medical_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/241\/conversions\/amsel_medical_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/241\/conversions\/amsel_medical_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/241\/conversions\/amsel_medical_logo-large.webp"},"type":"presenter","description":"

Amsel Medical is developing and commercializing an occlusion device that is designed to easily and securely close blood vessels (veins or arteries) as well as tubular structures during open surgical procedures. The Amsel Occluder Device employs a proprietary mechanical occlusion technology is intended for use in open general surgery procedures on tubular structures or vessels wherever a metal ligating clip is indicated and within the size range of 2.0mm to 7.0mm diameter.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-22T23:02:24.000000Z"}],"created_at":"2024-05-22T23:03:18.000000Z"},{"id":94,"name":"Declan Soden","title":"CEO","photo":{"id":245,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/245\/declan-soden-mirai.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/245\/conversions\/declan-soden-mirai-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/245\/conversions\/declan-soden-mirai-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/245\/conversions\/declan-soden-mirai-large.webp"},"category":"innovators","roles":["C"],"company_name":"Mirai Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/declan-soden-b404945\/","biography":"

Declan is CEO and founder of Mirai Medical. He has spent over 20 years working in cancer research working in medical device and immunotherapy research. Dr. Soden has published extensively on electroporation and its development in cancer treatment leading to a number of clinical studies which have assisted in validating this exciting technology.<\/p>","companies":[{"id":66,"name":"Mirai Medical","logo":{"id":244,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/244\/Mirai-Medical.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/244\/conversions\/Mirai-Medical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/244\/conversions\/Mirai-Medical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/244\/conversions\/Mirai-Medical-large.webp"},"type":"presenter_innovator","description":"

Mirai Medical ePORE therapy is a unique precision therapy platform that targets and destroy tumor tissue without harming surrounding healthy tissue. The minimally invasive technology delivers pulsed electrical fields that create pores in the cell membrane of tumor cells, catalyzing cellular death. Mirai's technology has been developed for external (skin) and internal (endoscopic) tumor treatment. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-30T21:34:43.000000Z"}],"created_at":"2024-05-30T21:36:17.000000Z"},{"id":95,"name":"Karl von Mangoldt","title":"Managing Director","photo":{"id":1123,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1123\/karl-vonmangoldt-protembis.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1123\/conversions\/karl-vonmangoldt-protembis-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1123\/conversions\/karl-vonmangoldt-protembis-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1123\/conversions\/karl-vonmangoldt-protembis-large.webp"},"category":"innovators","roles":["C"],"company_name":"Protembis","linkedin_profile":"https:\/\/www.linkedin.com\/in\/karl-von-mangoldt\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":67,"name":"Protembis","logo":{"id":246,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/246\/Protembis.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/246\/conversions\/Protembis-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/246\/conversions\/Protembis-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/246\/conversions\/Protembis-large.webp"},"type":"presenter","description":"

Silent brain infarcts occur in nearly all patients who undergo transcatheter aortic valve replacement. These stealth incidents lead to cognitive decline and significantly increase a patient's risk of future stroke. To combat this, Protembis are developing the ProtEmbo Cerebral Protection System. This catheter-based solution is deployed during leftsided heart procedures to deflect embolic material away from cerebrovascular circulation.<\/p>\r\n

Visit website<\/a>.<\/p>","created_at":"2024-05-30T21:43:05.000000Z"}],"created_at":"2024-05-30T21:44:45.000000Z"},{"id":97,"name":"Kambiz Behzadi","title":"President","photo":{"id":360,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/360\/behzadi-1-e1660707765497.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/360\/conversions\/behzadi-1-e1660707765497-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/360\/conversions\/behzadi-1-e1660707765497-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/360\/conversions\/behzadi-1-e1660707765497-large.webp"},"category":"innovators","roles":["C"],"company_name":"BMD","linkedin_profile":"https:\/\/www.linkedin.com\/in\/kambiz-b-2951b737\/","biography":"

Dr. Kambiz Behzadi is an orthopedic surgeon in Pleasanton California. His practice is primarily focused on adult joint reconstruction and sports related injuries. He has particular interest in physical sciences. His research interests include efforts to improve surgical techniques and to produce novel medical devices to enhance reliability and safety of orthopedic procedures for the ultimate goal of improving outcomes.<\/p>","companies":[{"id":74,"name":"BMD","logo":{"id":255,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/255\/BMD.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/255\/conversions\/BMD-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/255\/conversions\/BMD-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/255\/conversions\/BMD-large.webp"},"type":"presenter","description":"

Novel medical devices to enhance the reliability and safety of orthopedics procedures. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-05-30T21:53:38.000000Z"}],"created_at":"2024-05-30T21:54:42.000000Z"},{"id":848,"name":"Carol Burns","title":"CEO","photo":{"id":1772,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1772\/Carol-Burns.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1772\/conversions\/Carol-Burns-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1772\/conversions\/Carol-Burns-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1772\/conversions\/Carol-Burns-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Signum Surgical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/carol-burns-339428\/","biography":"

Carol has had a distinguished career as a serial entrepreneur with over 25 years experience in the medical device industry,  leading and successfully commercializing innovative therapies which include serration angioplasty, endovascular abdominal aortic aneurysm, and endoscopic vein harvesting. Ms. Burns previously co-founded and served as CEO of both Cagent Vascular and Intact Vascular. In addition, she has worked at Embrella Cardiovascular, Animas\/J&J, Ventrica and Guidant Corporation.<\/u><\/u><\/u><\/p>\r\n

Ms. Burns recently joined Signum Surgical, as CEO to develop and initiate the commercial program for the BioHealx Anal Fistula Device.  Signum Surgical, is addressing a huge unmet need to treat a debilitating problem called fistula-in-ano.  Those who suffer with fistulas,  predominantly males aged 18-50, often require multiple procedures to cure the fistula adding significant costs to the healthcare system. Current surgical procedures, performed by Colorectal surgeons,  have suboptimal results leading to persistence or recurrence, poor quality of life and incontinence. We believe this first of its kind BioHealx device, a bioresorbable implant is the solution. If interested in learning more about BioHealx please contact me.<\/p>","companies":[],"created_at":"2025-03-19T03:58:45.000000Z"},{"id":98,"name":"Yassaman Salas","title":"Partner, Global Head of Medical Device","photo":{"id":257,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/257\/Yassaman-Salas.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/257\/conversions\/Yassaman-Salas-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/257\/conversions\/Yassaman-Salas-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/257\/conversions\/Yassaman-Salas-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Goldman Sachs","linkedin_profile":"https:\/\/www.linkedin.com\/in\/yassaman-salas-5264148\/","biography":"

Yassaman is a partner in the Healthcare Investment Banking Group and runs the medical device coverage effort. She served as the group's business unit manager in 2008. Yassaman is co-head of the Georgetown University undergraduate and MBA recruiting efforts for the Investment Banking Division. She joined Goldman Sachs in 2005 as an associate and was named managing director in 2013 and partner in 2020.<\/p>\r\n

Prior to joining the firm, Yassaman worked in the Investment Banking Division of Morgan Stanley and in the Corporate Development group at Avaya. Yassaman earned a BS in Foreign Service and an MBA, both from Georgetown University.<\/p>","companies":[],"created_at":"2024-06-03T18:44:17.000000Z"},{"id":99,"name":"Steven Gottlieb","title":"Chairman & CEO","photo":{"id":258,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/258\/steven-gottlieb-valueaccelertion.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/258\/conversions\/steven-gottlieb-valueaccelertion-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/258\/conversions\/steven-gottlieb-valueaccelertion-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/258\/conversions\/steven-gottlieb-valueaccelertion-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Value Acceleration Group","linkedin_profile":"https:\/\/www.linkedin.com\/in\/steven-gottlieb-md-041200\/","biography":"

Steven M. Gottlieb, M.D., is a physician executive and healthcare serial entrepreneur who seeks innovative companies in which he can invest, add value and accelerate growth. Dr. Gottlieb has more than 30 years of senior leadership experience in the healthcare industry, and has founded, managed, funded, grown and exited several successful healthcare companies<\/p>","companies":[],"created_at":"2024-06-03T18:48:26.000000Z"},{"id":100,"name":"Biren Mehta","title":"Vice President, Venture Investments","photo":{"id":259,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/259\/biren-mehta-j&j.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/259\/conversions\/biren-mehta-j&j-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/259\/conversions\/biren-mehta-j&j-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/259\/conversions\/biren-mehta-j&j-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Johnson & Johnson","linkedin_profile":"https:\/\/www.linkedin.com\/in\/biren-mehta-2697a81\/","biography":"

Based in Irvine, California, Biren Mehta is the Vice President, Venture Investments – MedTech, where he initiates and manages equity investments to drive business innovation and deliver new and sustainable business for the MedTech sector. He is responsible for existing and new MedTech investments on the West Coast, ensuring targeted strategic options are shaped for success. Biren plays a critical role in building and maintaining networks in the venture capital community, entrepreneurs, startups, incubators and accelerators and other venture organizations that fit the strategic interests of the MedTech sector, sourcing new opportunities for the sector and positioning JJDC as the partner of choice.<\/p>\r\n

Most recently, Biren was Vice President of Business Development for the Cardiovascular & Specialty Solutions (CSS) Group and J&J Vision. This represents a portfolio of six diverse, high-growth businesses within MedTech.   In this role, he provided strategic leadership in executing acquisitions, investments, distribution transactions, and other collaborations to support the growth and innovation agenda of these businesses.<\/p>\r\n

Prior to joining Johnson & Johnson, Biren was a medical device analyst at Roth Capital Partners. In that role, he wrote and published recommendations on publicly traded small and midcap medical device companies. Before joining the investment bank, he worked as a project manager and software engineer at Intralase Corporation, now owned by J&J Surgical Vision.<\/p>\r\n

Biren completed his bachelor’s degree in Cybernetics at UCLA. He earned master’s degrees in Biomedical Engineering and Computer Science from the University of Southern California. He also earned his MBA from the UCLA Anderson School of Management.<\/p>","companies":[],"created_at":"2024-06-03T18:51:49.000000Z"},{"id":101,"name":"Omid Akhavan","title":"Managing Director & Founder","photo":{"id":260,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/260\/omid-akhavan-anthro.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/260\/conversions\/omid-akhavan-anthro-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/260\/conversions\/omid-akhavan-anthro-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/260\/conversions\/omid-akhavan-anthro-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Anthro Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/martinomidakhavan\/","biography":"

Investing across healthcare companies with a network of funds, family offices and HNWs.

Focused on Venture Capital and Private Equity opportunities<\/p>","companies":[],"created_at":"2024-06-03T18:53:15.000000Z"},{"id":103,"name":"Tal Wenderow","title":"Managing Partner","photo":{"id":262,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/262\/tal-wenderow-genesismedtech.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/262\/conversions\/tal-wenderow-genesismedtech-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/262\/conversions\/tal-wenderow-genesismedtech-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/262\/conversions\/tal-wenderow-genesismedtech-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Star51 Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/wenderow\/","biography":"

An experienced executive with proven track record in small and mid-size companies turns investor.
Founded and led Corindus Vascular Robotics since inception through several executive leadership roles to a successful $1.1 Billion sale to Siemens Healthineers<\/p>","companies":[],"created_at":"2024-06-03T18:56:14.000000Z"},{"id":104,"name":"Will Mauldin","title":"Chairman& CEO","photo":{"id":264,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/264\/Will-Mauldin---Rivanna-Medical.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/264\/conversions\/Will-Mauldin---Rivanna-Medical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/264\/conversions\/Will-Mauldin---Rivanna-Medical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/264\/conversions\/Will-Mauldin---Rivanna-Medical-large.webp"},"category":"innovators","roles":["C"],"company_name":"Rivanna Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/will-mauldin-9a77214\/","biography":"

Dr. Mauldin received his doctorate in biomedical engineering from the University of Virginia with an undergraduate degree in applied science from the University of North Carolina, Chapel Hill. Immediately following his graduate training, Dr. Mauldin held an academic appointment as an Assistant Research Professor in the department of biomedical engineering at the University of Virginia where he developed an extensive record in clinical ultrasound research and currently holds over 60 peer-reviewed publications and patents. Dr. Mauldin currently serves as Chairman and CEO of Rivanna Medical, Inc. where he is building and leading a talented team of industry professionals to elevate global standards of care through the commercialization of the company’s world-first Accuro product line and associated medical imaging-based technologies. In this capacity, Dr. Mauldin has led strategic planning, formed industry partnerships, and attracted over $90M in funding through private and public sources that includes an up-to $65M contract with the Biomedical Advanced Research and Development Authority (BARDA).<\/p>","companies":[{"id":75,"name":"Rivanna Medical","logo":{"id":263,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/263\/Rivanna-Logo.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/263\/conversions\/Rivanna-Logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/263\/conversions\/Rivanna-Logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/263\/conversions\/Rivanna-Logo-large.webp"},"type":"presenter","description":"

Rivanna Medical are the makers of Accuro, and FDA-cleared device for epidural guidance. The device uses diagnostic ultrasound imaging to improve the efficiency, safety, and speed of neuraxial anesthesia procedures. The company's technology improves localization and eliminates the need for the palpation-based approach.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-06-04T19:03:22.000000Z"}],"created_at":"2024-06-04T19:03:23.000000Z"},{"id":110,"name":"Jeff Luber","title":"CEO","photo":{"id":275,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/275\/jeff-luber-binx.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/275\/conversions\/jeff-luber-binx-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/275\/conversions\/jeff-luber-binx-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/275\/conversions\/jeff-luber-binx-large.webp"},"category":"innovators","roles":["C"],"company_name":"Clairity","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jeffrey-r-luber-2003154\/","biography":"

\r\n

Jeff Luber is the CEO of Clairity. As a veteran life sciences and award-winning CEO, Jeff has served as CEO of multiple healthcare companies across oncology, genetic sequencing, infectious disease and digital health. Prior to joining Clairity, Jeff served as CEO of binx health where he led the company from proof-of-concept through FDA clearance and rapid commercialization of the first ever point-of-care molecular platform of its kind for infectious disease testing and he continues to serve as the company’s Chairman. Prior to binx, Jeff served as CEO of Good Start Genetics, the first company to bring next generation sequencing to reproductive health. Under Jeff’s leadership, testing volumes grew by double digits, revenues climbed to the highest mark in the company’s history, culminating in the successful sale of the company in August 2017.<\/p>\r\n

Jeff has served on numerous boards of directors of both public and private companies and earned his Juris Doctor and MBA from Suffolk University. He is also the winner of the 2022 EY Entrepreneur of the Year Award and currently serves as a judge for the annual competition. <\/p>\r\n<\/div>","companies":[{"id":80,"name":"Clairity","logo":{"id":916,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/916\/Screenshot-2024-11-22-134100.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/916\/conversions\/Screenshot-2024-11-22-134100-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/916\/conversions\/Screenshot-2024-11-22-134100-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/916\/conversions\/Screenshot-2024-11-22-134100-large.webp"},"type":"presenter","description":"

 <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-11-22T20:08:51.000000Z"}],"created_at":"2024-06-04T19:14:52.000000Z"},{"id":7,"name":"Kevin Schimelfenig","title":"Managing Partner","photo":{"id":11,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/11\/kevin-schimelfenig-mcgeever.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/11\/conversions\/kevin-schimelfenig-mcgeever-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/11\/conversions\/kevin-schimelfenig-mcgeever-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/11\/conversions\/kevin-schimelfenig-mcgeever-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"McGeever Family Office","linkedin_profile":"https:\/\/www.linkedin.com\/in\/kevin-schimelfenig-a280221\/","biography":"

Kevin is the Founder and Managing Partner of the McGeever family office, which focuses on achieving the financial and philanthropic goals of the family. McGeever’s investment portfolio places an emphasis on Healthcare, but also includes Technology, Energy and Real Estate.

To support the success of McGeever’s investments, Kevin founded SalesForce4Hire, a company that provides strategic commercialization solutions for medical device, diagnostics, biopharma and information technology companies and their investors. SalesForce4Hire has played an instrumental role in the successful implementation of customized sales solutions with Fortune 500 and startup companies.

Kevin is also an active angel investor who enjoys working closely with CEOs and leadership teams on strategic partnering and commercialization activities. He has held several executive-level and board-level positions, including Audit and Compensation Committee Member, Committee Chairman, Board Chairman and is an advisory board member of the Cameron School of Business at the University of North Carolina Wilmington.<\/p>","companies":[],"created_at":"2024-04-26T18:40:06.000000Z"},{"id":112,"name":"Lloyd Mencinger","title":"President & CEO","photo":{"id":1554,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1554\/Lloyd-Mencinger.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1554\/conversions\/Lloyd-Mencinger-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1554\/conversions\/Lloyd-Mencinger-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1554\/conversions\/Lloyd-Mencinger-large.webp"},"category":"innovators","roles":["C"],"company_name":"Aqua Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/lloyd-mencinger-b588673\/","biography":"

High energy CEO, Sales, Marketing, & Business Development leader with over twelve years as an International expatriate.

Strong track record of delivering results in both blue chip and early-stage companies. Expert at developing new markets, driving growth, executing turnarounds, and creating winning cultures.

History of driving rapid market penetration for new medical device technology, through: 1) field sales effectiveness, 2) strong customer development, 3) clinical economic arguments, 4) targeted physician & referral pathway marketing

Specialties:
- Sales, Marketing, Strategy, New Business Development
- International Growth Execution, Europe, Asia, Americas
- Sales & Field Force Effectiveness
- Physician Adoption, New Market Development
- Marketing to Physicians & Direct-to-Patients
- General Management
- Early-Stage Company Growth, Turnarounds
- Global Product Commercialization
- R&D Product Development & Manufacturing
- Organization Design to Drive P&L Growth<\/p>","companies":[{"id":81,"name":"Aqua Medical","logo":{"id":282,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/282\/aqua-medical.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/282\/conversions\/aqua-medical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/282\/conversions\/aqua-medical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/282\/conversions\/aqua-medical-large.webp"},"type":"presenter","description":"

Treating gastrointestinal disease with disruptive, vapor-based endoscopic ablation therapy.<\/p>\r\n

Visit website<\/em>.<\/a><\/p>","created_at":"2024-06-21T22:42:11.000000Z"}],"created_at":"2024-06-21T22:42:12.000000Z"},{"id":113,"name":"Victor Gura","title":"CEO","photo":{"id":285,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/285\/victor-gura.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/285\/conversions\/victor-gura-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/285\/conversions\/victor-gura-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/285\/conversions\/victor-gura-large.webp"},"category":"innovators","roles":["C"],"company_name":"Wearable Artificial Organs","linkedin_profile":null,"biography":"

Dr. Victor Gura is a world-renowned board-certified internist and nephrologist serving patients throughout the Beverly Hills, California area. Specializing in the diagnosis and treatment of kidney diseases and dialysis technology in addition to internal medicine, Dr. Gura offers patients a comprehensive array of treatment options using the most advanced techniques and approaches to care, including treatment for diabetes, high blood pressure (hypertension), acute kidney injury (AKI), chronic kidney disease, end-stage renal disease (ESRD) and proteinuria, as well as routine physical exams and preventative medicine aimed at helping patients maintain optimal health at every age and every stage of life.

At his practice in Beverly Hills, California, Dr. Gura provides compassionate, patient-centered care based on each patient’s unique needs to help ensure the best possible outcomes. The office is equipped with state-of-the-art technology to provide patients with cutting-edge care in a relaxed setting designed for patient comfort. Every patient receives in-depth information about their care options and their medical condition so they can feel confident about their care throughout treatment.<\/p>","companies":[{"id":82,"name":"Wearable Artificial Organs","logo":{"id":284,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/284\/wearable-artificial-organs.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/284\/conversions\/wearable-artificial-organs-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/284\/conversions\/wearable-artificial-organs-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/284\/conversions\/wearable-artificial-organs-large.webp"},"type":"presenter","description":"

Wearable Artificial Organs is developing truly portable solutions for use in patients with End Stage Renal Disease (ESRD). The company has currently prototyped two wearable device, a cordless continuous renal replacement therapy (CRRT) system and a wearable artificial kidney. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-06-21T22:43:26.000000Z"}],"created_at":"2024-06-21T22:43:27.000000Z"},{"id":114,"name":"Greg Roche","title":"CEO","photo":{"id":287,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/287\/greg-roche-distalmotion.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/287\/conversions\/greg-roche-distalmotion-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/287\/conversions\/greg-roche-distalmotion-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/287\/conversions\/greg-roche-distalmotion-large.webp"},"category":"innovators","roles":["C"],"company_name":"Distalmotion","linkedin_profile":"https:\/\/www.linkedin.com\/in\/greg-roche-ba09569\/","biography":"

Experienced Medical Device Executive with a demonstrated history of building high performance cultures. Skilled in Medical Devices, Sales and Marketing, General Management, Operations, M&A, and Product Development. Received Juris Doctorate from Cleveland State University - Cleveland-Marshall College of Law and Bachelor of Arts from Miami University.<\/p>","companies":[{"id":83,"name":"Distalmotion","logo":{"id":286,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/286\/Screenshot-2024-01-23-123426.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/286\/conversions\/Screenshot-2024-01-23-123426-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/286\/conversions\/Screenshot-2024-01-23-123426-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/286\/conversions\/Screenshot-2024-01-23-123426-large.webp"},"type":"presenter","description":"

Distalmotion is a medical device company founded in Lausanne, Switzerland with a mission to empower robotic surgery to more hospitals, surgeons, and patients worldwide.  Distalmotion is commercial with multiple installations across France, Germany, and Switzerland. Its surgical robot Dexter® is designed to deliver the benefits of robotics to more hospitals by being simple and straightforward to use, and more accessible as a modular, small format, and open system. As an open system, Dexter is designed to work natively with third party 3D imaging systems, energy devices, vessel sealers and other laparoscopic devices. It has a suite of fully wristed single use instruments providing the user with dexterity, precision of movement, reliable instrument performance, and lower reprocessing requirements.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-06-21T22:45:08.000000Z"}],"created_at":"2024-06-21T22:45:09.000000Z"},{"id":115,"name":"Thang Vo-Ta","title":"CEO & Co-Founder","photo":{"id":288,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/288\/thang-vo-ta-calla_lily.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/288\/conversions\/thang-vo-ta-calla_lily-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/288\/conversions\/thang-vo-ta-calla_lily-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/288\/conversions\/thang-vo-ta-calla_lily-large.webp"},"category":"innovators","roles":["C"],"company_name":"Calla Lily Clinical Care","linkedin_profile":"https:\/\/www.linkedin.com\/in\/thangv\/","biography":"

It's my privilege and honour to be an advocate and entrepreneur in the Women's Health space. I co-founded Calla Lily Clinical Care with Dr Lara Zibners, which has invented Callavid® a new leak-free, convenient and dosage-confident delivery platform for vaginally-delivered drugs. We are initially focused on delivering progesterone for miscarriage prevention and IVF, where there is an unmet need for a patient-friendlier means of drug administration during an already stressful fertility journey. Our platform device has a wide array of further applications being developed including for a healthy vaginal microbiome through live biotherapeutic (LBP) delivery, and as an effective sample diagnostic collection device.

I am also the co-founder of Callaly, a period care brand which invented, developed and manufactures the Tampliner® - named one of TIME's Best Inventions of the Year as \"the next-gen Tampon\". Fast Company named us one of the world's Most Innovative Companies; Calla Lily Clinical Care \/ Callaly has proudly been a Certified B-Corp since 2017.<\/p>","companies":[{"id":84,"name":"Calla Lily Clinical Care","logo":{"id":289,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/289\/calla_lily_clinical_care_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/289\/conversions\/calla_lily_clinical_care_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/289\/conversions\/calla_lily_clinical_care_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/289\/conversions\/calla_lily_clinical_care_logo-large.webp"},"type":"presenter","description":"

Calla Lily Clinical Care is a women's health focused company which has developed the proprietary Callavid® platform for intravaginal drug delivery. Initial target indications are in IVF and miscarriage prevention, followed by delivery of live biotherapeutics (LBPs) to reduce antibiotic usage which contributes to antimicrobial resistance (AMR). Further use-cases include effective sample collection to facilitate the next generation of biomarker-based diagnostic tests for endometriosis and a wide range of other conditions.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-06-21T22:53:15.000000Z"}],"created_at":"2024-06-21T22:51:13.000000Z"},{"id":116,"name":"Lara Zibners","title":"Co-Founder & Chairman","photo":{"id":290,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/290\/Dr-Lara-Zibners-Lohr---square.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/290\/conversions\/Dr-Lara-Zibners-Lohr---square-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/290\/conversions\/Dr-Lara-Zibners-Lohr---square-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/290\/conversions\/Dr-Lara-Zibners-Lohr---square-large.webp"},"category":"innovators","roles":["C"],"company_name":"Calla Lily Clinical Care","linkedin_profile":"https:\/\/www.linkedin.com\/in\/laraz\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":84,"name":"Calla Lily Clinical Care","logo":{"id":289,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/289\/calla_lily_clinical_care_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/289\/conversions\/calla_lily_clinical_care_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/289\/conversions\/calla_lily_clinical_care_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/289\/conversions\/calla_lily_clinical_care_logo-large.webp"},"type":"presenter","description":"

Calla Lily Clinical Care is a women's health focused company which has developed the proprietary Callavid® platform for intravaginal drug delivery. Initial target indications are in IVF and miscarriage prevention, followed by delivery of live biotherapeutics (LBPs) to reduce antibiotic usage which contributes to antimicrobial resistance (AMR). Further use-cases include effective sample collection to facilitate the next generation of biomarker-based diagnostic tests for endometriosis and a wide range of other conditions.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-06-21T22:53:15.000000Z"}],"created_at":"2024-06-25T23:26:50.000000Z"},{"id":117,"name":"Richard Vincent","title":"CEO","photo":{"id":296,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/296\/Richard-Vincent.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/296\/conversions\/Richard-Vincent-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/296\/conversions\/Richard-Vincent-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/296\/conversions\/Richard-Vincent-large.webp"},"category":"innovators","roles":["C"],"company_name":"FundamentalVR","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ravincent\/","biography":"

Richard brings 20+ years’ experience in building international businesses and has throughout his career sought opportunities for positive market disruption through technological application.
It was this desire that led him to co-found FundamentalVR to help address an age-old problem for the medical market; how to create safe, realistic, measurable spaces to learn and develop skills.
In his role as CEO Richard is responsible for building a world-class team of medical, learning, and technologist who together can realize the company’s ambition of creating the world’s first global, haptically enabled, low-cost ‘flight simulator for surgeons’.<\/p>","companies":[{"id":85,"name":"FundamentalVR","logo":{"id":295,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/295\/fundamentalvr.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/295\/conversions\/fundamentalvr-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/295\/conversions\/fundamentalvr-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/295\/conversions\/fundamentalvr-large.webp"},"type":"presenter","description":"

FundamentalVR offers an Immersive VR platform for specialty suite procedures and is a strategic partner helping med-device leaders to solve the Competency at Scale Gap. Through its purpose-built immersive VR platform, FundamentalVR provides high-fidelity VR, including unique HapticVR capabilities, for the precision of specialty surgeries, as well as behavioral telemetry and assessment data for AI\/ML-driven insights. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-06-25T23:31:50.000000Z"}],"created_at":"2024-06-25T23:38:54.000000Z"},{"id":118,"name":"Thomas Nichols","title":"President","photo":{"id":298,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/298\/Thomas-Nichols-Pretika.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/298\/conversions\/Thomas-Nichols-Pretika-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/298\/conversions\/Thomas-Nichols-Pretika-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/298\/conversions\/Thomas-Nichols-Pretika-large.webp"},"category":"innovators","roles":["C"],"company_name":"Pretika","linkedin_profile":"https:\/\/www.linkedin.com\/in\/thomasnicholsca\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":86,"name":"Pretika","logo":{"id":297,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/297\/pretika-medtech.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/297\/conversions\/pretika-medtech-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/297\/conversions\/pretika-medtech-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/297\/conversions\/pretika-medtech-large.webp"},"type":"presenter_innovator","description":"

Pretika MedTech is reimagining outpatient and inpatient care with AI-powered Connected Wound Care technology.  The company's non-invasive, embedded medical device and wireless digital care cloud platform provides on demand or continuous imaging, sensor and data analytics for physicians and nursing teams to monitor post-surgery, wound and disease healing remotely or in-person without having to remove the surgical dressings, bandages, wraps or casts.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-06-25T23:41:13.000000Z"}],"created_at":"2024-06-25T23:41:14.000000Z"},{"id":119,"name":"Joseph Rafferty","title":"CEO","photo":{"id":300,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/300\/joseph-rafferty-vesteck.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/300\/conversions\/joseph-rafferty-vesteck-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/300\/conversions\/joseph-rafferty-vesteck-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/300\/conversions\/joseph-rafferty-vesteck-large.webp"},"category":"innovators","roles":["C"],"company_name":"VESTECK","linkedin_profile":"https:\/\/www.linkedin.com\/in\/joseph-w-rafferty-a5579b4\/","biography":"

Joseph W. Rafferty Sr. is a Founder and CEO of VESTECK, Inc.

VESTECK is a clinical stage endovascular platform technology in the aortic repair, structural heart and surgical markets.  The “Suture-Tight”tm catheter delivers preloaded nitinol sutures to EVAR\/TEVAR endovascular grafts securing the grafts to the aorta, either at the time of initial implant or reintervention.  Global opinion leaders tell us that the “Suture-Tight”tm will bring significant benefit to patients, physicians and payors.

Mr. Rafferty has leveraged his education with global strategic organizations like ACS\/Guidant, CR Bard and J&J Ethicon, to create value, bringing novel technology to the global health care community at startup companies like Pathway Medical, NMS and VESTECK.

Mr. Rafferty is a proud graduate of The Temple University, Philadelphia, PA.  
He and his wife Beth are the proud parents of 4 wonderful children and 4 beautiful grandchildren.<\/p>","companies":[{"id":87,"name":"VESTECK","logo":{"id":299,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/299\/Vesteck.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/299\/conversions\/Vesteck-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/299\/conversions\/Vesteck-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/299\/conversions\/Vesteck-large.webp"},"type":"presenter","description":"

VESTECK Suture-Tight catheter secures endovascular aortic grafts to the aorta at the time of implant or during repair procedures.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-06-25T23:42:44.000000Z"}],"created_at":"2024-06-25T23:42:44.000000Z"},{"id":124,"name":"Conner Herman","title":"CEO","photo":{"id":309,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/309\/conner-herman-percy.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/309\/conversions\/conner-herman-percy-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/309\/conversions\/conner-herman-percy-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/309\/conversions\/conner-herman-percy-large.webp"},"category":"innovators","roles":["C"],"company_name":"Percy","linkedin_profile":"https:\/\/www.linkedin.com\/in\/connerherman\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":91,"name":"Percy","logo":{"id":307,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/307\/Screenshot-2023-11-28-153853.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/307\/conversions\/Screenshot-2023-11-28-153853-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/307\/conversions\/Screenshot-2023-11-28-153853-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/307\/conversions\/Screenshot-2023-11-28-153853-large.webp"},"type":"presenter","description":"

Percy is using technology to capture insights that are converted into science-backed behavioral changes to improve sleep.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-06-25T23:45:28.000000Z"}],"created_at":"2024-06-25T23:47:46.000000Z"},{"id":125,"name":"Howard Leonhardt","title":"CEO","photo":{"id":362,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/362\/Howard-badge-photo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/362\/conversions\/Howard-badge-photo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/362\/conversions\/Howard-badge-photo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/362\/conversions\/Howard-badge-photo-large.webp"},"category":"innovators","roles":["C"],"company_name":"Lionheart Health","linkedin_profile":"https:\/\/www.linkedin.com\/in\/howard-leonhardt-6694185\/","biography":"

Founder, Executive Chairman & CEO of Lionheart Health, Inc. and Leonhardt Ventures LLC. Leonhardt Ventures LLC just celebrated their 40th Anniversary year in 2022. Over 700,000 patients have been treated with Leonhardt inventions.  Over 700 patent claims issued, pending, optioned or licensed to Howard Leonhardt for healthspan longevity extension, organ regeneration and healing. Inventions generate nearly $2 billion in revenues annually for their acquirers. Competing for $101 million XPRIZE for HealthSpan Extension. Founder of over 40 startups since 1982. Inventor of leading stent graft and percutaneous heart valve systems. Led team that completed first stem cell regeneration of a human heart without surgery in 2001. Working on developing a TOTAL BODY REGENERATION CHAMBER \"Womb for Adults\".  <\/p>","companies":[{"id":92,"name":"Lionheart Health","logo":{"id":310,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/310\/Lionheart.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/310\/conversions\/Lionheart-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/310\/conversions\/Lionheart-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/310\/conversions\/Lionheart-large.webp"},"type":"presenter","description":"

Lionheart Health is using targeted bioelectric treatment to stimulate the body's natural healing and regeneration. Specific bioelectric signaling sequences have been shown to promote the expression of proteins for cosmetic purposes, as well as in pathways related to brain, muscle and nerve regeneration. The core stimulation technology has been purposefully implemented into a number of wearable devices targeting specific clinical indications. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-06-25T23:48:46.000000Z"}],"created_at":"2024-06-25T23:48:47.000000Z"},{"id":126,"name":"Britton Garrett","title":"CEO","photo":{"id":315,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/315\/britton-garrett-io_urology.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/315\/conversions\/britton-garrett-io_urology-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/315\/conversions\/britton-garrett-io_urology-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/315\/conversions\/britton-garrett-io_urology-large.webp"},"category":"innovators","roles":["C"],"company_name":"IO Urology","linkedin_profile":"https:\/\/www.linkedin.com\/in\/britton-garrett-7682b574\/","biography":"

Britton Garrett is a visionary executive with extensive experience in the healthcare sector, particularly in disruptive technologies and urology. As CEO of iO Urology, he leads strategic initiatives and drives growth in innovative urologic care solutions. He has deep past and current success raising capital and scaling organizations to meet their potential.<\/p>\r\n

Previously, Britton was President of Senior Health & Wellness at Consortia Health, where he built and scaled the senior health business. His 11 year tenure at Medtronic included leading the commercialization of PTNM therapy and managing strategic market development. With a background in leadership, sales, and market strategy, Britton excels in shaping and executing commercial strategies in the healthcare industry.<\/p>\r\n

 <\/p>","companies":[{"id":93,"name":"IO Urology","logo":{"id":316,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/316\/io_urology.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/316\/conversions\/io_urology-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/316\/conversions\/io_urology-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/316\/conversions\/io_urology-large.webp"},"type":"presenter","description":"

iO Urology aims to improve the lives of people living with urologic conditions. The company’s CarePath device is a remote patient monitoring system to promote urologic care at home. CarePath provides real-time, quantitative measurement of urinary output and flow to support the management of lower urinary tract symptoms from conditions such and benign prostatic hypertrophy and overactive bladder. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-07-19T05:23:10.000000Z"}],"created_at":"2024-07-19T05:18:17.000000Z"},{"id":127,"name":"Amrish Nair","title":"Founder\/Director","photo":{"id":1175,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1175\/Amrish-Nair-Biorithm-usa.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1175\/conversions\/Amrish-Nair-Biorithm-usa-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1175\/conversions\/Amrish-Nair-Biorithm-usa-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1175\/conversions\/Amrish-Nair-Biorithm-usa-large.webp"},"category":"innovators","roles":["C"],"company_name":"Biorithm","linkedin_profile":"https:\/\/www.linkedin.com\/in\/amrish-nair-a654314b\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":94,"name":"Biorithm","logo":{"id":320,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/320\/Screenshot-2024-07-30-114716.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/320\/conversions\/Screenshot-2024-07-30-114716-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/320\/conversions\/Screenshot-2024-07-30-114716-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/320\/conversions\/Screenshot-2024-07-30-114716-large.webp"},"type":"presenter","description":"

Femom is a comprehensive maternity care platform to improve perinatal outcomes through mobile technology and data science. Designed for in-home and hospital use, Femom's priority solution enables healthcare professionals to gain new insights to the health of the mother and fetus while offering more convenience and information.<\/p>\r\n

Visit website<\/a><\/em>.<\/p>","created_at":"2024-07-30T18:48:14.000000Z"}],"created_at":"2024-07-30T18:49:01.000000Z"},{"id":128,"name":"Alex Jiao","title":"CEO","photo":{"id":1720,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1720\/Alex-Jiao_edited.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1720\/conversions\/Alex-Jiao_edited-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1720\/conversions\/Alex-Jiao_edited-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1720\/conversions\/Alex-Jiao_edited-large.webp"},"category":"innovators","roles":["C"],"company_name":"Scout Health","linkedin_profile":"https:\/\/www.linkedin.com\/in\/alexjiao\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":95,"name":"Scout Health","logo":{"id":322,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/322\/scout.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/322\/conversions\/scout-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/322\/conversions\/scout-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/322\/conversions\/scout-large.webp"},"type":"presenter","description":"

Scout Health is bringing rapid molecular testing to the point-of-care. The Scout System packages similar technology to PCR lab-grade tests that normally require a clinic to be performed into a small hub and single-use tests. The system is currently approved for the testing of COVID, with additional tests for common illnesses in development. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-07-30T22:41:57.000000Z"}],"created_at":"2024-07-30T22:43:00.000000Z"},{"id":129,"name":"Codi Gharagouzloo","title":"CEO","photo":{"id":324,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/324\/codi-gharagouzloo-imaginostics.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/324\/conversions\/codi-gharagouzloo-imaginostics-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/324\/conversions\/codi-gharagouzloo-imaginostics-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/324\/conversions\/codi-gharagouzloo-imaginostics-large.webp"},"category":"innovators","roles":["C"],"company_name":"Imaginostics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/cghara\/","biography":"

Codi Gharagouzloo, Ph.D., is the scientific founder and CEO of Imaginostics, a health tech startup specializing in the development of groundbreaking vascular imaging biomarkers. Based in Lake Nona Medical City, Orlando, FL, Imaginostics is at the forefront of revolutionizing precision medicine. Dr. Gharagouzloo's leadership and innovation have been central to the development of the Quantitative Ultra-short Time-to-echo Contrast-Enhanced (QUTE-CE) MRI technology, which is reshaping diagnostic approaches for longevity and in neurology, cardiology, and oncology.

Dr. Gharagouzloo, an expert in MRI physics and nanoparticle contrast-enhanced imaging, earned his Ph.D. in Bioengineering from Northeastern University. His academic journey included a transformative two-year T-32 postdoctoral fellowship at the Gordon Center for Medical Imaging, Massachusetts General Hospital, and Harvard Medical School. He obtained his Master of Science in Biophotonics from the Ecole Normale Supérieure de Paris-Saclay, France, specializing in nonlinear optical microscopy. His undergraduate education resulted in dual Bachelor of Science degrees in Physics and Mechanical & Nuclear Engineering from Kansas State University, complemented by a tenure as a National Science Foundation research fellow in particle physics at the Eidgenössische Technische Hochschule in Zürich, Switzerland.

In 2018, Dr. Gharagouzloo founded Imaginostics to translate his groundbreaking quantum physics based medical imaging invention from the bench to bedside. The company's focus is on addressing complex diseases through innovative, gadolinium-free, and renal-safe imaging solutions that offer unparalleled insight into vascular structures, including those around metallic vascular implants. The QUTE-CE MRI technology offers tenfold enhancement of soft tissue visualization compared to traditional gadolinium-based methods and offers the first suite of precision medicine imaging biomarkers for vascular assessment.

Dr. Gharagouzloo's work is driven by a passion for creating the next generation of precision medicine diagnostic tools to understand the brain, and to transform personalized healthcare, accelerate drug development, and fight aging. He leads Imaginostics with a vision to provide early, precise, and less invasive diagnostic solutions, facilitate effective patient stratification in clinical trials, and map the real-time pharmacokinetics of drugs.<\/p>","companies":[{"id":96,"name":"Imaginostics (DO NOT PUBLISH)","logo":{"id":325,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/325\/imaginostics_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/325\/conversions\/imaginostics_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/325\/conversions\/imaginostics_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/325\/conversions\/imaginostics_logo-large.webp"},"type":"presenter","description":"

Imaginostics is developing next-generation diagnostic solutions to support clinicians and drug developers. The company’s QUTE-CE MRI technology is a noninvasive quantitative imaging solution that enhances existing MRI machines with quantitative measuring capabilities to measure vascular function and structure. Imaginostics is actively utilizing its technology in pre-clinical and clinical research in the fields of cardiology, oncology and neuroscience.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-07-30T22:46:53.000000Z"}],"created_at":"2024-07-30T22:46:00.000000Z"},{"id":130,"name":"Evan Luxon","title":"CEO","photo":{"id":364,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/364\/Luxon-Headshot.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/364\/conversions\/Luxon-Headshot-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/364\/conversions\/Luxon-Headshot-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/364\/conversions\/Luxon-Headshot-large.webp"},"category":"innovators","roles":["C"],"company_name":"Centese","linkedin_profile":"https:\/\/www.linkedin.com\/in\/evanluxon\/","biography":"

Evan Luxon is the Co-Founder and CEO of Centese Inc. Prior to founding Centese, he held a variety of technical and management roles in early-stage medtech companies, most recently as the technical co-founder of Potrero Medical. Evan holds engineering degrees from the University of Nebraska (BS), Johns Hopkins (MS), and Stanford (MS<\/p>","companies":[{"id":97,"name":"Centese","logo":{"id":363,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/363\/centese.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/363\/conversions\/centese-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/363\/conversions\/centese-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/363\/conversions\/centese-large.webp"},"type":"presenter","description":"

Transforming surgical drainage with intelligent digital devices to reduce complications and costs in patients recovering from cardiothoracic surgery.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-08-07T18:34:02.000000Z"}],"created_at":"2024-08-07T18:35:04.000000Z"},{"id":131,"name":"Steve Liu","title":"President & CEO","photo":{"id":369,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/369\/steve-liu-rfsafety.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/369\/conversions\/steve-liu-rfsafety-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/369\/conversions\/steve-liu-rfsafety-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/369\/conversions\/steve-liu-rfsafety-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"RF Safety Laboratory","linkedin_profile":"https:\/\/www.linkedin.com\/in\/steveliu97\/","biography":"

Steve Liu is founder & CEO of RF Safety Laboratory, a third-party regulatory compliance lab that helps medtech companies navigate US FCC regulatory and CE mark requirements. He supports companies at key stages—from Seed to Clinical to Commercialization—working in parallel with the FDA process.<\/p>\r\n

For products incorporating technologies like NFC, Bluetooth, or Wi-Fi, etc. his goal is to partner with you to get to the finish line quickly and ultimately saving you valuable time to go to market.<\/p>","companies":[],"created_at":"2024-08-16T19:07:05.000000Z"},{"id":132,"name":"Jamal Rushdy","title":"CEO","photo":{"id":371,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/371\/JR-Portrait-(1).PNG","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/371\/conversions\/JR-Portrait-(1)-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/371\/conversions\/JR-Portrait-(1)-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/371\/conversions\/JR-Portrait-(1)-large.webp"},"category":"innovators","roles":["C"],"company_name":"Arcuro Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jamalrushdy\/","biography":"

Jamal has over 28 years of medical device industry experience. As an executive and board member in public and private PE\/VC-backed companies, he helped secure financing and achieve five successful shareholder exits in companies ranging from less than $5 million to over $300 million. He most recently served as CEO of Collagen Solutions, a high-growth biomaterials CDMO that was listed on the London Stock Exchange and taken private by a U.S. conglomerate. Prior to Collagen Solutions, Jamal was a VP at Tornier, a global orthopedics company, and also held senior leadership positions at DJO, a global orthopedic rehabilitation company now known as Enovis. He holds an MBA from UC Irvine, and a BSME from the UC San Diego. He also serves as Chairman of SetBone Medical, a spinal surgical products company.<\/p>","companies":[{"id":98,"name":"Arcuro Medical","logo":{"id":370,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/370\/ArcuroLogo.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/370\/conversions\/ArcuroLogo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/370\/conversions\/ArcuroLogo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/370\/conversions\/ArcuroLogo-large.webp"},"type":"presenter","description":"

Arcuro Medical is a commercial-stage medical device company focused on meniscus preservation, a high-growth area of orthopedics with unmet clinical needs. The company’s first product, the SuperBall™ Meniscal Repair System, has been successfully utilized in over 4,000 successful surgical cases since commercial launch. The company continues the development of game-changing technologies for sports medicine to improve the lives of patients.<\/p>\r\n

Visit website<\/a><\/em>.<\/p>","created_at":"2024-08-20T16:49:37.000000Z"}],"created_at":"2024-08-20T17:07:29.000000Z"},{"id":146,"name":"Ray Liu","title":"CEO & Co-Founder","photo":{"id":390,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/390\/RAY-LIU_Vena-Vitals.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/390\/conversions\/RAY-LIU_Vena-Vitals-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/390\/conversions\/RAY-LIU_Vena-Vitals-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/390\/conversions\/RAY-LIU_Vena-Vitals-large.webp"},"category":"innovators","roles":["C"],"company_name":"Vena Vitals","linkedin_profile":"https:\/\/www.linkedin.com\/in\/rayliu\/","biography":"

Mr. Liu will share the Vena Vitals story at the Emerging Medtech Summit and will discuss investment and strategic partnering opportunities. <\/p>\r\n

Ray is an executive leader in healthcare technology, with expertise in building, launching, and running products and services for both startups and multinationals. Prior to Vena Vitals, he ran product and operations for Ediom, where he created hospital decision support tools that led to the company's acquisition by Vizient, Inc. Ray also led product for Socialwellth, where he directed the development and launch of a consumer health engagement platform that was rolled out to 15.2M users, leading to the company's acquisition by Cigna. <\/p>\r\n

At Siemens, Ray developed strategies, turnaround plans, and new market entries for the healthcare, energy, and industrial business units, and at GE Healthcare, he led the global launch of patient vital sign monitoring devices from China to the rest of the world. In addition to co-founding and running Vena Vitals, Ray also serves as an advisor to MDstewardship, a telemedicine company focused on antimicrobial stewardship. Ray holds an MBA from Harvard Business School, an MS from the University of California at Berkeley, and a BS from the University of Illinois at Urbana-Champaign. <\/p>","companies":[{"id":103,"name":"Vena Vitals","logo":{"id":389,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/389\/vena-vitals.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/389\/conversions\/vena-vitals-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/389\/conversions\/vena-vitals-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/389\/conversions\/vena-vitals-large.webp"},"type":"presenter","description":"

Vena Vitals is an early stage med-tech company focused on non-invasive continuous blood pressure monitoring. The company's proprietary technology is a soft flexible sensor that conforms to the skin for direct pressure measurement at theradial artery. The company's technology is intended to replace unnecessarily invasive arterial line measurements as well as non-continuous cuff-based methods in both the hospital and at home.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-08-20T17:53:57.000000Z"}],"created_at":"2024-08-20T17:53:58.000000Z"},{"id":148,"name":"Christine Horton","title":"CEO","photo":{"id":393,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/393\/Christine-Horton-Visura.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/393\/conversions\/Christine-Horton-Visura-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/393\/conversions\/Christine-Horton-Visura-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/393\/conversions\/Christine-Horton-Visura-large.webp"},"category":"innovators","roles":["C"],"company_name":"Visura Technologies","linkedin_profile":"https:\/\/www.linkedin.com\/in\/christine-h-10a81930\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":104,"name":"Visura Technologies","logo":{"id":392,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/392\/Visura.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/392\/conversions\/Visura-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/392\/conversions\/Visura-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/392\/conversions\/Visura-large.webp"},"type":"presenter","description":"

Visura manufacturers the world's first, FDA-cleared, disposable camera, the TEECAD System, that seamlessly connects to a transesophageal echocardiogram (TEE) echo probe, providing physicians real-time visualization for more efficient and effective probe placement for safer intubation.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-08-20T17:56:51.000000Z"}],"created_at":"2024-08-20T17:56:52.000000Z"},{"id":149,"name":"David Giarracco","title":"CEO","photo":{"id":395,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/395\/1585764816766.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/395\/conversions\/1585764816766-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/395\/conversions\/1585764816766-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/395\/conversions\/1585764816766-large.webp"},"category":"innovators","roles":["C"],"company_name":"Noninvasix","linkedin_profile":"https:\/\/www.linkedin.com\/in\/davidgiarracco\/","biography":"

I am a medical device executive with over twenty-five years of leadership experience spanning quality, engineering, and operations including product line, business integrations and new product launches, six-sigma implementations for both operations and business process, and US and global marketing in surgical and monitoring environments.

My leadership was crafted in big corporate America as well as within the start-up ecosystem. My experiences span business development (target identification, business case development, diligence), product development (concept through commercialization), into tactical commercial execution bringing innovative solutions to new sites. Market segments span the \"admit to discharge\" care continuum including the highest acuity in the OR\/ICU through terminal chronic care and home care environments.<\/p>","companies":[{"id":105,"name":"Noninvasix","logo":{"id":394,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/394\/1650262182192.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/394\/conversions\/1650262182192-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/394\/conversions\/1650262182192-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/394\/conversions\/1650262182192-large.webp"},"type":"presenter","description":"

Noninvasix is using optoacoustic technology to monitor critically ill patients in the hospital. The company is developing a non-invasive device monitor patients for sepsis and septic shock in real-time. The device will enable healthcare providers to rapidly diagnose, monitor, and respond to these life-threatening conditions in patients.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-08-20T17:58:57.000000Z"}],"created_at":"2024-08-20T17:58:57.000000Z"},{"id":150,"name":"Scott Crawley","title":"Co-Founder, CEO","photo":{"id":397,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/397\/1684531376003.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/397\/conversions\/1684531376003-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/397\/conversions\/1684531376003-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/397\/conversions\/1684531376003-large.webp"},"category":"innovators","roles":["C"],"company_name":"Compass HealthAI","linkedin_profile":"https:\/\/www.linkedin.com\/in\/scott-crawley\/","biography":"

Proven MedTech commercial leader. Emphasis on launching and scaling disruptive innovations and therapies. Core strengths in strategic sales & marketing, Government relations and Distribution\/Operations for all major clinical areas and channels. International management experience in the US, Canada, and Asia Pacific.<\/span><\/p>","companies":[{"id":106,"name":"Compass HealthAI (DO NOT PUBLISH)","logo":{"id":396,"mime_type":"image\/svg+xml","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/396\/compass-logo.svg","url_small":null,"url_medium":null,"url_large":null},"type":"presenter","description":"

Compass HealthAI is medical technology platform company developing diagnostic & interventional solutions for the treatment of age-related diseases. The company's leading platform is a Corneal Photo-Vitrification Laser that immediately restores unprecedented visual acuity in late-stage macular disease patients.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-08-20T18:02:03.000000Z"}],"created_at":"2024-08-20T18:03:50.000000Z"},{"id":153,"name":"Eduardo Fonseca","title":"CEO","photo":{"id":417,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/417\/Eduardo_Gradient.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/417\/conversions\/Eduardo_Gradient-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/417\/conversions\/Eduardo_Gradient-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/417\/conversions\/Eduardo_Gradient-large.webp"},"category":"innovators","roles":["C"],"company_name":"EndoQuest Robotics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/efw\/","biography":"

XCath Chief Executive Officer Eduardo Fonseca was formerly an Investment Director in the Crescent Group Investments Team and the Chief Corporate Development Officer of Gulftainer USA.

In addition to leading the strategic direction of XCath, he is a member of the Board of Directors for Endoquest Robotics Inc. Prior to joining Crescent Group, Fonseca was the first Panamanian Ambassador to the United Arab Emirates and the first Ambassador to Saudi Arabia. 

He holds an MBA from INSEAD, a BS in Commerce from Santa Clara University, and is a member of the National Association of Corporate Directors (NACD.)                    <\/p>\r\n

                                                    <\/p>","companies":[{"id":107,"name":"XCath (DO NOT PUBLISH)","logo":{"id":401,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/401\/xcath_red.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/401\/conversions\/xcath_red-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/401\/conversions\/xcath_red-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/401\/conversions\/xcath_red-large.webp"},"type":"presenter","description":"

Found in 2017, XCath is a dynamic startup focused on the development of neuro-endovascular telerobotics. It develops next-generation endovascular robotic systems and steerable guidewires to treat cerebrovascular disorders and other life-threatening conditions. XCath is headquartered in Houston and has a robotics R&D office in South Korea.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-08-20T18:14:16.000000Z"}],"created_at":"2024-08-20T18:11:58.000000Z"},{"id":154,"name":"Yoonho Kim","title":"Founder and CEO","photo":{"id":402,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/402\/1720470176631.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/402\/conversions\/1720470176631-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/402\/conversions\/1720470176631-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/402\/conversions\/1720470176631-large.webp"},"category":"innovators","roles":["C"],"company_name":"Magnendo","linkedin_profile":"https:\/\/www.linkedin.com\/in\/yoonhokim409\/","biography":"

Inventor and technical lead, MIT Technology Review Innovator Under 35 (2022)<\/p>","companies":[{"id":108,"name":"Magnendo","logo":{"id":403,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/403\/magnendo_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/403\/conversions\/magnendo_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/403\/conversions\/magnendo_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/403\/conversions\/magnendo_logo-large.webp"},"type":"presenter","description":"

Magnendo is developing a robotic system that will enable physicians to reach previously untreatable areas of the brain. Difficult to reach aneurysms and strokes can delay treatment and lead to poor clinical outcomes for patients. The company's magnetically steerable soft-robotic guidewire enables expedited and safer access to hard-to-reach regions of the brain that will add value to physicians and improve the lives of patients requiring neurovascular care.<\/p>\r\n

Visit website<\/a>.<\/em><\/p>","created_at":"2024-08-20T18:19:13.000000Z"}],"created_at":"2024-08-20T18:17:45.000000Z"},{"id":155,"name":"John Wong","title":"Co-Founder and CEO","photo":{"id":404,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/404\/1645410287308.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/404\/conversions\/1645410287308-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/404\/conversions\/1645410287308-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/404\/conversions\/1645410287308-large.webp"},"category":"innovators","roles":["C"],"company_name":"Fluid Biomed","linkedin_profile":"https:\/\/www.linkedin.com\/in\/john-wong-neurosurgeon\/","biography":"

\r\n
\r\n
\r\n
Dr. John H. Wong is an associate professor in the Departments of Clinical Neurosciences and Radiology at the Cumming School of Medicine. He serves as Director of Cerebrovascular and Endovascular Neurosurgery and maintains an active clinical practice dedicated to treating brain aneurysms and stroke. Dr. Wong received his medical education and neurosurgical training at the University of Alberta. After a one-year fellowship in neurovascular surgery at Yale University and further two-year specialization in interventional neuroradiology in New York City, he was recruited to Calgary in 2001. Since then, he has helped develop one of the most collaborative and productive neurovascular and stroke units in North America with colleagues in neurology, radiology, and neurosurgery. Dr. Wong has co-authored numerous peer-reviewed manuscripts and has served on several grant review panels including for the Canadian Institute of Health Research, and the National Institutes of Health in the U.S. He has held numerous local and national leadership roles including the former president of the Alberta Neurosurgical Society for over a decade, past Division Head of Neurosurgery at the University of Calgary, and is the current Vice President of the Canadian Neurosurgical Society. Dr. Wong received his MBA from the Wharton Executive MBA program in San Francisco. He is also co-founder and CEO of Fluid Biomed Inc., a venture-backed medical device startup company that is commercializing innovative brain stent technology.<\/span>Dr. John H. Wong is an associate professor in the Departments of Clinical Neurosciences and Radiology at the Cumming School of Medicine. He serves as Director of Cerebrovascular and Endovascular Neurosurgery and maintains an active clinical practice dedicated to treating brain aneurysms and stroke. Dr. Wong received his medical education and neurosurgical training at the University of Alberta. After a one-year fellowship in neurovascular surgery at Yale University and further two-year specialization in interventional neuroradiology in New York City, he was recruited to Calgary in 2001. Since then, he has helped develop one of the most collaborative and productive neurovascular and stroke units in North America with colleagues in neurology, radiology, and neurosurgery. Dr. Wong has co-authored numerous peer-reviewed manuscripts and has served on several grant review panels including for the Canadian Institute of Health Research, and the National Institutes of Health in the U.S. He has held numerous local and national leadership roles including the former president of the Alberta Neurosurgical Society for over a decade, past Division Head of Neurosurgery at the University of Calgary, and is the current Vice President of the Canadian Neurosurgical Society. Dr. Wong received his MBA from the Wharton Executive MBA program in San Francisco. He is also co-founder and CEO of Fluid Biomed Inc., a venture-backed medical device startup company that is commercializing innovative brain stent technology.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[{"id":109,"name":"Fluid Biomed","logo":{"id":405,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/405\/fluid_biotech_inc_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/405\/conversions\/fluid_biotech_inc_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/405\/conversions\/fluid_biotech_inc_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/405\/conversions\/fluid_biotech_inc_logo-large.webp"},"type":"presenter","description":"

Fluid Biomed is a VC-backed pre-clinical medical device start-up that has developed the world’s first bio-resorbable stent to cure brain aneurysms. The company's innovative polymer technology allows physicians the versatility of treating a wider variety of aneurysms more safely and efficiently. <\/p>\r\n

Visit website<\/a>.<\/em><\/p>","created_at":"2024-08-20T18:23:10.000000Z"}],"created_at":"2024-08-20T18:22:10.000000Z"},{"id":156,"name":"Barry Allen","title":"CEO","photo":{"id":407,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/407\/barry-allen.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/407\/conversions\/barry-allen-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/407\/conversions\/barry-allen-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/407\/conversions\/barry-allen-large.webp"},"category":"innovators","roles":["C"],"company_name":"Sonic Incytes Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/barry-allen-9316237\/","biography":"

Barry Allen is a serial founder and operator with more than 25 years of executive management and board experience in the medtech, software and digital industries in both public and private companies. Barry’s start-up experience includes Founder, Chair and CEO of Zolo, President & CEO of PureWeb Inc., Founder and CEO of VSM MedTech, Founder and CEO of Urodynamix. Barry’s community involvement includes Associate Creative Destruction Labs West and Rockies,  Founder and Chair of the BC Excels Program, Entrepreneur in Residence at Ventures West, and lead mentor with BC Innovation Council. Barry has held a number of directorships in private and public companies and is currently the Chair and Director of Zolo and Orpyx.<\/p>","companies":[{"id":110,"name":"Sonic Incytes Medical","logo":{"id":406,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/406\/sonic-incytes-medical.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/406\/conversions\/sonic-incytes-medical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/406\/conversions\/sonic-incytes-medical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/406\/conversions\/sonic-incytes-medical-large.webp"},"type":"presenter","description":"

Velacur is a portable, handheld ultrasound that integrates machine learning to enhance image guidance, resulting in a confident assessment of liver health in all body types.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-08-20T18:27:31.000000Z"}],"created_at":"2024-08-20T18:27:32.000000Z"},{"id":157,"name":"Patrick MacCarthy","title":"CEO","photo":{"id":409,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/409\/1714764938730.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/409\/conversions\/1714764938730-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/409\/conversions\/1714764938730-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/409\/conversions\/1714764938730-large.webp"},"category":"innovators","roles":["C"],"company_name":"Butterfly Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/patrick-maccarthy-bb51aa6\/","biography":"

\r\n
\r\n
\r\n
Commercial leader with broad-based experience in the medical device and technology sectors. Strong technical background combined with rigorous business development and management experience. Full P&L responsibility, with experience launching a start-up medical device portfolio as well as growing a $20M product line into a thriving $100M+ business in five years. Proven record of rapid advancement and leadership, spanning Fortune 500 to start-up organizations. Passion for working with people, along with a high tolerance for change and ambiguity.<\/span>Commercial leader with broad-based experience in the medical device and technology sectors. Strong technical background combined with rigorous business development and management experience. Full P&L responsibility, with experience launching a start-up medical device portfolio as well as growing a $20M product line into a thriving $100M+ business in five years. Proven record of rapid advancement and leadership, spanning Fortune 500 to start-up organizations. Passion for working with people, along with a high tolerance for change and ambiguity.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[{"id":111,"name":"Butterfly Medical","logo":{"id":408,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/408\/1631375743708.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/408\/conversions\/1631375743708-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/408\/conversions\/1631375743708-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/408\/conversions\/1631375743708-large.webp"},"type":"presenter","description":"

Butterfly Medical is developing an innovative treatment for benign prostatic hyperplasia (BPH). The company's implantable device can be inserted without surgery to provide relief from symptomatic BPH. The implantation procedure can be performed in under ten minutes in a physician's office using local anesthesia.<\/p>\r\n

Visit website<\/a>.<\/em><\/p>","created_at":"2024-08-20T18:29:55.000000Z"}],"created_at":"2024-08-20T18:35:16.000000Z"},{"id":158,"name":"Tomir Kosowski","title":"Co-Founder and CEO","photo":{"id":410,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/410\/1565011174388.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/410\/conversions\/1565011174388-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/410\/conversions\/1565011174388-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/410\/conversions\/1565011174388-large.webp"},"category":"innovators","roles":["C"],"company_name":"Altach Biomedical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/tomir-kosowski-8331504a\/","biography":"

\r\n
\r\n
\r\n
Enthusiastic, entrepreneurial and dynamic executive focused on Orthopaedics and Sports Medicine. Currently Chief Executive Officer at Altach Biomedical(and NLC Venture). Experience in sales, marketing, management and business development, with pre & post-commercial experience in start-ups, SME’s and multinational organisations. Passion for breakthrough technologies and joint preservation.

Altach Biomedical (and NLC Venture) is focused on becoming the new gold standard in regenerative cartilage technology. We are a spin-out from Trinity College in Dublin and are currently in the process of raising funds for our next phase of product development. If you are interested more about the opportunity to take part in an early stage health tech investment please email me at: t.kosowski@altach.health<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[{"id":112,"name":"Altach","logo":{"id":411,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/411\/altach_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/411\/conversions\/altach_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/411\/conversions\/altach_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/411\/conversions\/altach_logo-large.webp"},"type":"presenter","description":"

Altach is developing a portfolio of biomimetic cartilage scaffolds to address the increasing global burden of cartilage defects. Utilizing Type II collagen, the company is creating biocompatible scaffolds that can be used alone or in conjunction with cell-based therapies to create an environment that is conducive to cell migration and regeneration of cartilage, as well as osteochondral defects.<\/p>\r\n

Visit website<\/a>.<\/em><\/p>","created_at":"2024-08-20T18:42:28.000000Z"}],"created_at":"2024-08-20T18:41:32.000000Z"},{"id":159,"name":"Antony Odell","title":"CEO","photo":{"id":412,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/412\/1723180384870.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/412\/conversions\/1723180384870-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/412\/conversions\/1723180384870-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/412\/conversions\/1723180384870-large.webp"},"category":"innovators","roles":["C"],"company_name":"Echopoint Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/antonyrodell\/","biography":"

\r\n
\r\n
\r\n
I am a proactive, strategic thinking individual that has grown multiple businesses from the ground up as well as ‘turnarounds’. Experience includes, listing on AIM, securing new blue-chip investors and completing multiple funding rounds as well as M&A. I'm currently working with a number of exciting start-ups in Medtech, Pharma and Agrochemicals in both executive and non-executive capacities.<\/span>I am a proactive, strategic thinking individual that has grown multiple businesses from the ground up as well as ‘turnarounds’. Experience includes, listing on AIM, securing new blue-chip investors and completing multiple funding rounds as well as M&A. I'm currently working with a number of exciting start-ups in Medtech, Pharma and Agrochemicals in both executive and non-executive capacities.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[{"id":102,"name":"Echopoint Medical","logo":{"id":378,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/378\/echopoint-logo-1.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/378\/conversions\/echopoint-logo-1-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/378\/conversions\/echopoint-logo-1-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/378\/conversions\/echopoint-logo-1-large.webp"},"type":"presenter","description":"

Echopoint Medical is developing a family of optical-fiber based sensors which integrate into microcatheters to guide and improve outcomes during interventional cardiology procedures. The company's iKor platform translates ultrasonic signals to measure blood pressure and flow to more accurately assess, diagnose and treat patients with coronary artery disease and coronary microvascular dysfunction.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-08-20T17:31:44.000000Z"}],"created_at":"2024-08-20T19:22:40.000000Z"},{"id":160,"name":"Vishal Gulati","title":"Founder and Managing Partner","photo":{"id":1731,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1731\/86F98258-745B-42E7-9065-6E38FED29ABD.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1731\/conversions\/86F98258-745B-42E7-9065-6E38FED29ABD-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1731\/conversions\/86F98258-745B-42E7-9065-6E38FED29ABD-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1731\/conversions\/86F98258-745B-42E7-9065-6E38FED29ABD-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Recode Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/healthtechvc\/","biography":"

\r\n
\r\n
\r\n
Dr. Vishal Gulati is a specialist venture capital investor backing scientists and tech founders bring their innovations to market. Prior to becoming a VC, Vishal trained as a clinician scientist at University of Oxford and Imperial College, London which gives him a rare and unique perspective on the journey of scientific discoveries all the way to commercially successful products. Vishal's investment thesis is based around the convergence of healthcare, data and engineering.

Vishal's investment career spanning over two decades includes founding Recode Ventures in San Francisco and serving at leading venture firms such as Atlas Venture, Oxford Science Enterprises and Molten Ventures (fka DFJ Esprit), and also making independent private investments in ground breaking healthtech companies led by exceptional founders.

Vishal has served on the boards of over fifteen public and private health and life sciences companies; from Horizon Discovery (a leading player in CRISPR gene editing now acquired by Perkin Elmer) to the world's most scalable DNA synthesis platform (Evonetix). He was an early backer of some of the pioneering European companies in digital health and AI drug discovery space  such as Clue, Ieso Digital Health, Quit Genius, Zoe, Kheiron, Arctoris, Turbine, Relation Therapeutics,  and AI Vivo. His portfolio of over 30 VC and angel investments makes him one of the most active investors in this space.

Vishal chairs the investment committee of Cancer Research UK seed fund, and holds similar roles at The Francis Crick Institute, (KQ Labs), British Heart Foundation, Medical Research Council, and Innovate UK. Vishal also serves on the advisory board of Reuben College, the newest of the Oxford University Colleges focusing on biology and artificial intelligence.<\/span>Dr. Vishal Gulati is a specialist venture capital investor backing scientists and tech founders bring their innovations to market. Prior to becoming a VC, Vishal trained as a clinician scientist at University of Oxford and Imperial College, London which gives him a rare and unique perspective on the journey of scientific discoveries all the way to commercially successful products. Vishal's investment thesis is based around the convergence of healthcare, data and engineering. Vishal's investment career spanning over two decades includes founding Recode Ventures in San Francisco and serving at leading venture firms such as Atlas Venture, Oxford Science Enterprises and Molten Ventures (fka DFJ Esprit), and also making independent private investments in ground breaking healthtech companies led by exceptional founders. Vishal has served on the boards of over fifteen public and private health and life sciences companies; from Horizon Discovery (a leading player in CRISPR gene editing now acquired by Perkin Elmer) to the world's most scalable DNA synthesis platform (Evonetix). He was an early backer of some of the pioneering European companies in digital health and AI drug discovery space  such as Clue, Ieso Digital Health, Quit Genius, Zoe, Kheiron, Arctoris, Turbine, Relation Therapeutics,  and AI Vivo. His portfolio of over 30 VC and angel investments makes him one of the most active investors in this space. Vishal chairs the investment committee of Cancer Research UK seed fund, and holds similar roles at The Francis Crick Institute, (KQ Labs), British Heart Foundation, Medical Research Council, and Innovate UK. Vishal also serves on the advisory board of Reuben College, the newest of the Oxford University Colleges focusing on biology and artificial intelligence.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-20T21:01:34.000000Z"},{"id":162,"name":"Amy Salzhauer","title":"Founder and Managing Partner","photo":{"id":415,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/415\/1586358658182.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/415\/conversions\/1586358658182-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/415\/conversions\/1586358658182-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/415\/conversions\/1586358658182-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Good Growth Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/amy-salzhauer\/","biography":"
\r\n
\r\n
\r\n
Good Growth Capital is an early-stage venture capital fund with an exceptional track record of funding and founding early-stage, transformative science companies. Our team has the operating experience and technical expertise to assess, launch, and grow deep technology companies and science-based businesses. The GGC partners are happy to coach founders early, working collaboratively to develop deep relationships with our entrepreneurs.

Good Growth Capital is the most active venture capital fund in South Carolina and one of the only early-stage investors in our Southeast region, with partners and venture partners in South Carolina, North Carolina, Boston, California, London, and the Netherlands. We invest in seed-stage, and Series A deals through our general fund family and in pre-seed and seed-stage companies through our Infinite Corridor Fund, which primarily targets MIT-affiliated and transformative science start-ups.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-20T21:10:17.000000Z"},{"id":164,"name":"Chris Japp","title":"Head of Board","photo":{"id":418,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/418\/1528793014596.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/418\/conversions\/1528793014596-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/418\/conversions\/1528793014596-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/418\/conversions\/1528793014596-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Tramway Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/chris-japp-b331011\/","biography":"
\r\n
\r\n
\r\n
Venture Capital Investor \/ Chief Executive Officer \/ Business Group Leader \/ Non-Executive Board member with over 30 years in medical device, medical capital equipment, and biotech industries. Extensive global experience, having lived and worked in Europe, UK, Japan, Asia, and North America. A strong track record of developing and nurturing high performance global teams in customer-focused innovation, product development, operational excellence, manufacturing, M&A, sales, marketing, and overall business transformation and growth. Leadership experience at large multinational companies as well as mid size and startups. Hold triple citizenship (Canada, USA, UK).<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T16:25:40.000000Z"},{"id":165,"name":"Alix Sipahi","title":"Manager, Venture Capital","photo":{"id":419,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/419\/alix-sipahi.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/419\/conversions\/alix-sipahi-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/419\/conversions\/alix-sipahi-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/419\/conversions\/alix-sipahi-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Medtronic","linkedin_profile":"https:\/\/www.linkedin.com\/in\/alix-s-79953976\/","biography":"

Alix holds a Master’s degree in Social Sciences and Economics from the Catholic University of Paris, France, and an MBA with a specialization in Finance from Northeastern University.<\/p>","companies":[],"created_at":"2024-08-26T16:31:51.000000Z"},{"id":167,"name":"Gowri Raman","title":"Director of Venture Capital","photo":{"id":421,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/421\/1619144321463.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/421\/conversions\/1619144321463-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/421\/conversions\/1619144321463-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/421\/conversions\/1619144321463-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Medtronic","linkedin_profile":"https:\/\/www.linkedin.com\/in\/gsraman\/","biography":"

\r\n
\r\n
\r\n
I am part of the Corporate Venture Capital group at Medtronic. I am involved in originating and managing minority investments in early-stage medical device technologies that are of strategic interest to Medtronic. I represent Medtronic in the boards of the venture portfolio companies and provide guidance and input to the management teams.

I have been with Medtronic for 15+ years and have held roles spanning clinical support, enterprise sales, marketing and venture capital. Prior to the venture capital role, I managed new market opportunity and portfolio optimization for a high growth segment within the Structural Heart business. Before that, I spent a number of years in the field in various clinical and sales roles including direct responsibility of sales of key Medtronic cardiovascular products to large healthcare systems in New York.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T16:35:37.000000Z"},{"id":168,"name":"Rachel Rea","title":"Senior Director, Business Development","photo":{"id":422,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/422\/1684201690379.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/422\/conversions\/1684201690379-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/422\/conversions\/1684201690379-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/422\/conversions\/1684201690379-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Stryker","linkedin_profile":"https:\/\/www.linkedin.com\/in\/rachelmrea\/","biography":"

Corporate development and strategy leader with 15+ years of experience in the MedTech industry.

I am an energetic, strategic, and collaborative Corporate Development leader who has found success by leveraging relationships and building trust across organizations. I have led 20+ transactions including acquisitions, divestitures, venture investments, structured acquisitions, distribution, and licensing deals <\/span><\/p>","companies":[],"created_at":"2024-08-26T16:38:14.000000Z"},{"id":169,"name":"Zhou Yu","title":"Director, Computed Tomography","photo":{"id":423,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/423\/1607549678882.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/423\/conversions\/1607549678882-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/423\/conversions\/1607549678882-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/423\/conversions\/1607549678882-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Canon Medical Research USA, Inc.","linkedin_profile":"https:\/\/www.linkedin.com\/in\/yuzhou05\/","biography":"

\r\n
\r\n
\r\n
Dr. Yu has 10+ years R&D and leadership experience in the field of medical imaging. He started his career at GE Healthcare, where he played a pivotal role in developing world's first fully model based iterative reconstruction algorithm for commercial CT.

Dr. Yu joined Canon (formerly Toshiba) Medical Research Institute USA, Inc (CMRU) in 2013. In this role, he leads a high impact research team (10+ Ph.Ds) to identify business needs, develop innovative
solutions and deliver to the product. In 2016, the team developed world's fastest MBIR reconstruction engine and received Toshiba President's Award for this accomplishment. In 2018, the team developed world's first deep learning based CT image reconstruction product, which can significantly improve image quality.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T16:42:45.000000Z"},{"id":170,"name":"Albert Wiegman","title":"Head","photo":{"id":424,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/424\/1516275443089.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/424\/conversions\/1516275443089-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/424\/conversions\/1516275443089-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/424\/conversions\/1516275443089-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Fresenius Medical Care Ventures GMBH","linkedin_profile":"https:\/\/www.linkedin.com\/in\/alwiegman\/","biography":"

With over 20 years of experience in venture capital, I have a profound understanding of how challenging it is for entrepreneurs to create and build successful companies, and how vital it is to choose the right partners and investors to successfully navigate the journey.

During my tenure, I have generated a successful track record across the technology and healthcare sectors. I have directly participated in 35+ early-stage venture investments in software, healthcare IT, medical devices and healthcare services. A hands-on board member and an achievement-oriented investor, I am passionate about investment and value-creation processes combined with a unique blend of strategic and operational expertise. I am adept at actively assisting portfolio companies to formulate corporate strategies to facilitate growth, financings and exit opportunities.<\/span><\/p>","companies":[],"created_at":"2024-08-26T16:45:32.000000Z"},{"id":171,"name":"Tim Keefe","title":"Vice President, Corporate Strategy","photo":{"id":425,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/425\/1710721676375.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/425\/conversions\/1710721676375-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/425\/conversions\/1710721676375-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/425\/conversions\/1710721676375-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Zimmer Biomet","linkedin_profile":"https:\/\/www.linkedin.com\/in\/tim-keefe-0609bb6\/","biography":"

Strategy, Acquisitions, Divestitures<\/span><\/p>","companies":[],"created_at":"2024-08-26T16:47:57.000000Z"},{"id":172,"name":"Gabriel Sanchez","title":"CEO","photo":{"id":426,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/426\/1626481503190.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/426\/conversions\/1626481503190-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/426\/conversions\/1626481503190-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/426\/conversions\/1626481503190-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Enspectra Health","linkedin_profile":"https:\/\/www.linkedin.com\/in\/gabriel-sanchez-a6719837\/","biography":"

Leveraging his extensive experience innovating in the fields of optics and electromechanical devices, Gabriel serves as the visionary for Enspectra Health. Working with a team of experts, Gabriel is leading the rapid advancement and development of Enspectra's multiphoton imaging device to evaluate a broad spectrum of skin conditions. <\/p>","companies":[],"created_at":"2024-08-26T16:50:34.000000Z"},{"id":173,"name":"Devon Bream","title":"Global GM & President, Invasive Cardiology","photo":{"id":427,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/427\/1646864126790.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/427\/conversions\/1646864126790-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/427\/conversions\/1646864126790-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/427\/conversions\/1646864126790-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"GE HealthCare","linkedin_profile":"https:\/\/www.linkedin.com\/in\/devonbream\/","biography":"

\r\n
\r\n
\r\n
Experienced Global Executive with a demonstrated history of working in the medical device industry. Skilled in Executive Management, Medical Devices, M&A, Sales Management, and Global Management. Strong information technology professional with a Master's Degree focused in Healthcare Administration- School of Public Health from University of California, Los Angeles. Fellow American College Healthcare Executives.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T16:52:30.000000Z"},{"id":174,"name":"Nicole J Walker","title":"Advisor, Executive Committee","photo":{"id":428,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/428\/1681266492367.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/428\/conversions\/1681266492367-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/428\/conversions\/1681266492367-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/428\/conversions\/1681266492367-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Health Innovation Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/nicole-j-walker\/","biography":"
\r\n
\r\n
\r\n
Nicole is a Healthcare Advisor & Connector, Board Director, Family-Senior Care advocate, and a former Managing Partner with Arboretum Ventures, Baird Capital, Abbott Biotech Ventures.

Originally trained as an engineer at Stanford University, Nicole has a career evenly weighted between operating roles and venture investing. She started her career with ACS\/Guidant as a process development intern and advanced through multiple R&D and management roles until her final position as Head of Marketing, Asia-Pac, based in Hong Kong. Then moving onto Abbott, Nicole led strategic market activities for Abbott’s OUS discrete glucose monitoring and continuous glucose monitoring brands, with a final role as the Founding Director of the Abbott Biotech Ventures team.

Nicole is passionate about healthtech investing and working with entrepreneurs to transform the delivery of healthcare by focusing on innovations at the intersection of biology & technology.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T16:55:11.000000Z"},{"id":175,"name":"Liliane Chamas","title":"Health Tech Principal","photo":{"id":429,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/429\/1671190523748.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/429\/conversions\/1671190523748-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/429\/conversions\/1671190523748-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/429\/conversions\/1671190523748-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Amber Therapeutics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/liliane-chamas-phd-1a8b4717\/","biography":"

Multilingual Human Geneticist (DPhil\/PhD at Oxford, Rhodes Scholar) building and investing in early-stage companies. Prior experience conducting cutting-edge science, developing & evaluating health innovation policies globally.

Currently at Oxford Sciences Entreprises where I source and build early stage companies from the latest healthcare breakthroughs at the University of Oxford. I am the founding investor and business builder of 4 early stage companies, currently sitting on the board of 3 of them. I have also led later stage deals, commercial and technical diligence across Series A&B health tech companies that are currently in the OSE portfolio.

I previously worked in health innovation policy, diplomacy and health system strengthening roles in emerging and low-resource contexts in over 10 countries with various international organisations (WHO, PAHO, UNRWA) and national institutions (UK NHS, UK Foreign Commonwealth Office, Health Education England).

I established and ran the first 6 years of selection for the Rhodes Scholarships for Syria, Jordan, Lebanon and Palestine.<\/span><\/p>","companies":[],"created_at":"2024-08-26T16:57:53.000000Z"},{"id":176,"name":"Ruben Osnabrugge","title":"Partner","photo":{"id":430,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/430\/1695948140683.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/430\/conversions\/1695948140683-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/430\/conversions\/1695948140683-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/430\/conversions\/1695948140683-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"415 Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/rubenosnabrugge\/","biography":"

With over twelve years of medical, scientific, and industry experience, I am a partner at 415 Capital, a specialist venture capital firm that invests in early- and development-stage MedTech companies in Europe, the United States, and Israel. My mission is to improve lives by funding and supporting innovative medical device technologies that address cardiovascular and neurovascular diseases, the leading causes of death and disability worldwide.

Trained in cardiothoracic surgery, clinical research, and health economics, I bring a unique perspective and expertise to the MedTech sector. I have published more than 40 articles in high-impact medical journals, co-authored two chapters in the ESC Textbook of Cardiovascular Medicine, and contributed to a European clinical guideline. I have also received a Fulbright Scholarship, a young investigator award, and served as an editorial board member and faculty at prestigious cardiology and surgery societies. In the Chief Medical Office of Philips I led the Value-based care strategy and supported strategic deep dives.

At 415 Capital, I leverage my extensive network and knowledge to identify, evaluate, and mentor promising MedTech entrepreneurs and companies that have the potential to make a difference for patients and healthcare systems.<\/span><\/p>","companies":[],"created_at":"2024-08-26T17:03:46.000000Z"},{"id":177,"name":"Paul Russo","title":"CEO","photo":{"id":431,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/431\/1517709548786.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/431\/conversions\/1517709548786-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/431\/conversions\/1517709548786-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/431\/conversions\/1517709548786-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"K2X Tech & Life Science","linkedin_profile":"https:\/\/www.linkedin.com\/in\/paul-m-russo-phd-106a416\/","biography":"

\r\n
\r\n
\r\n
Strong vision and strategy skills. Good at understanding technology adoption trends. Significant experience in public and private high tech boards. Strong experience in investing at the seed\/angel level in technology and life science. Seeking public company board position in a company that is re-thinking its strategy and would benefit from a strong visionary leader. Very experienced in rapidly growing auto safety systems from camera processors to Head-Up displays. More recently, gaining a lot of experience from investing in Life Science start-ups via KYTO. Active in the Band of Angels and the Keiretsu Forum.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T17:06:02.000000Z"},{"id":178,"name":"Heather Roxborough","title":"Partner","photo":{"id":432,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/432\/1647862737753.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/432\/conversions\/1647862737753-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/432\/conversions\/1647862737753-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/432\/conversions\/1647862737753-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Oxford Science Entreprises","linkedin_profile":"https:\/\/www.linkedin.com\/in\/heather-roxborough-58935b3\/","biography":"
\r\n
\r\n
\r\n
Entrepreneurial venture capitalist with global investment experience across a range of industry sectors including healthtech, medtech, consumer healthcare, foodtech and life sciences.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T17:11:19.000000Z"},{"id":179,"name":"Luc Marengere","title":"Managing Partner","photo":{"id":433,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/433\/1606223305109.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/433\/conversions\/1606223305109-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/433\/conversions\/1606223305109-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/433\/conversions\/1606223305109-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"TVM Capital Life Science","linkedin_profile":"https:\/\/www.linkedin.com\/in\/dr-luc-marengere-74b7865b\/","biography":"

Luc joined TVM Partners in 2012. He is responsible for TVM Partners overall investment strategy and global fund operations.<\/p>\r\n

Luc has more than 25 years of venture capital experience. He is a key driver of the investment strategy for TVM LSI I and TVM LSI II Funds. He is a Director on the Boards of late-stage company Panthera Dental, Egg Medical, Kent Imaging, Emovi and Access Vascular as well as early-stage companies Vespina, Occellaris and Auricula. In addition, Luc was a Director on the Board of NASDAQ listed Acer Therapeutics (sold to Zevra Tharapeutics) and Colucid Pharma Inc. (sold to Eli Lilly for US$960M) as well as privately held Aurka Pharma Inc. (sold to Eli Lilly for US$575M; total value includes upfront plus CVRs) and Acanthas Pharma (sold to Eli Lilly for US$430M; total value includes upfront plus CVRs).<\/p>\r\n

Luc brought a significant track record to TVM given his experience as a venture capitalist. Notable deals during Luc‘s tenure as Managing Partner at Toronto-based VG Partners where he founded the life science investment practice include Cytochroma Inc. (sold to Opko for US$400M); VisualSonics (sold to Sonosite for US$75M), CITA Neuropharma (sold to Vernalis Plc for US$85M) and Trillium Therapeutics (sold to Pfizer for US$2.2B). Prior to joining VG Partners, Luc focused on venture investments in the life science sector while at Montreal-based Caisse De Depot (CDP) as well as MDS Capital and MedTech Partners.<\/p>\r\n

Prior to his venture capital career, he conducted commercially oriented research in the fields of immunology and oncology at Amgen. Luc holds a Ph.D. from University of Toronto (Medical Biophysics and Molecular Genetics), a Master’s degree from Queen’s University (Biochemistry) and a degree from University of Ottawa (Bachelor’s degree, Biochemistry, Magna Cum Laude).<\/p>","companies":[],"created_at":"2024-08-26T17:14:16.000000Z"},{"id":180,"name":"Sascha Berger","title":"General Partner","photo":{"id":434,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/434\/1660688760481.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/434\/conversions\/1660688760481-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/434\/conversions\/1660688760481-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/434\/conversions\/1660688760481-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"TVM Capital Life Science","linkedin_profile":"https:\/\/www.linkedin.com\/in\/sasber\/","biography":"

\r\n
\r\n
\r\n
Dr. Sascha Berger is a General Partner at TVM Capital Life Science, a transatlantic venture capital firm that invests in innovative pharmaceutical, medtech, diagnostic, and digital health technologies. With over 17 years of professional experience, Sascha has helped to raise and deploy the current $480M fund, and has supported multiple portfolio companies as a board member or observer.

Sascha combines his academic background in chemistry and finance with his previous consulting and M&A skills to identify and evaluate promising opportunities, and to partner with entrepreneurs and founders to advance their technologies to the next value inflection points. Sascha is passionate about fostering the biotech ecosystem, bridging the gap between science and business, and creating a positive impact for patients and society.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T17:20:25.000000Z"},{"id":182,"name":"Assaf Barnea","title":"CEO","photo":{"id":436,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/436\/1718315846409.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/436\/conversions\/1718315846409-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/436\/conversions\/1718315846409-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/436\/conversions\/1718315846409-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Sanara Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/assaf-barnea-76b373\/","biography":"

Mr. Assaf Barnea is a seasoned entrepreneur and venture professional, with extensive, multidisciplinary
experience in building innovation platforms and leading investments & commercialization processes in healthcare and life science related technologies. He leads, since its inception in 2014, Sanara Ventures, a healthcare innovation fund, backed by Phillips and Teva investing in digital health, medical devices & Bio-Convergence technologies. He is also the Founder & Managing Partner of Sanara Capital, a follow up fund of Sanara Ventures, that focuses on A&B rounds investments in healthcare related technologies.
Parallel to his role at Sanara, Mr. Barnea Chairs also the Life Science Advisory Board at the Israel Export Institute, on behalf of the Israeli government, promoting and advancing the export of Israeli technologies in the medical, biotech, pharma and digital fields in global markets. Previously, Mr. Barnea was also advising the World Bank’s IFC venture capital team and is a co-founder of the IFC’s Tech Emerge program; a unique acceleration platform that connects healthcare startups from around the world with leading corporations and hospitals in emerging economies. In 2018, Tech Emerge Health has won the world bank group president’s award for innovation.
For over a decade, Mr. Barnea was a BOD & co-founder of CardioSense, a medtech startup company.
Assaf served as CEO of Kinrot Ventures, spearheading its acquisition by Hutchison Water in 2012. Prior to this, he headed business development at Mekorot, Israel’s national water company, where he oversaw the establishment of WaTech, the Entrepreneurship & Partnership Center for Water Technologies. For his role and accomplishments in both Mekorot and Kinrot, he received the Cleantech Group’s Innovation Hero Award in 2013 (see video below).

Previously, Mr. Barnea served as a director of business development at Comverse, where he also co-chaired the Mobile Marketing Association.
A unique highlight in Assaf’s story is his former stint as a college basketball player at New Jersey’s Seton Hall University, where he won the Big East championship against Georgetown in 1991. Assaf holds LLB and Business degrees from the Interdisciplinary Center in Herzelia, a BA in political science and psychology (with honor) from Tel-Aviv University.<\/span><\/p>","companies":[],"created_at":"2024-08-26T17:26:57.000000Z"},{"id":186,"name":"Katie Ellias","title":"Managing Director","photo":{"id":440,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/440\/1633488763557.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/440\/conversions\/1633488763557-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/440\/conversions\/1633488763557-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/440\/conversions\/1633488763557-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"T1D Fund","linkedin_profile":"https:\/\/www.linkedin.com\/in\/katie-ellias\/","biography":"

\r\n
\r\n
\r\n
Venture Capital, marketing and business development professional focused in the life sciences field, including biotech\/pharma, medical devices and digital health. VC since 2011. Managing Director at single disease impact fund (venture philanthropy). Board director and observer experience for 10+ early and later-stage companies in the US, Canada and Europe. Significant previous experience in Europe managing several product launches in interventional cardiology (e.g., DES), and background in cardiac surgery, CRM, others. Global M&A experience.

Interested in life sciences venture investing. Also open to non-profit healthcare or education board of director opportunities.

Specialties: Venture Capital, business development, marketing, product launches, Europe, interventional cardiology, cardiac surgery, med tech innovation, negotiation<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T17:38:01.000000Z"},{"id":187,"name":"Sean Cheng","title":"Managing Director","photo":{"id":441,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/441\/1667228895202.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/441\/conversions\/1667228895202-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/441\/conversions\/1667228895202-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/441\/conversions\/1667228895202-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Ascension Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/seancheng\/","biography":"

As a Managing Director at Ascension Ventures, I lead early-stage investments in healthcare and life sciences, leveraging my 15+ years of experience in business, technology, and regulatory domains ranging from Fortune 500s to start-ups to government agencies. I invest on behalf of 13 health systems and 462 acute care facilities across 42 states in the US, supporting innovative companies that improve the quality and accessibility of care for millions of patients.

Currently focused on early-stage investments in medical devices, diagnostics, and life sciences.<\/span><\/p>","companies":[],"created_at":"2024-08-26T17:40:37.000000Z"},{"id":188,"name":"Kevin Chu","title":"Healthcare Venture Capital","photo":{"id":442,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/442\/1548315057362.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/442\/conversions\/1548315057362-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/442\/conversions\/1548315057362-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/442\/conversions\/1548315057362-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"F-Prime Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/kevin-chu-b214891a\/","biography":"

Invest venture capital in private biopharmaceutical, medical technology, and healthcare IT and services companies

Senior Associate: 2019 - 2020
Associate: 2017 - 2019
Analyst: 2014 - 2016<\/span><\/p>","companies":[],"created_at":"2024-08-26T17:49:28.000000Z"},{"id":189,"name":"Craig Matturro","title":"Principal","photo":{"id":443,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/443\/1704848947083.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/443\/conversions\/1704848947083-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/443\/conversions\/1704848947083-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/443\/conversions\/1704848947083-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"1315 Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/craig-matturro-24b78474\/","biography":"

\r\n

Craig Matturro joined 1315 Capital in 2016 after two years as an Analyst in the Investment Banking Group of Leerink Partners, LLC, where he worked on multiple M&A and private placement engagements for small to mid-cap public and private companies across all healthcare subsectors.<\/p>\r\n

During his time at 1315 Capital, Craig went on secondment to serve as Director of Business Development for 1315 Capital portfolio company, JDS Therapeutics, where he led the divesture of the Company’s Nutrition21 division to Everwell Health, as well as the acquisition of patented nutraceutical assets by the Company’s Bonafide Health division (acquired by Pharmavite).<\/p>\r\n

Craig currently serves on the board of Restorative Therapies, Spineology, and Triple Ring Technologies, is a board observer for Onkos Surgical, and previously was a board observer for Solsys Medical (acquired by Misonix) and Centurion Service Group (acquired by TRIMEDX).<\/p>\r\n

Craig received a BSc from Carnegie Mellon University in Business Administration – Concentration in Finance with University Honors, and a minor in Engineering Studies.<\/p>\r\n<\/div>","companies":[],"created_at":"2024-08-26T17:52:56.000000Z"},{"id":190,"name":"Azin Parhizgar","title":"Managing Director","photo":{"id":2967,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/2967\/azin-parhizgar-415capital-usa.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/2967\/conversions\/azin-parhizgar-415capital-usa-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/2967\/conversions\/azin-parhizgar-415capital-usa-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/2967\/conversions\/azin-parhizgar-415capital-usa-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"415 Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/azin-parhizgar-phd-3135b26\/","biography":"

\r\n
\r\n
\r\n
....I am not what has happened to me. I am what I chose to become...CJ<\/span>...<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T17:57:21.000000Z"},{"id":191,"name":"Frederik Groenewegen","title":"Co-Founder and General Partner","photo":{"id":617,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/617\/frederik-groenewegen-415Capital.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/617\/conversions\/frederik-groenewegen-415Capital-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/617\/conversions\/frederik-groenewegen-415Capital-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/617\/conversions\/frederik-groenewegen-415Capital-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"415 Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/frederik-groenewegen-57b8b129\/","biography":"

Frederik Groenewegen<\/strong> is a Co-Founder and General Partner of 415C. He has been an investor in more than a dozen of innovative medical technology companies and led the firm’s investments in Supira, CorFlow, Cardiac Success, Aktiia, Distalmotion, R3 Vascular and TRiCares. He currently serves as a Board Director at R3 Vascular and TRiCares. Prior to co-founding 415C, Frederik served as Business Development Manager at Regis Medical, a Germany based medical device distributor where he helped source and evaluate new partnerships and investment opportunities.<\/p>\r\n

Previously, Frederik worked in HSBC’s Leveraged & Acquisition Finance group in New York City where he structured financings for private equity-backed buyouts and corporate M&A transactions including several large-cap Healthcare transactions. Before moving to New York City, he was an Analyst at HSBC in London where he advised clients on cross-border M&A transactions and IPOs. Frederik holds an Hon. B.A. in Economics magna cum laude from the University of Toronto (University College), Canada.<\/p>","companies":[],"created_at":"2024-08-26T18:01:31.000000Z"},{"id":192,"name":"Anthony Williams","title":"EVP, Strategy","photo":{"id":446,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/446\/Anthony-Williams-300.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/446\/conversions\/Anthony-Williams-300-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/446\/conversions\/Anthony-Williams-300-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/446\/conversions\/Anthony-Williams-300-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Globus Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/williams-anthony\/","biography":"

\r\n

Anthony Williams joined HealthQuest in 2019. Before joining HealthQuest, Anthony spent eight years at Globus Medical, Inc. (NYSE: GMED), a multinational medical device company focused on developing products that promote healing in patients suffering from musculoskeletal disorders. He served in a variety of leadership roles during his tenure at Globus and ultimately spent the last 3½ years as President of the company. He currently serves as a board member on portfolio companies ENT Specialty Partners and 83bar, and as an observer for Magnolia, TigerConnect and Trice.<\/p>\r\n

Prior to joining Globus Medical, Anthony was a partner with Wyrick Robbins Yates & Ponton LLP, a law firm based in Raleigh, North Carolina, where he specialized in corporate and transactional work for high growth life sciences companies and their investors, including public and private financings, mergers, acquisitions and other strategic transactions, and corporate governance matters. <\/p>\r\n

Throughout his career, Anthony has been a frequent speaker to entrepreneurial groups, such as the Durham, NC-based Council for Entrepreneurial Development. He previously served on the board of directors of SEBIO and is currently a mentor to entrepreneurs through the Philadelphia-based Mentor Connect, a program sponsored by Ben Franklin Technology Partners and the Philadelphia Alliance for Capital and Technologies (PACT), and Austin-based Texas Health Catalyst, a collaborative initiative of Dell Medical School and the University of Texas at Austin,  both of which provide much-needed mentoring to inventors and entrepreneurs.<\/p>\r\n<\/div>","companies":[],"created_at":"2024-08-26T18:36:38.000000Z"},{"id":193,"name":"Akhilesh Pathipati","title":"Partner","photo":{"id":447,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/447\/1521416519356.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/447\/conversions\/1521416519356-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/447\/conversions\/1521416519356-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/447\/conversions\/1521416519356-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"MVM Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/akhileshpathipati\/","biography":"

\r\n

Akhilesh joined MVM in 2019. Prior to joining, he practiced medicine as a resident at Beth Israel Deaconess Medical Center and Signature Healthcare Brockton Hospital. In addition, his research on healthcare systems has led to more than a dozen scientific publications and 50 articles in the popular press, including in The Washington Post and Scientific American.<\/p>\r\n

Akhilesh received an MD at the Stanford School of Medicine and an MBA at the Stanford Graduate School of Business. He also holds an AB magna cum laude with highest honors from Harvard University.<\/p>\r\n

Akhilesh is a member of the board of AccuVein, Inc. and Neurolens, Inc., and represents MVM’s investment in InBrace. He was previously a board observer of Patient Connect Ltd (acquired by Clarivate).<\/p>\r\n<\/div>","companies":[],"created_at":"2024-08-26T18:38:31.000000Z"},{"id":194,"name":"Tico Blumenthal","title":"VP of Product","photo":{"id":448,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/448\/1517739143746.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/448\/conversions\/1517739143746-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/448\/conversions\/1517739143746-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/448\/conversions\/1517739143746-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Eko","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ticoblumenthal\/","biography":"

As the VP of Product at Eko, I lead the product innovation and strategy for transforming cardiopulmonary care with AI and cloud computing. With over 20 years of experience in healthcare product leadership, I have launched impactful solutions across services, software, implantable and wearable devices that have improved patient outcomes and user experiences worldwide.

My core competencies include defining and validating user needs, mapping customers' jobs to be done, understanding the value chain, and identifying new opportunities for clinical and business impact. I also have extensive experience in conducting market research, segmentation, and ethnography, developing portfolio strategy, managing product lifecycle, and driving market-aligned scope and risk mitigation. I have directly led the initiation, development, and launch of products and services that have touched over 8 million patient lives in domains such as interventional pulmonology, thoracic surgery, peripheral and endovascular therapies, renal care, and digital health. My mission is to grow the impact of cardiopulmonary screening and intervention on patient lives, globally.<\/span><\/p>","companies":[],"created_at":"2024-08-26T18:39:57.000000Z"},{"id":195,"name":"Karthik Bolisetty","title":"Senior Associate","photo":{"id":449,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/449\/1594334460031.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/449\/conversions\/1594334460031-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/449\/conversions\/1594334460031-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/449\/conversions\/1594334460031-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Glide Healthcare","linkedin_profile":"https:\/\/www.linkedin.com\/in\/karthik-bolisetty-6a517575\/","biography":"

\r\n
\r\n
\r\n
Investor in medical devices, life science tools, diagnostics, and digital health. Feel free to drop a line if you’re an entrepreneur or investor in any of these spaces.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T18:42:14.000000Z"},{"id":196,"name":"Eddie Hanlon","title":"Investment Manager","photo":{"id":450,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/450\/1690481580900.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/450\/conversions\/1690481580900-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/450\/conversions\/1690481580900-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/450\/conversions\/1690481580900-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Glide Healthcare","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ehanlon22\/","biography":"

Investing <\/span>in <\/span>medical device, digital health, and health IT opportunities.<\/span><\/p>","companies":[],"created_at":"2024-08-26T18:44:07.000000Z"},{"id":197,"name":"Terri Burke","title":"Senior Partner","photo":{"id":451,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/451\/1517029561944.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/451\/conversions\/1517029561944-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/451\/conversions\/1517029561944-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/451\/conversions\/1517029561944-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Intuitive Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/terriburke2004\/","biography":"

\r\n
\r\n
\r\n
Dynamic healthcare executive and investment professional with more than 25 years of broad experience delivering exceptional results for innovative technologies in complex, worldwide markets, by keeping the customer and brand at the forefront. Strategic and agile leadership to build, develop and invest in top-notch companies, manage technical and commercial programs, fundraise successfully, navigate strategic relationships, provide strong board leadership and governance, and deliver proven execution to optimize profitability.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T18:46:11.000000Z"},{"id":198,"name":"Tamir Meiri","title":"Director, Venture Investments","photo":{"id":452,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/452\/1517739921664.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/452\/conversions\/1517739921664-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/452\/conversions\/1517739921664-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/452\/conversions\/1517739921664-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Johnson & Johnson","linkedin_profile":"https:\/\/www.linkedin.com\/in\/tamir-meiri-694a9b10\/","biography":"
\r\n
\r\n
\r\n
Tamir is tasked with leading supporting the investment process in Israel and Europe, working closely with JJDC and J&J stakeholders on developing and executing investment transactions across J&J’s sectors. Tamir's main focus is Medical Devices, Digital Technologies and Consumer products.
Tamir has a B.Sc in Chemistry from Tel-Aviv University and has extensive background in Bio-Medical engineering and entrepreneurship, as well as an MBA with focus on Finance, from the Interdisciplinary Center in Herzliya.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T18:48:04.000000Z"},{"id":199,"name":"Dennis McWilliams","title":"Partner","photo":{"id":453,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/453\/1567283668424.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/453\/conversions\/1567283668424-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/453\/conversions\/1567283668424-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/453\/conversions\/1567283668424-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"SANT\u00c9","linkedin_profile":"https:\/\/www.linkedin.com\/in\/dennismcwilliams\/","biography":"
\r\n
\r\n
\r\n
Serial life science entrepreneur and innovator dedicated to globally commercializing world changing medical technologies. Leadership experience from early idea stages through global product launches in both private and public companies, with significant domestic and international management experience.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T18:49:23.000000Z"},{"id":200,"name":"Kyle Dempsey","title":"Partner","photo":{"id":454,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/454\/1619463041545.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/454\/conversions\/1619463041545-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/454\/conversions\/1619463041545-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/454\/conversions\/1619463041545-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"MVM Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/kyleedempsey\/","biography":"
\r\n
\r\n
\r\n
I invest in commercial-stage healthcare and life science companies in the following subsectors: medical technology\/devices, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and research tools.

Ideal target investment opportunities address significant unmet needs with large addressable markets, including medical conditions for which there are no adequate treatments, therapies for which existing treatments are too expensive, or diseases that lack accurate diagnostic capability, along with the various businesses and products that enable these solutions.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T18:54:05.000000Z"},{"id":201,"name":"Ann Gaddy","title":"Managing Director","photo":{"id":455,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/455\/1516068204767.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/455\/conversions\/1516068204767-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/455\/conversions\/1516068204767-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/455\/conversions\/1516068204767-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"BioPacific Investors","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ann-gaddy-5975496a\/","biography":"

Prior to managing angel groups the past twenty years, Ann was involved in mergers and acquisitions with Toshiba and Hitachi, amongst others. Ann was Co-Founder and Managing Director of Life Science Angels (LSA) for eight years, investing $30m amongst 42 companies, with almost $1b follow-on funding for portfolio companies. Ann co-Founded BioPacific Investors (BPI) in 2013 with Greg Scott, CEO of ChinaBio, who was former President and Co-Founder of LSA. BPI invests in companies that are interested in performing development work in China, or commercializing their products in Asia. BPI is pre-venture capital and can contribute business, scientific and regional expertise to companies to improve probability for success.<\/p>","companies":[],"created_at":"2024-08-26T18:56:35.000000Z"},{"id":202,"name":"Lisa Suennen","title":"Managing Partner","photo":{"id":456,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/456\/1718828209835.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/456\/conversions\/1718828209835-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/456\/conversions\/1718828209835-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/456\/conversions\/1718828209835-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"American Heart Venture Association","linkedin_profile":"https:\/\/www.linkedin.com\/in\/lisasuennen\/","biography":"

30+ Years of Healthcare and Team Leadership - living in the center of the Venn diagram between healthcare, entrepreneurship, and technology. Very comfortable coloring outside the lines.

I love to lead and work alongside creative, exceptional talent to build high value healthcare enterprises that thrive in a transforming world.

I have worked in and\/or with all sides of the healthcare continuum (digital health\/health IT\/payer\/provider\/ health services \/medical device\/pharma); I have also worked on multiple sides of the business equation (executive\/operations leadership, venture investor, strategy consultant, board member). As such, I think of myself as having a sort of Rubik’s Cube of healthcare knowledge that I can apply to new situations in a highly flexible way. From a practical standpoint, it means that I have an unusually broad perspective on the interplay among the different healthcare disciplines, the economics that drive them and the incentives that make buyers\/decision-makers pay attention.

I combine that knowledge with a broad skill set in executive and operational leadership, strategy\/BD, sales & marketing, partnering, and fund-raising to deliver results, whether it's launching a new company or product, developing new go-to-market and partnering strategies, building a team and ensuring esprit de corps, accelerating growth in existing and\/or new markets or raising capital. I'm keenly aware of the need for balancing strategy with the pragmatic realities of money and markets - a need that applies across early stage, growth and established companies. I draw energy from things that are new, different, transformative but also actionable.

What I've Done: Executive\/Operating Leadership, Venture Capital Partnership (Corporate Venture and Independent Funds), Strategy Consultant, Board Member, Advisor to companies large and small<\/span><\/p>","companies":[],"created_at":"2024-08-26T18:59:52.000000Z"},{"id":205,"name":"Armen Vidian","title":"Founder & Managing Partner","photo":{"id":459,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/459\/armen_vidian-e1716390020668-ezgif.com-webp-to-jpg-converter.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/459\/conversions\/armen_vidian-e1716390020668-ezgif.com-webp-to-jpg-converter-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/459\/conversions\/armen_vidian-e1716390020668-ezgif.com-webp-to-jpg-converter-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/459\/conversions\/armen_vidian-e1716390020668-ezgif.com-webp-to-jpg-converter-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Recode Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/armenatrecodevc\/","biography":"

Armen has nearly 30 years of experience as an engineer, entrepreneur, and investor in technology and healthcare. Armen started his career creating first-in-class products in medical technology. He then co-founded BlueTalon [acquired by MSFT], which initially focused on the interface between data federation and clinical trials. His experience in healthcare and technology has focused his interests on the application of generative AI, robotics, AR\/VR, and brain-computer interfaces in healthcare and the life sciences.<\/p>\r\n

\r\n

After BlueTalon, Armen was an early Partner at DCVC, the first venture capital firm with an AI-centric thesis. At DCVC, he played a leadership role in the investment of the first companies applying AI to healthcare and the life sciences. Some of Armen’s board responsibilities included: Board Chairman at Caption Health<\/a> [acquired by GE HealthCare]; and Board Director at Proprio<\/a>. In addition to these responsibilities, Armen led or co-led investment in AbCellera<\/a> [NASD: ABCL], Recursion<\/a> [NASD: RXRX], and Healthmode<\/a> [NASD:MNMD].<\/p>\r\n

Armen holds an S.B. in Mechanical Engineering from the Massachusetts Institute of Technology (MIT) and an M.S. in Management Science and Engineering from Stanford University. His history with data and healthcare goes back to college, during which he co-authored a paper on the use of autoregressive moving average analysis (ARMA) to characterize baroreflex gain in a 1996 issue of the American Journal of Physiology: Heart and Circulation. Originally from Racine, Wisconsin, Armen’s perspective as a venture capitalist is influenced as a first generation college graduate.<\/p>\r\n<\/div>","companies":[],"created_at":"2024-08-26T19:59:54.000000Z"},{"id":206,"name":"Auriel August, MD","title":"Principal","photo":{"id":460,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/460\/1628739034513.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/460\/conversions\/1628739034513-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/460\/conversions\/1628739034513-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/460\/conversions\/1628739034513-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"SANT\u00c9","linkedin_profile":"https:\/\/www.linkedin.com\/in\/aurielaugust\/","biography":"

\r\n
\r\n
\r\n
Auriel August MD is physician, innovator and investor passionate about driving change in healthcare.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T20:01:31.000000Z"},{"id":207,"name":"David Kereiakes","title":"Managing Partner","photo":{"id":461,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/461\/1570566524982.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/461\/conversions\/1570566524982-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/461\/conversions\/1570566524982-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/461\/conversions\/1570566524982-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Windham Capital Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/david-kereiakes-7b0b5321\/","biography":"
\r\n
\r\n
\r\n
David is a successful healthcare investor helping to lead Windham Venture Partners. David most recently was involved in driving strategic growth initiatives and investments for Providence, helping to shape the future of one of America's largest comprehensive health care organizations.

As an investor and board member, David has helped support talented entrepreneurs realize over $1 billion in value. Over his career, he has led or co-led over $250 million in private placements including investments in Bolder Surgical (sold), Veran Medical (sold), TissueTech (sold), Advanced Practice Strategies (sold), SurgiQuest (sold), TailorMed, MacroHealth, OrthAlign, and NICO Corporation. Additionally, David currently or previously served on the Board of Directors of DexCare, Wildflower Health, and AVIA Health.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T20:04:28.000000Z"},{"id":208,"name":"Addie Harris","title":"Executive In Residence","photo":{"id":462,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/462\/1674149773101.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/462\/conversions\/1674149773101-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/462\/conversions\/1674149773101-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/462\/conversions\/1674149773101-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"1955 Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/addie-h-6b74604\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-08-26T20:09:01.000000Z"},{"id":209,"name":"Dam\u00e9 Medarski","title":"COO & Co-Founder","photo":{"id":463,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/463\/1712834448146.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/463\/conversions\/1712834448146-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/463\/conversions\/1712834448146-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/463\/conversions\/1712834448146-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"GS Capital Connect","linkedin_profile":"https:\/\/www.linkedin.com\/in\/medarski\/","biography":"

As the COO and Co-Founder of GS Capital Connect, I lead a transformative venture connecting MedTech startups with visionary investors. Witnessing numerous promising MedTech startups struggle to secure funding for their transformative solutions has fuelled our vision to create an exclusive network of investors, from venture capitalists to compassionate angel investors, united by a shared passion for medical breakthroughs.
We take pride in fostering an ecosystem where innovation thrives, nurturing long-lasting relationships that pave the way for groundbreaking medical advancements.

I am also part of the senior leadership team at Guided Solutions, the global executive search and selection partner to the medical device industry. I manage a global team of employees in three different locations, hunting after new creative approaches in target audience attraction and solid fruitful partnerships gain. I have been heavily involved in expanding the target market and customer base globally, leading to over 9500 placements in 40 countries.

I am passionate about the MedTech sector and its impact on healthcare and society. I am always looking to strengthen my LinkedIn network with professionals with medical devices experience and\/or an interest in the MedTech sector. <\/span><\/p>","companies":[],"created_at":"2024-08-26T20:11:21.000000Z"},{"id":210,"name":"Manish Bhandari","title":"Managing Partner \/ Founder","photo":{"id":464,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/464\/1590692998127.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/464\/conversions\/1590692998127-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/464\/conversions\/1590692998127-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/464\/conversions\/1590692998127-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Angel Physicians Fund","linkedin_profile":"https:\/\/www.linkedin.com\/in\/manish-bhandari-md-3974583\/","biography":"

\r\n
\r\n
\r\n
With over two decades of experience in the healthcare sector, I am the Managing Partner and Founder of Angel Physicians Fund, a venture capital firm that supports early-stage healthcare technology companies. I have a MD from Harvard Medical School and an e-MBA from McKinsey, and I am driven by a mission to improve patient outcomes, advance medical innovation, and drive healthcare transformation.

As a medical oncologist, a healthcare executive, and a strategy consultant, I bring a unique combination of clinical, operational, and financial expertise to identify, evaluate, and invest in promising opportunities in the healthcare sector. I also serve on the board of directors of several portfolio companies, where I provide strategic guidance, industry insights, and mentorship to the founders and management teams. Additionally, I advise Catalyst Health Ventures and AngelMD, two leading healthcare investment platforms. I have multiple publications and patents in the field of oncology and medical devices, and I was named \"Doctor of the Year\" by Cincinnati Magazine in 2018.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T20:13:57.000000Z"},{"id":211,"name":"Aurel Schoeller","title":"President","photo":{"id":465,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/465\/1646910387215.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/465\/conversions\/1646910387215-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/465\/conversions\/1646910387215-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/465\/conversions\/1646910387215-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"pfm medical gmbh","linkedin_profile":"https:\/\/www.linkedin.com\/in\/aurel-schoeller-097a01ab\/","biography":"


Seasoned Manager and Shareholder, +20 yrs. leadership experience, Medtec\/Healthcare and Textile Industry, +15 yrs. Top-Management. Germany (National) and International (Global)<\/span><\/p>","companies":[],"created_at":"2024-08-26T20:18:24.000000Z"},{"id":212,"name":"Drew Trivisonno","title":"Operating Partner","photo":{"id":466,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/466\/IMG_9289-scaled.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/466\/conversions\/IMG_9289-scaled-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/466\/conversions\/IMG_9289-scaled-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/466\/conversions\/IMG_9289-scaled-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Precision Life Science Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/drew-trivisonno-0648214\/","biography":"

\r\n
\r\n
\r\n
Finance executive with over 30 years of experience of operating experience, building teams, debt & equity financing. Critical member of the senior management team for six early-stage companies. Over 15 years as a leading expert in M&A and financing orthopedic transactions including developing deal structures, negotiating & execution. Significant experience growing and establishing organizational effectiveness and developing teams to drive company growth. Thorough understanding of finance and accounting, partnering, strategic development, tactical deployment. Significant experience with resource management, cash management and delivering results in an early stage Life Science company.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T20:21:33.000000Z"},{"id":213,"name":"Michael Ryan","title":"VP, VC & Business Development","photo":{"id":467,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/467\/1660013815758.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/467\/conversions\/1660013815758-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/467\/conversions\/1660013815758-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/467\/conversions\/1660013815758-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Boston Scientific","linkedin_profile":"https:\/\/www.linkedin.com\/in\/tai-hah-3348a013\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-08-26T20:45:32.000000Z"},{"id":217,"name":"Kristopher Carver","title":"Venture Capital","photo":{"id":471,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/471\/1516617389828.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/471\/conversions\/1516617389828-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/471\/conversions\/1516617389828-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/471\/conversions\/1516617389828-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Boston Scientific","linkedin_profile":"https:\/\/www.linkedin.com\/in\/kristophercarver\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-08-26T21:02:41.000000Z"},{"id":218,"name":"Craig Smith","title":"Senior Director, Venture Capital","photo":{"id":472,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/472\/1517686820550.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/472\/conversions\/1517686820550-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/472\/conversions\/1517686820550-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/472\/conversions\/1517686820550-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Boston Scientific","linkedin_profile":"https:\/\/www.linkedin.com\/in\/craig-smith-4a05096\/","biography":"

\r\n
\r\n
\r\n
Over 20 years experience in med device with experience in strategic, venture capital, M&A and legal issues unique to the health care field. Valued leader with demonstrated ability to advise and guide senior leadership on complex business and legal matters.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T21:04:41.000000Z"},{"id":219,"name":"Adam Seivert","title":"Analyst","photo":{"id":473,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/473\/1720669960910.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/473\/conversions\/1720669960910-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/473\/conversions\/1720669960910-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/473\/conversions\/1720669960910-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Dexcom Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/adamseivert\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-08-26T21:06:07.000000Z"},{"id":220,"name":"Yosuke Matsubara","title":"Senior Manager","photo":{"id":474,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/474\/1713292682420.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/474\/conversions\/1713292682420-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/474\/conversions\/1713292682420-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/474\/conversions\/1713292682420-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Teijin Pharma Ltd.","linkedin_profile":"https:\/\/www.linkedin.com\/in\/yosuke-matsubara-93a7b0225\/","biography":"

\r\n
\r\n
\r\n
Yosuke Matsubara serves as the Business Development and Licensing Manager at Teijin Pharma, a Japan-based company operating in both the pharmaceutical and medical device sectors. Yosuke obtained his Ph.D. in medical science prior to joining Teijin Pharma in 2008. With over a decade of experience in drug development within the company, Yosuke specializes in clinical trials, navigating regulatory approvals, and project management. He also acquired his PMP (Project Management Professional) certification in 2017.

Since 2022, Yosuke has been working in the US, where he is responsible for sourcing innovative products for the Japanese market. His role centers on fostering collaborations and partnerships with startups in the medical device and pharmaceutical industries. Teijin Pharma's medical device division concentrates on home-use devices, such as CPAP ventilators for OSA patients and Home Oxygen Therapy primarily for COPD patients, where the company holds a leading market position in Japan. Given that many of these products are sourced from overseas, Yosuke plays a crucial role in licensing-in activities. To optimize the licensing-in process, he collaborates with venture capital partners in the US, leveraging Teijin's venture capital fund.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-08-26T21:08:08.000000Z"},{"id":223,"name":"Chris Wood","title":"CEO","photo":{"id":477,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/477\/unnamed.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/477\/conversions\/unnamed-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/477\/conversions\/unnamed-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/477\/conversions\/unnamed-large.webp"},"category":"innovators","roles":["C"],"company_name":"Reveal-Dx","linkedin_profile":"https:\/\/www.linkedin.com\/in\/chris-wood-3ba6661\/","biography":"
\r\n
\r\n
\r\n
I am fighting cancer by building companies that enable early diagnosis using Medical Imaging. I am a medical physicist and experienced CEO\/CTO with exceptional radiology industry knowledge. I previously founded two startups in medical imaging software. Both companies successfully exited to larger companies. I believe that giving Radiologists the tools they need to add more clinical value will result in a healthier and happier world for all. This has been, and continues to be, my life's work.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[{"id":113,"name":"Reveal-Dx","logo":{"id":478,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/478\/RevealDx-Logo.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/478\/conversions\/RevealDx-Logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/478\/conversions\/RevealDx-Logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/478\/conversions\/RevealDx-Logo-large.webp"},"type":"innovator","description":"

Reveal-Dx is a Seattle-based software company whose vision is to dramatically improve lung cancer outcomes. The company achieves this by delivering the most advanced, radiomics and AI enabled, lung cancer decision support software. The result is faster diagnosis and reductions in unnecessary procedures. The company's software has been extensively validated in clinical trials and years of research. <\/p>\r\n

 <\/p>","created_at":"2024-08-27T15:50:43.000000Z"}],"created_at":"2024-08-27T15:49:36.000000Z"},{"id":224,"name":"Hamed Hanafi","title":"CEO","photo":{"id":479,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/479\/1686606913563.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/479\/conversions\/1686606913563-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/479\/conversions\/1686606913563-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/479\/conversions\/1686606913563-large.webp"},"category":"innovators","roles":["C"],"company_name":"NovaResp Technologies","linkedin_profile":"https:\/\/www.linkedin.com\/in\/hamed-hanafi\/","biography":"

\r\n
\r\n
\r\n
My professional passions include:

* Innovating and commercializing healthcare technologies that can improve patients’ quality of life

* Forming and supporting talented teams so they can reach their highest potential as individuals and as a group

I am an electronics engineer with a Ph.D. in Biomedical Engineering from Dalhousie University. I am additionally trained in the commercialization of medical devices with several years of experience, and have several issued and pending patents. I continue to draw on my background in engineering, my knowledge of breathing mechanics and entrepreneurial spirit to successfully develop our lead technology, cMAP™.

As the CEO at NovaResp, I have led our team to pioneering the very first use of AI on Positive Airway Pressure (PAP) therapy in obstructive sleep apnea (OSA) patients. The goal of this technology is to help OSA patients like my father have a more comfortable experience with their CPAP, and higher adherence to therapy.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[{"id":115,"name":"NovaResp Technologies","logo":{"id":481,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/481\/1689875963593.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/481\/conversions\/1689875963593-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/481\/conversions\/1689875963593-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/481\/conversions\/1689875963593-large.webp"},"type":"presenter","description":"

NovaResp has developed a patented, AI-enabled software compatible with any positive airway pressure (PAP) machine to dramatically improve comfort and adherence to therapy for obstructive sleep apnea (OSA) patients. The company's platform software uses artificial intelligence and machine learning during PAP therapy to predict and prevent episodes of apnea before they would occur. As a result, personalized therapy can be delivered via PAP machines at a substantially lower, more comfortable air pressure levels, ensuring a significantly better patient experience and adherence to therapy.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-08-27T16:22:22.000000Z"}],"created_at":"2024-08-27T15:54:04.000000Z"},{"id":225,"name":"Sydney Robinson","title":"CEO & Co-Founder","photo":{"id":483,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/483\/sydney-robinson.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/483\/conversions\/sydney-robinson-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/483\/conversions\/sydney-robinson-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/483\/conversions\/sydney-robinson-large.webp"},"category":"innovators","roles":["C"],"company_name":"Vessl Prosthetics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/sydneymrobinson\/","biography":"

Sydney is a dedicated engineer with a lifelong commitment to enhancing lives through innovation. After earning a Mechanical Engineering degree from Queen's University, Sydney pursued a master's in biomedical engineering at Western University, where a passion for medical device design was sparked by a capstone project creating an ankle foot orthosis. This journey led Sydney to join the Medical Innovation Fellowship, where the challenges faced by amputees with ill-fitting prosthetics inspired the founding of Vessl. Focused on developing innovative tools like an automatically adjusting prosthetic socket, Sydney is committed to building a high-performing team at Vessl, striving to leave a lasting legacy of compassion and integrity.<\/p>","companies":[{"id":116,"name":"Vessl Prosthetics","logo":{"id":482,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/482\/vessl-prosthetics.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/482\/conversions\/vessl-prosthetics-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/482\/conversions\/vessl-prosthetics-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/482\/conversions\/vessl-prosthetics-large.webp"},"type":"presenter","description":"

Vessl is providing a solution for the hundreds of thousands of amputees that struggle to adapt to loss of limb. The company is designing an automatically adjusting prosthetic socket which redistributes pressure around the leg in response to changes in limb size. The isoform prosthetic socket will improve quality-of-life for thousands of patients - allowing them to lead active and fulfilling lives.<\/p>\r\n

Visit website<\/a>.<\/em><\/p>","created_at":"2024-08-27T16:23:10.000000Z"}],"created_at":"2024-08-27T16:23:10.000000Z"},{"id":226,"name":"Christina Goudy","title":"CEO & Co-Founder","photo":{"id":542,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/542\/ChristinaGoudy2-(1).png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/542\/conversions\/ChristinaGoudy2-(1)-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/542\/conversions\/ChristinaGoudy2-(1)-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/542\/conversions\/ChristinaGoudy2-(1)-large.webp"},"category":"innovators","roles":["C"],"company_name":"Reach Orthopaedics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/christina-goudy\/","biography":"

Christina has been instrumental in Reach Orthopaedics’ success. Originally hired as operations manager, it wasn’t long before she was brought on as a co-founder and CEO. Under her direction the company increased its profile, raised an oversubscribed pre-seed round of financing and received FDA Breakthrough Device designation. Prior to joining Reach Orthopaedics, Christina was an account coordinator at a boutique marketing and communications firm, and a corporate banking analyst at a top Canadian bank. Christina completed her MBA and BSc from Dalhousie University in Halifax, Canada.<\/span><\/p>","companies":[{"id":117,"name":"Reach Orthopaedics","logo":{"id":540,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/540\/ReachLogo-darkgrey.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/540\/conversions\/ReachLogo-darkgrey-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/540\/conversions\/ReachLogo-darkgrey-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/540\/conversions\/ReachLogo-darkgrey-large.webp"},"type":"innovator","description":"

Reach Orthopaedics is developing a durable shoulder implant to treat middle-aged patients suffering from massive irreparable rotator cuff tears (MIRCT). Almost ten percent of the over-50 population has a MIRCT, but the middle-aged population is underserved by current treatment options. Designed by a team of orthopaedic surgeons and engineers with over 100-years of combined experience, Reach Orthopaedics’ novel implant restores shoulder alignment – increasing mobility and function, while reducing chronic pain. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-08-27T16:34:58.000000Z"}],"created_at":"2024-08-27T16:32:35.000000Z"},{"id":231,"name":"Joanna Nathan","title":"CEO","photo":{"id":492,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/492\/640000c860a135132726d325_Prana-Thoracic-Joanna-Nathan--1000px-p-500.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/492\/conversions\/640000c860a135132726d325_Prana-Thoracic-Joanna-Nathan--1000px-p-500-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/492\/conversions\/640000c860a135132726d325_Prana-Thoracic-Joanna-Nathan--1000px-p-500-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/492\/conversions\/640000c860a135132726d325_Prana-Thoracic-Joanna-Nathan--1000px-p-500-large.webp"},"category":"innovators","roles":["C"],"company_name":"Prana Surgical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/joannacnathan\/","biography":"

Entrepreneur serving patients and their families by alleviating the challenges of diagnosing and fighting disease.<\/p>","companies":[{"id":122,"name":"Prana Surgical","logo":{"id":1243,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1243\/Prana-Surgical-Logo----Color.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1243\/conversions\/Prana-Surgical-Logo----Color-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1243\/conversions\/Prana-Surgical-Logo----Color-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1243\/conversions\/Prana-Surgical-Logo----Color-large.webp"},"type":"presenter","description":"

Prana Surgical is developing an innovative approach to improve the early diagnosis of lung cancer. The company is developing the ThoraCore System, a CT-guided, catheter-based approach to perform a nodulectomy. The technology will be capable of safely coring, capturing suspicious pulmonary nodules, while sealing lung tissue using bipolar radiofrequency energy.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-08-27T16:40:19.000000Z"}],"created_at":"2024-08-27T16:40:20.000000Z"},{"id":232,"name":"Christopher Haig","title":"Co-Founder\/Chief Executive Officer","photo":{"id":494,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/494\/1550707416549.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/494\/conversions\/1550707416549-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/494\/conversions\/1550707416549-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/494\/conversions\/1550707416549-large.webp"},"category":"innovators","roles":["C"],"company_name":"Efemoral Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/christopher-haig-7b899512\/","biography":"

Mr. Haig has a proven track record with more than 25 years of experience in the field of medical technology, primarily in the domain of cardiovascular devices, at large, multi-national corporations as well as growth-phase companies with novel technologies. At Guidant Corporation and Abbott Vascular, he held numerous positions of increasing responsibility in marketing, sales and business development functions. Mr. Haig also has extensive start-up experience in senior management positions at Calypso Medical (acquired by Varian Medical Systems) and QT Vascular (S$55 million IPO in 2014), where he built the company’s commercial infrastructure and successfully launched several innovative devices. He holds a B.A. degree from UC Berkeley and an M.B.A. degree from the Kenan Flagler School of Management at the University of North Carolina, Chapel Hill.<\/p>","companies":[{"id":123,"name":"Efemoral Medical","logo":{"id":493,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/493\/Screenshot-2023-12-22-at-12.02.05-PM.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/493\/conversions\/Screenshot-2023-12-22-at-12.02.05-PM-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/493\/conversions\/Screenshot-2023-12-22-at-12.02.05-PM-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/493\/conversions\/Screenshot-2023-12-22-at-12.02.05-PM-large.webp"},"type":"presenter","description":"

Efemoral Medical is a clinical stage startup developing a next-generation drug-eluting bioresorbable scaffold for the treatment of PAD. Using a minimally invasive procedure, the Efemoral Vascular Scaffold System is inserted into the leg and expanded inside the artery to restore a channel for blood flow to the foot. The scaffold is strong enough to hold the vessel open, is flexible enough to accommodate the complex skeletal motion of the leg, and elutes a drug to prevent scarring inside the vessel which leads to the need for repeat procedures. The scaffold is naturally absorbed by the body over time, thus leaving behind no permanent implant.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-08-27T16:42:01.000000Z"}],"created_at":"2024-08-27T16:42:02.000000Z"},{"id":233,"name":"Dan Rizzuto","title":"CEO & CTO","photo":{"id":496,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/496\/dan-rizzuto-nia.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/496\/conversions\/dan-rizzuto-nia-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/496\/conversions\/dan-rizzuto-nia-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/496\/conversions\/dan-rizzuto-nia-large.webp"},"category":"innovators","roles":["C"],"company_name":"Nia Therapeutics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/rizzuto\/","biography":"

Dr. Dan Rizzuto is the founder, Chief Executive Officer and Chief Technology Officer at Nia Therapeutics. Dan developed Nia’s core technology for treating memory disorders with Dr. Michael Kahana at the University of Pennsylvania, where they demonstrated, for the first time, that personalized neurostimulation could significantly improve human verbal memory performance. He completed his doctoral training at Brandeis University in the neuroscience of human memory, his postdoctoral training at Caltech in brain-machine interfaces, and previously ran large-scale neurotechnology development projects at Northstar Neuroscience, Swedish Neuroscience Institute and the Allen Institute for Brain Science. Dan received Researcher of the Year and Most Promising Startup awards from Neurotech Reports.<\/p>","companies":[{"id":124,"name":"Nia Therapeutics","logo":{"id":616,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/616\/Nia-logo-white-background.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/616\/conversions\/Nia-logo-white-background-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/616\/conversions\/Nia-logo-white-background-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/616\/conversions\/Nia-logo-white-background-large.webp"},"type":"presenter","description":"

The Smart Neurostimulation System (SNS) delivers a precision neurostimulation therapy for the treatment of memory loss. It combines brain sensing with stimulation, and is securely connected to the cloud, using artificial intelligence to personalize the therapy for each patient. SNS generates massive data sets that help to accelerate the pace of therapy innovation.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-08-27T16:43:15.000000Z"}],"created_at":"2024-08-27T16:43:16.000000Z"},{"id":234,"name":"Allan May","title":"Chairman of the Board","photo":{"id":497,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/497\/Allan-May---Life-science-angels.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/497\/conversions\/Allan-May---Life-science-angels-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/497\/conversions\/Allan-May---Life-science-angels-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/497\/conversions\/Allan-May---Life-science-angels-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"FundamentalVR","linkedin_profile":"https:\/\/www.linkedin.com\/in\/allan-may-40bb0811\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-08-27T17:24:59.000000Z"},{"id":235,"name":"Will Glass","title":"Partner","photo":{"id":498,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/498\/1665677480874.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/498\/conversions\/1665677480874-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/498\/conversions\/1665677480874-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/498\/conversions\/1665677480874-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Perella Weinberg Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/william-glass-866b29a\/","biography":"

Mr. Glass is a Partner in Perella Weinberg Partners’ Advisory business. He focuses on advising clients in the Healthcare sector.<\/p>\r\n

Mr. Glass has more than 14 years of investment banking experience assisting companies on a wide range of financial and strategic matters. During his tenure at Perella Weinberg Partners, he has advised on strategic sales, mergers, acquisitions and separation transactions as well as provided capital markets advisory services to large multinational and emerging growth clients in the life sciences sector.<\/p>\r\n

Prior to joining Perella Weinberg Partners in June of 2009, Mr. Glass was a Senior Financial Analyst in AIG’s Financial Services Division. Mr. Glass began his career as an Analyst in the Technology, Media, and Telecom Group at Bear Stearns.<\/p>\r\n

Mr. Glass earned a B.A. from the College of William & Mary in Finance and International Relations.<\/p>","companies":[],"created_at":"2024-08-27T17:34:09.000000Z"},{"id":236,"name":"Adam Lubart","title":"Managing Director","photo":{"id":499,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/499\/1517586069608.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/499\/conversions\/1517586069608-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/499\/conversions\/1517586069608-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/499\/conversions\/1517586069608-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Perella Weinberg Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/adam-lubart-6959a061\/","biography":"

Mr. Lubart is a Managing Director in Perella Weinberg Partners’ Advisory business. He focuses on advising clients in the Healthcare sector.<\/p>\r\n

During his tenure at Perella Weinberg Partners, Mr. Lubart has advised on wide range of strategic sales, mergers, acquisitions and separation transactions as well as provided capital markets advisory services to a broad range of multinational and emerging growth clients in the life sciences sector.<\/p>\r\n

He started his career in at American Express, where he worked in a variety of finance and deal structuring roles<\/p>\r\n

Mr. Lubart received a B.A. in Philosophy from Hamilton College and an M.B.A. from Columbia Business School, where he graduated with Dean’s Honors.<\/p>","companies":[],"created_at":"2024-08-27T17:36:13.000000Z"},{"id":237,"name":"Gregory Fischer","title":"Co-Founder & Chief Science Advisor","photo":{"id":527,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/527\/gregory-fischer.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/527\/conversions\/gregory-fischer-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/527\/conversions\/gregory-fischer-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/527\/conversions\/gregory-fischer-large.webp"},"category":"innovators","roles":["C"],"company_name":"AiM Medical Robotics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/gregfischer\/","biography":"

Gregory Fischer has spent his career developing innovative technologies for image-guided surgical interventions. He is a pioneer in MRI-compatible surgical robotics capable of utilizing real-time images from inside the body to guide precision robot-assisted interventions. Dr. Fischer is a Founder of AiM Medical Robotics, a company leveraging technology from his team's research to revolutionize the neurosurgery experience. Dr. Fischer is also the William Smith Dean’s Professor of Robotics Engineering at Worcester Polytechnic Institute (WPI) and PI of the Automation and Interventional Medicine Robotics Research Laboratory (AIM Lab) where his research focuses on medical robotics, specifically the use of real-time feedback to guide surgical procedures. He is Director of the PracticePoint Research and Development Center for Healthcare Cyber-physical Systems, a state-supported Medtech accelerator with advanced point-of-practice clinical testing facilities including an OR and 3T MRI suite dedicated to research and product development.<\/p>","companies":[{"id":125,"name":"AiM Medical Robotics","logo":{"id":526,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/526\/aim-medical-robotics.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/526\/conversions\/aim-medical-robotics-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/526\/conversions\/aim-medical-robotics-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/526\/conversions\/aim-medical-robotics-large.webp"},"type":"presenter","description":"

AiM Medical Robotics is developing a portable MRI compatible surgical robot for use in the OP and MRI suite. The system is being designed for the treatment of functional brain disorders (e.g. epilepsy, Parkinson's disease).<\/p>\r\n

Visit website.<\/em><\/a><\/p>","created_at":"2024-08-30T18:05:01.000000Z"}],"created_at":"2024-08-30T18:05:02.000000Z"},{"id":238,"name":"Robert Neusner","title":"COO & CBO","photo":{"id":575,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/575\/blueskysstudio-2888-(1).jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/575\/conversions\/blueskysstudio-2888-(1)-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/575\/conversions\/blueskysstudio-2888-(1)-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/575\/conversions\/blueskysstudio-2888-(1)-large.webp"},"category":"innovators","roles":["C"],"company_name":"BMI OrganBank","linkedin_profile":"https:\/\/www.linkedin.com\/in\/robert-neusner-029548b\/","biography":"

25+ years of life science experience, including over 20 years with Johnson & Johnson, a leading pharmaceutical and medical device company.<\/p>\r\n

Wide range of leadership positions in the commercialization and development of drugs and devices. Notable career experiences include planning launches for novel devices and drugs, establishing research, development and commercial partnerships, and overseeing payor strategy and patient support services for a multi-billion-dollar product franchise. Co-invented and led the development of a diagnostic device now under ongoing approval by regulators around the globe.<\/p>\r\n

Bachelor of Science in Chemical Engineering from Rice University and MBA from Columbia Business School.<\/p>","companies":[{"id":127,"name":"BMI OrganBank","logo":{"id":531,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/531\/BMI_OrganBank_logo_vert_glow-ezgif.com-webp-to-jpg-converter.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/531\/conversions\/BMI_OrganBank_logo_vert_glow-ezgif.com-webp-to-jpg-converter-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/531\/conversions\/BMI_OrganBank_logo_vert_glow-ezgif.com-webp-to-jpg-converter-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/531\/conversions\/BMI_OrganBank_logo_vert_glow-ezgif.com-webp-to-jpg-converter-large.webp"},"type":"presenter","description":"

BMI OrganBank is transforming transplantation.  Their flagship device has potential to eliminate the waitlist for lifesaving organ transplants by dramatically improving organ assessment and transport capabilities.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-08-30T18:08:43.000000Z"}],"created_at":"2024-08-30T18:08:44.000000Z"},{"id":239,"name":"Joe Landolina","title":"CEO and Co-Founder","photo":{"id":533,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/533\/1667858886488.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/533\/conversions\/1667858886488-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/533\/conversions\/1667858886488-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/533\/conversions\/1667858886488-large.webp"},"category":"investors_strategics","roles":["C"],"company_name":"Cresilon","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jlandolina\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":128,"name":"Cresilon","logo":{"id":534,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/534\/cresilon_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/534\/conversions\/cresilon_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/534\/conversions\/cresilon_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/534\/conversions\/cresilon_logo-large.webp"},"type":"innovator","description":"

Cresilon develops hemostatic solutions to stop traumatic bleeding. The company's initial product, Vetigel, is indicated for use in the veterinary market. Cresilon's proprietary, plant-based hemogel can be applied internally and externally to stop bleeding. The company plans to continue development of its technology for use in human trauma and human surgical applications.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-08-30T18:45:23.000000Z"}],"created_at":"2024-08-30T18:30:46.000000Z"},{"id":241,"name":"Brian Smith","title":"Principal","photo":{"id":536,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/536\/1651757416198.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/536\/conversions\/1651757416198-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/536\/conversions\/1651757416198-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/536\/conversions\/1651757416198-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Unorthodox Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/brian-smith-7b35414\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-08-30T18:55:42.000000Z"},{"id":242,"name":"Pieter Wijffels","title":"Venture Partner","photo":{"id":537,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/537\/1583434481636.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/537\/conversions\/1583434481636-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/537\/conversions\/1583434481636-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/537\/conversions\/1583434481636-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"NLC Health Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/wijffels\/","biography":"

\r\n
\r\n
\r\n
NLC was founded to bring healthcare inventions to life. We team up with the world’s top universities and healthcare companies and use ‘entrepreneurship at scale’ to turn their intellectual property into ventures that bring these life-saving inventions to the patient. We have built over 120 ventures (‘start-ups’) to date, and are gaining speed, building about 25 ventures per year.

Please reach out to me if you
-are an inventor whose healthcare invention has to be brought to the market
-want to invest in promising healthcare ventures
-are interested in becoming CEO of a healthtec venture<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-09-03T15:04:31.000000Z"},{"id":243,"name":"Jaap Haemers","title":"Investment Manager","photo":{"id":538,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/538\/1643749884529.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/538\/conversions\/1643749884529-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/538\/conversions\/1643749884529-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/538\/conversions\/1643749884529-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"NLC Health Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jaaphaemers\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-09-03T15:06:05.000000Z"},{"id":244,"name":"Mohamed Abou-Alam","title":"CEO","photo":{"id":549,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/549\/1709809827817.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/549\/conversions\/1709809827817-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/549\/conversions\/1709809827817-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/549\/conversions\/1709809827817-large.webp"},"category":"innovators","roles":["C"],"company_name":"Precision Cardiovascular","linkedin_profile":"https:\/\/www.linkedin.com\/in\/mohamedaboualam\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":129,"name":"Precision Cardiovascular Ltd.","logo":{"id":550,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/550\/precision_cv_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/550\/conversions\/precision_cv_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/550\/conversions\/precision_cv_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/550\/conversions\/precision_cv_logo-large.webp"},"type":"innovator","description":"

Precision Cardiovascular is focused on enhancing the outcomes and quality of life for patients with heart failure. The company is developing a miniature sensor that is placed in the pulmonary artery to continuously collect and analyze data to improve the remote management of cardiovascular diseases.<\/p>\r\n

Visit website<\/a>.<\/em><\/p>","created_at":"2024-09-09T16:06:48.000000Z"}],"created_at":"2024-09-09T16:05:23.000000Z"},{"id":245,"name":"Tiffany Brown","title":"CEO","photo":{"id":551,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/551\/1517356455831.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/551\/conversions\/1517356455831-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/551\/conversions\/1517356455831-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/551\/conversions\/1517356455831-large.webp"},"category":"innovators","roles":["C"],"company_name":"Avobis Bio","linkedin_profile":"https:\/\/www.linkedin.com\/in\/tiffany-j-brown\/","biography":"

\r\n
\r\n
\r\n
Passion for improving lives fuels everything I do. High impact leader driving exceptional results for patients, customers and businesses. <\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[{"id":130,"name":"Avobis Bio","logo":{"id":552,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/552\/avobis_bio_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/552\/conversions\/avobis_bio_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/552\/conversions\/avobis_bio_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/552\/conversions\/avobis_bio_logo-large.webp"},"type":"innovator","description":"

Avobis Bio is developing a solution to address the complexity of healing chronic wounds. Through a combination of implantable, bioabsorbable materials and mesenchymal stem cells, the company aims to treat a variety of different indications. The lead product in development at Avobis is for patients suffering from chronic fistulas related to Crohn's Disease.  <\/p>\r\n

Visit website<\/em><\/a>.<\/em><\/p>","created_at":"2024-09-09T16:26:56.000000Z"}],"created_at":"2024-09-09T16:22:46.000000Z"},{"id":246,"name":"Clement Vidal","title":"Business Unit Director","photo":{"id":562,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/562\/1707081091659.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/562\/conversions\/1707081091659-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/562\/conversions\/1707081091659-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/562\/conversions\/1707081091659-large.webp"},"category":"innovators","roles":["C"],"company_name":"eCential Robotics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/clement-vidal-59804b30\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":137,"name":"eCential Robotics","logo":{"id":561,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/561\/ecential_robotics_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/561\/conversions\/ecential_robotics_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/561\/conversions\/ecential_robotics_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/561\/conversions\/ecential_robotics_logo-large.webp"},"type":"presenter","description":"

eCential Robotics is a company specializing in bone surgical robotics. The company develops and markets a unique system unifying 2D\/3D robotic imaging and real-time navigation and surgical robotics. The eCential Robotics platform is a universal system open to all implants and enabling third parties to develop surgical apps.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-09-09T16:42:15.000000Z"}],"created_at":"2024-09-09T16:42:16.000000Z"},{"id":247,"name":"Helene Wahl","title":"Global Finance and M&A Director","photo":{"id":563,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/563\/1603745147422.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/563\/conversions\/1603745147422-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/563\/conversions\/1603745147422-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/563\/conversions\/1603745147422-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"KARL STORZ","linkedin_profile":"https:\/\/www.linkedin.com\/in\/helene-wahl-44696\/","biography":"

\r\n
\r\n
\r\n
Trusted Director with career-long contributions in mergers and acquisitions (M&A) leadership in the Medical Device Industry and other industries. In the last 5 years, successfully transitioned a reactive M&A approach to a strategic proactive and programmatic approach, resulting in 2 to 5 successful closing and integration, annually.
Specific M&A skills and achievements include:
• Developed a Global M&A Strategy and M&A Process, and their continuous improvement.
• Leads M&A opportunities with a team of dedicated functional global and local experts.
• Effectively conducts modelling and valuation and other finance related M&A activities.
• Analyses options and makes recommendations for deal structuring.
• Plans for the integration M&A opportunities based on expected deal value and deal type.
• Effectively communicates M&A transaction rationale, critical value drivers and risk, conclusions, and recommendations to the Executive Management Team and Board.
• Negotiates deal terms with sellers and consistently achieves most positive outcomes.
• Partners with legal and other external advisors in completing purchase agreements.
• Recognized as a trusted and skillful partner by global and local company leaders.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-09-09T17:25:06.000000Z"},{"id":248,"name":"Marc Jacob","title":"Manager, M&A","photo":{"id":564,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/564\/1663220706398.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/564\/conversions\/1663220706398-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/564\/conversions\/1663220706398-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/564\/conversions\/1663220706398-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"KARL STORZ","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jacob-marc\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-09-09T17:28:05.000000Z"},{"id":249,"name":"Juliet Wegener","title":"Head of Strategy - US","photo":{"id":565,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/565\/1557276825571.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/565\/conversions\/1557276825571-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/565\/conversions\/1557276825571-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/565\/conversions\/1557276825571-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"KARL STORZ","linkedin_profile":"https:\/\/www.linkedin.com\/in\/julietwegener\/","biography":"

Passionate about health care innovation, entrepreneurship and developing scaled and differentiated solutions to enable value-driven healthcare. Broad experience developing and executing strategy across the healthcare ecosystem including: provider (practice management, specialty pharmacy, infusion), biopharmaceutical (R&D and commercial services), supply chain and medical device \/ medtech. Corporate investment and M&A diligence experience.<\/span><\/p>","companies":[],"created_at":"2024-09-09T17:29:38.000000Z"},{"id":250,"name":"Christianne Goudet","title":"Vice President, Emerging Technologies: Strategy, Sales, Marketing, Operations","photo":{"id":566,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/566\/1710559653699.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/566\/conversions\/1710559653699-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/566\/conversions\/1710559653699-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/566\/conversions\/1710559653699-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"KARL STORZ","linkedin_profile":"https:\/\/www.linkedin.com\/in\/christygaudet\/","biography":"

Executive Leadership, Cross Functional Leadership, Problem Solving, Emerging Technologies, Product Development, Project Management, Business Development, Strategy Creation, Operational Deployment, Marketing, Brand Management, Excellent Presentation Skills, Creative Execution, Harnessing and Disseminating Content, Global Markets, Execution<\/span><\/p>","companies":[],"created_at":"2024-09-09T17:37:15.000000Z"},{"id":251,"name":"Chris Landon","title":"CEO","photo":{"id":567,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/567\/1548686915302.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/567\/conversions\/1548686915302-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/567\/conversions\/1548686915302-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/567\/conversions\/1548686915302-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Natus Neuro","linkedin_profile":"https:\/\/www.linkedin.com\/in\/chrislandon\/","biography":"

\r\n
\r\n
\r\n
As the CEO of Natus Neuro, I am responsible for the strategic direction and operational excellence of the global leader in neurodiagnostic solutions. I have over 21 years of experience in the medical device industry, with a focus on image-guided therapy devices, cardiology, and neurodiagnostics. I also serve as the Vice Chairman of the Board at The Medical Alley Association, a network of healthcare leaders and innovators. My mission is to advance the global impact and influence of the medical device sector.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-09-09T17:39:20.000000Z"},{"id":252,"name":"Christopher Cleary","title":"CEO","photo":{"id":568,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/568\/1709411181132.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/568\/conversions\/1709411181132-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/568\/conversions\/1709411181132-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/568\/conversions\/1709411181132-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Biomergence Capital LLC","linkedin_profile":"https:\/\/www.linkedin.com\/in\/christopher-cleary-1a753612\/","biography":"
\r\n
\r\n
\r\n
Chris was Senior Vice President of Corporate Development for Medtronic, with responsibility for acquisitions, dispositions and minority investments. During 2014, Chris led the corporate development efforts for Medtronic’s $50 billion acquisition of Covidien. Since, Chris and the corporate development team have led more than 35 acquisitions, 25 investments and the $6 billion sale of Covidien medical supply assets to Cardinal Health.

Prior to 2014, Chris was CEO of Alesia Capital Services, a management consulting firm for Fortune 500 companies, including Medtronic, Goldman Sachs, Ally, Macquarie Capital and Terex. From 1995 to 2011, Chris led M&A teams within several businesses at GE Capital, closing acquisitions totaling more than $60B across 200+ transactions in the US, Canada, Europe, Asia and Latin America<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-09-09T17:41:20.000000Z"},{"id":253,"name":"Erich Wolff","title":"Private Equity, Member of Management, Health & Life","photo":{"id":569,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/569\/1596300512420.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/569\/conversions\/1596300512420-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/569\/conversions\/1596300512420-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/569\/conversions\/1596300512420-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Partners Group","linkedin_profile":"https:\/\/www.linkedin.com\/in\/erichwolff\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-09-09T17:45:28.000000Z"},{"id":254,"name":"Nicole Kruijs","title":"Vice President","photo":{"id":570,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/570\/1677685480872.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/570\/conversions\/1677685480872-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/570\/conversions\/1677685480872-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/570\/conversions\/1677685480872-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Apax Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/nicole-kruijs-3509245b\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-09-09T17:46:55.000000Z"},{"id":255,"name":"Colleen Gray","title":"Senior Vice President","photo":{"id":571,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/571\/1708024535933.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/571\/conversions\/1708024535933-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/571\/conversions\/1708024535933-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/571\/conversions\/1708024535933-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"US Capital Group","linkedin_profile":"https:\/\/www.linkedin.com\/in\/colleenmgray\/","biography":"

\r\n
\r\n
\r\n
\r\n


As a successful executive, I know what strings to pull. Whether it is successfully managing a P&L, developing business strategies for new and innovative companies, taking an initial idea through successful product launch, or inspiring management teams, I leverage my experience and education in finance to quickly understand the economic plumbing of companies in diverse industries to significantly increase revenues at both mature and start-up type companies.<\/p>\r\n

I strongly believe in healthcare solutions that improve patients’ lives and decrease overall system costs, and I know what it takes to get customers to adopt new products and technologies.<\/p>\r\n

I am an excellent company spokesperson and enjoy telling a company’s story to investors. Having successfully raised over $300M during my career, I have also led several merger and acquisition transactions as well as participated as Chief Financial Officer in a successful public offering. Along the way, I have built great relationships with board members, key shareholders and lenders through fostering a culture of cross-functional collaboration. <\/p>\r\n

In addition to domestic work, I have extensive experience selling outside of the US and negotiating cross- border contracts in Europe, Asia and Central and South America.<\/p>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-09-09T17:49:42.000000Z"},{"id":256,"name":"Andrew Cleeland","title":"CEO","photo":{"id":572,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/572\/1651789083099.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/572\/conversions\/1651789083099-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/572\/conversions\/1651789083099-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/572\/conversions\/1651789083099-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Fogarty Innovation","linkedin_profile":"https:\/\/www.linkedin.com\/in\/andrew-cleeland-7024a44\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-09-09T17:54:55.000000Z"},{"id":257,"name":"William Dai","title":"Founding Managing Partner","photo":{"id":573,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/573\/1521010981649.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/573\/conversions\/1521010981649-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/573\/conversions\/1521010981649-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/573\/conversions\/1521010981649-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"ShangBay Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/william-dai-65402419\/","biography":"

\r\n
\r\n
\r\n
Experienced Founding Partner with a demonstrated history of working in the venture capital and private equity industry. Skilled in Business Planning, Investor Relations, Corporate Finance, Business Development, and Strategic Planning. Strong entrepreneurship professional with a MBA focused in Finance from Michigan State University - The Eli Broad Graduate School of Management<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-09-09T17:58:39.000000Z"},{"id":258,"name":"Rachna Dayal","title":"Founder & Managing Partner","photo":{"id":574,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/574\/1687712209981.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/574\/conversions\/1687712209981-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/574\/conversions\/1687712209981-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/574\/conversions\/1687712209981-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Sugati Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/rachnadayalgoel\/","biography":"
\r\n
\r\n
\r\n
I have global experience in leading teams, global commercial and supply chain strategy and business operations for big corporations. My experiences include managing complex P&L's of hundreds of million dollars and leading & positioning disruptive technologies and products for launch. Founded and managed a technology startup in my early years of career. Key skill sets include a solutions mindset, learning agility & ability to influence and perform in complex environments, matrix structures and ambiguity.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[],"created_at":"2024-09-09T18:01:40.000000Z"},{"id":259,"name":"Matthew S Morris","title":"CEO","photo":{"id":1718,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1718\/matthew-morris-altra.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1718\/conversions\/matthew-morris-altra-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1718\/conversions\/matthew-morris-altra-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1718\/conversions\/matthew-morris-altra-large.webp"},"category":"innovators","roles":["C"],"company_name":"Altra Inc.","linkedin_profile":"https:\/\/www.linkedin.com\/in\/mgmorris3\/","biography":"
Through his 8 years working with the Altra team, he has cultivated a unique understanding of the intricate challenges and opportunities in designing and developing advanced medical devices.

With an MBA from the Rady School of Management and a BS in Engineering Physics from UC San Diego, Matt brings a unique blend of technical engineering expertise and strategic business insight to every challenge.<\/div>\r\n
 <\/div>\r\n
Please let me know if there is anything else we can provide.<\/div>","companies":[{"id":59,"name":"Altra","logo":{"id":229,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/229\/altra.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/229\/conversions\/altra-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/229\/conversions\/altra-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/229\/conversions\/altra-large.webp"},"type":"presenter","description":"


Altra has engineered a novel infusion pump, inspired by the human heart, to address adverse events and challenges associated with drug delivery. The company's infusion pump utilizes dual chamber pumping technology to enable safe and effective infusion therapy.

Visit website<\/em><\/a>. <\/span><\/p>","created_at":"2024-05-16T19:55:37.000000Z"}],"created_at":"2024-09-09T21:15:15.000000Z"},{"id":263,"name":"Tara Ghazi","title":"Co-Founder & COO","photo":{"id":585,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/585\/2023_TaraGhazi_headshot.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/585\/conversions\/2023_TaraGhazi_headshot-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/585\/conversions\/2023_TaraGhazi_headshot-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/585\/conversions\/2023_TaraGhazi_headshot-large.webp"},"category":"innovators","roles":["C"],"company_name":"MALCOVA","linkedin_profile":"https:\/\/www.linkedin.com\/in\/taraghazi\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":140,"name":"MALCOVA","logo":{"id":583,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/583\/MALCOVA.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/583\/conversions\/MALCOVA-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/583\/conversions\/MALCOVA-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/583\/conversions\/MALCOVA-large.webp"},"type":"presenter","description":"

MALCOVA is utilizing proprietary computed tomography technology to provide a safe, comfortable, and effective imaging solution for the early detection and diagnosis of breast cancer, particularly in women with dense breasts. This technology is at the heart of a three-pronged approach that leverages the company’s advances in hardware, AI-based software, and patient-surrogate phantoms to yield a significant paradigm shift in the way breast cancer is detected and treated.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-09-11T20:29:12.000000Z"}],"created_at":"2024-09-11T20:30:48.000000Z"},{"id":267,"name":"Malcolm Hebblewhite","title":"President","photo":{"id":592,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/592\/malcolm-hebblewhite-atmo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/592\/conversions\/malcolm-hebblewhite-atmo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/592\/conversions\/malcolm-hebblewhite-atmo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/592\/conversions\/malcolm-hebblewhite-atmo-large.webp"},"category":"innovators","roles":["C"],"company_name":"Atmo Biosciences","linkedin_profile":"https:\/\/www.linkedin.com\/in\/malcolm-hebblewhite-5aa39\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":143,"name":"Atmo Biosciences","logo":{"id":590,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/590\/Atmo-logo.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/590\/conversions\/Atmo-logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/590\/conversions\/Atmo-logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/590\/conversions\/Atmo-logo-large.webp"},"type":"presenter","description":"

The Atmo Gas Capsule is a unique ingestible capsule to provides unique insights into gut health and microbiome function. The device assesses the functional health of the GI system by means of measuring gaseous biomarkers as it passes through the GI system. Atmo Biosciences investigational device offers the potential to shed new light on disorders of the gut, beginning with highly prevalent motility disorders such as gastroparesis and slow transit constipation.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-09-11T20:38:55.000000Z"}],"created_at":"2024-09-11T20:40:52.000000Z"},{"id":268,"name":"Ben Holmes","title":"CEO","photo":{"id":596,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/596\/Ben.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/596\/conversions\/Ben-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/596\/conversions\/Ben-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/596\/conversions\/Ben-large.webp"},"category":"innovators","roles":["C"],"company_name":"NANOCHON","linkedin_profile":"https:\/\/www.linkedin.com\/in\/benjamin-holmes-31bab878\/","biography":"

Ben Holmes, Ph.D., is the CEO of Nanochon, with a background in biomedical engineering. He earned his doctorate from The George Washington University, where he focused on tissue engineering and regenerative medicine. He is also an alumni of the UCSF Rosenman Innovators program, MedTech Innovator, and a Johnson and Johnson Quickfire Awardee. With years of experience in developing cutting-edge medical devices, Dr. Holmes has leveraged his expertise to lead Nanochon in creating innovative solutions for cartilage repair and orthopedic care.<\/p>","companies":[{"id":144,"name":"NANOCHON","logo":{"id":597,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/597\/nanochon_400.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/597\/conversions\/nanochon_400-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/597\/conversions\/nanochon_400-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/597\/conversions\/nanochon_400-large.webp"},"type":"presenter","description":"

Nanochon's flagship product, Chondrograft™, is an off the shelf implant composed of 3D-printed nanomaterial polymer, designed to replace damaged cartilage while promoting natural tissue regeneration. This innovative solution offers a minimally invasive treatment for joint injuries, aiming to improve patient outcomes and reduce the need for total joint replacements long term.<\/p>\r\n

Visit website<\/a>.<\/p>","created_at":"2024-09-25T20:04:52.000000Z"}],"created_at":"2024-09-25T20:05:56.000000Z"},{"id":270,"name":"Luis Alvarez","title":"CEO","photo":{"id":777,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/777\/luis-alvarez-theradaptive.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/777\/conversions\/luis-alvarez-theradaptive-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/777\/conversions\/luis-alvarez-theradaptive-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/777\/conversions\/luis-alvarez-theradaptive-large.webp"},"category":"innovators","roles":["C"],"company_name":"Theradaptive","linkedin_profile":"https:\/\/www.linkedin.com\/in\/luisthx\/","biography":"

With over 20 years of work experience in bioengineering, cell biology, and regenerative medicine, I am the CEO and Founder of Theradaptive, a biotech company that develops novel therapeutics for tissue regeneration and repair. I previously led the Organ Manufacturing Group at United Therapeutics, a public biotechnology company that aims to create an unlimited supply of transplantable organs. I have a PhD in Biological Engineering from MIT with a focus on protein engineering to enable targeted delivery of therapeutics using biomaterials as a vehicle. My core competencies include leading multidisciplinary teams, innovating cutting-edge solutions in therapeutics design, and advancing the field of organ and tissue engineering. I am passionate about creating a positive impact on human health and well-being, and I seek to collaborate with diverse and talented professionals who share my vision and values. As an Army veteran I am also committed to bringing new therapies to the clinic that address the needs of wounded service members.<\/p>","companies":[{"id":146,"name":"Theradaptive","logo":{"id":600,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/600\/Screenshot-2024-09-25-131756.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/600\/conversions\/Screenshot-2024-09-25-131756-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/600\/conversions\/Screenshot-2024-09-25-131756-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/600\/conversions\/Screenshot-2024-09-25-131756-large.webp"},"type":"presenter","description":"

Theradaptive has developed a novel platform to modify proteins to coat orthopedic implants, medical devices, and injectable carriers to improve how the body interacts with the implant. It is the company's mission to develop solutions that improve the way the human body interacts with implanted materials to improve tissue regeneration and repair. The company's lead product, the OsteoAdapt SP spinal fusion implant, is currently being evaluated in the OASIS Trial for degenerative disc disease treatment.<\/p>\r\n

Visit website<\/a>.<\/p>","created_at":"2024-09-25T20:18:54.000000Z"}],"created_at":"2024-09-25T20:20:01.000000Z"},{"id":271,"name":"Andrew Mullen","title":"CEO","photo":{"id":602,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/602\/andrew-mullen-charco.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/602\/conversions\/andrew-mullen-charco-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/602\/conversions\/andrew-mullen-charco-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/602\/conversions\/andrew-mullen-charco-large.webp"},"category":"innovators","roles":["C"],"company_name":"Charco Neurotech","linkedin_profile":"https:\/\/www.linkedin.com\/in\/andrew-mullen-209a3322\/","biography":"

I have a strong background in Operational leadership roles with extensive experience in leading new product development, managing complex supply chains, manufacturing, global customer support, quality and regulatory activities.

Before entering the medical technology space, I worked across a range of quality and safety critical industries from coal mining to defence.<\/p>","companies":[{"id":147,"name":"Charco Neurotech","logo":{"id":603,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/603\/charco.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/603\/conversions\/charco-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/603\/conversions\/charco-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/603\/conversions\/charco-large.webp"},"type":"presenter","description":"

Charco Neurotech's CUE Device is a noninvasive platform technology that utilizes pulsed vibrotactile stimulation to mitigate the symptoms of patients with Parkinson's disease. Through extensive research and testing, the device delivers a specialized pattern of stimulation that elicits sensory nervous signals that reduce stiffness and slowness by keeping the body in a \"ready-to-move\" state.<\/p>\r\n

Visit website<\/a>.<\/p>","created_at":"2024-09-25T20:28:31.000000Z"}],"created_at":"2024-09-25T20:23:53.000000Z"},{"id":272,"name":"Mark Pacyna","title":"CEO","photo":{"id":605,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/605\/mark-pacyna-repreive.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/605\/conversions\/mark-pacyna-repreive-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/605\/conversions\/mark-pacyna-repreive-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/605\/conversions\/mark-pacyna-repreive-large.webp"},"category":"innovators","roles":["C"],"company_name":"Reprieve Cardiovascular","linkedin_profile":"https:\/\/www.linkedin.com\/in\/mark-pacyna-3b5135\/","biography":"

Mark joined Reprieve Cardiovascular as the CEO in May of 2021. Before Reprieve, Mark spent 16 years with Medtronic in various leadership positions. Most recently, Mark served as the VP & General Manager of Medtronic’s Peripheral Vascular Business. He also held several leadership roles in Strategy & Business Development, Corporate Development, and Sales Leadership across Medtronic’s Cardiovascular and Spine businesses. Mark graduated with a B.S.B in Management Information Systems from the University of Minnesota Carlson School of Business and an M.B.A from the University of Michigan.<\/p>","companies":[{"id":148,"name":"Reprieve Cardiovascular","logo":{"id":604,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/604\/reprieve_cardiovascular_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/604\/conversions\/reprieve_cardiovascular_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/604\/conversions\/reprieve_cardiovascular_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/604\/conversions\/reprieve_cardiovascular_logo-large.webp"},"type":"presenter","description":"

Reprieve Cardiovascular is developing a new approach to improve outcomes in patients suffering from acute decompensated heart failure (ADHF). The Reprieve System is designed to safely remove fluids from patients and prevent hospital readmissions. The system is capable of monitoring physiological parameters to deliver personalized diuretic therapy for patients. Using real-time, continuous urine output monitoring, a dose-finding algorithm personalizes a patient's diuretic dose. Dosing can be adjusted during therapy in order to maximize urine output and maintain renal function.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-09-25T20:30:56.000000Z"}],"created_at":"2024-09-25T20:32:21.000000Z"},{"id":273,"name":"Bernard Peperstraete","title":"Cofounder & CEO","photo":{"id":607,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/607\/Bernard-Peperstraete-0751-RTC.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/607\/conversions\/Bernard-Peperstraete-0751-RTC-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/607\/conversions\/Bernard-Peperstraete-0751-RTC-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/607\/conversions\/Bernard-Peperstraete-0751-RTC-large.webp"},"category":"innovators","roles":["C"],"company_name":"Acuamark Diagnostics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/bpeperstraete\/","biography":"

Bernard Peperstraete is the CEO and Co-Founder of AcuamarkDx, bringing more than 20 years of experience in the life sciences industry. He has held leadership and board positions at several companies, including ACT Biotech, NGN Capital and Exosome Diagnostics. With a medical background, Bernard has also worked at Novartis, Tan Tock Seng Hospital and BMS Singapore. He earned his MD from Katholieke Universiteit Leuven and an MBA from Harvard Business School\u200b.<\/p>","companies":[{"id":149,"name":"Acuamark Diagnostics","logo":{"id":606,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/606\/Acuamark-Logo.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/606\/conversions\/Acuamark-Logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/606\/conversions\/Acuamark-Logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/606\/conversions\/Acuamark-Logo-large.webp"},"type":"presenter","description":"

Acuamark Diagnostics is optimizing qPCR and dPCR for early cancer detection and cancer recurrence. Its approach is designed to provide highly accurate results to physicians and patients at a fraction of the cost per life saved. With market leading clinical results in stage 1-4 colorectal cancer, Acuamark is currently developing diagnostics for multiple cancers. US launch of its first products is estimated in 2026. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-09-25T20:35:42.000000Z"}],"created_at":"2024-09-25T20:37:26.000000Z"},{"id":274,"name":"Thorsten Waloschek","title":"CEO","photo":{"id":608,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/608\/thorsten-waloschek-neopredix.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/608\/conversions\/thorsten-waloschek-neopredix-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/608\/conversions\/thorsten-waloschek-neopredix-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/608\/conversions\/thorsten-waloschek-neopredix-large.webp"},"category":"innovators","roles":["C"],"company_name":"NeoPredics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/thorstenwaloschek\/","biography":"

Thorsten Waloschek is a multi-business founder, consultant, and leader in MedTech marketing. He is the CEO of NeoPrediX AG and the founder and owner of CCIAOTM, LLC, a MedTech marketing and sales consultant firm. He has also served as President of Draeger Neonatal Care, Senior Director of Marketing for Natus Newborn Care, Founder of InfanDx, and CEO of Babybe.<\/p>\r\n

Thorsten is a high-performing, visionary leader with a 20-year track record in healthcare, including extended projects on several continents incl. the following countries: Germany, USA, France and Switzerland. His distinctive leadership and cross-cultural experience in the MedTech industry include groundbreaking developments in maternal and neonatal applications and innovations in digital health and predictive analysis.<\/p>\r\n

As CEO of NeoPrediX AG, Thorsten leads a Digital Health MedTech company that develops predictive analytics for neonatal and maternal care applications. Passionate about providing every baby with the best possible start into life, he guides a dedicated team that delivers outstanding results in a highly regulated and competitive market.<\/p>\r\n

Thorsten is the founder\/owner of CCIAOTM L.L.C., a MedTech marketing and sales consulting firm based in Germany and the US, focused on go-to-market and distribution channel strategy for medical devices. CCIAOTM stands for Communication, Change, Integrity, Accountability, and Ownership, qualities of Thorsten’s mission and commitment to teamwork and company culture. His belief in transparent communication, positive change, integrity, accountability for words and actions, and 100% ownership without excuses has been a hallmark of his career success.<\/p>\r\n

Thorsten Waloschek holds an MBA in International Business from the University of Bradford (UK) and certifications in Management Education (Rutgers University and Babson College) and New Medical Device Regulation. A popular and engaging speaker and panelist on the topics of neonatology, women’s as well as digital health, he has been featured at recent U.S. conferences, including DxPx, Delphi, LSI, and PlatforMed as well as in the incubator and the uncaged podcast. Thorsten supports SOS Children’s Villages and enjoys reading autobiographies in his spare time.<\/p>","companies":[{"id":150,"name":"NeoPredics","logo":{"id":900,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/900\/NeoPredics-new.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/900\/conversions\/NeoPredics-new-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/900\/conversions\/NeoPredics-new-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/900\/conversions\/NeoPredics-new-large.webp"},"type":"presenter","description":"

NeoPredics develops advanced predictive clinical decision support solutions using machine learning and AI algorithms to assess maternal and neonatal health risks. Their primary focus is on early detection of conditions such as preeclampsia and jaundice, providing data-driven insights to improve outcomes in high-risk pregnancies and newborn care.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-09-25T20:47:34.000000Z"}],"created_at":"2024-09-25T20:44:27.000000Z"},{"id":275,"name":"Dr Shieak Tzeng","title":"Co-founder & CEO","photo":{"id":1033,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1033\/shieak-tzeng-wellumio-cropped.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1033\/conversions\/shieak-tzeng-wellumio-cropped-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1033\/conversions\/shieak-tzeng-wellumio-cropped-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1033\/conversions\/shieak-tzeng-wellumio-cropped-large.webp"},"category":"innovators","roles":["C"],"company_name":"Wellumio","linkedin_profile":"https:\/\/www.linkedin.com\/in\/shieaktzeng\/","biography":"

Shieak is the co-founder and CEO of Wellumio, a venture-backed company focused on portable MRI technologies. Before Wellumio, Shieak co-founded and led a bioinformatics startup as CEO and founding inventor writing the company's first product and driving sales to leading US, UK, and Australasian institutions. At the University of Otago in New Zealand, Shieak founded the Centre for Translational Research and led the Centre for Bioengineering and Nanomedicine as board director. He also led the Wellington Medical Technology group for 15 years as an award-winning physician-scientist and technical pioneer in neurovascular physiology and medical device instrumentation R&D with over 100 scientific publications. Shieak received his medical degree and PhD from Otago University and was a National Heart Foundation Fellow and Sir Charles Hercus Fellow. Shieak completed his post-doctoral fellowship in computational physiology at Spaulding Rehabilitation Hospital, Harvard Medical School.<\/p>","companies":[{"id":151,"name":"Wellumio","logo":{"id":610,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/610\/99d-wellumio-logo-RGB_wellumio_main.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/610\/conversions\/99d-wellumio-logo-RGB_wellumio_main-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/610\/conversions\/99d-wellumio-logo-RGB_wellumio_main-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/610\/conversions\/99d-wellumio-logo-RGB_wellumio_main-large.webp"},"type":"presenter","description":"

Wellumio is a venture-backed company specializing in portable MRI solutions for acute neuroimaging applications. The company’s core enabling technology is a novel pulse-gradient free nuclear magnetic resonance sensor platform with an initial focus on acute stroke triage and diagnosis.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-09-25T20:51:47.000000Z"}],"created_at":"2024-09-25T20:53:06.000000Z"},{"id":276,"name":"John Brumfield","title":"CEO","photo":{"id":612,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/612\/john-brumfield-biotronik.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/612\/conversions\/john-brumfield-biotronik-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/612\/conversions\/john-brumfield-biotronik-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/612\/conversions\/john-brumfield-biotronik-large.webp"},"category":"innovators","roles":["C"],"company_name":"Berlin Heals","linkedin_profile":"https:\/\/www.linkedin.com\/in\/johnbrumfield\/","biography":"

Med Tech executive with over 20 years experience across R&D, product management, sales, marketing and corporate strategy leadership roles<\/p>","companies":[{"id":152,"name":"Berlin Heals","logo":{"id":613,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/613\/berlinheals_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/613\/conversions\/berlinheals_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/613\/conversions\/berlinheals_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/613\/conversions\/berlinheals_logo-large.webp"},"type":"presenter","description":"

Berlin Heals is developing the C-MIC system, an implantable electroceutical device that delivers a constant, but minimal, electrical direct current that mimics the physiological electrical currents produced by the heart. The device is a near-curative treatment for patients with heart failure that propagates the reverse remodeling of cardiac muscle tissue to restore heart function and size, thereby reducing the symptoms of heart failure and improving quality of life.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-09-25T20:57:53.000000Z"}],"created_at":"2024-09-25T20:56:46.000000Z"},{"id":277,"name":"Pablo Belmonte","title":"CEO","photo":{"id":614,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/614\/Screenshot-2024-09-25-140243.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/614\/conversions\/Screenshot-2024-09-25-140243-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/614\/conversions\/Screenshot-2024-09-25-140243-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/614\/conversions\/Screenshot-2024-09-25-140243-large.webp"},"category":"innovators","roles":["C"],"company_name":"Newmanbrain","linkedin_profile":"https:\/\/www.linkedin.com\/in\/pablo-belmonte-99410714\/","biography":"

Businessman and entrepreneur. Graduated in commercial aviation from the University of Salamanca and the Civil aviation authority. <\/p>\r\n

MBA and master’s degree in business management and marketing in the European school of business.<\/p>\r\n

He has trained in finance, strategy Analysis and Marketing.<\/p>","companies":[{"id":153,"name":"Newmanbrain","logo":{"id":615,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/615\/Screenshot-2024-09-25-140417.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/615\/conversions\/Screenshot-2024-09-25-140417-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/615\/conversions\/Screenshot-2024-09-25-140417-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/615\/conversions\/Screenshot-2024-09-25-140417-large.webp"},"type":"presenter","description":"

\r\n
Newmanbrain's mission is to enable mass pre-screening of mild cognitive impairment.<\/div>\r\n
The company's fNIRS (functional near-infrared spectroscopy) device, THEIA, is the world's first non-invasive and highly accurate technique designed to objectively support clinicians in assessing mild cognitive impairment. Theia is portable, easy to use, and suitable for both ambulatory and clinical settings. The THEIA system correlates diverse areas of the brain with mental functions to support clinicians in the evaluation, diagnosis, and treatment of cognitive-related conditions.<\/div>\r\n<\/div>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-09-25T21:04:53.000000Z"}],"created_at":"2024-09-25T21:03:44.000000Z"},{"id":10,"name":"Bruce Lichorowic","title":"Managing Director","photo":{"id":340,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/340\/2b8be9ef-97e3-40af-94b1-96e36a6e6ffb_medium.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/340\/conversions\/2b8be9ef-97e3-40af-94b1-96e36a6e6ffb_medium-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/340\/conversions\/2b8be9ef-97e3-40af-94b1-96e36a6e6ffb_medium-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/340\/conversions\/2b8be9ef-97e3-40af-94b1-96e36a6e6ffb_medium-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"BlueFire Venture Fund","linkedin_profile":"https:\/\/www.linkedin.com\/in\/brucelichorowic\/","biography":"

Mr. Lichorowic served as Co-founder, President and CEO of Galen Robotics, where he leverages technology solutions to tackle existing challenges in AI, SAAS, and Medical robotics. His expertise lies at the intersection of technology and multiple market segments, creating opportunities for convergence and driving significant change to enhance lives. With a pioneering spirit, he has led the way in commercializing AI adaptive agents for simplifying real-time data analytics and artificial intelligence applications.

As a \"crossover\" CEO, Mr. Lichorowic merges his high-tech and medical backgrounds to offer innovation, leadership, and visionary guidance in advancing the next generation of surgical robotics. Under his leadership, Galen Robotics, an affiliate of Johns Hopkins University, is at the forefront of revolutionizing minimally invasive high-precision surgeries. They have developed a groundbreaking surgical robotics platform for microsurgeries that combines robotics with advanced capabilities, including AI and data analytics, to support surgeons. This platform is currently undergoing FDA review, and Galen Robotics is preparing for its highly anticipated launch later this year.

Mr. Lichorowic's professional journey includes serving as the President and Chief Executive Officer of Trak Surgical and holding the position of Managing Director at BlueFire Capital Partners, where he focused on fostering the growth of technology-based mid-market companies in Silicon Valley, California. Additionally, he co-founded Madison Lane Consulting Group, where he implemented a unique \"business engineering\" approach to merge technology and medicine, leading to groundbreaking advancements in treatments and capabilities.

Beyond his entrepreneurial endeavors, Mr. Lichorowic has actively collaborated with local and state officials, advocating for policy changes that promote the advancement of innovative technologies. His expertise and insights have garnered recognition globally, making him a sought-after speaker at industry conferences. Professionals in both the technology and business sectors frequently seek his counsel and benefit from his visionary perspectives.<\/p>","companies":[],"created_at":"2024-04-26T19:06:31.000000Z"},{"id":278,"name":"Juan-Pablo Mas","title":"Partner","photo":{"id":618,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/618\/juan-pablo-mas-actionpotential.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/618\/conversions\/juan-pablo-mas-actionpotential-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/618\/conversions\/juan-pablo-mas-actionpotential-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/618\/conversions\/juan-pablo-mas-actionpotential-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Action Potential Venture Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jpmas\/","biography":"

Investor, electrical engineer, and medical technology enthusiast. Focused on \"Energy as Medicine\", i.e. bioelectronic medicines, next generation neuromodulation, digital therapeutics, and tech-enabled healthcare.

Also a founding Board member of LatinxVC and dedicated to seeing diverse representation within the life science industry, venture capital, and on private and public Boards.<\/p>","companies":[],"created_at":"2024-09-26T21:59:51.000000Z"},{"id":280,"name":"Daniel Teo","title":"Managing Partner","photo":{"id":620,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/620\/daniel-teo-hunniwell.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/620\/conversions\/daniel-teo-hunniwell-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/620\/conversions\/daniel-teo-hunniwell-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/620\/conversions\/daniel-teo-hunniwell-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Hunniwell Lake Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/daniel-teo-hunniwell\/","biography":"

• Venture capitalist currently investing in medical devices that improve surgical outcomes
• Seasoned finance & corporate development professional with broad international exposure in N. America, Europe & Asia
• Have closed 28 investments totaling $450M, 5 divestments ($440M), 15 rounds of financing ($700M)
• Led strategy, M&A, restructuring, integration and IPO preparation efforts, as well as implementation of new financial systems, cost reduction, internal control\/compliance and working capital initiatives in a number of different environments incl. MNCs, start-up, publicly listed and privately held
• Graduate of Stanford Graduate School of Business and of Cambridge University (UK)
• Certified in Accounting & Finance (ACCA). Familiarity with both IRFS & US GAAP, as well as Project Management & Six Sigma. Fluent in both English & Chinese (Mandarin).<\/p>","companies":[],"created_at":"2024-09-26T22:08:05.000000Z"},{"id":281,"name":"Christopher Campbell","title":"Director, Software and Sensors - VELYS Digital Surgery (Global Strategic Marketing)","photo":{"id":621,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/621\/christopher-campbell.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/621\/conversions\/christopher-campbell-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/621\/conversions\/christopher-campbell-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/621\/conversions\/christopher-campbell-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"DePuy Synthes, Johnson & Johnson","linkedin_profile":"https:\/\/www.linkedin.com\/in\/christopher-campbell-a0b995a\/","biography":"

Global strategic leadership within the health care and MedTech industries with a focus on delivering innovative business models, software and solutions that advance patient care & drive profitable growth.<\/p>","companies":[],"created_at":"2024-09-26T22:13:14.000000Z"},{"id":282,"name":"Owen Willis","title":"Founder and General Partner","photo":{"id":622,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/622\/owen-willis-opal.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/622\/conversions\/owen-willis-opal-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/622\/conversions\/owen-willis-opal-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/622\/conversions\/owen-willis-opal-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Opal Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/johnowenwillis\/","biography":"

Owen is the founder and General Partner of Opal Ventures. He previously built On Deck Health, a community for earliest-stage health tech founders and was COO at Osmosis, a Felicis and Greycroft-back health tech startup acquired by Elseiver. Owen began his career as a special education teacher in Washington, DC through Teach For America.<\/p>","companies":[],"created_at":"2024-09-26T22:18:38.000000Z"},{"id":283,"name":"Brad Sutton","title":"Chief Medical Officer","photo":{"id":623,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/623\/brad-sutton-bostonscientific.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/623\/conversions\/brad-sutton-bostonscientific-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/623\/conversions\/brad-sutton-bostonscientific-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/623\/conversions\/brad-sutton-bostonscientific-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Boston Scientific","linkedin_profile":"https:\/\/www.linkedin.com\/in\/brad-sutton-251b293\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-09-26T22:30:46.000000Z"},{"id":284,"name":"Kevin Clifford","title":"Senior Director, Innovation Strategy and Portfolio Management - Diagnostics","photo":{"id":624,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/624\/kevin-clifford-danaher.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/624\/conversions\/kevin-clifford-danaher-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/624\/conversions\/kevin-clifford-danaher-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/624\/conversions\/kevin-clifford-danaher-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Danaher","linkedin_profile":"https:\/\/www.linkedin.com\/in\/kevin-clifford-716ab97\/","biography":"

Business leader spanning Aerospace and BioPharma and Lifescience industries. Expertise in leading business strategy, generating market insights, corporate transformation, and portfolio management.<\/p>","companies":[],"created_at":"2024-09-26T22:33:39.000000Z"},{"id":285,"name":"Steven Pacelli","title":"Executive Vice President and Managing Director, Dexcom Ventures","photo":{"id":625,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/625\/Screenshot-2024-09-26-153615.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/625\/conversions\/Screenshot-2024-09-26-153615-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/625\/conversions\/Screenshot-2024-09-26-153615-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/625\/conversions\/Screenshot-2024-09-26-153615-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Dexcom","linkedin_profile":null,"biography":"

Steve Pacelli is Executive Vice President and Managing Director, Dexcom Ventures.<\/span><\/div>\r\n
In this role, Steve is focused on investment opportunities in sensing technology, data analytics, remote patient monitoring and population health, broadening Dexcom’s commitment to advancing better outcomes in healthcare.<\/span><\/div>\r\n
Prior to this role, Steve was Executive Vice President of Strategy and Corporate Development from 2012 to 2021. Since joining Dexcom in April 2006, Steve has served in roles of increasing responsibility, including Chief Operating Officer, Chief Administrative Officer, Senior Vice President of Corporate Affairs and Vice President of Legal Affairs.<\/span><\/div>\r\n
Prior to Dexcom, Steve served as a corporate attorney specializing in finance, mergers and acquisitions, and general corporate matters, and in an executive role as general counsel of several privately held companies.<\/span><\/div>\r\n
Steve currently serves as a member of the Board of Directors of Biocom California, the largest and most experienced leader and advocate for California’s life science sector. He also serves as a member of the Board of Directors of Connect, a community nonprofit supporting innovators and entrepreneurs in Southern California by providing access to investors, mentors, and education, and as a member of the Board of Directors of EvoNexus, California’s leading non-profit startup technology incubator.<\/span><\/div>\r\n
Steve is also a dedicated philanthropist, choosing to focus his efforts as a member of the Board of Directors of Big Brothers Big Sisters of San Diego, an organization dedicated to creating and supporting one-to-one mentoring relationships that ignite the power and promise of youth. He also serves as a member of the Board of Trustees of Pacific Ridge School, a group of dedicated and informed community leaders who are passionate about the value of education and are committed to building and strengthening the school.<\/span><\/div>\r\n
Steve earned a Bachelor of Arts from the University of California, Los Angeles, and a JD from the University of Virginia. He is a member of the State Bar of California.<\/span><\/div>","companies":[],"created_at":"2024-09-26T22:38:36.000000Z"},{"id":286,"name":"Kelly Krajnik","title":"Senior Director Business Development","photo":{"id":626,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/626\/kelly-krajnik-mayoclinic.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/626\/conversions\/kelly-krajnik-mayoclinic-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/626\/conversions\/kelly-krajnik-mayoclinic-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/626\/conversions\/kelly-krajnik-mayoclinic-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Mayo Clinic","linkedin_profile":"https:\/\/www.linkedin.com\/in\/kelly-krajnik-93b6909\/","biography":"

Kelly joined Business Development in 2006 and is responsible for facilitating the development and commercialization of Mayo Clinic technologies by working with Mayo Clinic staff, external companies, entrepreneurs, and investors. She is a member of the Mayo Clinic Ventures Executive Committee, leads the technology and business development function, and administers MCV’s seed\/angel fund program and chairs its investment committee.<\/p>\r\n

Prior to joining Business Development, Kelly worked as a senior research technologist developing and conducting microarray expression protocols in support of Mayo Clinic research programs and served on a Mayo Clinic Institutional Review Board.<\/p>\r\n

Kelly received her BS in Microbiology from University of Wisconsin – La Crosse, and her MBA from the University of St. Thomas. She is also a registered Patent Agent with the USPTO.<\/p>","companies":[],"created_at":"2024-09-26T22:41:34.000000Z"},{"id":287,"name":"Kevin Dempsey","title":"Sr. Director, Technology Development Group, Emphysys","photo":{"id":627,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/627\/kevin-dempsey-tecan.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/627\/conversions\/kevin-dempsey-tecan-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/627\/conversions\/kevin-dempsey-tecan-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/627\/conversions\/kevin-dempsey-tecan-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"TECAN","linkedin_profile":"https:\/\/www.linkedin.com\/in\/kevin-demp\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-09-26T22:44:53.000000Z"},{"id":288,"name":"Stephen Cox","title":"CEO & co-founder","photo":{"id":1029,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1029\/Stephen-Cox-(InVera-Medical-CEO)-cropped.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1029\/conversions\/Stephen-Cox-(InVera-Medical-CEO)-cropped-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1029\/conversions\/Stephen-Cox-(InVera-Medical-CEO)-cropped-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1029\/conversions\/Stephen-Cox-(InVera-Medical-CEO)-cropped-large.webp"},"category":"innovators","roles":["C"],"company_name":"InVera Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/stephen-cox\/","biography":"

CEO & co-founder of InVera Medical, a Bioinnovate Ireland biodesign fellowship medical device company developing a less-invasive, effective and pain-free device for the office-based treatment of varicose veins and venous ulcers, known as chronic venous disease, a condition that affects one in four people worldwide. An accomplished technologist and leader of innovative high-growth start-up organisations. Experienced in successfully funding and building complex products, and leading large teams across international locations.<\/p>","companies":[{"id":154,"name":"InVera Medical","logo":{"id":628,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/628\/InVera_Medical_Identity_CMYK_cropped.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/628\/conversions\/InVera_Medical_Identity_CMYK_cropped-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/628\/conversions\/InVera_Medical_Identity_CMYK_cropped-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/628\/conversions\/InVera_Medical_Identity_CMYK_cropped-large.webp"},"type":"presenter","description":"

InVera Medical is a clinical-stage medical device company transforming the treatment of chronic venous disease. The company's minimally invasive technology provides a pain-free alternative to conventional methods, meeting the global demand for improved care of varicosities and venous ulcers. Utilizing an advanced mechanochemical (MOCA) device that eliminates the need for thermal burning or glue-based procedures, not only enhances patient outcomes but also enables clinicians to treat more patients per day - substantially increasing clinic revenue.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-01T15:58:53.000000Z"}],"created_at":"2024-10-01T16:00:21.000000Z"},{"id":289,"name":"Barry Fell","title":"Co-Founder","photo":{"id":1310,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1310\/barry-fell-cranialdevices.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1310\/conversions\/barry-fell-cranialdevices-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1310\/conversions\/barry-fell-cranialdevices-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1310\/conversions\/barry-fell-cranialdevices-large.webp"},"category":"innovators","roles":["C"],"company_name":"Cranial Devices","linkedin_profile":"https:\/\/www.linkedin.com\/in\/barry-fell-innovation\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":155,"name":"Cranial Devices","logo":{"id":630,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/630\/Cranial-Devices.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/630\/conversions\/Cranial-Devices-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/630\/conversions\/Cranial-Devices-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/630\/conversions\/Cranial-Devices-large.webp"},"type":"presenter","description":"

Cranial Devices is an early-stage neurosurgical company developing a physiological cerebrospinal fluid shunt to improve the lives of patients with hydrocephalus. The device is intended to significantly reduce reintervention and reoperation rates seen with current shunt technologies.<\/p>","created_at":"2024-10-01T23:18:31.000000Z"}],"created_at":"2024-10-01T23:19:41.000000Z"},{"id":290,"name":"Ruben Molina","title":"CEO & Co-Founder","photo":{"id":646,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/646\/DSC05211.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/646\/conversions\/DSC05211-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/646\/conversions\/DSC05211-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/646\/conversions\/DSC05211-large.webp"},"category":"innovators","roles":["C"],"company_name":"INNITIUS","linkedin_profile":"https:\/\/www.linkedin.com\/in\/molinaruben\/","biography":"

\r\n

Rubén Molina is a Building Engineer specializing in Structural Calculation and a Structural Engineer specializing in Biomechanics and damage assessment of human tissue with non-destructive techniques, both from the University of Granada. He has also completed the Advanced Management Program at IESE Business School. Rubén is the CEO & Co-founder of INNITIUS and has been recognized as one of the top 100 entrepreneurial profiles in Spain 2023 and Forbes 30 under 30 2023.<\/p>\r\n<\/div>\r\n

\r\n

He has been entrepreneurial since the beginning of his professional career, starting in research. During his PhD, Rubén's curiosity in the technology now being developed by INNITIUS led him to not finish his PhD thesis and create the company. He is a young professional with a lot of energy, driven by challenges, and has a clear vision for the company with discipline and focus.<\/p>\r\n<\/div>\r\n

\r\n

Although he began his career in science, Rubén's core skills now lie in managing and leading the business, understanding obstetricians' needs, and translating them into the company's vision. Over 8 years, INNITIUS has achieved significant milestones such as progressing from a laboratory prototype to a frozen, clinically validated product design, assembling a team of over 15 people, and securing over €7M of funding to advance the product's development. Their aim is to eliminate the uncertainty associated with birth timing, impacting the lives of million of women worldwide each year.<\/p>\r\n<\/div>","companies":[{"id":156,"name":"INNITIUS","logo":{"id":645,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/645\/Innitius_400x400.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/645\/conversions\/Innitius_400x400-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/645\/conversions\/Innitius_400x400-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/645\/conversions\/Innitius_400x400-large.webp"},"type":"presenter","description":"

INNITIUS develops a medical device that combines intravaginal hardware to measure cervical tissue consistency with shear elastic waves and machine learning algorithms. The device aims to provide diagnostics for multiple women’s health conditions related to childbirth timing, with dedicated algorithms for each specific indication<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-01T23:26:17.000000Z"}],"created_at":"2024-10-01T23:29:04.000000Z"},{"id":291,"name":"Elizabeth Hoff","title":"Board Member","photo":{"id":686,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/686\/Ehoff_Headshot.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/686\/conversions\/Ehoff_Headshot-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/686\/conversions\/Ehoff_Headshot-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/686\/conversions\/Ehoff_Headshot-large.webp"},"category":"innovators","roles":["C"],"company_name":"Somavac","linkedin_profile":"https:\/\/www.linkedin.com\/in\/elizabeth-hoff-1a899188\/","biography":"

Elizabeth Hoff joined SOMAVAC as CEO in 2024, bringing over 30 years of executive
leadership and commercialization experience in MedTech companies such as Guidant,
Gore, and Medtronic. Throughout her career, Elizabeth has successfully launched five
standard-of-care changing technologies, including endovascular aortic repair, saphenous vein harvesting, and implantable cardiac monitoring.<\/p>\r\n

During her tenure at Medtronic, Elizabeth served as the VP\/GM of Cardiac Diagnostics, where she was the first General Manager of this business unit. She scaled the division from one employee to several thousand, launched a dedicated sales force, and grew sales to $300 million. Additionally, she set the R&D vision for the $1 billion LinQ device, which has transformed cardiac diagnostics.<\/p>\r\n

Elizabeth joined SOMAVAC with a mission to accelerate the commercialization of their patented, FDA-cleared technology that significantly enhances patient outcomes and experiences. Her commitment to this mission is deeply personal, driven by the journey of her best friend from her 20s, who faced the challenges of breast cancer and reconstruction.<\/p>\r\n

Elizabeth holds a Bachelor of Arts in Business and Psychology from Rice University.
Her extensive commercial experience and passion for improving patient care align
perfectly with SOMAVAC&#39;s mission to revolutionize surgical wound care and prioritize
the well-being of breast cancer survivors and all patients. Elizabeth is dedicated to
putting patients first and driving innovations that enhance their quality of life.<\/p>","companies":[{"id":157,"name":"Somavac","logo":{"id":685,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/685\/SOMAVAC-Logo-hor-W_Blue-copy.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/685\/conversions\/SOMAVAC-Logo-hor-W_Blue-copy-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/685\/conversions\/SOMAVAC-Logo-hor-W_Blue-copy-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/685\/conversions\/SOMAVAC-Logo-hor-W_Blue-copy-large.webp"},"type":"presenter","description":"

The Somavac system is designed to apply deep tissue Negative Pressure Therapy to reduce and prevent the occurrence of seroma in patients who have recently undergone breast reconstruction and mastectomies. Somavac is intended to reduce post-operative complications and the time requiring surgical drains following surgery. The system is self-contained within a belt to discretely remove fluid and prevent build-up that can lead to complications. <\/p>\r\n

Visit website<\/a>.<\/p>","created_at":"2024-10-01T23:31:01.000000Z"}],"created_at":"2024-10-01T23:32:15.000000Z"},{"id":293,"name":"Caitlin Morse","title":"CEO","photo":{"id":639,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/639\/caitlin-morse-brainspace.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/639\/conversions\/caitlin-morse-brainspace-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/639\/conversions\/caitlin-morse-brainspace-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/639\/conversions\/caitlin-morse-brainspace-large.webp"},"category":"innovators","roles":["C"],"company_name":"BrainSpace","linkedin_profile":"https:\/\/www.linkedin.com\/in\/caitlinmorse\/","biography":"

I am passionate about impacting global health by leveraging my medical device and international experience to improve access, efficacy, efficiency and affordability. I believe this all starts with meaningful communication: understanding the needs and priorities of patients, practitioners, payers, governments, device creators and distributors is key to creating targeted solutions with lasting impact and financial sustainability. In addition to being an entrepreneur, I also enjoy empowering other entrepreneurs.<\/p>","companies":[{"id":159,"name":"BrainSpace (DO NOT PUBLISH)","logo":{"id":638,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/638\/braiinspace.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/638\/conversions\/braiinspace-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/638\/conversions\/braiinspace-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/638\/conversions\/braiinspace-large.webp"},"type":"presenter","description":"

BrainSpace is developing a solution to simplify critical care in neurocritical patients. BrainSpace is committed to improving the way brain pressure is managed in patients recovering from stroke, traumatic brain injury, and neurosurgery. Currently patients requiring intracranial pressure management must be meticulously monitored and measured hourly by a nurse. The company has developed an automated monitoring solution as an alternative to the antiquated drainage monitoring relying on a manometer-based drain and blood pressure monitor that eliminates the hassle for patients and providers while improving the quality of data being captured for researchers and physicians.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-01T23:40:26.000000Z"}],"created_at":"2024-10-01T23:42:20.000000Z"},{"id":295,"name":"Chris Springate","title":"CEO","photo":{"id":644,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/644\/Chris-Springate-ARC-Medical.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/644\/conversions\/Chris-Springate-ARC-Medical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/644\/conversions\/Chris-Springate-ARC-Medical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/644\/conversions\/Chris-Springate-ARC-Medical-large.webp"},"category":"innovators","roles":["C"],"company_name":"ARC Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/chrisspringate\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":162,"name":"ARC Medical","logo":{"id":642,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/642\/ARC-Medical.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/642\/conversions\/ARC-Medical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/642\/conversions\/ARC-Medical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/642\/conversions\/ARC-Medical-large.webp"},"type":"presenter","description":"

ARC Medical is a clinical-stage medtech company developing a liquid medical device which forms a temporary barrier film to prevent surgical adhesions throughout the entire surgical area. ARC Medical’s products are backed by positive Phase 1 clinical trial safety data in 76 participants and superior nonclinical efficacy data in head-to-head comparisons against 3 of the top marketed products. Surgical indications include gynecological & abdominal and orthopedic surgeries – knee, shoulder & hip.<\/p>\r\n

Visit website<\/a>.<\/p>","created_at":"2024-10-01T23:46:37.000000Z"}],"created_at":"2024-10-01T23:49:44.000000Z"},{"id":296,"name":"John Erbey","title":"CEO","photo":{"id":650,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/650\/john-erbey-roivios.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/650\/conversions\/john-erbey-roivios-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/650\/conversions\/john-erbey-roivios-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/650\/conversions\/john-erbey-roivios-large.webp"},"category":"innovators","roles":["C"],"company_name":"Roivios","linkedin_profile":"https:\/\/www.linkedin.com\/in\/johnerbey\/","biography":"

\r\n

John is the founder and CEO of Roivios. He has spent the past 25 years bringing innovative therapeutics and medical devices to the market.<\/p>\r\n<\/div>\r\n

\r\n

Prior to founding Roivios, John held roles of increasing responsibility across the pharmaceutical and medical device industries.<\/p>\r\n<\/div>\r\n

\r\n

He holds a PhD in epidemiology from the University of Pittsburgh’s Graduate School of Public Health. His dissertation on the cardiovascular risk associated with insulin resistance in adults with type 1 diabetes earned him induction into Delta Omega, the National Honor Society for Public Health.  He has published 17 peer reviewed articles and delivered dozens of conference presentations and invited lectures.<\/p>\r\n<\/div>","companies":[{"id":163,"name":"Roivios","logo":{"id":649,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/649\/Roivios-logo.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/649\/conversions\/Roivios-logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/649\/conversions\/Roivios-logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/649\/conversions\/Roivios-logo-large.webp"},"type":"presenter","description":"

Roivios is a clinical-stage medtech company developing the JuxtaFlow Renal Assist Device (RAD). JuxtaFlow is designed to sustain or enhance kidney function in patients undergoing cardiac surgery that have pre-existing renal insufficiency. The JuxtaFlow system consists of a proprietary catheter and pump that delivers targeted negative pressure to enhance filtration and reabsorption, while mitigating kidney stressors during surgery.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-03T20:11:08.000000Z"}],"created_at":"2024-10-03T20:12:18.000000Z"},{"id":297,"name":"Nicholas Rafkind","title":"CEO","photo":{"id":652,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/652\/nicholas-rafkind-irisxr.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/652\/conversions\/nicholas-rafkind-irisxr-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/652\/conversions\/nicholas-rafkind-irisxr-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/652\/conversions\/nicholas-rafkind-irisxr-large.webp"},"category":"innovators","roles":["C"],"company_name":"IRIS XR","linkedin_profile":"https:\/\/www.linkedin.com\/in\/nickrafkind\/","biography":"

Inventor | Founder | CEO of IRIS XR. I'm passionate about collaborative augmented reality solutions that enhance teamwork and knowledge sharing for healthcare professionals.<\/p>","companies":[{"id":164,"name":"IRIS XR","logo":{"id":651,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/651\/iris_xr.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/651\/conversions\/iris_xr-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/651\/conversions\/iris_xr-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/651\/conversions\/iris_xr-large.webp"},"type":"presenter","description":"

The company is developing a platform that uses augmented reality (AR) to turn real-world OR experiences into collaborative, interactive, accessible simulations accessible on any device (phone, tablet. eyewear). The solution eliminates scheduling conflicts or limited training opportunities at medical device companies and hospitals.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-31T16:00:00.000000Z"}],"created_at":"2024-10-03T20:16:32.000000Z"},{"id":298,"name":"Teresa Prego","title":"CEO","photo":{"id":653,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/653\/teresa-prego-epiwatch.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/653\/conversions\/teresa-prego-epiwatch-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/653\/conversions\/teresa-prego-epiwatch-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/653\/conversions\/teresa-prego-epiwatch-large.webp"},"category":"innovators","roles":["C"],"company_name":"EpiWatch","linkedin_profile":"https:\/\/www.linkedin.com\/in\/teresaprego\/","biography":"

Teresa Prego is the Chief Executive Officer for EpiWatch, She has led the introduction and commercialization of multiple disruptive products and services in the healthcare industry, including digital health offerings in neurology and primary care (PKG Health, Nile AI),  robotics for both neurosurgical and orthopedic application (ROSA, now part of Zimmer Biomet); ablation technologies for the treatment of cancers; neurostimulation, and virtual care and services for specific populations and chronic diseases. Her passion is finding the balance of engaging healthcare consumers, patients, clinicians, technologies and healthcare systems to create better solutions and expand access to care.<\/p>\r\n

Teresa has a BS in Engineering and Earth Sciences from the University of Notre Dame, and an MBA from the Carroll School of Management at Boston College.  <\/p>","companies":[{"id":165,"name":"EpiWatch","logo":{"id":679,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/679\/EpiWatchlogo4.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/679\/conversions\/EpiWatchlogo4-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/679\/conversions\/EpiWatchlogo4-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/679\/conversions\/EpiWatchlogo4-large.webp"},"type":"presenter","description":"

EpiWatch is  an innovative company bringing continuous seizure monitoring (CSM), seizure detection and alerting to individuals and families living with epilepsy. EpiWatch is  a SaMD (software as a medical device) AI\/ML based platform running on an Apple Watch, providing real-world, objective seizure data that improves safety, care management, and ultimately risk forecasting and precision medicine for epilepsy.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-11-04T17:00:00.000000Z"}],"created_at":"2024-10-03T20:19:32.000000Z"},{"id":300,"name":"Aditya Tallapragada","title":"President","photo":{"id":658,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/658\/aditya-tallapragada-akthealth.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/658\/conversions\/aditya-tallapragada-akthealth-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/658\/conversions\/aditya-tallapragada-akthealth-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/658\/conversions\/aditya-tallapragada-akthealth-large.webp"},"category":"innovators","roles":["C"],"company_name":"AKT Health","linkedin_profile":"https:\/\/www.linkedin.com\/in\/adityakt\/","biography":"

-> Managing both Healthcare & Technology companies
-> Experienced in delivering solutions based on Blockchain Technology, Machine Learning, Artificial Intelligence and IoT.
-> Healthcare and Technology Professional with more than 10 years experience in Life Sciences Consulting, Clinical Research.
-> Technical & Investment Advisor for Enterprise Blockchain, Healthcare & IT
-> Commercial & Marketing Strategies Consultant along with experience in Financial Industry as Quantitative Analyst in early career.
-> Experienced in delivering Market Access, Pricing & Reimbursement projects<\/p>","companies":[{"id":167,"name":"AKT Health","logo":{"id":657,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/657\/akthealth.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/657\/conversions\/akthealth-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/657\/conversions\/akthealth-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/657\/conversions\/akthealth-large.webp"},"type":"presenter","description":"

AKT Health is developing a Software as Medical Device (SaMD) solution.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-11-06T17:00:00.000000Z"}],"created_at":"2024-10-03T20:30:42.000000Z"},{"id":301,"name":"Daniel Adler","title":"Co-Founder & CEO","photo":{"id":660,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/660\/Daniel-Adler-BioT.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/660\/conversions\/Daniel-Adler-BioT-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/660\/conversions\/Daniel-Adler-BioT-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/660\/conversions\/Daniel-Adler-BioT-large.webp"},"category":"innovators","roles":["C"],"company_name":"BioT Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/adlerdaniel\/","biography":"

Bio comming soon.<\/p>","companies":[{"id":168,"name":"BioT Medical","logo":{"id":659,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/659\/BioT.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/659\/conversions\/BioT-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/659\/conversions\/BioT-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/659\/conversions\/BioT-large.webp"},"type":"innovator","description":"

BioT's cloud platform simplifies the creation of a connected care ecosystem. The platform is self-service and requires no coding to connect medical devices, patient management portals, caregivers, and EHRs in an integrated space.<\/p>\r\n

Visit website<\/a>.<\/p>","created_at":"2024-10-03T21:17:07.000000Z"}],"created_at":"2024-10-03T21:17:08.000000Z"},{"id":305,"name":"Anmol Kapoor","title":"CEO","photo":{"id":667,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/667\/anmol-kapoor-bioaro.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/667\/conversions\/anmol-kapoor-bioaro-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/667\/conversions\/anmol-kapoor-bioaro-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/667\/conversions\/anmol-kapoor-bioaro-large.webp"},"category":"innovators","roles":["C"],"company_name":"Bioaro","linkedin_profile":"https:\/\/www.linkedin.com\/in\/anmol-kapoor-373631a\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":171,"name":"BioAro","logo":{"id":665,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/665\/biaro.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/665\/conversions\/biaro-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/665\/conversions\/biaro-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/665\/conversions\/biaro-large.webp"},"type":"presenter","description":"

BioAro is a biotechnology company specializing in genomics, artificial intelligence and blockchain technologies. The company offers whole genome sequencing, microbiome testing, and software solutions to support clinical testing offerings and improve overall efficiency of healthcare practices.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-07T22:15:50.000000Z"}],"created_at":"2024-10-07T22:17:30.000000Z"},{"id":306,"name":"Matthew Kuhn","title":"CEO","photo":{"id":668,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/668\/matthew-kuhn-taurus.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/668\/conversions\/matthew-kuhn-taurus-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/668\/conversions\/matthew-kuhn-taurus-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/668\/conversions\/matthew-kuhn-taurus-large.webp"},"category":"innovators","roles":["C"],"company_name":"Taurus Vascular","linkedin_profile":"https:\/\/www.linkedin.com\/in\/matthew-t-kuhn\/","biography":"

 am an engineer turned entrepreneur on a mission to develop cutting-edge medical device technologies to address serious illnesses.

Currently, as the Founder & CEO of Taurus Vascular, I lead our team in developing innovative solutions for aortic aneurysms. Our minimally-invasive, catheter-based technology aims to address the critical issue of endoleaks after Endovascular Aneurysm Repair (EVAR), significantly improving long-term patient outcomes. Founded in 2023 from the Texas Medical Center Innovation Biodesign Program, Taurus Vascular is dedicated to reducing the risk and impact of endoleaks with our novel stent technology.

I began my career by spending over five years at Johnson & Johnson in various roles covering nearly every stage of the medical device commercialization lifecycle. These experiences gave me an intimate, first-hand understanding of what it takes to bring medical device products to market. My work at the Johnson & Johnson MedTech Center for Device Innovation instilled in me an entrepreneurial drive to challenge the status quo as well as provided me with a strategic mindset to think from the perspectives of investors, clinicians, patients, payors, and corporate strategic partners.

As an active innovator, I am a named inventor on 40+ US patents covering a broad spectrum of medical device technologies, including cardiovascular electrophysiology, surgical oncology, cardiovascular access devices, orthopedics, and neurovascular therapies.

I am invested in growing and supporting Houston’s life science community as a mentor and advocate for students and aspiring entrepreneurs. I currently serve as an advisor for several early-stage medtech startups.<\/p>","companies":[{"id":172,"name":"Taurus Vascular","logo":{"id":669,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/669\/taurus_vascular_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/669\/conversions\/taurus_vascular_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/669\/conversions\/taurus_vascular_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/669\/conversions\/taurus_vascular_logo-large.webp"},"type":"presenter","description":"

Taurus Vascular is addressing one of the most common complications in the endovascular repair of aortic aneurysms - endoleak. Today, approximately 20% of patients who undergo endovascular repair require a secondary intervention to address endoleaks. The company is developing a catheter-based technology that places a self-deploying stent near the site of the aneurysm sac. Once deployed, the device allows for the continuous drainage and depressurization of the aneurysm sac following endovascular repair.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-07T22:21:53.000000Z"}],"created_at":"2024-10-07T22:20:47.000000Z"},{"id":309,"name":"Scott White","title":"CCO","photo":{"id":674,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/674\/Scott-White-Delpinus.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/674\/conversions\/Scott-White-Delpinus-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/674\/conversions\/Scott-White-Delpinus-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/674\/conversions\/Scott-White-Delpinus-large.webp"},"category":"innovators","roles":["C"],"company_name":"Delphinus Medical Technologies","linkedin_profile":"https:\/\/www.linkedin.com\/in\/scott-white-4977b773\/","biography":"

As Chief Executive Officer, Scott leads our Sales, Marketing and Customer Success organizations while executing our commercial strategy for growth. Scott has over 25 years of experience in the healthcare and technology industries, leading commercial and operational teams.<\/u><\/u><\/u><\/p>\r\n

Scott was previously the Chief Commercial Officer of Hyperfine (HYPR), developer of a bedside neurological MRI platform, where he led the development of their commercial strategy and supported the company’s IPO in 2022. In addition, he built a global commercial business throughout North America, Europe and APAC for Rapid Micro Biosystems (RPID), the developer of the Growth Direct System, which also led to a successful IPO in 2021. Scott also spent seven years at Intuitive Surgical as a VP of Sales, where he grew revenues in excess of $200 million annually.<\/u><\/u><\/u><\/p>\r\n

Scott has a bachelor’s degree in business from the University of Florida and a master’s in business from the University of Miami. He has also successfully completed several courses from Harvard’s Executive Education Programs.<\/p>","companies":[{"id":174,"name":"Delphinus Medical Technologies","logo":{"id":672,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/672\/1519922057175.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/672\/conversions\/1519922057175-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/672\/conversions\/1519922057175-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/672\/conversions\/1519922057175-large.webp"},"type":"presenter","description":"

Delphinus Medical Technologies develop and commercialize ultrasound technologies specifically for the early detection of breast cancer. The company's flagship product, SoftVue, utilizes proprietary TriAD (triple acoustic detection) technology to capture reflection echoes from all directions around the breast while simultaneously gathering transmitted signals through the breast. SoftVue is specifically designed for use in women with dense breast, who have historically been inadequately served with conventional imaging modalities. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-07T22:24:28.000000Z"}],"created_at":"2024-10-07T22:25:53.000000Z"},{"id":310,"name":"Douglas Fairbanks","title":"CEO","photo":{"id":676,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/676\/1678670402536.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/676\/conversions\/1678670402536-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/676\/conversions\/1678670402536-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/676\/conversions\/1678670402536-large.webp"},"category":"innovators","roles":["C"],"company_name":"VISIE","linkedin_profile":"https:\/\/www.linkedin.com\/in\/doug-fairbanks-futureoflight\/","biography":"

As the CEO of Advanced Scanners, I lead a visionary and strategic team that is transforming the medical device industry with cutting-edge robotics and digital surgery solutions. With over 15 years of experience in this field, I have a deep understanding of the market needs, challenges, and opportunities for innovation and growth.

One of my proudest achievements was leading a cross-functional team at Johnson & Johnson to achieve the first in human clinical use of an orthopedic robotic assisted device, a crucial priority for the company. I also expanded this initiative to build a comprehensive capital framework for robotic assisted devices and other enabling technologies. My mission is to leverage my expertise and passion for technology commercialization, product launch, and go-to-market strategy to create value for patients, providers, and partners.<\/p>","companies":[{"id":175,"name":"VISIE","logo":{"id":675,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/675\/01---Primary-Logo---FULL-COLOR-1000px.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/675\/conversions\/01---Primary-Logo---FULL-COLOR-1000px-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/675\/conversions\/01---Primary-Logo---FULL-COLOR-1000px-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/675\/conversions\/01---Primary-Logo---FULL-COLOR-1000px-large.webp"},"type":"presenter","description":"

Formerly known as Advanced Scanners, VISIE is a 3D computer vision and spatial computing company researching, developing, and commercializing revolutionary optical scanners for robotic and navigated orthopedic, neuro, and spine surgery. VISIE’s proprietary imaging hardware and software combines the power of optical physics and deep tech to make the unseen seen in surgery. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-07T22:27:08.000000Z"}],"created_at":"2024-10-07T22:27:10.000000Z"},{"id":312,"name":"James Mainwaring","title":"Chief Commercial & Operating Officer","photo":{"id":1034,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1034\/James-Mainwaring-innotive-cropped.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1034\/conversions\/James-Mainwaring-innotive-cropped-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1034\/conversions\/James-Mainwaring-innotive-cropped-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1034\/conversions\/James-Mainwaring-innotive-cropped-large.webp"},"category":"innovators","roles":["C"],"company_name":"Innotive Diagnostics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jftmainwaring\/","biography":"

James has experience in setting up key operating functions in early stage companies and delivering strategic analysis projects. Before moving into the medical device industry, James was a medical device investment analyst covering the US and European medical device markets at Atlantic Equities and before that at US investment bank, Stifel. James has a degree in Biology from the University of Bristol and is a CFA Charterholder.<\/p>","companies":[{"id":177,"name":"Innotive Diagnostics","logo":{"id":681,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/681\/Innotive_DX_RGB_Primary_Dark.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/681\/conversions\/Innotive_DX_RGB_Primary_Dark-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/681\/conversions\/Innotive_DX_RGB_Primary_Dark-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/681\/conversions\/Innotive_DX_RGB_Primary_Dark-large.webp"},"type":"presenter","description":"

Innotive Diagnostics is developing a novel bacterial infection diagnostic system to revolutionize the diagnosis of urinary tract infections (UTIs). The company’s system delivers a 99% reduction in time to result at the point of care using its diagnostic system vs. gold standard laboratory methods. Innotive’s technology is based on novel single-cell analysis that could be applicable across a range of bacterial infections.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-11-06T17:00:00.000000Z"}],"created_at":"2024-10-11T15:44:42.000000Z"},{"id":313,"name":"Manish Chand","title":"Director and Chief Medical Officer","photo":{"id":684,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/684\/Manish_Chand_02-(2).JPG","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/684\/conversions\/Manish_Chand_02-(2)-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/684\/conversions\/Manish_Chand_02-(2)-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/684\/conversions\/Manish_Chand_02-(2)-large.webp"},"category":"innovators","roles":["C"],"company_name":"OstomySecure","linkedin_profile":"https:\/\/www.linkedin.com\/in\/manish-chand-md-mba-phd-48490a71\/","biography":"

Manish Chand is a practising robotic colorectal surgeon at University College Hospital, London; as well as a Clinical Academic and Professor of Surgery at University College London.<\/span><\/p>\r\n

His clinical interest and expertise is minimally-invasive surgery (laparoscopy and robotic) for colorectal cancer and advanced endometriosis for which he is recognised as a global trainer and key opinion leader. .<\/span><\/p>\r\n

His research interests are in surgical technology which include surgical technology, image-guided surgery,AI and Augmented Reality. He has published over 250 peer-reviewed articles and continues to research into these areas and their integration into the next generation robotic platforms. He has an excellent record on first in man studies and believes in enhancing cutting edge technology for patient care holding NIHR and EAES grants. To this end, he is on the technology committees for the ACS, EAES and ASCRS.<\/span><\/p>\r\n

In addition to his clinical and research interests, Manish advises a number of companies from start-ups to established strategics and has a detailed knowledge and experience of getting innovations through inception to commercialisation and adoption. <\/span>  <\/span><\/p>","companies":[{"id":178,"name":"OstomySecure","logo":{"id":683,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/683\/ostomysecure.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/683\/conversions\/ostomysecure-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/683\/conversions\/ostomysecure-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/683\/conversions\/ostomysecure-large.webp"},"type":"presenter","description":"

OstomySecure is the creator of TIES, an innovative medical device with the potential transform the quality of life of millions of stoma patients worldwide. It is a discrete titanium implant with an innovative digital lid that replaces the need for permanent stoma bags and allows patients to manage their stoma with confidence. This enables ostomates to regain continence, reclaim their dignity, and take back control. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-11T16:05:00.000000Z"}],"created_at":"2024-10-11T16:55:14.000000Z"},{"id":314,"name":"Anita Brinks","title":"COO","photo":{"id":688,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/688\/Anita-Brinks.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/688\/conversions\/Anita-Brinks-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/688\/conversions\/Anita-Brinks-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/688\/conversions\/Anita-Brinks-large.webp"},"category":"innovators","roles":["C"],"company_name":"ATRO Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/anitabrinks\/","biography":"

Anita Brinks is a dedicated professional in the medical technology field, committed to improving joint health through innovative solutions. Currently as COO at ATRO Medical, she plays a crucial role in developing advanced therapies for joint-related issues, making a real difference in patients' lives.
 
Anita has a medical and business administration background and held several impactful roles in healthcare and the medical devices sector. She has worked on various projects, working from cardiac surgery to joint preservations and improving surgical instruments, always with a focus on enhancing patient care.
 
Now at ATRO Medical, Anita is excited to collaborate with others who share her passion for innovation in healthcare. If you're interested in advancing joint health or exploring potential partnerships, Anita would love to hear from you. Get in touch with her to discover how you can be part of the groundbreaking work at ATRO Medical. Reach out to Anita today!<\/p>","companies":[{"id":179,"name":"ATRO Medical","logo":{"id":687,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/687\/ATRO.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/687\/conversions\/ATRO-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/687\/conversions\/ATRO-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/687\/conversions\/ATRO-large.webp"},"type":"presenter","description":"

ATRO Medical's Artimis prosthesis is intended to provide patients who are too young for a knee replacement yet suffering from chronic knee pain with a viable solution. Artimis is a flexible, artificial meniscus that offers patients a less invasive alternative for treating chronic knee pain.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-11T17:17:48.000000Z"}],"created_at":"2024-10-11T17:19:32.000000Z"},{"id":317,"name":"Rodney Schutt","title":"CEO","photo":{"id":690,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/690\/Rodney-Schutt-(2)-orion.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/690\/conversions\/Rodney-Schutt-(2)-orion-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/690\/conversions\/Rodney-Schutt-(2)-orion-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/690\/conversions\/Rodney-Schutt-(2)-orion-large.webp"},"category":"innovators","roles":["C"],"company_name":"Orion Innovations","linkedin_profile":"https:\/\/www.linkedin.com\/in\/rodney-schutt-78730b6\/","biography":"

Proven Multiple Time President & CEO (Publicly Traded, Privately Held, VC and PE backed Companies). Extensive Global Experience, Financially Trained Leader Making Step Change Improvement in EBITDA in Every Assignment in Medical Device, Medical Imaging, Information Technology and Consumer Electronics. Accomplished Skills in Strategy Development, Decisive Leadership, High Performing Growth Oriented Teams, Global Channel Development, Product Portfolio Management, Strong Financial Acumen, Customer Focused, Operational Excellence, Manufacturing Production, R&D, Engineering Leadership and Retail Healthcare \/ Physician Practice Management Multi-Unit Retail Acquisitions \/ Roll Up. Outstanding Communication Skills.<\/p>","companies":[{"id":180,"name":"Orion Innovations","logo":{"id":689,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/689\/orion_innovations_group_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/689\/conversions\/orion_innovations_group_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/689\/conversions\/orion_innovations_group_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/689\/conversions\/orion_innovations_group_logo-large.webp"},"type":"presenter","description":"

Orion Innovations is focused on new and disruptive technologies that improve patient safety for the highest quality outcomes. The company’s portfolio includes the MedLite ID Smart-Lite solution (www.medliteid.com) for the acute healthcare market to prevent infusion Adverse Drug Events, NoGag (www.nogag.com) as a solution to dental procedures and patients impacted by the gag reflex, and Oxyswitch as an oxygen switching device for the hospital reducing Time-Without-O2. All smart, simple, and patented.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-11-04T17:00:00.000000Z"}],"created_at":"2024-10-11T17:25:15.000000Z"},{"id":318,"name":"Howard Hechler","title":"President & COO","photo":{"id":692,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/692\/howard-hechler-lumicell.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/692\/conversions\/howard-hechler-lumicell-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/692\/conversions\/howard-hechler-lumicell-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/692\/conversions\/howard-hechler-lumicell-large.webp"},"category":"innovators","roles":["C"],"company_name":"Lumicell","linkedin_profile":"https:\/\/www.linkedin.com\/in\/howard-hechler\/","biography":"

Howard joined Lumicell in 2020 as Senior Vice President of Strategy and Corporate Development, and now serves as Chief Business and Strategy Officer. He brings almost 20 years of focused life-sciences experience in market access, strategy, and operations. Prior to Lumicell, Howard worked at Locust Walk, PolarityTE, Smith & Nephew, Medtronic, and Mallinckrodt Pharmaceuticals. Howard graduated cum laude with a B.A. from Harvard University, and received his M.B.A. and Juris Doctorate degrees from the University of Virginia.<\/p>","companies":[{"id":181,"name":"Lumicell","logo":{"id":691,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/691\/lumicell.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/691\/conversions\/lumicell-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/691\/conversions\/lumicell-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/691\/conversions\/lumicell-large.webp"},"type":"presenter","description":"

Lumicell is focused on innovative fluorescence-guided technologies for cancer surgery. The company's Lumicell Direct Visualization System is intended to guide the removal of residual cancer during surgery in real time. The platform technology consists of an optical imaging agent, a handheld device, and patient-calibrated tumor detection software that work together to find, view and guide the resection of residual cancer. Lumicell is currently investigating the use of its technology for use during breast cancer surgery.<\/p>\r\n

Visit website<\/a>.<\/em><\/p>","created_at":"2024-10-11T17:27:36.000000Z"}],"created_at":"2024-10-11T17:27:37.000000Z"},{"id":320,"name":"Michael Nagel","title":"CEO","photo":{"id":869,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/869\/Business-Photo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/869\/conversions\/Business-Photo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/869\/conversions\/Business-Photo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/869\/conversions\/Business-Photo-large.webp"},"category":"innovators","roles":["C"],"company_name":"Vomaris Innovations","linkedin_profile":"https:\/\/www.linkedin.com\/in\/michaelpnagel\/","biography":"

Mike is a seasoned executive leader with a passion for driving innovation and efficiency in emerging-growth medical technology companies. At Vomaris, Mike has expanded the technology's scientific and clinical evidence platform, its product portfolio, and its global commercial presence. Before his tenure at Vomaris, Mike served as Chief Commercial Officer at Neomend, overseeing the successful commercial launch of the ProGEL surgical sealant, which achieved rapid sales growth and contributed to the company's acquisition by C.R. Bard. Prior to that, he co-founded Vascular Solutions, where he played a key role in the company's IPO and the launch of innovative vascular closure devices, ultimately leading to its acquisition by Teleflex for over $900 million. With over 35 years in the industry, Mike also serves on Boards at VenoStent, EndoShunt, and Chairperson of the Board for Kiromic BioPhama (KRBP).<\/p>","companies":[{"id":183,"name":"Vomaris Innovations","logo":{"id":868,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/868\/PowerHeal_Logo_BK_1200px.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/868\/conversions\/PowerHeal_Logo_BK_1200px-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/868\/conversions\/PowerHeal_Logo_BK_1200px-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/868\/conversions\/PowerHeal_Logo_BK_1200px-large.webp"},"type":"presenter","description":"

Vomaris’s award winning microcell-battery technology powers antibacterial products for advanced wound and incision care. Previously available only by prescription, Vomaris recently launched OTC under the brand name PowerHeal® Bioelectric Bandages. PowerHeal is the only bioelectric bandage in the consumer market, finally giving patients easy access to advanced wound care products at home. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-11T17:34:04.000000Z"}],"created_at":"2024-10-11T17:35:59.000000Z"},{"id":321,"name":"Pramote Hochareon","title":"Founder & CEO","photo":{"id":698,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/698\/pramote.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/698\/conversions\/pramote-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/698\/conversions\/pramote-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/698\/conversions\/pramote-large.webp"},"category":"innovators","roles":["C"],"company_name":"NirvaMed","linkedin_profile":"https:\/\/www.linkedin.com\/in\/phochareon\/","biography":"

Former Senior Scientist at Boston Scientific; Ph.D. in Bioengineering from Penn State University.; Postdoc in Biomedical Engineering at the University of Minnesota; MD from Faculty of Medicine Siriraj Hospital, Bangkok, Thailand.<\/p>","companies":[{"id":184,"name":"NirvaMed","logo":{"id":697,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/697\/nirvamed.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/697\/conversions\/nirvamed-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/697\/conversions\/nirvamed-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/697\/conversions\/nirvamed-large.webp"},"type":"presenter","description":"

NirvaMed is an early-stage medtech company developing a novel treatment for ST-Elevation Myocardial Infarction (STEMI). The company's solution is a rapid cooling system that can be deployed in parallel with standard devices for PCI to enable cardiac tissue preservation that addresses the shortcomings of previous hypothermic treatments. The device is delivered to the right side of the heart to prevent disruptions to standard left side of the heart procedures to provide ischemic relief prior to reperfusion therapy.<\/p>\r\n

Visit website<\/a>.<\/em><\/p>","created_at":"2024-10-11T17:44:09.000000Z"}],"created_at":"2024-10-11T17:44:10.000000Z"},{"id":322,"name":"Kristina Bartolo","title":"CTO","photo":{"id":699,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/699\/kristina-bartolo-orthonika.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/699\/conversions\/kristina-bartolo-orthonika-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/699\/conversions\/kristina-bartolo-orthonika-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/699\/conversions\/kristina-bartolo-orthonika-large.webp"},"category":"innovators","roles":["C"],"company_name":"Orthonika","linkedin_profile":"https:\/\/www.linkedin.com\/in\/mkbartolo\/","biography":"

Ambitious challenge-oriented biomedical engineer with experience in product design and development, biomechanics and orthopaedics. <\/p>","companies":[{"id":185,"name":"Orthonika","logo":{"id":700,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/700\/orthonika.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/700\/conversions\/orthonika-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/700\/conversions\/orthonika-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/700\/conversions\/orthonika-large.webp"},"type":"presenter","description":"

Orthonika is a spin-out from Imperial College London developing a Total Meniscus Replacement, an orthopaedic implant for the knee joint. Our innovative device is in the final stages of pre-clinical development. Encouraging data supports its role as a long-term joint-preserving treatment option for patients with irreparable meniscal damage, addressing an unmet market need valued in excess of $1.6bn.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-17T17:53:19.000000Z"}],"created_at":"2024-10-11T17:52:31.000000Z"},{"id":323,"name":"Ivan Lo","title":"CEO","photo":{"id":702,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/702\/ivan-lo-breathdiagnostics.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/702\/conversions\/ivan-lo-breathdiagnostics-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/702\/conversions\/ivan-lo-breathdiagnostics-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/702\/conversions\/ivan-lo-breathdiagnostics-large.webp"},"category":"innovators","roles":["C"],"company_name":"Breath Diagnostics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ivanyhlo\/","biography":"

Ivan Lo works closely with brokers, money managers and industry reporters to bring them new ideas and insights on the market and often acts as a capital markets advisor, who has helped raised millions for his portfolio companies – many of which have led to successful exits through buyouts and capital market appreciation, including clients with successful exits in excess of $1 billion.

Ivan is also involved in all aspects of seed to early stage financing, public markets consulting, and anything that involves the Captial markets and the people within it.<\/p>","companies":[{"id":186,"name":"Breath Diagnostics","logo":{"id":701,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/701\/breath-diagnostics.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/701\/conversions\/breath-diagnostics-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/701\/conversions\/breath-diagnostics-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/701\/conversions\/breath-diagnostics-large.webp"},"type":"presenter_innovator","description":"

Breath Diagnostics is OneBreath is a patented and cost-effective screening method for the early detection of lung cancer and other diseases. Captured organic compounds are analyzed using a benchtop micro-reactor that provides results within 3 to 4 business days.<\/p>\r\n

Visit website<\/a>.<\/p>","created_at":"2024-11-06T17:00:00.000000Z"}],"created_at":"2024-10-11T18:27:29.000000Z"},{"id":324,"name":"Jeff Pompeo","title":"President & CEO","photo":{"id":704,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/704\/jeff-pompeo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/704\/conversions\/jeff-pompeo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/704\/conversions\/jeff-pompeo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/704\/conversions\/jeff-pompeo-large.webp"},"category":"innovators","roles":["C"],"company_name":"Caretaker Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jeffpompeo\/","biography":"

Serial entrepreneur, Angel Investor, and Board\/Advisor with a proven track record leading, growing and monetizing technology-driven companies across the full life-cycle of inception & funding to product-launch & exit. Twenty-five years of success building world-class organizations and executing \"idea-to-implementation\" hyper-growth strategies for FDA-regulated MedTechs, University spin-outs, Tech-company turnarounds, IoT businesses, and Disruptive Technology Innovations.<\/p>","companies":[{"id":187,"name":"Caretaker Medical","logo":{"id":703,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/703\/caretaker-medical.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/703\/conversions\/caretaker-medical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/703\/conversions\/caretaker-medical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/703\/conversions\/caretaker-medical-large.webp"},"type":"presenter","description":"

\r\n
\r\n
\r\n
\r\n
\r\n
\r\n

Caretaker Medical’s VitalStream™ Wireless Hemodynamic Monitoring platform is FDA-cleared to measure Continuous Beat-by-Beat Blood Pressure, Cardiac Output, Fluid Response, and other Advanced Hemodynamic parameters for ICU-quality continuous Remote Patient Monitoring at all points of care.  The company’s patented Pulse Decomposition Analysis™ AI Technology, wearable Finger Sensor, Remote App, and New A-Line Interface <\/strong><\/u>deliver both Invasive and Non-Invasive hemodynamic monitoring<\/strong><\/em> modes that wirelessly stream continuous physiological data for early warning of patient deterioration and better clinical decision-making.<\/p>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-11T18:31:12.000000Z"}],"created_at":"2024-10-11T18:31:14.000000Z"},{"id":325,"name":"Stephen McGovern","title":"Principal","photo":{"id":705,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/705\/stephen-mcgovern-crystalventure.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/705\/conversions\/stephen-mcgovern-crystalventure-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/705\/conversions\/stephen-mcgovern-crystalventure-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/705\/conversions\/stephen-mcgovern-crystalventure-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Crystal Venture Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/stephen-mcgovern\/","biography":"

Stephen McGovern has dedicated his career to investing and advising early-stage Insurance & Technology businesses. Over the last decade, Stephen has helped founders and executive teams to navigate capital markets, build scalable operations and execute high-growth corporate strategies to drive shareholder returns.

Prior to joining Crystal Venture Partners, Stephen was part of the founding team at Eos Venture Partners. At Eos, Stephen oversaw deal sourcing, execution, and portfolio company improvement for several Eos Investments in North America and Europe. In addition, Stephen served on the board of Eos investments, Players Health and Elpha Secure.<\/p>","companies":[],"created_at":"2024-10-11T18:50:52.000000Z"},{"id":326,"name":"Zoar Engelman","title":"Founder & CSO","photo":{"id":706,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/706\/zoar.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/706\/conversions\/zoar-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/706\/conversions\/zoar-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/706\/conversions\/zoar-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Deerfield Catalyst","linkedin_profile":"https:\/\/www.linkedin.com\/in\/zoar-engelman-b0687421\/","biography":"

My professional goal is to use my expertise and passion for medical science in the identification and development of new technologies that improve patient care.<\/p>","companies":[],"created_at":"2024-10-11T18:53:23.000000Z"},{"id":327,"name":"Scott Huennekens","title":"Executive Chairman","photo":{"id":707,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/707\/scott-huennekens-frontfoot.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/707\/conversions\/scott-huennekens-frontfoot-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/707\/conversions\/scott-huennekens-frontfoot-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/707\/conversions\/scott-huennekens-frontfoot-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Front Foot Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/scott-huennekens-0b538b111\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-10-11T18:55:23.000000Z"},{"id":328,"name":"Howard Levin","title":"CEO & CMO","photo":{"id":708,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/708\/howard-levin-deerfield.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/708\/conversions\/howard-levin-deerfield-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/708\/conversions\/howard-levin-deerfield-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/708\/conversions\/howard-levin-deerfield-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Deerfield Catalyst","linkedin_profile":"https:\/\/www.linkedin.com\/in\/howard-levin\/","biography":"

Howard Levin, M.D., a heart failure transplant cardiologist by training, is an expert in creating novel therapies for cardiac, respiratory, neuro, and renal patients<\/p>","companies":[],"created_at":"2024-10-11T18:57:14.000000Z"},{"id":329,"name":"Tyler Wanke","title":"Investor & CEO","photo":{"id":709,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/709\/tyler-wanke-wankefamilyoffice.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/709\/conversions\/tyler-wanke-wankefamilyoffice-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/709\/conversions\/tyler-wanke-wankefamilyoffice-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/709\/conversions\/tyler-wanke-wankefamilyoffice-large.webp"},"category":"investors_strategics","roles":["I","C"],"company_name":"Wanke Family Office\/MadSci","linkedin_profile":"https:\/\/www.linkedin.com\/in\/tyler-wanke-a116862b\/","biography":"

 Tyler Wanke, MD, MBA, MEM\/MSDI is a MedTech investor, entrepreneur, and professor. He is also CEO & Co-founder of Madison Scientific (MadSci), a UW-Madison spin-out company developing a Smart Shunt for hydrocephalus. Tyler invests in MedTech venture on behalf of his family office as an angel investor. He previously was co-founder\/CEO of Innoblative, a breast cancer ablation company spun out of Northwestern, and currently serves on the board. He has also served on the board of EDGe Surgical, a revenue-stage Orthopaedic and Spine medical device company. <\/p>\r\n

Additionally, Tyler is an adjunct professor at Northwestern University where he teaches NUvention Medical, Northwestern’s BioDesign<\/em> curriculum. <\/p>\r\n

He completed an MD from Feinberg School of Medicine, MBA from Kellogg School of Management, a Masters of Engineering Management (MEM) \/ Masters of Science of Design Innovation (MSDI) from McCormick School of Engineering \/ Segal Design Institute, and a BS in Neurobiology from the University of Wisconsin – Madison. <\/p>\r\n

He volunteers on a Board of Cures Within Reach (CWR), a non-profit dedicated to funding research of “re-purposed” drugs and devices to cure diseases. <\/p>","companies":[{"id":445,"name":"MadSci","logo":{"id":1583,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1583\/madsci.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1583\/conversions\/madsci-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1583\/conversions\/madsci-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1583\/conversions\/madsci-large.webp"},"type":"presenter","description":"

Madison Scientific is developing SmartShunt™, a neurosurgical device for the treatment and monitoring of hydrocephalus. Unlike traditional shunts that rely on mechanical valves, SmartShunt integrates a proprietary microvalve with an intracranial pressure sensor to optimize fluid drainage and reduce the risk of shunt failure. The device also enables advanced monitoring, potentially decreasing the need for invasive and costly hospital-based diagnostic procedures.<\/p>\r\n

Visit website<\/em><\/a>.<\/span><\/p>","created_at":"2025-03-07T15:00:00.000000Z"}],"created_at":"2024-10-11T18:58:56.000000Z"},{"id":330,"name":"Edward Ruppel","title":"Partner, Co-Founder, VP of R&D","photo":{"id":710,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/710\/Edward_Ruppel-Deerfield.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/710\/conversions\/Edward_Ruppel-Deerfield-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/710\/conversions\/Edward_Ruppel-Deerfield-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/710\/conversions\/Edward_Ruppel-Deerfield-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Deerfield Catalyst","linkedin_profile":"https:\/\/www.linkedin.com\/in\/edward-ruppel-iii-83614885\/","biography":"

Designing the next generation of unconventional device therapies. <\/p>","companies":[],"created_at":"2024-10-11T19:01:09.000000Z"},{"id":331,"name":"Anna Hildebrand","title":"Analyst","photo":{"id":711,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/711\/anna-hildebrand-iag.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/711\/conversions\/anna-hildebrand-iag-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/711\/conversions\/anna-hildebrand-iag-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/711\/conversions\/anna-hildebrand-iag-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"IAG Capital Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/anna-hildebrand-b44a15178\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-10-11T19:06:57.000000Z"},{"id":332,"name":"Jonathan Norris","title":"Managing Director","photo":{"id":712,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/712\/FEDZZKEF-Presenter-NorrisJ.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/712\/conversions\/FEDZZKEF-Presenter-NorrisJ-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/712\/conversions\/FEDZZKEF-Presenter-NorrisJ-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/712\/conversions\/FEDZZKEF-Presenter-NorrisJ-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"HSBC Innovation","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jonathan-norris-248556\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-10-11T19:09:03.000000Z"},{"id":333,"name":"Anou Singhvi","title":"Partner","photo":{"id":713,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/713\/anou-singhvi-angelphysicians.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/713\/conversions\/anou-singhvi-angelphysicians-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/713\/conversions\/anou-singhvi-angelphysicians-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/713\/conversions\/anou-singhvi-angelphysicians-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Angel Physicians Fund","linkedin_profile":"https:\/\/www.linkedin.com\/in\/anousinghvi\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-10-11T20:26:58.000000Z"},{"id":334,"name":"Finn Haley","title":"Senior Vice President, Corporate Development","photo":{"id":714,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/714\/finn-haley-edwards.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/714\/conversions\/finn-haley-edwards-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/714\/conversions\/finn-haley-edwards-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/714\/conversions\/finn-haley-edwards-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Edwards Lifesciences","linkedin_profile":"https:\/\/www.linkedin.com\/in\/finnhaley\/","biography":"

I’m a Business Development, M&A, and Strategy professional with experience at investment banks, Fortune 100 multinationals, and high-growth companies. I’ve been a trusted advisor to senior execs and c-suite leaders. I’ve led a wide variety of transactions, including acquisitions, divestitures, corporate carve-outs, venture capital, partnerships, legal settlements, and cross-border M&A. Additionally, I’ve successfully led the strategic planning process in a big industrial conglomerate, working with many different functional teams. I’m passionate about driving growth and creating value in every role I take on.<\/p>","companies":[],"created_at":"2024-10-11T20:29:27.000000Z"},{"id":335,"name":"Amy Cooper","title":"Senior Director of Strategic Development","photo":{"id":715,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/715\/amy-cooper-terumo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/715\/conversions\/amy-cooper-terumo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/715\/conversions\/amy-cooper-terumo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/715\/conversions\/amy-cooper-terumo-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Terumo Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/amy-cooper-cfa\/","biography":"

As a Corporate Development & Strategy leader, my focus is on accelerating global business growth through new strategies, transactions, partnerships, and initiatives. Working closely with senior executives, I spearhead opportunities from identification and planning through negotiation and execution. <\/p>","companies":[],"created_at":"2024-10-11T20:34:51.000000Z"},{"id":336,"name":"Andre LaFreniere","title":"Vice President, Commercial Sales","photo":{"id":716,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/716\/andre-lafreniere-battele.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/716\/conversions\/andre-lafreniere-battele-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/716\/conversions\/andre-lafreniere-battele-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/716\/conversions\/andre-lafreniere-battele-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Vice President, Commercial Sales","linkedin_profile":"https:\/\/www.linkedin.com\/in\/andrelafreniere\/","biography":"

Experienced business development professional with a demonstrated history of working in the pharmaceutical, biotech, and medical device industry with a broad range of client relationships from the Fortune 100 to start-up organizations and everything in-between. Extensive professional and personal network includes regional, nationwide (U.S.), and international (Europe, Asia) markets.<\/p>","companies":[],"created_at":"2024-10-11T20:41:09.000000Z"},{"id":337,"name":"Christian O'Connor","title":"Medtech Executive","photo":{"id":717,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/717\/1682857941783.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/717\/conversions\/1682857941783-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/717\/conversions\/1682857941783-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/717\/conversions\/1682857941783-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Independent","linkedin_profile":"https:\/\/www.linkedin.com\/in\/christiancoconnor\/","biography":"

Bio coming soon.<\/p>","companies":[],"created_at":"2024-10-11T20:46:01.000000Z"},{"id":338,"name":"Edward \u201cTed\u201d Ruppel","title":"President and CEO","photo":{"id":722,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/722\/1656435847501.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/722\/conversions\/1656435847501-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/722\/conversions\/1656435847501-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/722\/conversions\/1656435847501-large.webp"},"category":"innovators","roles":["C"],"company_name":"Shape Memory Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/tedruppel\/","biography":"

Ted brings nearly 30 years of entrepreneurial and medical device company management experience, including the IPO of of Micrus Endovascular Corp., followed by its purchase by Codman &amp; Shurtleff, and J&amp;J company. Past executive and senior leadership roles include EVP\/CFO of Vascular Dynamics, Executive VP of R&amp;D and Operations at Micrus Endovascular Corporation (J&J), and management and operations roles at CBYON Inc., Biometric Imaging (BD), Applied Biosystems, and Spectra-Physics Lasers. Ted has a BSME from the University of Rochester and an MBA from TRIUM (jointly conferred by London Schoolof Economics and Political Science, NYU Stern School of Business, and HEC Paris).<\/p>","companies":[{"id":188,"name":"Shape Memory Medical","logo":{"id":721,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/721\/SMM_LOGO_SF_BLUE_R.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/721\/conversions\/SMM_LOGO_SF_BLUE_R-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/721\/conversions\/SMM_LOGO_SF_BLUE_R-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/721\/conversions\/SMM_LOGO_SF_BLUE_R-large.webp"},"type":"presenter","description":"

Shape Memory Medical is focused on innovative, therapeutic solutions for endovascular markets with its proprietary shape memory polymers (SMP). SMP is a bioabsorbable polyurethane embolic scaffold that supports rapid conversion to organized thrombus followed by tissue ingrowth. With commercialized devices in peripheral vascular embolization space, the company is actively leveraging its platform technology to develop novel applications for the management of complex aortic pathologies including aortic aneurysms.<\/span><\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-22T18:15:53.000000Z"}],"created_at":"2024-10-22T18:17:54.000000Z"},{"id":340,"name":"Charles Allan","title":"CEO","photo":{"id":726,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/726\/1621361065445-2.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/726\/conversions\/1621361065445-2-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/726\/conversions\/1621361065445-2-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/726\/conversions\/1621361065445-2-large.webp"},"category":"innovators","roles":["C"],"company_name":"MY01","linkedin_profile":"https:\/\/www.linkedin.com\/in\/charlesallanmy01\/","biography":"

Charlie is passionate about using really small things to solve big problems. This fascination began in school; during undergrad, he helped build a microfluidic pump for an implantable therapeutic for glaucoma. During his master's, he helped form a team that developed micro solutions, which led to the formation of three companies (MY01, Stathera and Nxtsens), all of which are growing today.<\/p>","companies":[{"id":190,"name":"MY01","logo":{"id":725,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/725\/1644589899709.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/725\/conversions\/1644589899709-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/725\/conversions\/1644589899709-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/725\/conversions\/1644589899709-large.webp"},"type":"presenter","description":"

MY01 has developed a device to continuously monitor and manage acute compartment syndrome in muscles. The MY01 device is a sterile, single-use device that quickly measures muscle pressure following orthopedic surgery for trauma.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-22T18:32:14.000000Z"}],"created_at":"2024-10-22T18:32:15.000000Z"},{"id":341,"name":"Danguole Altman","title":"CEO","photo":{"id":729,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/729\/danguole-altman-cxprecision.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/729\/conversions\/danguole-altman-cxprecision-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/729\/conversions\/danguole-altman-cxprecision-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/729\/conversions\/danguole-altman-cxprecision-large.webp"},"category":"innovators","roles":["C"],"company_name":"Cx Precision Medicine","linkedin_profile":"https:\/\/www.linkedin.com\/in\/danguolealtman\/","biography":"

Danguole is an experienced CEO with a history of success in life sciences and health care services. She joined CxPM as President and CEO in January 2020.<\/p>\r\n

She has founded two successful firms, raised over $40 Million in capital and recruited top-notch management teams.<\/p>\r\n

As founder and past CEO of Vapogenix, Danguole built a pain management company that is developing a novel class of non-opioid analgesics, leading the company from pre-clinical through the start of its Phase 2 trial. She was past CEO of FemPartners, a private equity backed women’s health care services firm which grew to be one of the largest such firms in the industry.<\/p>","companies":[{"id":192,"name":"Cx Precision Medicine","logo":{"id":728,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/728\/cx_precision_medicine_inc_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/728\/conversions\/cx_precision_medicine_inc_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/728\/conversions\/cx_precision_medicine_inc_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/728\/conversions\/cx_precision_medicine_inc_logo-large.webp"},"type":"presenter","description":"

CxPrecision Medicine's NeuroFirst products are intended to reduce the complexity of diagnosing neurological disorders such as dementia, Parkinson's disease, and Alzheimer's. The company combines proteomics and machine learning to identify biomarkers that support personalized pharmaceutical management of patients and rule out neurodegenerative disorders.<\/p>\r\n

Visit website<\/a>.<\/p>","created_at":"2024-10-22T18:57:42.000000Z"}],"created_at":"2024-10-22T18:59:01.000000Z"},{"id":342,"name":"Stuart Mitchell","title":"CEO","photo":{"id":732,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/732\/stuart-mitchell-novuson.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/732\/conversions\/stuart-mitchell-novuson-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/732\/conversions\/stuart-mitchell-novuson-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/732\/conversions\/stuart-mitchell-novuson-large.webp"},"category":"innovators","roles":["C"],"company_name":"Novuson Surgical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/mitchellsb\/","biography":"

Dr. Mitchell will share the story of Novuson at the Emerging Medtech Summit and will discuss their financing objectives and strategic partnering plans.<\/p>\r\n

Dr. Mitchell is a graduate of the University of Washington and he has been designing biomedical instrumentation and devices for approximately 20 years. Dr. Mitchell has extensive experience in biomechanics (soft tissue and orthopedic), tissue engineering, instrumentation, electronics, and mechanical design.<\/p>\r\n

While at the university, Dr. Mitchell managed and conducted research in multimillion dollar DARPA projects where he developed relationships with medical industry leaders. He has conducted research in biomechanics, tissue engineering, acoustic hemostasis and high intensity focused ultrasound (HIFU) for tumor treatment. Dr. Mitchell has been involved in helping HIFU gain recognition in the clinical setting and has led research teams in conducting application studies.<\/p>","companies":[{"id":194,"name":"Novuson Surgical","logo":{"id":731,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/731\/novuson.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/731\/conversions\/novuson-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/731\/conversions\/novuson-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/731\/conversions\/novuson-large.webp"},"type":"presenter","description":"

Novuson’s patented DTU technology will represent the first substantive innovation in over 25 years for targeting vessel sealing \/ dividing, and hemostasis (bleeding control) in surgical and trauma applications.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-22T19:00:50.000000Z"}],"created_at":"2024-10-22T19:02:26.000000Z"},{"id":343,"name":"James Lancaster","title":"CEO","photo":{"id":734,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/734\/james-lancaster.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/734\/conversions\/james-lancaster-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/734\/conversions\/james-lancaster-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/734\/conversions\/james-lancaster-large.webp"},"category":"innovators","roles":["C"],"company_name":"Solenic Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jylancaster\/","biography":"

James Y. Lancaster, Chief Executive Officer, is a seasoned entrepreneur and business development executive with 30 years of experience across multiple industries. He was most recently the Founder and Managing Director of the Innovate Family of Companies with client technologies including a variety of software, innovative materials, internet-of-things, robotics, autonomous vehicles, drone technologies, medical device, biological control, and waste recycling technologies. Prior to becoming an entrepreneur, he worked for Deloitte Consulting in Dallas with Fortune 500 and held other executive positions in business software and services, medical technologies, and IT solutions. <\/p>","companies":[{"id":195,"name":"Solenic Medical","logo":{"id":733,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/733\/solenic-medical.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/733\/conversions\/solenic-medical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/733\/conversions\/solenic-medical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/733\/conversions\/solenic-medical-large.webp"},"type":"presenter","description":"

Solenic Medical is developing a non-invasive medical device that utilizes alternating magnetic fields to eradicate biofilms that form on implants. The company's platform uses external magnetic coils to destroy infective biofilms on the surface of knee and hip replacement implants, as well as plates and rods for trauma related procedures. Solenic's solution is being developed to replace the expensive and risky two-step revision surgery, which is the current standard of care for chronic infections on medical implants.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-22T19:03:34.000000Z"}],"created_at":"2024-10-22T19:03:35.000000Z"},{"id":344,"name":"Marc Zemel","title":"CEO","photo":{"id":736,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/736\/Marc-Zemel-Retia-Medical.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/736\/conversions\/Marc-Zemel-Retia-Medical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/736\/conversions\/Marc-Zemel-Retia-Medical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/736\/conversions\/Marc-Zemel-Retia-Medical-large.webp"},"category":"innovators","roles":["C"],"company_name":"Retia Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/marc-zemel-digitalhealth\/","biography":"

A serial entrepreneur and experienced leader at Fortune 500 companies and startups in the medical device, imaging, and capital equipment markets, Mr. Zemel has a long track record of raising capital and building high-performing teams to develop, launch and sell innovative new products.  Prior to founding Retia, Mr. Zemel had several leadership roles in engineering, marketing and sales at a capital equipment startup and Becton Dickinson. He also authored 23 approved or pending patents. Mr. Zemel received his MS in Mechanical Engineering from the Massachusetts Institute of Technology and his MBA from the Yale School of Management.<\/p>","companies":[{"id":196,"name":"Retia Medical","logo":{"id":735,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/735\/Retia-Medical.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/735\/conversions\/Retia-Medical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/735\/conversions\/Retia-Medical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/735\/conversions\/Retia-Medical-large.webp"},"type":"presenter","description":"

Retia makes advanced hemodynamic monitors using the patented Multi-Beat Analysis MBA™ algorithm to guide care for high-risk surgical and ICU patients. Using the data from our monitor, clinicians implement proven protocols that reduce acute kidney injuries, myocardial injuries and other costly complications.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-22T19:04:33.000000Z"}],"created_at":"2024-10-22T19:04:34.000000Z"},{"id":345,"name":"Julius Heil","title":"CEO","photo":{"id":738,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/738\/Julius-Heil---Intalere---1.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/738\/conversions\/Julius-Heil---Intalere---1-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/738\/conversions\/Julius-Heil---Intalere---1-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/738\/conversions\/Julius-Heil---Intalere---1-large.webp"},"category":"innovators","roles":["C"],"company_name":"Sterile Processing Express","linkedin_profile":"https:\/\/www.linkedin.com\/in\/juliusfheil\/","biography":"

Senior executive & business leader with demonstrable commercial\/operational success. Enhanced top\u2010line growth & bottom\u2010line performance of several companies. Led top\u2010performing & cross\u2010functional teams across the U.S., Europe & Asia. Extensive and varied board experience. Expertise in strategic leadership; global operations’ supply chain (SC) & new, supporting technology, sourcing, procurement management; strategic planning\/ growth; corporate governance; M&A; expansion into emerging markets; Lean Operational Practices; cost management \/ P&L; on-time performance; and building\/ developing\/leading and retaining high-performing\/inclusive teams. Collaborative, innovative mindset (own 10 US patents) and high energy informs all work.

Concurrently, served as President, CEO & Board Member of Intalere, a group purchasing pioneer—now a provider-led healthcare supply chain company—empowering health-care organizations to elevate their clinical, operational\/financial performance. Led Intalere in the creation of significant shareholder value. Built highly-skilled leadership team; developed people, returned the Company to profitability early during tenure, grew revenue, improved security\/access, and reduced risk.

Before, served in leadership roles for several companies. Started career with UPS, held progressive roles with a few other companies.

Thought leader, presenter at major industry conferences addressing Fortune 500 executives. Received many industry honors and awards. Numerous professional affiliations.

B.S., Ohio State University (finished extensive Chemical Engineering coursework), Completed the Challenge of Leadership and Blue Ocean Strategy executive program, INSEAD, France.<\/p>","companies":[{"id":197,"name":"Sterile Processing Express","logo":{"id":737,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/737\/SPDX.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/737\/conversions\/SPDX-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/737\/conversions\/SPDX-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/737\/conversions\/SPDX-large.webp"},"type":"presenter","description":"

Sterile Processing Express supports healthcare providers with retrieval, processing, and delivery of sterilized instrument trays. Ancillary surgical facility services, such as instrument sharpening, instrument use histories, and asset tracking are additional opportunities that will be available to SPDx customers due to the company's centralized location. <\/p>\r\n

Visit website<\/a>.<\/em><\/p>","created_at":"2024-10-22T19:14:07.000000Z"}],"created_at":"2024-10-22T19:14:09.000000Z"},{"id":346,"name":"Jessica Walsh","title":"Founder - CEO","photo":{"id":1689,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1689\/jessica-walsh-rxbandz.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1689\/conversions\/jessica-walsh-rxbandz-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1689\/conversions\/jessica-walsh-rxbandz-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1689\/conversions\/jessica-walsh-rxbandz-large.webp"},"category":"innovators","roles":["C"],"company_name":"Rx Bandz","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jessica-walsh-3025807\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":198,"name":"Rx Bandz","logo":{"id":739,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/739\/rxbandz.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/739\/conversions\/rxbandz-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/739\/conversions\/rxbandz-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/739\/conversions\/rxbandz-large.webp"},"type":"presenter","description":"

Rx Bandz has developed a platform of innovative auto-injectors and formulations that provide a simple solution for patients, first responders, and the military. The company's auto-injectors include single- and dual-chamber sterile injection designs that ensure reliability, ease-of-use, durability, and portability. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-11-06T17:00:00.000000Z"}],"created_at":"2024-10-22T19:23:21.000000Z"},{"id":347,"name":"John Ehteshami","title":"CEO","photo":{"id":742,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/742\/john-ehteshami-additive_implants.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/742\/conversions\/john-ehteshami-additive_implants-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/742\/conversions\/john-ehteshami-additive_implants-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/742\/conversions\/john-ehteshami-additive_implants-large.webp"},"category":"innovators","roles":["C"],"company_name":"Additive Implants","linkedin_profile":"https:\/\/www.linkedin.com\/in\/john-ehteshami-47b90195\/","biography":"

John Ehteshami, MD practice focuses on the cervical spine. He is based in Phoenix, AZ and his goal of trying to address as much of his patient’s pathology through anterior approach led to development of Additive Implants. Dr. Ehteshami completed his BS in Civil Engineering at the University of California, Berkeley. He received his medical degree from Jefferson Medical College, then proceeded to complete an orthopedic residency at the Hospital for Special Surgery, Cornell which is ranked number one in US News and World Report’s for Orthopedic Hospitals. He did his Spinal Surgery fellowship at Rush Medical Center. Dr. Ehteshami spent five years in experimental research and implant analysis and biomechanical research at: UC Davis, University of Vienna, and Hospital for Special Surgery. With over 20 publications and presentations credited to his name, he has received numerous awards for his work. He is currently in clinical practice at Cervical Spine Centers, focusing on cervical spinal pathologies.<\/p>","companies":[{"id":199,"name":"Additive Implants","logo":{"id":741,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/741\/Screenshot-2024-10-22-122815.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/741\/conversions\/Screenshot-2024-10-22-122815-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/741\/conversions\/Screenshot-2024-10-22-122815-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/741\/conversions\/Screenshot-2024-10-22-122815-large.webp"},"type":"presenter","description":"

Additive Implants is focused on addressing unmet needs in spine surgery. The company designs and manufactures 3D printed cervical implants for fusion procedures.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-11-06T17:00:00.000000Z"}],"created_at":"2024-10-22T19:30:30.000000Z"},{"id":348,"name":"Bart Sanders","title":"CEO","photo":{"id":746,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/746\/bart-sanders-stentit.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/746\/conversions\/bart-sanders-stentit-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/746\/conversions\/bart-sanders-stentit-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/746\/conversions\/bart-sanders-stentit-large.webp"},"category":"innovators","roles":["C"],"company_name":"STENTiT","linkedin_profile":"https:\/\/www.linkedin.com\/in\/bart-sanders-96a77280\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":202,"name":"STENTiT","logo":{"id":745,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/745\/Stentit.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/745\/conversions\/Stentit-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/745\/conversions\/Stentit-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/745\/conversions\/Stentit-large.webp"},"type":"presenter","description":"

STENTiT is focused on the development of regenerative endovascular implants. The company's technology will be bioresorbable and capable of activating the body's naturally healing response to restore diseased arteries from the inside-out. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":null}],"created_at":"2024-10-22T19:36:13.000000Z"},{"id":349,"name":"Werner Vorster","title":"CEO","photo":{"id":747,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/747\/werner-vorster-vitls.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/747\/conversions\/werner-vorster-vitls-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/747\/conversions\/werner-vorster-vitls-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/747\/conversions\/werner-vorster-vitls-large.webp"},"category":"innovators","roles":["C"],"company_name":"Vitls","linkedin_profile":"https:\/\/www.linkedin.com\/in\/wernervorster\/","biography":"

I'm the co-founder and CEO of Vitls, a platform that includes the thinnest, most unobtrusive wearable available today that can monitor a full suite of vital signs reliably and continuously.

In 2004 I co-founded a2btransfers.com, an airport transfers company. We have offices in London, South Africa, and Greece. Today, Hoppa.com (formerly a2btransfers.com) is the world's nr 1 transfer specialist, serving 7,500 cities and resorts through 700 Airports, Ports and Train Stations in 116 countries. I sold a majority stake in the company and although still a shareholder, I'm no longer actively involved in the day-to-day.

In 2014, along with an amazing team of people, I started a new chapter for the Entrepreneurs Organisation in Durban, South Africa and took on the role of President.

When I'm not working, I enjoy spending time with family and friends, reading, hunting and exercising.<\/p>","companies":[{"id":203,"name":"Vitls","logo":{"id":748,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/748\/vitls.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/748\/conversions\/vitls-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/748\/conversions\/vitls-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/748\/conversions\/vitls-large.webp"},"type":"presenter","description":"

Wireless Connected Healthcare is a platform that enables doctors and nurses to continuously and remotely monitor a patient’s vital signs, reliably and undisturbed. Real-time, continuous monitoring enables, amongst other things, early detection of patient deterioration which leads to reductions in length of stay and treatment costs. The company's wearables are small, flexible, waterproof, discreet and noninvasive.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-11-07T17:00:00.000000Z"}],"created_at":"2024-10-22T19:40:14.000000Z"},{"id":350,"name":"Sanjay Shrivastava","title":"CEO","photo":{"id":750,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/750\/sanjay-shrivastava-innova-vascular.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/750\/conversions\/sanjay-shrivastava-innova-vascular-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/750\/conversions\/sanjay-shrivastava-innova-vascular-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/750\/conversions\/sanjay-shrivastava-innova-vascular-large.webp"},"category":"innovators","roles":["C"],"company_name":"Innova Vascular","linkedin_profile":"https:\/\/www.linkedin.com\/in\/sanjay-shrivastava-ph-d-189260\/","biography":"

\r\n
\r\n
\r\n

Dr. Sanjay Shrivastava is the founder and CEO of Innova Vascular.  Sanjay has been involved in developing, commercializing, evaluating, and acquiring medical devices for over 20 years.  During his career, Sanjay has held leadership positions at leading medical device companies including senior director, business development at Johnson & Johnson, vice president, upstream marketing and strategy at BTG, plc. (acquired by Boston Scientific Corporation), director global marketing at Medtronic, and director, research & development at Covidien\/ev3 (merged with Medtronic). Sanjay cofounded BlackSwan Vascular–a clinical stage medical device startup company, where he serves on the board of directors. In 2020, BlackSwan Vascular, Inc. entered in a strategic alliance with Sirtex Medical.  Additionally, Sanjay serves as a member of the board of directors at enVVeno Medical Corporation (Nasdaq: NVNO). <\/p>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n

\r\n
\r\n
\r\n

Sanjay holds over 30 issued US patents and numerous international patents in medical devices and has edited two books including one titled “Medical Device Materials” published by ASM International.  He was named among 100 Notable People in Medical Device Industry by the prestigious MD&DI (Medical Devices and Diagnostics Industry) magazine.  He has been an invited speaker at clinical, business, and engineering conferences to speak about medical device innovation and commercialization.  Sanjay holds a doctorate in materials science and engineering from the University of Florida and a bachelor’s from the Indian Institute of Technology. <\/p>\r\n<\/div>\r\n<\/div>\r\n<\/div>","companies":[{"id":204,"name":"Innova Vascular","logo":{"id":749,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/749\/Innova-Vascular.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/749\/conversions\/Innova-Vascular-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/749\/conversions\/Innova-Vascular-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/749\/conversions\/Innova-Vascular-large.webp"},"type":"presenter","description":"

Innova Vascular develops medical devices for the treatment of thromboembolism. The company's portfolio of vascular interventions include aspiration catheters and clot retrievers for the treatment of arterial and venous thromboembolism.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-22T19:43:45.000000Z"}],"created_at":"2024-10-22T19:43:47.000000Z"},{"id":351,"name":"Mauricio Toro","title":"CEO","photo":{"id":752,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/752\/mauricio-toro-techfit.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/752\/conversions\/mauricio-toro-techfit-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/752\/conversions\/mauricio-toro-techfit-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/752\/conversions\/mauricio-toro-techfit-large.webp"},"category":"innovators","roles":["C"],"company_name":"TECHFIT Digital Surgery","linkedin_profile":"https:\/\/www.linkedin.com\/in\/mauricio-toro-76855514\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":205,"name":"TECHFIT Digital Surgery","logo":{"id":751,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/751\/techfit_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/751\/conversions\/techfit_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/751\/conversions\/techfit_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/751\/conversions\/techfit_logo-large.webp"},"type":"presenter","description":"

TECHFIT Digital Surgery offers a comprehensive suite of digital solutions for musculoskeletal reconstructive surgery, integrating seamlessly into hospital workflows without upfront costs. Their DISRP platform provides access to expert surgical planning, while their point-of-care (POC) 3D printing services enable on-site, validated 3D printing with quality assurance. With ISO 13485-certified facilities, TECHFIT produces patient-matched and custom implants in advanced materials like Titanium and PEEK, supporting high-complexity cases and empowering hospitals to enhance patient care.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-11-14T16:00:00.000000Z"}],"created_at":"2024-10-22T19:48:27.000000Z"},{"id":352,"name":"Robert Wilson","title":"CEO","photo":{"id":754,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/754\/About-Pics-01.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/754\/conversions\/About-Pics-01-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/754\/conversions\/About-Pics-01-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/754\/conversions\/About-Pics-01-large.webp"},"category":"innovators","roles":["C"],"company_name":"EGG Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/robert-wilson-a90b002\/","biography":"

Dr. Wilson is the founder and Chief Executive Officer at Egg Medical, and a practicing Interventional Cardiologist at the University of Minnesota, where he has been on staff since 1986.<\/p>\r\n

He was the Director of the Cardiac Cath Lab from 1988-2004 and served as Chief of Cardiology from 2008-2013.<\/p>\r\n

Dr. Wilson has a passion for advancing the Science of Interventional Cardiology and has been active in research and Product Development for many years.<\/p>\r\n

Before starting Egg Medical, Dr. Wilson was the catalyst behind ACIST Medical. <\/p>","companies":[{"id":206,"name":"Egg Medical","logo":{"id":753,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/753\/EggMedical-Logo-retina-new.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/753\/conversions\/EggMedical-Logo-retina-new-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/753\/conversions\/EggMedical-Logo-retina-new-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/753\/conversions\/EggMedical-Logo-retina-new-large.webp"},"type":"presenter","description":"

Egg Medical was founded in 2014 to develop and market the next generation of radiation protection devices for hospital x-ray labs. The company's first product, the Egg Nest, reduces staff radiation exposure by >90%! We launched commercial sales in late 2019- and the R&D and commercial buildout continues.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-22T19:51:13.000000Z"}],"created_at":"2024-10-22T19:51:14.000000Z"},{"id":353,"name":"James Leech","title":"Chief Financial & Strategy Officer","photo":{"id":755,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/755\/james-leech-moximed.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/755\/conversions\/james-leech-moximed-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/755\/conversions\/james-leech-moximed-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/755\/conversions\/james-leech-moximed-large.webp"},"category":"innovators","roles":["C"],"company_name":"Moximed","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jamesleech1\/","biography":"

James has extensive financial, strategic, and operational experience in med tech, including advising or leading >$2B in life sciences M&A activity over the course of his career. Most recently, James was a founding team member and Chief Business Officer at Palette Life Sciences where he helped drive a successful acquisition by Teleflex. With his track record of successfully scaling growth-stage companies, James will be instrumental to realizing the full potential of Moximed’s market opportunity.<\/p>","companies":[{"id":207,"name":"Moximed","logo":{"id":756,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/756\/moximed_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/756\/conversions\/moximed_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/756\/conversions\/moximed_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/756\/conversions\/moximed_logo-large.webp"},"type":"presenter","description":"

Moximed has developed an implantable shock absorber for patients with medial knee osteoarthritis.The MISHA device reduces the overall loading on the knee and serves as an alternative to pain medication, knee braces and joint-altering knee surgery. Placed during an outpatient procedure, the device provides 13kg (30 lbs.) of weight unloading to the knee.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-31T16:00:00.000000Z"}],"created_at":"2024-10-22T19:56:47.000000Z"},{"id":354,"name":"Amaan Mazhar","title":"CEO","photo":{"id":758,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/758\/1517730705749.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/758\/conversions\/1517730705749-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/758\/conversions\/1517730705749-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/758\/conversions\/1517730705749-large.webp"},"category":"innovators","roles":["C"],"company_name":"Modulim","linkedin_profile":"https:\/\/www.linkedin.com\/in\/amazhar\/","biography":"

Biomedical engineer with a training emphasis in biomedical optics. Currently involved in medical device development & committed to translating biomedical technologies from lab to marketplace so patients can benefit.<\/p>","companies":[{"id":208,"name":"Modulim","logo":{"id":757,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/757\/1551771480530.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/757\/conversions\/1551771480530-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/757\/conversions\/1551771480530-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/757\/conversions\/1551771480530-large.webp"},"type":"presenter","description":"

Modulim’s mission is to help clinicians prevent the onset or escalation of diabetic foot ulcers—and other complications of vascular compromise. The Clarifi device is a noninvasive, non-contact, diagnostic wide-field imaging system that provides a fast, reliable, and objective method of assessing tissue oxygen saturation, hemoglobin quantity, and distribution at different depths in patients with compromised circulation.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-22T20:00:34.000000Z"}],"created_at":"2024-10-22T20:00:35.000000Z"},{"id":355,"name":"Thomas West","title":"CEO","photo":{"id":760,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/760\/thomas-west-nalu.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/760\/conversions\/thomas-west-nalu-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/760\/conversions\/thomas-west-nalu-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/760\/conversions\/thomas-west-nalu-large.webp"},"category":"innovators","roles":["C"],"company_name":"Nalu Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/thomas-a-west-8a947819\/","biography":"

Mr. West has served as our President and Chief Executive Officer and as a member of our board of directors since August 2022. Prior to joining Nalu, Mr. West served from 2019 to 2022 as President, Chief Executive Officer and Director at Intersect ENT, Inc., a publicly-traded medical device and drug delivery company. Intersect was acquired by Medtronic in May of 2022. Prior to Intersect, Mr. West served as Worldwide President, Diagnostic Solutions at Hologic from 2015 to 2019. Mr. West began his healthcare career at Johnson & Johnson where he assumed roles of increasing responsibility over a twenty-three year tenure including Worldwide President of Strategy and Business Development for the J&J Family of Diabetes Solutions Companies, Division President of LifeScan North America and Division President of LifeScan EMEA. Mr. West also currently serves as an independent member of the Board of Directors of Orthofix, a role he took on in 2021. Mr. West received a B.A. in Politics and Economics from Princeton University and an M.B.A. from the University of Pennsylvania, Wharton School.<\/p>","companies":[{"id":209,"name":"Nalu Medical","logo":{"id":759,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/759\/nalu_medical_inc_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/759\/conversions\/nalu_medical_inc_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/759\/conversions\/nalu_medical_inc_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/759\/conversions\/nalu_medical_inc_logo-large.webp"},"type":"presenter","description":"

Nalu Medical has developed a battery-free, micro-implantable neurostimulation system for both peripheral nerve stimulation (PNS) and spinal cord stimulation (SCS) for the treatment of chronic pain. The Nalu Neurostimulation System is significantly smaller than other commercially available implantable pulse generators and offers features to patients and providers that make the system easy to use and update. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-11-14T16:00:00.000000Z"}],"created_at":"2024-10-22T20:05:10.000000Z"},{"id":356,"name":"David Kaiser","title":"CEO","photo":{"id":762,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/762\/david-kaiser-memorycareai.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/762\/conversions\/david-kaiser-memorycareai-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/762\/conversions\/david-kaiser-memorycareai-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/762\/conversions\/david-kaiser-memorycareai-large.webp"},"category":"innovators","roles":["C"],"company_name":"MemoryCareAI","linkedin_profile":"https:\/\/www.linkedin.com\/in\/davidkaiser369\/","biography":"

Founder and CEO of MemoryCareAI, an AI-driven Neuro Tech SaaS platform start-up transforming memory care by providing healthcare professionals with real-time insights to diagnose and manage Alzheimer's, related dementias, and traumatic brain injuries. The platform features \"Rachel,\" an intelligent avatar that administers neuropsychological tests and analyzes speech, facial expressions, and eye movements. MemoryCareAI also incorporates a specialized Large Language Model (LLM) designed for cognitive health, delivering personalized care recommendations and real-time monitoring. By seamlessly integrating into healthcare workflows, MemoryCareAI empowers providers with data-driven insights, improving both the quality of care and outcomes for patients and caregivers.

As a dynamic entrepreneur and seasoned leader with over 20 years of distinguished experience in executive roles, including Chief Marketing Officer (CMO) and Chief Operating Officer (COO), David brings a wealth of expertise in behavioral health and neuroscience to his role. Throughout his career, David has built or significantly contributed to numerous startups in the behavioral healthcare space, leveraging his deep understanding of the market to drive strategic growth and innovation.

David’s leadership is characterized by a relentless drive for excellence and transformation. He has spearheaded transformative initiatives that have propelled organizations to new heights of success. With a keen eye for identifying emerging opportunities and forging strategic partnerships, David has played a pivotal role in driving business development initiatives, expanding market reach, and cultivating lasting relationships with key stakeholders.

His entrepreneurial spirit and passion for innovation have positioned him as a trailblazer in the healthcare landscape, continually pushing the boundaries of innovation to create impactful solutions that make a meaningful difference in the lives of millions.<\/p>","companies":[{"id":210,"name":"MemoryCareAI","logo":{"id":761,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/761\/memorycareai.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/761\/conversions\/memorycareai-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/761\/conversions\/memorycareai-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/761\/conversions\/memorycareai-large.webp"},"type":"presenter","description":"

MemoryCareAI is advancing cognitive health with an AI-driven platform that enables early detection, personalized care, and ongoing management for conditions such as Alzheimer’s, dementia, and Parkinson’s. Leveraging speech biomarkers, a proprietary dataset of over 2 million patient records, and engaging digital human interfaces, MemoryCareAI offers scalable solutions for both B2B and B2C markets. Their tools empower healthcare providers, insurers, and individuals with accessible assessments and proactive care pathways, aiming to improve quality of life through early detection and personalized, data-driven insights.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-11-14T16:00:00.000000Z"}],"created_at":"2024-10-22T20:14:21.000000Z"},{"id":357,"name":"Christian Howell","title":"CEO","photo":{"id":763,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/763\/christian-howell-cognito_therapeutics.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/763\/conversions\/christian-howell-cognito_therapeutics-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/763\/conversions\/christian-howell-cognito_therapeutics-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/763\/conversions\/christian-howell-cognito_therapeutics-large.webp"},"category":"innovators","roles":["C"],"company_name":"Cognito Therapeutics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/christianfhowell\/","biography":"

Christian Howell is a recognized healthcare leader possessing over 20 years of experience across startup and corporate landscapes, managing P&L from early stage to mature markets.

Early in his career as an officer in the U.S. Navy, Christian developed a philosophy that would guide his future endeavors: his work had to make a positive social impact. This led him, over 20 years ago, to medical devices, where he navigated responsibilities in business development, commercial leadership, product management, market development, and strategy. During his nearly 15 year tenure at Medtronic, Christian led Medtronic’s Value-Based Health Care Partnerships organization, as well as P&L responsibility for Medtronic’s Integrated Health Solutions program to improve delivery of care and patient experience with partner health systems. There, he gained an understanding of the critical role of data in the shift from volume to value in health care, so he adjusted his focus to encouraging stakeholders towards sharing data and making better decisions with accurate and high quality evidence.

Christian is continually looking around the corner and pushing the envelope with innovative approaches to deliver the greatest impact to patients. A serial intrapreneur, Christian pioneered a platform approach to value-based care delivery at Medtronic, conceptualizing a multi-stakeholder ecosystem to facilitate and streamline multi-sided interaction between manufacturers, payers, and providers. In his first two years at Aetion, Christian’s demonstrated effectiveness entering the Medical Device and Diagnostics verticals has gained recognition across the industry and his scope of responsibility has expanded to include oversight of Government and Value Based teams.

Christian’s ability to develop key relationships with providers, regulators, payers, and industry leaders has been instrumental in the success of the initiatives he leads, positioning him as a sought-after speaker at top industry events and conferences including occasions at Harvard, MIT, Stanford, the G20, and more.<\/p>","companies":[{"id":211,"name":"Cognito Therapeutics","logo":{"id":764,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/764\/cognito_therapeutrics.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/764\/conversions\/cognito_therapeutrics-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/764\/conversions\/cognito_therapeutrics-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/764\/conversions\/cognito_therapeutrics-large.webp"},"type":"presenter","description":"

Cognito Therapeutics is focused on discovering and developing new device-based treatments and preventive therapies for neurodegenerative diseases including Alzheimer's disease.
The company has developed a wearable headset that uses sensory stimulation to evoke gamma oscillations in the brain that have been shown to improve synaptic connections between neurons, activate microglia, and enhance removal of pathological proteins from the brain.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-11-14T16:00:00.000000Z"}],"created_at":"2024-10-22T20:17:28.000000Z"},{"id":359,"name":"Nathan Friedman","title":"CEO","photo":{"id":768,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/768\/nathan-friedan-hemasense.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/768\/conversions\/nathan-friedan-hemasense-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/768\/conversions\/nathan-friedan-hemasense-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/768\/conversions\/nathan-friedan-hemasense-large.webp"},"category":"innovators","roles":["C"],"company_name":"HemaSense","linkedin_profile":"https:\/\/www.linkedin.com\/in\/nathanfriedman\/","biography":"

Nathan has over 20 years in Medtech Innovation resulting in several successful device development and commercialization efforts. His degree in Mechanical and Materials Engineering from RPI is complemented by leadership positions in new market discovery and business development during his 19 years at WL Gore and Associates. Nathan has supported multiple M&A efforts and also successfully founded, grew, and sold a company in the beverage industry.<\/p>","companies":[{"id":213,"name":"HemaSense","logo":{"id":767,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/767\/hemasense.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/767\/conversions\/hemasense-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/767\/conversions\/hemasense-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/767\/conversions\/hemasense-large.webp"},"type":"presenter","description":"

HemaSense is addressing the significant problem of access site bleeding complications following catheter-based procedures.  The HemaSense monitoring device provides early detection and alerts of subcutaneous blood accumulation,  which accelerates recovery, improves patient safety, and shortens hospital stays.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-22T20:32:15.000000Z"}],"created_at":"2024-10-22T20:33:52.000000Z"},{"id":360,"name":"Uli Chettipally","title":"Founder & President","photo":{"id":769,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/769\/uli-chettipally-sirica.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/769\/conversions\/uli-chettipally-sirica-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/769\/conversions\/uli-chettipally-sirica-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/769\/conversions\/uli-chettipally-sirica-large.webp"},"category":"innovators","roles":["C"],"company_name":"Sirica Therapeutics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ulichettipally\/","biography":"

Dr. Uli K. Chettipally is an award-winning physician, researcher, and entrepreneur with over 20 years of experience in emergency medicine, clinical decision support, and digital therapeutics. He is the founder of Sirica Therapeutics, a start-up that is developing a novel device system for autism, using robotics, virtual reality, and video gaming. His mission is to make therapy fun and effective for children with autism and their families.

He is also the founder and President of InnovatorMD, the world's largest physician innovation platform that aims to inform, inspire, and ignite solutions that revolutionize patient care. He organizes events, classes, and meetups for physician innovators and startups, and runs a Health Tech pre-seed accelerator in partnership with Founder Institute. He has authored several publications and books, including \"Punish The Machine\u2015The Promise of Artificial Intelligence in Healthcare\". He serves on various boards and committees, and has received prestigious awards for his innovation and research. He is passionate about leveraging technology to improve healthcare outcomes, quality, and affordability.<\/p>","companies":[{"id":214,"name":"Sirica Therapeutics","logo":{"id":770,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/770\/sirica-therapeutics.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/770\/conversions\/sirica-therapeutics-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/770\/conversions\/sirica-therapeutics-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/770\/conversions\/sirica-therapeutics-large.webp"},"type":"presenter","description":"

Sirica Therapeutics is a digital therapeutics company focused on developing solutions for autism and other related disorders. The company is developing a new category of therapy called Cognitive Sensorimotor Therapy, which utilizes advanced robotics, virtual reality, and gamification to provide personalized and immersive therapy to patients and their families.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-11-14T17:00:00.000000Z"}],"created_at":"2024-10-22T20:38:18.000000Z"},{"id":363,"name":"David Nichols","title":"CEO","photo":{"id":1036,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1036\/David-L.-Nichols-ortobond-cropped.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1036\/conversions\/David-L.-Nichols-ortobond-cropped-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1036\/conversions\/David-L.-Nichols-ortobond-cropped-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1036\/conversions\/David-L.-Nichols-ortobond-cropped-large.webp"},"category":"innovators","roles":["C"],"company_name":"Orthobond","linkedin_profile":"https:\/\/www.linkedin.com\/in\/david-nichols-4b048933\/","biography":"

David Nichols is an industry veteran CEO who has held executive leadership roles at three Fortune 500 medical device companies, Zimmer Biomet, Synthes Spine and United States Surgical. Over the course of his career, David has led R&D for three successful startups, resulting in exits to large medical device companies totaling ~$400M. Prior to joining Orthobond in 2020, David served as the General Manager for Zimmer Biomet's $200M Early Intervention Division. Under David’s leadership, the Early Intervention Division led Zimmer Biomet’s growth in 2019 with 18% overall revenue growth. David formerly served as Vice President and General Manager of Zimmer Knee Creations, where he expanded release of the company’s subchrondroplasty portfolio to key international markets and achieved significant product adoption within 38 of the top 50 orthopedic hospitals in the U.S, earning his division the accolade “Business Unit of the Year.” David earned his BSME in Mechanical Engineering from The University of Memphis, where he also pursued graduate studies in Mechanical Engineering and Operations Management. He has been an inventor on 46 medical device patents.<\/p>","companies":[{"id":216,"name":"Orthobond","logo":{"id":781,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/781\/Screenshot-2024-10-29-123008.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/781\/conversions\/Screenshot-2024-10-29-123008-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/781\/conversions\/Screenshot-2024-10-29-123008-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/781\/conversions\/Screenshot-2024-10-29-123008-large.webp"},"type":"presenter","description":"

ORTHOBOND™ is a material science company that has developed OSTAGUARD™, an antibacterial surface treatment for medical implants. OSTAGUARD™ antibacterial surface treatment is the first of its kind to be granted U.S. Food and Drug Administration (FDA) De Novo classification. With an initial application in the field of orthopedic spinal implants, OSTAGUARD actively kills the bacteria that contaminate the surfaces of medical devices.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-31T16:00:00.000000Z"}],"created_at":"2024-10-29T19:26:24.000000Z"},{"id":364,"name":"Jeffrey Halbrecht, MD.","title":"Founder & CEO","photo":{"id":1038,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1038\/jeffrey-halbrecht-zkr_orthopedics-cropped.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1038\/conversions\/jeffrey-halbrecht-zkr_orthopedics-cropped-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1038\/conversions\/jeffrey-halbrecht-zkr_orthopedics-cropped-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/1038\/conversions\/jeffrey-halbrecht-zkr_orthopedics-cropped-large.webp"},"category":"innovators","roles":["C"],"company_name":"ZKR Orthopedics","linkedin_profile":null,"biography":"

Jeff Halbrecht is a nationally renowned Orthopedic Surgeon who saw the need for a new method of treating Patellofemoral Arthritis.  <\/span>Jeff is founder and CEO of ZKR Orthopedics, a medical device Company offering a minimally invasive treatment option for patients with cartilage degeneration of the knee affecting the Patellofemoral joint. Jeff is a graduate of Columbia University, NYU Medical School and The Hospital for Joint Diseases in NY, and has numerous patents and publications for innovative Orthopedic treatments.  <\/span>Jeff is also the Founder of the Institute for Arthroscopy and Sports Medicine, as well as a Founder of the Pacific Heights Surgery Center in San Francisco. <\/span><\/p>","companies":[{"id":217,"name":"ZKR Orthopedics","logo":{"id":782,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/782\/Screenshot-2024-10-29-123515.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/782\/conversions\/Screenshot-2024-10-29-123515-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/782\/conversions\/Screenshot-2024-10-29-123515-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/782\/conversions\/Screenshot-2024-10-29-123515-large.webp"},"type":"presenter","description":"

Millions of people in the U.S. suffer from degenerative arthritis of their knees. At least 20% of these patients have arthritis localized to their patellofemoral joint ( knee cap) with an addressable market of $2 Billion. Until now the only available options have been highly invasive surgeries, including knee replacement. The ZKR Patella LIFT implant offers patients a minimally invasive alternative to knee replacement at a significantly lower cost and a much faster recovery.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-31T16:00:00.000000Z"}],"created_at":"2024-10-29T19:40:16.000000Z"},{"id":365,"name":"Praphakar Vemavarapu","title":"Founder & CEO","photo":{"id":785,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/785\/Headshot_PVV.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/785\/conversions\/Headshot_PVV-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/785\/conversions\/Headshot_PVV-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/785\/conversions\/Headshot_PVV-large.webp"},"category":"innovators","roles":["C"],"company_name":"XRMedix","linkedin_profile":"https:\/\/www.linkedin.com\/in\/pvemavarapu\/","biography":"

Prabhakar Vemavarapu, M.S., is the Founder and CEO of XRMedix, where he leads the development of AI-powered augmented reality (AR) technologies for precision medical procedures. With over 11 years of experience in Human-Computer Interaction and as a Ph.D. candidate in Virtual Reality at the University of Louisiana at Lafayette, Prabhakar specializes in leveraging AR\/VR technology to enhance both physical and cognitive health. He has extensive experience working in early-stage startups, where he was responsible for launching initial beta releases, gathering feedback, and overseeing full market releases. His work focuses on bringing innovative healthcare solutions to market, particularly in non-opioid pain management and precision-guided procedures.<\/p>","companies":[{"id":218,"name":"XRMedix","logo":{"id":784,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/784\/XRMedix-Final_Vertical_Cropped.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/784\/conversions\/XRMedix-Final_Vertical_Cropped-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/784\/conversions\/XRMedix-Final_Vertical_Cropped-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/784\/conversions\/XRMedix-Final_Vertical_Cropped-large.webp"},"type":"presenter","description":"

XRMedix is developing an AI-powered needle guidance system that combines augmented reality (AR) visualization and real-time needle tracking to enhance the accuracy of joint injections without the need for radiological imaging. This portable solution addresses the growing demand for non-opioid pain management, particularly in areas with limited specialist access, such as rural and underserved regions, within the expanding intra-articular injection market.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-11-14T16:00:00.000000Z"}],"created_at":"2024-10-29T20:45:45.000000Z"},{"id":366,"name":"Adrienn Nemeth","title":"Director of Sales and Marketing","photo":{"id":786,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/786\/adrienn-nemeth-vartid.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/786\/conversions\/adrienn-nemeth-vartid-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/786\/conversions\/adrienn-nemeth-vartid-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/786\/conversions\/adrienn-nemeth-vartid-large.webp"},"category":"innovators","roles":["C"],"company_name":"Vartid","linkedin_profile":"https:\/\/www.linkedin.com\/in\/adrienn-n%C3%A9meth-28b83085\/","biography":"

With a background as a former researcher, I bring a distinctive viewpoint and in-depth understanding of the scientific and technical intricacies of our products and services. Leveraging my analytical and critical thinking skills, I identify and capitalize on emerging market opportunities, ensuring that our solutions align perfectly with the evolving needs of the industry.

My passion lies in delivering exceptional value to our clients and partners. I am committed to advancing the global adoption of transformative technologies in medical and life sciences, that have the potential to enhance lives and reshape our world. By combining my technical insights with a strategic approach, I play a pivotal role in creating and executing effective sales and marketing strategies that propel Vartid to new heights<\/p>","companies":[{"id":219,"name":"Vartid","logo":{"id":787,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/787\/vartid.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/787\/conversions\/vartid-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/787\/conversions\/vartid-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/787\/conversions\/vartid-large.webp"},"type":"presenter_innovator","description":"

VARTID surgical augmented reality system fundamentally transforms specific orthopedic surgical procedures allowing simultaneous preoperative planning, intraoperative navigation and documentation. This AI enhanced, markerless innovation automatically identifies key reference points on X-ray and CT images, as well as within the anatomical body itself, providing real time tracking of bodily motions in 3D.<\/span><\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-11-14T17:00:00.000000Z"}],"created_at":"2024-10-29T20:50:21.000000Z"},{"id":367,"name":"Paul Mikus","title":"CEO","photo":{"id":789,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/789\/paul-mikus-polaris.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/789\/conversions\/paul-mikus-polaris-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/789\/conversions\/paul-mikus-polaris-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/789\/conversions\/paul-mikus-polaris-large.webp"},"category":"innovators","roles":["C"],"company_name":"PolarisAR","linkedin_profile":"https:\/\/www.linkedin.com\/in\/paul-m-0751148b\/","biography":"

Bio coming soon.<\/p>","companies":[{"id":220,"name":"PolarisAR","logo":{"id":788,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/788\/polarisar_logo.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/788\/conversions\/polarisar_logo-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/788\/conversions\/polarisar_logo-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/788\/conversions\/polarisar_logo-large.webp"},"type":"presenter","description":"

POLARISAR<\/sup> is pioneering a new era in surgery using mixed reality technology. The company is delivering what total joint robotic systems do in a mixed reality format. The company recently received FDA clearance for its first product, Stellar Knee, to measure, plan and guide a total knee arthroplasty procedure dynamically in real time.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-10-29T20:58:50.000000Z"}],"created_at":"2024-10-29T20:58:51.000000Z"},{"id":368,"name":"Machiel Van Der Leest","title":"President & Founder","photo":{"id":790,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/790\/machiel-vanderleest-guardmedical.jpeg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/790\/conversions\/machiel-vanderleest-guardmedical-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/790\/conversions\/machiel-vanderleest-guardmedical-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/790\/conversions\/machiel-vanderleest-guardmedical-large.webp"},"category":"innovators","roles":["C"],"company_name":"Guard Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/machiel-van-der-leest-0871057\/","biography":"

Machiel is a seasoned medical device professional and entrepreneur. He has developed and introduced over 10 class III devices in the interventional cardio- and neurovascular market. In his 20+ year career Machiel held executive positions as CTO, CSO and CEO. Prior to Guard Medical he was CEO of ART – bioresorbable stent. Machiel has raised funds and closed deals with an aggregated value of over $100 million. He holds a MSc degree from the Technical University Delft and is an inventor on 25+ patents.<\/p>","companies":[{"id":221,"name":"Guard Medical","logo":{"id":791,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/791\/Screenshot-2024-10-29-141421.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/791\/conversions\/Screenshot-2024-10-29-141421-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/791\/conversions\/Screenshot-2024-10-29-141421-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/791\/conversions\/Screenshot-2024-10-29-141421-large.webp"},"type":"presenter","description":"

Guard Medical develops solutions to improve healing and reduce surgical site infection (SSI). The Negative Pressure Wound Therapy (NPWT) technology used in the company's NPseal solution is a cost-effective and easy-to-use solution for a wide range of surgical wound sizes & types. The device utilizes an integrated pump to establish and maintain negative pressure to enable prophylactic wound care of closed surgical incisions. NPseal is well suited for use in inpatient, outpatient, ambulatory surgical centers and office-based procedures.<\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":"2024-11-14T17:00:00.000000Z"}],"created_at":"2024-10-29T21:13:21.000000Z"},{"id":371,"name":"Rashmi Prakash","title":"CEO","photo":{"id":797,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/797\/rashmi-prakash-aruna.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/797\/conversions\/rashmi-prakash-aruna-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/797\/conversions\/rashmi-prakash-aruna-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/797\/conversions\/rashmi-prakash-aruna-large.webp"},"category":"innovators","roles":["C"],"company_name":"Aruna Revolution","linkedin_profile":"https:\/\/www.linkedin.com\/in\/rashmi-prakash-28864190\/","biography":"

I'm deeply passionate about sustainably leveraging technology to enhance quality of life and ensure an equitable future.

My background in electrical & biomedical engineering and extensive skills in C\/C++\/C#, ARM\/VHDL, rapid prototyping, 3D modeling\/printing, and PCB\/circuit design, are complemented by proficiency in ISO compliance, medical device development, project management, and clinical regulations.

I thrive in environments that challenge me to step outside my comfort zone, constantly seeking new learning opportunities. My commitment extends beyond technical expertise; I am dedicated to innovating in women's health and bringing advanced healthcare to communities that have traditionally been overlooked in the healthcare sector.

I aspire to collaborate with forward-thinking teams and organizations to create impactful and inclusive health solutions, driving progress towards a healthier, more equitable world.<\/p>","companies":[{"id":225,"name":"Aruna Revolution","logo":{"id":798,"mime_type":"image\/png","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/798\/Screenshot-2024-10-29-142359.png","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/798\/conversions\/Screenshot-2024-10-29-142359-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/798\/conversions\/Screenshot-2024-10-29-142359-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/798\/conversions\/Screenshot-2024-10-29-142359-large.webp"},"type":"presenter","description":"

Aruna’s mission is to increase the sustainability of women’s health products to reduce their impact on the environment. The company develops biodegradable and compostable menstrual products. <\/p>\r\n

Visit website<\/em><\/a>.<\/p>","created_at":null}],"created_at":"2024-10-29T21:23:12.000000Z"},{"id":372,"name":"Elizabeth Jaworski","title":"CEO","photo":{"id":800,"mime_type":"image\/jpeg","url_original":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/800\/elizabeth-jaworski-xnhealth.jpg","url_small":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/800\/conversions\/elizabeth-jaworski-xnhealth-small.webp","url_medium":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/800\/conversions\/elizabeth-jaworski-xnhealth-medium.webp","url_large":"https:\/\/d2pm4w6bnltx0l.cloudfront.net\/800\/conversions\/elizabeth-jaworski-xnhealth-large.webp"},"category":"innovators","roles":["C"],"company_name":"XN Health","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ejaworski\/","biography":"

\r\n
\r\n